<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-0"><publication-reference><document-id><country>US</country><doc-number>20230002764</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="441pt" align="left"/><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>                               SEQUENCE LISTING</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;160&#x3e; NUMBER OF SEQ ID NOS: 633</entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 1</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 1</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 2</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 345</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: CEBP/B Protein Sequence</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 2</entry></row><row><entry> </entry></row><row><entry>Met Gln Arg Leu Val Ala Trp Asp Pro Ala Cys Leu Pro Leu Pro Pro</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Pro Pro Ala Phe Lys Ser Met Glu Val Ala Asn Phe Tyr Tyr Glu</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Ala Asp Cys Leu Ala Ala Ala Tyr Gly Gly Lys Ala Ala Pro Ala Ala</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Pro Pro Ala Ala Arg Pro Gly Pro Arg Pro Pro Ala Gly Glu Leu Gly</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ser Ile Gly Asp His Glu Arg Ala Ile Asp Phe Ser Pro Tyr Leu Glu</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Pro Leu Gly Ala Pro Gln Ala Pro Ala Pro Ala Thr Ala Thr Asp Thr</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Phe Glu Ala Ala Pro Pro Ala Pro Ala Pro Ala Pro Ala Ser Ser Gly</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Gln His His Asp Phe Leu Ser Asp Leu Phe Ser Asp Asp Tyr Gly Gly</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Lys Asn Cys Lys Lys Pro Ala Glu Tyr Gly Tyr Val Ser Leu Gly Arg</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Leu Gly Ala Ala Lys Gly Ala Leu His Pro Gly Cys Phe Ala Pro Leu</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>His Pro Pro Pro Pro Pro Pro Pro Pro Pro Ala Glu Leu Lys Ala Glu</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Pro Gly Phe Glu Pro Ala Asp Cys Lys Arg Lys Glu Glu Ala Gly Ala</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Pro Gly Gly Gly Ala Gly Met Ala Ala Gly Phe Pro Tyr Ala Leu Arg</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Ala Tyr Leu Gly Tyr Gln Ala Val Pro Ser Gly Ser Ser Gly Ser Leu</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Ser Thr Ser Ser Ser Ser Ser Pro Pro Gly Thr Pro Ser Pro Ala Asp</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Ala Lys Ala Pro Pro Thr Ala Cys Tyr Ala Gly Ala Ala Pro Ala Pro</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Ser Gln Val Lys Ser Lys Ala Lys Lys Thr Val Asp Lys His Ser Asp</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Glu Tyr Lys Ile Arg Arg Glu Arg Asn Asn Ile Ala Val Arg Lys Ser</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Arg Asp Lys Ala Lys Met Arg Asn Leu Glu Thr Gln His Lys Val Leu</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Glu Leu Thr Ala Glu Asn Glu Arg Leu Gln Lys Lys Val Glu Gln Leu</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Ser Arg Glu Leu Ser Thr Leu Arg Asn Leu Phe Lys Gln Leu Pro Glu</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Pro Leu Leu Ala Ser Ser Gly His Cys</entry></row><row><entry>            340                 345</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 3</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 2113</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: CEBP/B mRNA Sequence</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 3</entry></row><row><entry> </entry></row><row><entry>tcccaatccc ggggcggccg ggcgggggtg ggcagggggc gtgaggccgc ccctgcgtcc     60</entry></row><row><entry> </entry></row><row><entry>cgggggcccc ccgaaaacgc gctccgggtg cccggtccct ccgctgcgcc ctgccgccgt    120</entry></row><row><entry> </entry></row><row><entry>cctcccgggg gtctcgggcg gccgcggccg tgtccttcgc gtcccggcgg cgcggcggga    180</entry></row><row><entry> </entry></row><row><entry>ggggccggcg tgacgcagcg gttgctacgg gccgccctta taaataaccg ggctcaggag    240</entry></row><row><entry> </entry></row><row><entry>aaactttagc gagtcagagc cgcgcacggg actgggaagg ggacccaccc gagggtccag    300</entry></row><row><entry> </entry></row><row><entry>ccaccagccc cctcactaat agcggccacc ccggcagcgg cggcagcagc agcagcgacg    360</entry></row><row><entry> </entry></row><row><entry>cagcggcgac agctcagagc agggaggccg cgccacctgc gggccggccg gagcgggcag    420</entry></row><row><entry> </entry></row><row><entry>ccccaggccc cctccccggg cacccgcgtt catgcaacgc ctggtggcct gggacccagc    480</entry></row><row><entry> </entry></row><row><entry>atgtctcccc ctgccgccgc cgccgcctgc ctttaaatcc atggaagtgg ccaacttcta    540</entry></row><row><entry> </entry></row><row><entry>ctacgaggcg gactgcttgg ctgctgcgta cggcggcaag gcggcccccg cggcgccccc    600</entry></row><row><entry> </entry></row><row><entry>cgcggccaga cccgggccgc gcccccccgc cggcgagctg ggcagcatcg gcgaccacga    660</entry></row><row><entry> </entry></row><row><entry>gcgcgccatc gacttcagcc cgtacctgga gccgctgggc gcgccgcagg ccccggcgcc    720</entry></row><row><entry> </entry></row><row><entry>cgccacggcc acggacacct tcgaggcggc tccgcccgcg cccgcccccg cgcccgcctc    780</entry></row><row><entry> </entry></row><row><entry>ctccgggcag caccacgact tcctctccga cctcttctcc gacgactacg ggggcaagaa    840</entry></row><row><entry> </entry></row><row><entry>ctgcaagaag ccggccgagt acggctacgt gagcctgggg cgcctggggg ccgccaaggg    900</entry></row><row><entry> </entry></row><row><entry>cgcgctgcac cccggctgct tcgcgcccct gcacccaccg cccccgccgc cgccgccgcc    960</entry></row><row><entry> </entry></row><row><entry>cgccgagctc aaggcggagc cgggcttcga gcccgcggac tgcaagcgga aggaggaggc   1020</entry></row><row><entry> </entry></row><row><entry>cggggcgccg ggcggcggcg caggcatggc ggcgggcttc ccgtacgcgc tgcgcgctta   1080</entry></row><row><entry> </entry></row><row><entry>cctcggctac caggcggtgc cgagcggcag cagcgggagc ctctccacgt cctcctcgtc   1140</entry></row><row><entry> </entry></row><row><entry>cagcccgccc ggcacgccga gccccgctga cgccaaggcg cccccgaccg cctgctacgc   1200</entry></row><row><entry> </entry></row><row><entry>gggggccgcg ccggcgccct cgcaggtcaa gagcaaggcc aagaagaccg tggacaagca   1260</entry></row><row><entry> </entry></row><row><entry>cagcgacgag tacaagatcc ggcgcgagcg caacaacatc gccgtgcgca agagccgcga   1320</entry></row><row><entry> </entry></row><row><entry>caaggccaag atgcgcaacc tggagacgca gcacaaggtc ctggagctca cggccgagaa   1380</entry></row><row><entry> </entry></row><row><entry>cgagcggctg cagaagaagg tggagcagct gtcgcgcgag ctcagcaccc tgcggaactt   1440</entry></row><row><entry> </entry></row><row><entry>gttcaagcag ctgcccgagc ccctgctcgc ctcctccggc cactgctagc gcggcccccg   1500</entry></row><row><entry> </entry></row><row><entry>cgcgcgtccc cctgccggcc ggggctgaga ctccggggag cgcccgcgcc cgcgccctcg   1560</entry></row><row><entry> </entry></row><row><entry>cccccgcccc cggcggcgcc ggcaaaactt tggcactggg gcacttggca gcgcggggag   1620</entry></row><row><entry> </entry></row><row><entry>cccgtcggta attttaatat tttattatat atatatatct atatttttgt ccaaaccaac   1680</entry></row><row><entry> </entry></row><row><entry>cgcacatgca gatggggctc ccgcccgtgg tgttatttaa agaagaaacg tctatgtgta   1740</entry></row><row><entry> </entry></row><row><entry>cagatgaatg ataaactctc tgcttctccc tctgcccctc tccaggcgcc ggcgggcggg   1800</entry></row><row><entry> </entry></row><row><entry>ccggtttcga agttgatgca atcggtttaa acatggctga acgcgtgtgt acacgggact   1860</entry></row><row><entry> </entry></row><row><entry>gacgcaaccc acgtgtaact gtcagccggg ccctgagtaa tcgcttaaag atgttcctac   1920</entry></row><row><entry> </entry></row><row><entry>gggcttgttg ctgttgatgt tttgttttgt tttgtttttt ggtctttttt tgtattataa   1980</entry></row><row><entry> </entry></row><row><entry>aaaataatct atttctatga gaaaagaggc gtctgtatat tttgggaatc ttttccgttt   2040</entry></row><row><entry> </entry></row><row><entry>caagcattaa gaacactttt aataaacttt tttttgagaa tggttacaaa gccttttggg   2100</entry></row><row><entry> </entry></row><row><entry>ggcagtaaaa aaa                                                      2113</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 4</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 4</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 5</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 5</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 6</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 6</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 7</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 7</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 8</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 8</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 9</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 9</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 10</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 10</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 11</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 2113</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: CEBP/B mRNA Sequence</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 11</entry></row><row><entry> </entry></row><row><entry>tcccaatccc ggggcggccg ggcgggggtg ggcagggggc gtgaggccgc ccctgcgtcc     60</entry></row><row><entry> </entry></row><row><entry>cgggggcccc ccgaaaacgc gctccgggtg cccggtccct ccgctgcgcc ctgccgccgt    120</entry></row><row><entry> </entry></row><row><entry>cctcccgggg gtctcgggcg gccgcggccg tgtccttcgc gtcccggcgg cgcggcggga    180</entry></row><row><entry> </entry></row><row><entry>ggggccggcg tgacgcagcg gttgctacgg gccgccctta taaataaccg ggctcaggag    240</entry></row><row><entry> </entry></row><row><entry>aaactttagc gagtcagagc cgcgcacggg actgggaagg ggacccaccc gagggtccag    300</entry></row><row><entry> </entry></row><row><entry>ccaccagccc cctcactaat agcggccacc ccggcagcgg cggcagcagc agcagcgacg    360</entry></row><row><entry> </entry></row><row><entry>cagcggcgac agctcagagc agggaggccg cgccacctgc gggccggccg gagcgggcag    420</entry></row><row><entry> </entry></row><row><entry>ccccaggccc cctccccggg cacccgcgtt catgcaacgc ctggtggcct gggacccagc    480</entry></row><row><entry> </entry></row><row><entry>atgtctcccc ctgccgccgc cgccgcctgc ctttaaatcc atggaagtgg ccaacttcta    540</entry></row><row><entry> </entry></row><row><entry>ctacgaggcg gactgcttgg ctgctgcgta cggcggcaag gcggcccccg cggcgccccc    600</entry></row><row><entry> </entry></row><row><entry>cgcggccaga cccgggccgc gcccccccgc cggcgagctg ggcagcatcg gcgaccacga    660</entry></row><row><entry> </entry></row><row><entry>gcgcgccatc gacttcagcc cgtacctgga gccgctgggc gcgccgcagg ccccggcgcc    720</entry></row><row><entry> </entry></row><row><entry>cgccacggcc acggacacct tcgaggcggc tccgcccgcg cccgcccccg cgcccgcctc    780</entry></row><row><entry> </entry></row><row><entry>ctccgggcag caccacgact tcctctccga cctcttctcc gacgactacg ggggcaagaa    840</entry></row><row><entry> </entry></row><row><entry>ctgcaagaag ccggccgagt acggctacgt gagcctgggg cgcctggggg ccgccaaggg    900</entry></row><row><entry> </entry></row><row><entry>cgcgctgcac cccggctgct tcgcgcccct gcacccaccg cccccgccgc cgccgccgcc    960</entry></row><row><entry> </entry></row><row><entry>cgccgagctc aaggcggagc cgggcttcga gcccgcggac tgcaagcgga aggaggaggc   1020</entry></row><row><entry> </entry></row><row><entry>cggggcgccg ggcggcggcg caggcatggc ggcgggcttc ccgtacgcgc tgcgcgctta   1080</entry></row><row><entry> </entry></row><row><entry>cctcggctac caggcggtgc cgagcggcag cagcgggagc ctctccacgt cctcctcgtc   1140</entry></row><row><entry> </entry></row><row><entry>cagcccgccc ggcacgccga gccccgctga cgccaaggcg cccccgaccg cctgctacgc   1200</entry></row><row><entry> </entry></row><row><entry>gggggccgcg ccggcgccct cgcaggtcaa gagcaaggcc aagaagaccg tggacaagca   1260</entry></row><row><entry> </entry></row><row><entry>cagcgacgag tacaagatcc ggcgcgagcg caacaacatc gccgtgcgca agagccgcga   1320</entry></row><row><entry> </entry></row><row><entry>caaggccaag atgcgcaacc tggagacgca gcacaaggtc ctggagctca cggccgagaa   1380</entry></row><row><entry> </entry></row><row><entry>cgagcggctg cagaagaagg tggagcagct gtcgcgcgag ctcagcaccc tgcggaactt   1440</entry></row><row><entry> </entry></row><row><entry>gttcaagcag ctgcccgagc ccctgctcgc ctcctccggc cactgctagc gcggcccccg   1500</entry></row><row><entry> </entry></row><row><entry>cgcgcgtccc cctgccggcc ggggctgaga ctccggggag cgcccgcgcc cgcgccctcg   1560</entry></row><row><entry> </entry></row><row><entry>cccccgcccc cggcggcgcc ggcaaaactt tggcactggg gcacttggca gcgcggggag   1620</entry></row><row><entry> </entry></row><row><entry>cccgtcggta attttaatat tttattatat atatatatct atatttttgt ccaaaccaac   1680</entry></row><row><entry> </entry></row><row><entry>cgcacatgca gatggggctc ccgcccgtgg tgttatttaa agaagaaacg tctatgtgta   1740</entry></row><row><entry> </entry></row><row><entry>cagatgaatg ataaactctc tgcttctccc tctgcccctc tccaggcgcc ggcgggcggg   1800</entry></row><row><entry> </entry></row><row><entry>ccggtttcga agttgatgca atcggtttaa acatggctga acgcgtgtgt acacgggact   1860</entry></row><row><entry> </entry></row><row><entry>gacgcaaccc acgtgtaact gtcagccggg ccctgagtaa tcgcttaaag atgttcctac   1920</entry></row><row><entry> </entry></row><row><entry>gggcttgttg ctgttgatgt tttgttttgt tttgtttttt ggtctttttt tgtattataa   1980</entry></row><row><entry> </entry></row><row><entry>aaaataatct atttctatga gaaaagaggc gtctgtatat tttgggaatc ttttccgttt   2040</entry></row><row><entry> </entry></row><row><entry>caagcattaa gaacactttt aataaacttt tttttgagaa tggttacaaa gccttttggg   2100</entry></row><row><entry> </entry></row><row><entry>ggcagtaaaa aaa                                                      2113</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 12</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 345</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: CEBPn Amino Acid</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 12</entry></row><row><entry> </entry></row><row><entry>Met Gln Arg Leu Val Ala Trp Asp Pro Ala Cys Leu Pro Leu Pro Pro</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Pro Pro Ala Phe Lys Ser Met Glu Val Ala Asn Phe Tyr Tyr Glu</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Ala Asp Cys Leu Ala Ala Ala Tyr Gly Gly Lys Ala Ala Pro Ala Ala</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Pro Pro Ala Ala Arg Pro Gly Pro Arg Pro Pro Ala Gly Glu Leu Gly</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ser Ile Gly Asp His Glu Arg Ala Ile Asp Phe Ser Pro Tyr Leu Glu</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Pro Leu Gly Ala Pro Gln Ala Pro Ala Pro Ala Thr Ala Thr Asp Thr</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Phe Glu Ala Ala Pro Pro Ala Pro Ala Pro Ala Pro Ala Ser Ser Gly</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Gln His His Asp Phe Leu Ser Asp Leu Phe Ser Asp Asp Tyr Gly Gly</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Lys Asn Cys Lys Lys Pro Ala Glu Tyr Gly Tyr Val Ser Leu Gly Arg</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Leu Gly Ala Ala Lys Gly Ala Leu His Pro Gly Cys Phe Ala Pro Leu</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>His Pro Pro Pro Pro Pro Pro Pro Pro Pro Ala Glu Leu Lys Ala Glu</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Pro Gly Phe Glu Pro Ala Asp Cys Lys Arg Lys Glu Glu Ala Gly Ala</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Pro Gly Gly Gly Ala Gly Met Ala Ala Gly Phe Pro Tyr Ala Leu Arg</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Ala Tyr Leu Gly Tyr Gln Ala Val Pro Ser Gly Ser Ser Gly Ser Leu</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Ser Thr Ser Ser Ser Ser Ser Pro Pro Gly Thr Pro Ser Pro Ala Asp</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Ala Lys Ala Pro Pro Thr Ala Cys Tyr Ala Gly Ala Ala Pro Ala Pro</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Ser Gln Val Lys Ser Lys Ala Lys Lys Thr Val Asp Lys His Ser Asp</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Glu Tyr Lys Ile Arg Arg Glu Arg Asn Asn Ile Ala Val Arg Lys Ser</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Arg Asp Lys Ala Lys Met Arg Asn Leu Glu Thr Gln His Lys Val Leu</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Glu Leu Thr Ala Glu Asn Glu Arg Leu Gln Lys Lys Val Glu Gln Leu</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Ser Arg Glu Leu Ser Thr Leu Arg Asn Leu Phe Lys Gln Leu Pro Glu</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Pro Leu Leu Ala Ser Ser Gly His Cys</entry></row><row><entry>            340                 345</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 13</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 2113</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: human CEBP/B gene</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 13</entry></row><row><entry> </entry></row><row><entry>tcccaatccc ggggcggccg ggcgggggtg ggcagggggc gtgaggccgc ccctgcgtcc     60</entry></row><row><entry> </entry></row><row><entry>cgggggcccc ccgaaaacgc gctccgggtg cccggtccct ccgctgcgcc ctgccgccgt    120</entry></row><row><entry> </entry></row><row><entry>cctcccgggg gtctcgggcg gccgcggccg tgtccttcgc gtcccggcgg cgcggcggga    180</entry></row><row><entry> </entry></row><row><entry>ggggccggcg tgacgcagcg gttgctacgg gccgccctta taaataaccg ggctcaggag    240</entry></row><row><entry> </entry></row><row><entry>aaactttagc gagtcagagc cgcgcacggg actgggaagg ggacccaccc gagggtccag    300</entry></row><row><entry> </entry></row><row><entry>ccaccagccc cctcactaat agcggccacc ccggcagcgg cggcagcagc agcagcgacg    360</entry></row><row><entry> </entry></row><row><entry>cagcggcgac agctcagagc agggaggccg cgccacctgc gggccggccg gagcgggcag    420</entry></row><row><entry> </entry></row><row><entry>ccccaggccc cctccccggg cacccgcgtt catgcaacgc ctggtggcct gggacccagc    480</entry></row><row><entry> </entry></row><row><entry>atgtctcccc ctgccgccgc cgccgcctgc ctttaaatcc atggaagtgg ccaacttcta    540</entry></row><row><entry> </entry></row><row><entry>ctacgaggcg gactgcttgg ctgctgcgta cggcggcaag gcggcccccg cggcgccccc    600</entry></row><row><entry> </entry></row><row><entry>cgcggccaga cccgggccgc gcccccccgc cggcgagctg ggcagcatcg gcgaccacga    660</entry></row><row><entry> </entry></row><row><entry>gcgcgccatc gacttcagcc cgtacctgga gccgctgggc gcgccgcagg ccccggcgcc    720</entry></row><row><entry> </entry></row><row><entry>cgccacggcc acggacacct tcgaggcggc tccgcccgcg cccgcccccg cgcccgcctc    780</entry></row><row><entry> </entry></row><row><entry>ctccgggcag caccacgact tcctctccga cctcttctcc gacgactacg ggggcaagaa    840</entry></row><row><entry> </entry></row><row><entry>ctgcaagaag ccggccgagt acggctacgt gagcctgggg cgcctggggg ccgccaaggg    900</entry></row><row><entry> </entry></row><row><entry>cgcgctgcac cccggctgct tcgcgcccct gcacccaccg cccccgccgc cgccgccgcc    960</entry></row><row><entry> </entry></row><row><entry>cgccgagctc aaggcggagc cgggcttcga gcccgcggac tgcaagcgga aggaggaggc   1020</entry></row><row><entry> </entry></row><row><entry>cggggcgccg ggcggcggcg caggcatggc ggcgggcttc ccgtacgcgc tgcgcgctta   1080</entry></row><row><entry> </entry></row><row><entry>cctcggctac caggcggtgc cgagcggcag cagcgggagc ctctccacgt cctcctcgtc   1140</entry></row><row><entry> </entry></row><row><entry>cagcccgccc ggcacgccga gccccgctga cgccaaggcg cccccgaccg cctgctacgc   1200</entry></row><row><entry> </entry></row><row><entry>gggggccgcg ccggcgccct cgcaggtcaa gagcaaggcc aagaagaccg tggacaagca   1260</entry></row><row><entry> </entry></row><row><entry>cagcgacgag tacaagatcc ggcgcgagcg caacaacatc gccgtgcgca agagccgcga   1320</entry></row><row><entry> </entry></row><row><entry>caaggccaag atgcgcaacc tggagacgca gcacaaggtc ctggagctca cggccgagaa   1380</entry></row><row><entry> </entry></row><row><entry>cgagcggctg cagaagaagg tggagcagct gtcgcgcgag ctcagcaccc tgcggaactt   1440</entry></row><row><entry> </entry></row><row><entry>gttcaagcag ctgcccgagc ccctgctcgc ctcctccggc cactgctagc gcggcccccg   1500</entry></row><row><entry> </entry></row><row><entry>cgcgcgtccc cctgccggcc ggggctgaga ctccggggag cgcccgcgcc cgcgccctcg   1560</entry></row><row><entry> </entry></row><row><entry>cccccgcccc cggcggcgcc ggcaaaactt tggcactggg gcacttggca gcgcggggag   1620</entry></row><row><entry> </entry></row><row><entry>cccgtcggta attttaatat tttattatat atatatatct atatttttgt ccaaaccaac   1680</entry></row><row><entry> </entry></row><row><entry>cgcacatgca gatggggctc ccgcccgtgg tgttatttaa agaagaaacg tctatgtgta   1740</entry></row><row><entry> </entry></row><row><entry>cagatgaatg ataaactctc tgcttctccc tctgcccctc tccaggcgcc ggcgggcggg   1800</entry></row><row><entry> </entry></row><row><entry>ccggtttcga agttgatgca atcggtttaa acatggctga acgcgtgtgt acacgggact   1860</entry></row><row><entry> </entry></row><row><entry>gacgcaaccc acgtgtaact gtcagccggg ccctgagtaa tcgcttaaag atgttcctac   1920</entry></row><row><entry> </entry></row><row><entry>gggcttgttg ctgttgatgt tttgttttgt tttgtttttt ggtctttttt tgtattataa   1980</entry></row><row><entry> </entry></row><row><entry>aaaataatct atttctatga gaaaagaggc gtctgtatat tttgggaatc ttttccgttt   2040</entry></row><row><entry> </entry></row><row><entry>caagcattaa gaacactttt aataaacttt tttttgagaa tggttacaaa gccttttggg   2100</entry></row><row><entry> </entry></row><row><entry>ggcagtaaaa aaa                                                      2113</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 14</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 322</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: CEBPb Iso 2</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 14</entry></row><row><entry> </entry></row><row><entry>Met Glu Val Ala Asn Phe Tyr Tyr Glu Ala Asp Cys Leu Ala Ala Ala</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Tyr Gly Gly Lys Ala Ala Pro Ala Ala Pro Pro Ala Ala Arg Pro Gly</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Pro Arg Pro Pro Ala Gly Glu Leu Gly Ser Ile Gly Asp His Glu Arg</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ala Ile Asp Phe Ser Pro Tyr Leu Glu Pro Leu Gly Ala Pro Gln Ala</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Pro Ala Pro Ala Thr Ala Thr Asp Thr Phe Glu Ala Ala Pro Pro Ala</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Pro Ala Pro Ala Pro Ala Ser Ser Gly Gln His His Asp Phe Leu Ser</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Asp Leu Phe Ser Asp Asp Tyr Gly Gly Lys Asn Cys Lys Lys Pro Ala</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Glu Tyr Gly Tyr Val Ser Leu Gly Arg Leu Gly Ala Ala Lys Gly Ala</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Leu His Pro Gly Cys Phe Ala Pro Leu His Pro Pro Pro Pro Pro Pro</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Pro Pro Pro Ala Glu Leu Lys Ala Glu Pro Gly Phe Glu Pro Ala Asp</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Cys Lys Arg Lys Glu Glu Ala Gly Ala Pro Gly Gly Gly Ala Gly Met</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Ala Ala Gly Phe Pro Tyr Ala Leu Arg Ala Tyr Leu Gly Tyr Gln Ala</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Val Pro Ser Gly Ser Ser Gly Ser Leu Ser Thr Ser Ser Ser Ser Ser</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Pro Pro Gly Thr Pro Ser Pro Ala Asp Ala Lys Ala Pro Pro Thr Ala</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Cys Tyr Ala Gly Ala Ala Pro Ala Pro Ser Gln Val Lys Ser Lys Ala</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Lys Lys Thr Val Asp Lys His Ser Asp Glu Tyr Lys Ile Arg Arg Glu</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Arg Asn Asn Ile Ala Val Arg Lys Ser Arg Asp Lys Ala Lys Met Arg</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Asn Leu Glu Thr Gln His Lys Val Leu Glu Leu Thr Ala Glu Asn Glu</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Arg Leu Gln Lys Lys Val Glu Gln Leu Ser Arg Glu Leu Ser Thr Leu</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Arg Asn Leu Phe Lys Gln Leu Pro Glu Pro Leu Leu Ala Ser Ser Gly</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>His Cys</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 15</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 147</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: CEBPb Iso 3</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 15</entry></row><row><entry> </entry></row><row><entry>Met Ala Ala Gly Phe Pro Tyr Ala Leu Arg Ala Tyr Leu Gly Tyr Gln</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ala Val Pro Ser Gly Ser Ser Gly Ser Leu Ser Thr Ser Ser Ser Ser</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Ser Pro Pro Gly Thr Pro Ser Pro Ala Asp Ala Lys Ala Pro Pro Thr</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ala Cys Tyr Ala Gly Ala Ala Pro Ala Pro Ser Gln Val Lys Ser Lys</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ala Lys Lys Thr Val Asp Lys His Ser Asp Glu Tyr Lys Ile Arg Arg</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Glu Arg Asn Asn Ile Ala Val Arg Lys Ser Arg Asp Lys Ala Lys Met</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Arg Asn Leu Glu Thr Gln His Lys Val Leu Glu Leu Thr Ala Glu Asn</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Glu Arg Leu Gln Lys Lys Val Glu Gln Leu Ser Arg Glu Leu Ser Thr</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Leu Arg Asn Leu Phe Lys Gln Leu Pro Glu Pro Leu Leu Ala Ser Ser</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Gly His Cys</entry></row><row><entry>145</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 16</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 16</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 17</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 17</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 18</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 18</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 19</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 19</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 20</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 20</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 21</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 21</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 22</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 22</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 23</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 23</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 24</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 24</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 25</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 25</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 26</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 26</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 27</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 27</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 28</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 28</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 29</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 29</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 30</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 30</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 31</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 31</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 32</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 32</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 33</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 33</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 34</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 34</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 35</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 35</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 36</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 36</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 37</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 37</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 38</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 38</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 39</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 39</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 40</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 40</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 41</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 41</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 42</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 42</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 43</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 43</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 44</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 44</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 45</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 45</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 46</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 46</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 47</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 47</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 48</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 48</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 49</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 49</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 50</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 50</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 51</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 51</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 52</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 52</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 53</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 53</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 54</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 54</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 55</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 55</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 56</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 56</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 57</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 57</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 58</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 58</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 59</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 59</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 60</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 60</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 61</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 61</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 62</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 62</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 63</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 63</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 64</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 64</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 65</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 65</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 66</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 66</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 67</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 67</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 68</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 68</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 69</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 69</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 70</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 70</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 71</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 71</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 72</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 72</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 73</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 73</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 74</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 74</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 75</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 75</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 76</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 76</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 77</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 77</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 78</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 78</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 79</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 79</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 80</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 80</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 81</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 81</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 82</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 82</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 83</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 83</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 84</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 84</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 85</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 85</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 86</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 86</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 87</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 87</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 88</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 88</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 89</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 89</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 90</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: ASO (CEBP)</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 90</entry></row><row><entry> </entry></row><row><entry>tggatttaaa ggcaggcggc                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 91</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 91</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 92</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 92</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 93</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 93</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 94</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 94</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 95</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 95</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 96</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 96</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 97</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 97</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 98</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 98</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 99</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 99</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 100</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 100</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 101</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 101</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 102</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 102</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 103</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 103</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 104</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 104</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 105</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 105</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 106</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 106</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 107</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 107</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 108</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 108</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 109</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 109</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 110</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 110</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 111</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 111</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 112</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 112</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 113</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 113</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 114</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 114</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 115</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 115</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 116</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 116</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 117</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 117</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 118</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 118</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 119</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 119</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 120</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 120</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 121</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 121</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 122</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 122</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 123</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 123</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 124</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 124</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 125</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 125</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 126</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 126</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 127</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 127</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 128</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 128</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 129</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 129</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 130</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 130</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 131</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 131</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 132</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 132</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 133</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 133</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 134</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 134</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 135</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 135</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 136</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 136</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 137</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 137</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 138</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 138</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 139</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 139</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 140</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 140</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 141</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 141</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 142</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 142</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 143</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 143</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 144</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 144</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 145</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 145</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 146</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 146</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 147</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 147</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 148</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 148</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 149</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 149</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 150</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 150</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 151</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 151</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 152</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 152</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 153</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 153</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 154</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 154</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 155</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 155</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 156</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 156</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 157</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 157</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 158</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 158</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 159</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 159</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 160</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 160</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 161</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 119</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: brain derived neurotrophic factor</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 161</entry></row><row><entry> </entry></row><row><entry>His Ser Asp Pro Ala Arg Arg Gly Glu Leu Ser Val Cys Asp Ser Ile</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ser Glu Trp Val Thr Ala Ala Asp Lys Lys Thr Ala Val Asp Met Ser</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Gly Gly Thr Val Thr Val Leu Glu Lys Val Pro Val Ser Lys Gly Gln</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Leu Lys Gln Tyr Phe Tyr Glu Thr Lys Cys Asn Pro Met Gly Tyr Thr</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Lys Glu Gly Cys Arg Gly Ile Asp Lys Arg His Trp Asn Ser Gln Cys</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Arg Thr Thr Gln Ser Tyr Val Arg Ala Leu Thr Met Asp Ser Lys Lys</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Arg Ile Gly Trp Arg Phe Ile Arg Ile Asp Thr Ser Cys Val Cys Thr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Leu Thr Ile Lys Arg Gly Arg</entry></row><row><entry>        115</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 162</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 120</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: nerve growth factor</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 162</entry></row><row><entry> </entry></row><row><entry>Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Ser Arg Lys Ala Val Arg Arg Ala</entry></row><row><entry>        115                 120</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 163</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 119</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: neurotrophin</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 163</entry></row><row><entry> </entry></row><row><entry>Tyr Ala Glu His Lys Ser His Arg Gly Glu Tyr Ser Val Cys Asp Ser</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Glu Ser Leu Trp Val Thr Asp Lys Ser Ser Ala Ile Asp Ile Arg Gly</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>His Gln Val Thr Val Leu Gly Glu Ile Lys Thr Gly Asn Ser Pro Val</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Lys Gln Tyr Phe Tyr Glu Thr Arg Cys Lys Glu Ala Arg Pro Val Lys</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Asn Gly Cys Arg Gly Ile Asp Asp Lys His Trp Asn Ser Gln Cys Lys</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Thr Ser Gln Thr Tyr Val Arg Ala Leu Thr Ser Glu Asn Asn Lys Leu</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ser Cys Val Cys Ala Leu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Ser Arg Lys Ile Gly Arg Thr</entry></row><row><entry>        115</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 164</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 130</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: neurotrophin</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 164</entry></row><row><entry> </entry></row><row><entry>Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala Val</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala Val Asp</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro Ala Ala Gly</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg Cys Lys Ala Asp</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly Gly Gly Cys Arg Gly</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Val Asp Arg Arg His Trp Val Ser Glu Cys Lys Ala Lys Gln Ser Tyr</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Val Arg Ala Leu Thr Ala Asp Ala Gln Gly Arg Val Gly Trp Arg Trp</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Ile Arg Ile Asp Thr Ala Cys Val Cys Thr Leu Leu Ser Arg Thr Gly</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Arg Ala</entry></row><row><entry>    130</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 165</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 165</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 166</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 166</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 167</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 167</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 168</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 168</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 169</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 169</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 170</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 170</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 171</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 171</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 172</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 172</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 173</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 173</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 174</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 174</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 175</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 175</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 176</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 176</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 177</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 177</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 178</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 178</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 179</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 179</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 180</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 180</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 181</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 181</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 182</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 182</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 183</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 183</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 184</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 184</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 185</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 185</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 186</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 186</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 187</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 187</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 188</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 188</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 189</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 189</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 190</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 190</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 191</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 191</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 192</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 192</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 193</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 193</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 194</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 194</entry></row><row><entry> </entry></row><row><entry>agtccgcctc gtagt                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 195</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 195</entry></row><row><entry> </entry></row><row><entry>ttgccgccgt acgca                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 196</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 196</entry></row><row><entry> </entry></row><row><entry>cgccttgccg ccgta                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 197</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 197</entry></row><row><entry> </entry></row><row><entry>gctcgtggtc gccga                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 198</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 198</entry></row><row><entry> </entry></row><row><entry>cgtagtcgtc ggaga                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 199</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 199</entry></row><row><entry> </entry></row><row><entry>ccgtagtcgt cggag                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 200</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 200</entry></row><row><entry> </entry></row><row><entry>cccgtagtcg tcgga                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 201</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 201</entry></row><row><entry> </entry></row><row><entry>ccccgtagtc gtcgg                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 202</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 202</entry></row><row><entry> </entry></row><row><entry>cccccgtagt cgtcg                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 203</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 203</entry></row><row><entry> </entry></row><row><entry>gccgtactcg gccgg                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 204</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 204</entry></row><row><entry> </entry></row><row><entry>tagccgtact cggcc                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 205</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 205</entry></row><row><entry> </entry></row><row><entry>acgtagccgt actcg                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 206</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 206</entry></row><row><entry> </entry></row><row><entry>tcacgtagcc gtact                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 207</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 207</entry></row><row><entry> </entry></row><row><entry>agtccgcggg ctcga                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 208</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 208</entry></row><row><entry> </entry></row><row><entry>gcgcgtacgg gaagc                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 209</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 209</entry></row><row><entry> </entry></row><row><entry>agcgcgcagc gcgta                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 210</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 210</entry></row><row><entry> </entry></row><row><entry>aagcgcgcag cgcgt                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 211</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 211</entry></row><row><entry> </entry></row><row><entry>taagcgcgca gcgcg                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 212</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 212</entry></row><row><entry> </entry></row><row><entry>cgaggtaagc gcgca                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 213</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 213</entry></row><row><entry> </entry></row><row><entry>cgccggatct tgtac                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 214</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 214</entry></row><row><entry> </entry></row><row><entry>tcgcgccgga tcttg                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 215</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 215</entry></row><row><entry> </entry></row><row><entry>ctcgcgccgg atctt                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 216</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 216</entry></row><row><entry> </entry></row><row><entry>tcgcgcgaca gctgc                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 217</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 217</entry></row><row><entry> </entry></row><row><entry>gctcgcgcga cagct                                                      15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 218</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 218</entry></row><row><entry> </entry></row><row><entry>agtccgcctc gtagta                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 219</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 219</entry></row><row><entry> </entry></row><row><entry>cagtccgcct cgtagt                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 220</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 220</entry></row><row><entry> </entry></row><row><entry>tgccgccgta cgcagc                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 221</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 221</entry></row><row><entry> </entry></row><row><entry>ttgccgccgt acgcag                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 222</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 222</entry></row><row><entry> </entry></row><row><entry>cttgccgccg tacgca                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 223</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 223</entry></row><row><entry> </entry></row><row><entry>cgccttgccg ccgtac                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 224</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 224</entry></row><row><entry> </entry></row><row><entry>cgtggtcgcc gatgct                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 225</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 225</entry></row><row><entry> </entry></row><row><entry>tcgtggtcgc cgatgc                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 226</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 226</entry></row><row><entry> </entry></row><row><entry>cgctcgtggt cgccga                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 227</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 227</entry></row><row><entry> </entry></row><row><entry>cccccgtagt cgtcgg                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 228</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 228</entry></row><row><entry> </entry></row><row><entry>acgtagccgt actcgg                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 229</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 229</entry></row><row><entry> </entry></row><row><entry>ggctcacgta gccgta                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 230</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 230</entry></row><row><entry> </entry></row><row><entry>agtccgcggg ctcgaa                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 231</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 231</entry></row><row><entry> </entry></row><row><entry>cagtccgcgg gctcga                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 232</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 232</entry></row><row><entry> </entry></row><row><entry>ttccgcttgc agtccg                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 233</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 233</entry></row><row><entry> </entry></row><row><entry>acgggaagcc cgccgc                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 234</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 234</entry></row><row><entry> </entry></row><row><entry>tacgggaagc ccgccg                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 235</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 235</entry></row><row><entry> </entry></row><row><entry>aagcgcgcag cgcgta                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 236</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 236</entry></row><row><entry> </entry></row><row><entry>taagcgcgca gcgcgt                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 237</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 237</entry></row><row><entry> </entry></row><row><entry>gtaagcgcgc agcgcg                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 238</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 238</entry></row><row><entry> </entry></row><row><entry>accgcctggt agccga                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 239</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 239</entry></row><row><entry> </entry></row><row><entry>tcggcaccgc ctggta                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 240</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 240</entry></row><row><entry> </entry></row><row><entry>cgtcgctgtg cttgtc                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 241</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 241</entry></row><row><entry> </entry></row><row><entry>cgccggatct tgtact                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 242</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 242</entry></row><row><entry> </entry></row><row><entry>tcgcgccgga tcttgt                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 243</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 243</entry></row><row><entry> </entry></row><row><entry>gctcgcgccg gatctt                                                     16</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 244</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 244</entry></row><row><entry> </entry></row><row><entry>cagtccgcct cgtagta                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 245</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 245</entry></row><row><entry> </entry></row><row><entry>cttgccgccg tacgcag                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 246</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 246</entry></row><row><entry> </entry></row><row><entry>ccttgccgcc gtacgca                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 247</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 247</entry></row><row><entry> </entry></row><row><entry>cgccttgccg ccgtacg                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 248</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 248</entry></row><row><entry> </entry></row><row><entry>cgctcgtggt cgccgat                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 249</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 249</entry></row><row><entry> </entry></row><row><entry>gcgctcgtgg tcgccga                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 250</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 250</entry></row><row><entry> </entry></row><row><entry>ccgtagtcgt cggagaa                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 251</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 251</entry></row><row><entry> </entry></row><row><entry>cccccgtagt cgtcgga                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 252</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 252</entry></row><row><entry> </entry></row><row><entry>tgcccccgta gtcgtcg                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 253</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 253</entry></row><row><entry> </entry></row><row><entry>acgtagccgt actcggc                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 254</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 254</entry></row><row><entry> </entry></row><row><entry>cacgtagccg tactcgg                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 255</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 255</entry></row><row><entry> </entry></row><row><entry>ggctcacgta gccgtac                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 256</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 256</entry></row><row><entry> </entry></row><row><entry>gtacgggaag cccgccg                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 257</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 257</entry></row><row><entry> </entry></row><row><entry>cgcgtacggg aagcccg                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 258</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 258</entry></row><row><entry> </entry></row><row><entry>agcgcgcagc gcgtacg                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 259</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 259</entry></row><row><entry> </entry></row><row><entry>aagcgcgcag cgcgtac                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 260</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 260</entry></row><row><entry> </entry></row><row><entry>taagcgcgca gcgcgta                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 261</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 261</entry></row><row><entry> </entry></row><row><entry>gtaagcgcgc agcgcgt                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 262</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 262</entry></row><row><entry> </entry></row><row><entry>cggatcttgt actcgtc                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 263</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 263</entry></row><row><entry> </entry></row><row><entry>cgcgccggat cttgtac                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 264</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 264</entry></row><row><entry> </entry></row><row><entry>tcgcgccgga tcttgta                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 265</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 265</entry></row><row><entry> </entry></row><row><entry>ctcgcgccgg atcttgt                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 266</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 266</entry></row><row><entry> </entry></row><row><entry>cgctcgcgcc ggatctt                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 267</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 267</entry></row><row><entry> </entry></row><row><entry>ttgcgctcgc gccggat                                                    17</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 268</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 268</entry></row><row><entry> </entry></row><row><entry>cgccttgccg ccgtacgcag                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 269</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 269</entry></row><row><entry> </entry></row><row><entry>ccgccttgcc gccgtacgca                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 270</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 270</entry></row><row><entry> </entry></row><row><entry>ttgcccccgt agtcgtcgga                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 271</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 271</entry></row><row><entry> </entry></row><row><entry>taagcgcgca gcgcgtacgg                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 272</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 272</entry></row><row><entry> </entry></row><row><entry>gtaagcgcgc agcgcgtacg                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 273</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 273</entry></row><row><entry> </entry></row><row><entry>aggtaagcgc gcagcgcgta                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 274</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 274</entry></row><row><entry> </entry></row><row><entry>cgcgccggat cttgtactcg                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 275</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 275</entry></row><row><entry> </entry></row><row><entry>gcgctcgcgc cggatcttgt                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 276</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 276</entry></row><row><entry> </entry></row><row><entry>gcgctcgtgg tcgccgatgc                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 277</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 277</entry></row><row><entry> </entry></row><row><entry>tagccgtact cggccggctt                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 278</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 278</entry></row><row><entry> </entry></row><row><entry>gtagccgtac tcggccggct                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 279</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 279</entry></row><row><entry> </entry></row><row><entry>cgtagccgta ctcggccggc                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 280</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 280</entry></row><row><entry> </entry></row><row><entry>ggtaagcgcg cagcgcgtac                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 281</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 281</entry></row><row><entry> </entry></row><row><entry>tagccgaggt aagcgcgcag                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 282</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 282</entry></row><row><entry> </entry></row><row><entry>gtagccgagg taagcgcgca                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 283</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 283</entry></row><row><entry> </entry></row><row><entry>cggatcttgt actcgtcgct                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 284</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 284</entry></row><row><entry> </entry></row><row><entry>ttgcgctcgc gccggatctt                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 285</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 285</entry></row><row><entry> </entry></row><row><entry>gttgcgctcg cgccggatct                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 286</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 286</entry></row><row><entry> </entry></row><row><entry>cgctcgtggt cgccgatgct                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 287</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 287</entry></row><row><entry> </entry></row><row><entry>gcgcgctcgt ggtcgccgat                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 288</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 288</entry></row><row><entry> </entry></row><row><entry>acgtagccgt actcggccgg                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 289</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 289</entry></row><row><entry> </entry></row><row><entry>gcgccggatc ttgtactcgt                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 290</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 290</entry></row><row><entry> </entry></row><row><entry>tcgcgccgga tcttgtactc                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 291</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 291</entry></row><row><entry> </entry></row><row><entry>gctcgcgccg gatcttgtac                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 292</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 292</entry></row><row><entry> </entry></row><row><entry>cgcgctcgtg gtcgccgatg                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 293</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 293</entry></row><row><entry> </entry></row><row><entry>aagcgcgcag cgcgtacggg                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 294</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 294</entry></row><row><entry> </entry></row><row><entry>ccggatcttg tactcgtcgc                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 295</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 295</entry></row><row><entry> </entry></row><row><entry>ctcgcgccgg atcttgtact                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 296</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Antisense Oligo</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 296</entry></row><row><entry> </entry></row><row><entry>cgctcgcgcc ggatcttgta                                                 20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 297</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 297</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 298</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 298</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 299</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 299</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 300</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 300</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 301</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 879</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: PrX - PTGFRN (1)</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 301</entry></row><row><entry> </entry></row><row><entry>Met Gly Arg Leu Ala Ser Arg Pro Leu Leu Leu Ala Leu Leu Ser Leu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ala Leu Cys Arg Gly Arg Val Val Arg Val Pro Thr Ala Thr Leu Val</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Arg Val Val Gly Thr Glu Leu Val Ile Pro Cys Asn Val Ser Asp Tyr</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Asp Gly Pro Ser Glu Gln Asn Phe Asp Trp Ser Phe Ser Ser Leu Gly</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ser Ser Phe Val Glu Leu Ala Ser Thr Trp Glu Val Gly Phe Pro Ala</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Gln Leu Tyr Gln Glu Arg Leu Gln Arg Gly Glu Ile Leu Leu Arg Arg</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Thr Ala Asn Asp Ala Val Glu Leu His Ile Lys Asn Val Gln Pro Ser</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Asp Gln Gly His Tyr Lys Cys Ser Thr Pro Ser Thr Asp Ala Thr Val</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Gln Gly Asn Tyr Glu Asp Thr Val Gln Val Lys Val Leu Ala Asp Ser</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Leu His Val Gly Pro Ser Ala Arg Pro Pro Pro Ser Leu Ser Leu Arg</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Glu Gly Glu Pro Phe Glu Leu Arg Cys Thr Ala Ala Ser Ala Ser Pro</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Leu His Thr His Leu Ala Leu Leu Trp Glu Val His Arg Gly Pro Ala</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Arg Arg Ser Val Leu Ala Leu Thr His Glu Gly Arg Phe His Pro Gly</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Leu Gly Tyr Glu Gln Arg Tyr His Ser Gly Asp Val Arg Leu Asp Thr</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Val Gly Ser Asp Ala Tyr Arg Leu Ser Val Ser Arg Ala Leu Ser Ala</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Asp Gln Gly Ser Tyr Arg Cys Ile Val Ser Glu Trp Ile Ala Glu Gln</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Gly Asn Trp Gln Glu Ile Gln Glu Lys Ala Val Glu Val Ala Thr Val</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Val Ile Gln Pro Ser Val Leu Arg Ala Ala Val Pro Lys Asn Val Ser</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Val Ala Glu Gly Lys Glu Leu Asp Leu Thr Cys Asn Ile Thr Thr Asp</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Arg Ala Asp Asp Val Arg Pro Glu Val Thr Trp Ser Phe Ser Arg Met</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Pro Asp Ser Thr Leu Pro Gly Ser Arg Val Leu Ala Arg Leu Asp Arg</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Asp Ser Leu Val His Ser Ser Pro His Val Ala Leu Ser His Val Asp</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Ala Arg Ser Tyr His Leu Leu Val Arg Asp Val Ser Lys Glu Asn Ser</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Gly Tyr Tyr Tyr Cys His Val Ser Leu Trp Ala Pro Gly His Asn Arg</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Ser Trp His Lys Val Ala Glu Ala Val Ser Ser Pro Ala Gly Val Gly</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Val Thr Trp Leu Glu Pro Asp Tyr Gln Val Tyr Leu Asn Ala Ser Lys</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Val Pro Gly Phe Ala Asp Asp Pro Thr Glu Leu Ala Cys Arg Val Val</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Asp Thr Lys Ser Gly Glu Ala Asn Val Arg Phe Thr Val Ser Trp Tyr</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Tyr Arg Met Asn Arg Arg Ser Asp Asn Val Val Thr Ser Glu Leu Leu</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Ala Val Met Asp Gly Asp Trp Thr Leu Lys Tyr Gly Glu Arg Ser Lys</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Gln Arg Ala Gln Asp Gly Asp Phe Ile Phe Ser Lys Glu His Thr Asp</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Thr Phe Asn Phe Arg Ile Gln Arg Thr Thr Glu Glu Asp Arg Gly Asn</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Tyr Tyr Cys Val Val Ser Ala Trp Thr Lys Gln Arg Asn Asn Ser Trp</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Val Lys Ser Lys Asp Val Phe Ser Lys Pro Val Asn Ile Phe Trp Ala</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Leu Glu Asp Ser Val Leu Val Val Lys Ala Arg Gln Pro Lys Pro Phe</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Phe Ala Ala Gly Asn Thr Phe Glu Met Thr Cys Lys Val Ser Ser Lys</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Asn Ile Lys Ser Pro Arg Tyr Ser Val Leu Ile Met Ala Glu Lys Pro</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Val Gly Asp Leu Ser Ser Pro Asn Glu Thr Lys Tyr Ile Ile Ser Leu</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Asp Gln Asp Ser Val Val Lys Leu Glu Asn Trp Thr Asp Ala Ser Arg</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Val Asp Gly Val Val Leu Glu Lys Val Gln Glu Asp Glu Phe Arg Tyr</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Arg Met Tyr Gln Thr Gln Val Ser Asp Ala Gly Leu Tyr Arg Cys Met</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Val Thr Ala Trp Ser Pro Val Arg Gly Ser Leu Trp Arg Glu Ala Ala</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Thr Ser Leu Ser Asn Pro Ile Glu Ile Asp Phe Gln Thr Ser Gly Pro</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Ile Phe Asn Ala Ser Val His Ser Asp Thr Pro Ser Val Ile Arg Gly</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry>Asp Leu Ile Lys Leu Phe Cys Ile Ile Thr Val Glu Gly Ala Ala Leu</entry></row><row><entry>705                 710                 715                 720</entry></row><row><entry> </entry></row><row><entry>Asp Pro Asp Asp Met Ala Phe Asp Val Ser Trp Phe Ala Val His Ser</entry></row><row><entry>                725                 730                 735</entry></row><row><entry> </entry></row><row><entry>Phe Gly Leu Asp Lys Ala Pro Val Leu Leu Ser Ser Leu Asp Arg Lys</entry></row><row><entry>            740                 745                 750</entry></row><row><entry> </entry></row><row><entry>Gly Ile Val Thr Thr Ser Arg Arg Asp Trp Lys Ser Asp Leu Ser Leu</entry></row><row><entry>        755                 760                 765</entry></row><row><entry> </entry></row><row><entry>Glu Arg Val Ser Val Leu Glu Phe Leu Leu Gln Val His Gly Ser Glu</entry></row><row><entry>    770                 775                 780</entry></row><row><entry> </entry></row><row><entry>Asp Gln Asp Phe Gly Asn Tyr Tyr Cys Ser Val Thr Pro Trp Val Lys</entry></row><row><entry>785                 790                 795                 800</entry></row><row><entry> </entry></row><row><entry>Ser Pro Thr Gly Ser Trp Gln Lys Glu Ala Glu Ile His Ser Lys Pro</entry></row><row><entry>                805                 810                 815</entry></row><row><entry> </entry></row><row><entry>Val Phe Ile Thr Val Lys Met Asp Val Leu Asn Ala Phe Lys Tyr Pro</entry></row><row><entry>            820                 825                 830</entry></row><row><entry> </entry></row><row><entry>Leu Leu Ile Gly Val Gly Leu Ser Thr Val Ile Gly Leu Leu Ser Cys</entry></row><row><entry>        835                 840                 845</entry></row><row><entry> </entry></row><row><entry>Leu Ile Gly Tyr Cys Ser Ser His Trp Cys Cys Lys Lys Glu Val Gln</entry></row><row><entry>    850                 855                 860</entry></row><row><entry> </entry></row><row><entry>Glu Thr Arg Arg Glu Arg Arg Arg Leu Met Ser Met Glu Met Asp</entry></row><row><entry>865                 870                 875</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 302</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 192</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: PrX - PTGFRN fragment (33)</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 302</entry></row><row><entry> </entry></row><row><entry>Gly Pro Ile Phe Asn Ala Ser Val His Ser Asp Thr Pro Ser Val Ile</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Arg Gly Asp Leu Ile Lys Leu Phe Cys Ile Ile Thr Val Glu Gly Ala</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Ala Leu Asp Pro Asp Asp Met Ala Phe Asp Val Ser Trp Phe Ala Val</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>His Ser Phe Gly Leu Asp Lys Ala Pro Val Leu Leu Ser Ser Leu Asp</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Arg Lys Gly Ile Val Thr Thr Ser Arg Arg Asp Trp Lys Ser Asp Leu</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Ser Leu Glu Arg Val Ser Val Leu Glu Phe Leu Leu Gln Val His Gly</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Ser Glu Asp Gln Asp Phe Gly Asn Tyr Tyr Cys Ser Val Thr Pro Trp</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Val Lys Ser Pro Thr Gly Ser Trp Gln Lys Glu Ala Glu Ile His Ser</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Lys Pro Val Phe Ile Thr Val Lys Met Asp Val Leu Asn Ala Phe Lys</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Tyr Pro Leu Leu Ile Gly Val Gly Leu Ser Thr Val Ile Gly Leu Leu</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Ser Cys Leu Ile Gly Tyr Cys Ser Ser His Trp Cys Cys Lys Lys Glu</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Val Gln Glu Thr Arg Arg Glu Arg Arg Arg Leu Met Ser Met Glu Met</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 303</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 385</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: The BSG protein (9)</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 303</entry></row><row><entry> </entry></row><row><entry>Met Ala Ala Ala Leu Phe Val Leu Leu Gly Phe Ala Leu Leu Gly Thr</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>His Gly Ala Ser Gly Ala Ala Gly Phe Val Gln Ala Pro Leu Ser Gln</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Gln Arg Trp Val Gly Gly Ser Val Glu Leu His Cys Glu Ala Val Gly</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ser Pro Val Pro Glu Ile Gln Trp Trp Phe Glu Gly Gln Gly Pro Asn</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Asp Thr Cys Ser Gln Leu Trp Asp Gly Ala Arg Leu Asp Arg Val His</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Ile His Ala Thr Tyr His Gln His Ala Ala Ser Thr Ile Ser Ile Asp</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Thr Leu Val Glu Glu Asp Thr Gly Thr Tyr Glu Cys Arg Ala Ser Asn</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Asp Pro Asp Arg Asn His Leu Thr Arg Ala Pro Arg Val Lys Trp Val</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Arg Ala Gln Ala Val Val Leu Val Leu Glu Pro Gly Thr Val Phe Thr</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Thr Val Glu Asp Leu Gly Ser Lys Ile Leu Leu Thr Cys Ser Leu Asn</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Asp Ser Ala Thr Glu Val Thr Gly His Arg Trp Leu Lys Gly Gly Val</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Val Leu Lys Glu Asp Ala Leu Pro Gly Gln Lys Thr Glu Phe Lys Val</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Asp Ser Asp Asp Gln Trp Gly Glu Tyr Ser Cys Val Phe Leu Pro Glu</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Pro Met Gly Thr Ala Asn Ile Gln Leu His Gly Pro Pro Arg Val Lys</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Ala Val Lys Ser Ser Glu His Ile Asn Glu Gly Glu Thr Ala Met Leu</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Val Cys Lys Ser Glu Ser Val Pro Pro Val Thr Asp Trp Ala Trp Tyr</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Lys Ile Thr Asp Ser Glu Asp Lys Ala Leu Met Asn Gly Ser Glu Ser</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Arg Phe Phe Val Ser Ser Ser Gln Gly Arg Ser Glu Leu His Ile Glu</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Asn Leu Asn Met Glu Ala Asp Pro Gly Gln Tyr Arg Cys Asn Gly Thr</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Ser Ser Lys Gly Ser Asp Gln Ala Ile Ile Thr Leu Arg Val Arg Ser</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>His Leu Ala Ala Leu Trp Pro Phe Leu Gly Ile Val Ala Glu Val Leu</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Val Leu Val Thr Ile Ile Phe Ile Tyr Glu Lys Arg Arg Lys Pro Glu</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Asp Val Leu Asp Asp Asp Asp Ala Gly Ser Ala Pro Leu Lys Ser Ser</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Gly Gln His Gln Asn Asp Lys Gly Lys Asn Val Arg Gln Arg Asn Ser</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Ser</entry></row><row><entry>385</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 304</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 613</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: The IGSF8 protein (14)</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 304</entry></row><row><entry> </entry></row><row><entry>Met Gly Ala Leu Arg Pro Thr Leu Leu Pro Pro Ser Leu Pro Leu Leu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Leu Leu Met Leu Gly Met Gly Cys Trp Ala Arg Glu Val Leu Val</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Pro Glu Gly Pro Leu Tyr Arg Val Ala Gly Thr Ala Val Ser Ile Ser</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Cys Asn Val Thr Gly Tyr Glu Gly Pro Ala Gln Gln Asn Phe Glu Trp</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Phe Leu Tyr Arg Pro Glu Ala Pro Asp Thr Ala Leu Gly Ile Val Ser</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Thr Lys Asp Thr Gln Phe Ser Tyr Ala Val Phe Lys Ser Arg Val Val</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Ala Gly Glu Val Gln Val Gln Arg Leu Gln Gly Asp Ala Val Val Leu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Lys Ile Ala Arg Leu Gln Ala Gln Asp Ala Gly Ile Tyr Glu Cys His</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Thr Pro Ser Thr Asp Thr Arg Tyr Leu Gly Ser Tyr Ser Gly Lys Val</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Glu Leu Arg Val Leu Pro Asp Val Leu Gln Val Ser Ala Ala Pro Pro</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Gly Pro Arg Gly Arg Gln Ala Pro Thr Ser Pro Pro Arg Met Thr Val</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>His Glu Gly Gln Glu Leu Ala Leu Gly Cys Leu Ala Arg Thr Ser Thr</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Gln Lys His Thr His Leu Ala Val Ser Phe Gly Arg Ser Val Pro Glu</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Ala Pro Val Gly Arg Ser Thr Leu Gln Glu Val Val Gly Ile Arg Ser</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Asp Leu Ala Val Glu Ala Gly Ala Pro Tyr Ala Glu Arg Leu Ala Ala</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Gly Glu Leu Arg Leu Gly Lys Glu Gly Thr Asp Arg Tyr Arg Met Val</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Val Gly Gly Ala Gln Ala Gly Asp Ala Gly Thr Tyr His Cys Thr Ala</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Ala Glu Trp Ile Gln Asp Pro Asp Gly Ser Trp Ala Gln Ile Ala Glu</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Lys Arg Ala Val Leu Ala His Val Asp Val Gln Thr Leu Ser Ser Gln</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Leu Ala Val Thr Val Gly Pro Gly Glu Arg Arg Ile Gly Pro Gly Glu</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Pro Leu Glu Leu Leu Cys Asn Val Ser Gly Ala Leu Pro Pro Ala Gly</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Arg His Ala Ala Tyr Ser Val Gly Trp Glu Met Ala Pro Ala Gly Ala</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Pro Gly Pro Gly Arg Leu Val Ala Gln Leu Asp Thr Glu Gly Val Gly</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Ser Leu Gly Pro Gly Tyr Glu Gly Arg His Ile Ala Met Glu Lys Val</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Ala Ser Arg Thr Tyr Arg Leu Arg Leu Glu Ala Ala Arg Pro Gly Asp</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Ala Gly Thr Tyr Arg Cys Leu Ala Lys Ala Tyr Val Arg Gly Ser Gly</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Thr Arg Leu Arg Glu Ala Ala Ser Ala Arg Ser Arg Pro Leu Pro Val</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>His Val Arg Glu Glu Gly Val Val Leu Glu Ala Val Ala Trp Leu Ala</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Gly Gly Thr Val Tyr Arg Gly Glu Thr Ala Ser Leu Leu Cys Asn Ile</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Ser Val Arg Gly Gly Pro Pro Gly Leu Arg Leu Ala Ala Ser Trp Trp</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Val Glu Arg Pro Glu Asp Gly Glu Leu Ser Ser Val Pro Ala Gln Leu</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Val Gly Gly Val Gly Gln Asp Gly Val Ala Glu Leu Gly Val Arg Pro</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Gly Gly Gly Pro Val Ser Val Glu Leu Val Gly Pro Arg Ser His Arg</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Leu Arg Leu His Ser Leu Gly Pro Glu Asp Glu Gly Val Tyr His Cys</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Ala Pro Ser Ala Trp Val Gln His Ala Asp Tyr Ser Trp Tyr Gln Ala</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Gly Ser Ala Arg Ser Gly Pro Val Thr Val Tyr Pro Tyr Met His Ala</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Leu Asp Thr Leu Phe Val Pro Leu Leu Val Gly Thr Gly Val Ala Leu</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Val Thr Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys Phe Met Lys</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Arg Leu Arg Lys Arg</entry></row><row><entry>    610</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 305</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 748</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: The ITGB1 protein (21)</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 305</entry></row><row><entry> </entry></row><row><entry>Met Asn Leu Gln Pro Ile Phe Trp Ile Gly Leu Ile Ser Ser Val Cys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Cys Val Phe Ala Gln Thr Asp Glu Asn Arg Cys Leu Lys Ala Asn Ala</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Lys Ser Cys Gly Glu Cys Ile Gln Ala Gly Pro Asn Cys Gly Trp Cys</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Thr Asn Ser Thr Phe Leu Gln Glu Gly Met Pro Thr Ser Ala Arg Cys</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Asp Asp Leu Glu Ala Leu Lys Lys Lys Gly Cys Pro Pro Asp Asp Ile</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Glu Asn Pro Arg Gly Ser Lys Asp Ile Lys Lys Asn Lys Asn Val Thr</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Asn Arg Ser Lys Gly Thr Ala Glu Lys Leu Lys Pro Glu Asp Ile Thr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Gln Ile Gln Pro Gln Gln Leu Val Leu Arg Leu Arg Ser Gly Glu Pro</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Gln Thr Phe Thr Leu Lys Phe Lys Arg Ala Glu Asp Tyr Pro Ile Asp</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Leu Tyr Tyr Leu Met Asp Leu Ser Tyr Ser Met Lys Asp Asp Leu Glu</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Asn Val Lys Ser Leu Gly Thr Asp Leu Met Asn Glu Met Arg Arg Ile</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Thr Ser Asp Phe Arg Ile Gly Phe Gly Ser Phe Val Glu Lys Thr Val</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Met Pro Tyr Ile Ser Thr Thr Pro Ala Lys Leu Arg Asn Pro Cys Thr</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Ser Glu Gln Asn Cys Thr Ser Pro Phe Ser Tyr Lys Asn Val Leu Ser</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Leu Thr Asn Lys Gly Glu Val Phe Asn Glu Leu Val Gly Lys Gln Arg</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Ile Ser Gly Asn Leu Asp Ser Pro Glu Gly Gly Phe Asp Ala Ile Met</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Gln Val Ala Val Cys Gly Ser Leu Ile Gly Trp Arg Asn Val Thr Arg</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Leu Leu Val Phe Ser Thr Asp Ala Gly Phe His Phe Ala Gly Asp Gly</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Lys Leu Gly Gly Ile Val Leu Pro Asn Asp Gly Gln Cys His Leu Glu</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Asn Asn Met Tyr Thr Met Ser His Tyr Tyr Asp Tyr Pro Ser Ile Ala</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>His Leu Val Gln Lys Leu Ser Glu Asn Asn Ile Gln Thr Ile Phe Ala</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Val Thr Glu Glu Phe Gln Pro Val Tyr Lys Glu Leu Lys Asn Leu Ile</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Pro Lys Ser Ala Val Gly Thr Leu Ser Ala Asn Ser Ser Asn Val Ile</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Gln Leu Ile Ile Asp Ala Tyr Asn Ser Leu Ser Ser Glu Val Ile Leu</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Glu Asn Gly Lys Leu Ser Glu Gly Val Thr Ile Ser Tyr Lys Ser Tyr</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Cys Lys Asn Gly Val Asn Gly Thr Gly Glu Asn Gly Arg Lys Cys Ser</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Asn Ile Ser Ile Gly Asp Glu Val Gln Phe Glu Ile Ser Ile Thr Ser</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Asn Lys Cys Pro Lys Lys Asp Ser Asp Ser Phe Lys Ile Arg Pro Leu</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Gly Phe Thr Glu Glu Val Glu Val Ile Leu Gln Tyr Ile Cys Glu Cys</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Glu Cys Gln Ser Glu Gly Ile Pro Glu Ser Pro Lys Cys His Glu Gly</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Asn Gly Thr Phe Glu Cys Gly Ala Cys Arg Cys Asn Glu Gly Arg Val</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Gly Arg His Cys Glu Cys Ser Thr Asp Glu Val Asn Ser Glu Asp Met</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Asp Ala Tyr Cys Arg Lys Glu Asn Ser Ser Glu Ile Cys Ser Asn Asn</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Gly Glu Cys Val Cys Gly Gln Cys Val Cys Arg Lys Arg Asp Asn Thr</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Asn Glu Ile Tyr Ser Gly Ala Ser Asn Gly Gln Ile Cys Asn Gly Arg</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Gly Ile Cys Glu Cys Gly Val Cys Lys Cys Thr Asp Pro Lys Phe Gln</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Gly Gln Thr Cys Glu Met Cys Gln Thr Cys Leu Gly Val Cys Ala Glu</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>His Lys Glu Cys Val Gln Cys Arg Ala Phe Asn Lys Gly Glu Lys Lys</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Asp Thr Cys Thr Gln Glu Cys Ser Tyr Phe Asn Ile Thr Lys Val Glu</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Ser Arg Asp Lys Leu Pro Gln Pro Val Gln Pro Asp Pro Val Ser His</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Cys Lys Glu Lys Asp Val Asp Asp Cys Trp Phe Tyr Phe Thr Tyr Ser</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Val Asn Gly Asn Asn Glu Val Met Val His Val Val Glu Asn Pro Glu</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Cys Pro Thr Gly Pro Asp Ile Ile Pro Ile Val Ala Gly Val Val Ala</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Gly Ile Val Leu Ile Gly Leu Ala Leu Leu Leu Ile Trp Lys Leu Leu</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry>Met Ile Ile His Asp Arg Arg Glu Phe Ala Lys Phe Glu Lys Glu Lys</entry></row><row><entry>705                 710                 715                 720</entry></row><row><entry> </entry></row><row><entry>Met Asn Ala Lys Trp Asp Thr Gly Glu Asn Pro Ile Tyr Lys Ser Ala</entry></row><row><entry>                725                 730                 735</entry></row><row><entry> </entry></row><row><entry>Val Thr Thr Val Val Asn Pro Lys Tyr Glu Gly Lys</entry></row><row><entry>            740                 745</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 306</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 1032</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: The ITGA4 protein (22)</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 306</entry></row><row><entry> </entry></row><row><entry>Met Ala Trp Glu Ala Arg Arg Glu Pro Gly Pro Arg Arg Ala Ala Val</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Arg Glu Thr Val Met Leu Leu Leu Cys Leu Gly Val Pro Thr Gly Arg</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Pro Tyr Asn Val Asp Thr Glu Ser Ala Leu Leu Tyr Gln Gly Pro His</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Asn Thr Leu Phe Gly Tyr Ser Val Val Leu His Ser His Gly Ala Asn</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Arg Trp Leu Leu Val Gly Ala Pro Thr Ala Asn Trp Leu Ala Asn Ala</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Ser Val Ile Asn Pro Gly Ala Ile Tyr Arg Cys Arg Ile Gly Lys Asn</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Pro Gly Gln Thr Cys Glu Gln Leu Gln Leu Gly Ser Pro Asn Gly Glu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Pro Cys Gly Lys Thr Cys Leu Glu Glu Arg Asp Asn Gln Trp Leu Gly</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Val Thr Leu Ser Arg Gln Pro Gly Glu Asn Gly Ser Ile Val Thr Cys</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Gly His Arg Trp Lys Asn Ile Phe Tyr Ile Lys Asn Glu Asn Lys Leu</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Pro Thr Gly Gly Cys Tyr Gly Val Pro Pro Asp Leu Arg Thr Glu Leu</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Ser Lys Arg Ile Ala Pro Cys Tyr Gln Asp Tyr Val Lys Lys Phe Gly</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Glu Asn Phe Ala Ser Cys Gln Ala Gly Ile Ser Ser Phe Tyr Thr Lys</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Asp Leu Ile Val Met Gly Ala Pro Gly Ser Ser Tyr Trp Thr Gly Ser</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Leu Phe Val Tyr Asn Ile Thr Thr Asn Lys Tyr Lys Ala Phe Leu Asp</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Lys Gln Asn Gln Val Lys Phe Gly Ser Tyr Leu Gly Tyr Ser Val Gly</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Ala Gly His Phe Arg Ser Gln His Thr Thr Glu Val Val Gly Gly Ala</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Pro Gln His Glu Gln Ile Gly Lys Ala Tyr Ile Phe Ser Ile Asp Glu</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Lys Glu Leu Asn Ile Leu His Glu Met Lys Gly Lys Lys Leu Gly Ser</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Tyr Phe Gly Ala Ser Val Cys Ala Val Asp Leu Asn Ala Asp Gly Phe</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Ser Asp Leu Leu Val Gly Ala Pro Met Gln Ser Thr Ile Arg Glu Glu</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Gly Arg Val Phe Val Tyr Ile Asn Ser Gly Ser Gly Ala Val Met Asn</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Ala Met Glu Thr Asn Leu Val Gly Ser Asp Lys Tyr Ala Ala Arg Phe</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Gly Glu Ser Ile Val Asn Leu Gly Asp Ile Asp Asn Asp Gly Phe Glu</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Asp Val Ala Ile Gly Ala Pro Gln Glu Asp Asp Leu Gln Gly Ala Ile</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Tyr Ile Tyr Asn Gly Arg Ala Asp Gly Ile Ser Ser Thr Phe Ser Gln</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Arg Ile Glu Gly Leu Gln Ile Ser Lys Ser Leu Ser Met Phe Gly Gln</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Ser Ile Ser Gly Gln Ile Asp Ala Asp Asn Asn Gly Tyr Val Asp Val</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Ala Val Gly Ala Phe Arg Ser Asp Ser Ala Val Leu Leu Arg Thr Arg</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Pro Val Val Ile Val Asp Ala Ser Leu Ser His Pro Glu Ser Val Asn</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Arg Thr Lys Phe Asp Cys Val Glu Asn Gly Trp Pro Ser Val Cys Ile</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Asp Leu Thr Leu Cys Phe Ser Tyr Lys Gly Lys Glu Val Pro Gly Tyr</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Ile Val Leu Phe Tyr Asn Met Ser Leu Asp Val Asn Arg Lys Ala Glu</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Ser Pro Pro Arg Phe Tyr Phe Ser Ser Asn Gly Thr Ser Asp Val Ile</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Thr Gly Ser Ile Gln Val Ser Ser Arg Glu Ala Asn Cys Arg Thr His</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Gln Ala Phe Met Arg Lys Asp Val Arg Asp Ile Leu Thr Pro Ile Gln</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Ile Glu Ala Ala Tyr His Leu Gly Pro His Val Ile Ser Lys Arg Ser</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Thr Glu Glu Phe Pro Pro Leu Gln Pro Ile Leu Gln Gln Lys Lys Glu</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Lys Asp Ile Met Lys Lys Thr Ile Asn Phe Ala Arg Phe Cys Ala His</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Glu Asn Cys Ser Ala Asp Leu Gln Val Ser Ala Lys Ile Gly Phe Leu</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Lys Pro His Glu Asn Lys Thr Tyr Leu Ala Val Gly Ser Met Lys Thr</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Leu Met Leu Asn Val Ser Leu Phe Asn Ala Gly Asp Asp Ala Tyr Glu</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Thr Thr Leu His Val Lys Leu Pro Val Gly Leu Tyr Phe Ile Lys Ile</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Leu Glu Leu Glu Glu Lys Gln Ile Asn Cys Glu Val Thr Asp Asn Ser</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry>Gly Val Val Gln Leu Asp Cys Ser Ile Gly Tyr Ile Tyr Val Asp His</entry></row><row><entry>705                 710                 715                 720</entry></row><row><entry> </entry></row><row><entry>Leu Ser Arg Ile Asp Ile Ser Phe Leu Leu Asp Val Ser Ser Leu Ser</entry></row><row><entry>                725                 730                 735</entry></row><row><entry> </entry></row><row><entry>Arg Ala Glu Glu Asp Leu Ser Ile Thr Val His Ala Thr Cys Glu Asn</entry></row><row><entry>            740                 745                 750</entry></row><row><entry> </entry></row><row><entry>Glu Glu Glu Met Asp Asn Leu Lys His Ser Arg Val Thr Val Ala Ile</entry></row><row><entry>        755                 760                 765</entry></row><row><entry> </entry></row><row><entry>Pro Leu Lys Tyr Glu Val Lys Leu Thr Val His Gly Phe Val Asn Pro</entry></row><row><entry>    770                 775                 780</entry></row><row><entry> </entry></row><row><entry>Thr Ser Phe Val Tyr Gly Ser Asn Asp Glu Asn Glu Pro Glu Thr Cys</entry></row><row><entry>785                 790                 795                 800</entry></row><row><entry> </entry></row><row><entry>Met Val Glu Lys Met Asn Leu Thr Phe His Val Ile Asn Thr Gly Asn</entry></row><row><entry>                805                 810                 815</entry></row><row><entry> </entry></row><row><entry>Ser Met Ala Pro Asn Val Ser Val Glu Ile Met Val Pro Asn Ser Phe</entry></row><row><entry>            820                 825                 830</entry></row><row><entry> </entry></row><row><entry>Ser Pro Gln Thr Asp Lys Leu Phe Asn Ile Leu Asp Val Gln Thr Thr</entry></row><row><entry>        835                 840                 845</entry></row><row><entry> </entry></row><row><entry>Thr Gly Glu Cys His Phe Glu Asn Tyr Gln Arg Val Cys Ala Leu Glu</entry></row><row><entry>    850                 855                 860</entry></row><row><entry> </entry></row><row><entry>Gln Gln Lys Ser Ala Met Gln Thr Leu Lys Gly Ile Val Arg Phe Leu</entry></row><row><entry>865                 870                 875                 880</entry></row><row><entry> </entry></row><row><entry>Ser Lys Thr Asp Lys Arg Leu Leu Tyr Cys Ile Lys Ala Asp Pro His</entry></row><row><entry>                885                 890                 895</entry></row><row><entry> </entry></row><row><entry>Cys Leu Asn Phe Leu Cys Asn Phe Gly Lys Met Glu Ser Gly Lys Glu</entry></row><row><entry>            900                 905                 910</entry></row><row><entry> </entry></row><row><entry>Ala Ser Val His Ile Gln Leu Glu Gly Arg Pro Ser Ile Leu Glu Met</entry></row><row><entry>        915                 920                 925</entry></row><row><entry> </entry></row><row><entry>Asp Glu Thr Ser Ala Leu Lys Phe Glu Ile Arg Ala Thr Gly Phe Pro</entry></row><row><entry>    930                 935                 940</entry></row><row><entry> </entry></row><row><entry>Glu Pro Asn Pro Arg Val Ile Glu Leu Asn Lys Asp Glu Asn Val Ala</entry></row><row><entry>945                 950                 955                 960</entry></row><row><entry> </entry></row><row><entry>His Val Leu Leu Glu Gly Leu His His Gln Arg Pro Lys Arg Tyr Phe</entry></row><row><entry>                965                 970                 975</entry></row><row><entry> </entry></row><row><entry>Thr Ile Val Ile Ile Ser Ser Ser Leu Leu Leu Gly Leu Ile Val Leu</entry></row><row><entry>            980                 985                 990</entry></row><row><entry> </entry></row><row><entry>Leu Leu Ile Ser Tyr Val Met Trp  Lys Ala Gly Phe Phe  Lys Arg Gln</entry></row><row><entry>        995                 1000                 1005</entry></row><row><entry> </entry></row><row><entry>Tyr Lys  Ser Ile Leu Gln Glu  Glu Asn Arg Arg Asp  Ser Trp Ser</entry></row><row><entry>    1010                 1015                 1020</entry></row><row><entry> </entry></row><row><entry>Tyr Ile  Asn Ser Lys Ser Asn  Asp Asp</entry></row><row><entry>    1025                 1030</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 307</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 630</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: The SLC3A2 Protein, (23) wherethe first Met is</entry></row><row><entry>      processed</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 307</entry></row><row><entry> </entry></row><row><entry>Met Glu Leu Gln Pro Pro Glu Ala Ser Ile Ala Val Val Ser Ile Pro</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Arg Gln Leu Pro Gly Ser His Ser Glu Ala Gly Val Gln Gly Leu Ser</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Ala Gly Asp Asp Ser Glu Leu Gly Ser His Cys Val Ala Gln Thr Gly</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Leu Glu Leu Leu Ala Ser Gly Asp Pro Leu Pro Ser Ala Ser Gln Asn</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ala Glu Met Ile Glu Thr Gly Ser Asp Cys Val Thr Gln Ala Gly Leu</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Gln Leu Leu Ala Ser Ser Asp Pro Pro Ala Leu Ala Ser Lys Asn Ala</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Glu Val Thr Gly Thr Met Ser Gln Asp Thr Glu Val Asp Met Lys Glu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Val Glu Leu Asn Glu Leu Glu Pro Glu Lys Gln Pro Met Asn Ala Ala</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ser Gly Ala Ala Met Ser Leu Ala Gly Ala Glu Lys Asn Gly Leu Val</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Lys Ile Lys Val Ala Glu Asp Glu Ala Glu Ala Ala Ala Ala Ala Lys</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Phe Thr Gly Leu Ser Lys Glu Glu Leu Leu Lys Val Ala Gly Ser Pro</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Gly Trp Val Arg Thr Arg Trp Ala Leu Leu Leu Leu Phe Trp Leu Gly</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Trp Leu Gly Met Leu Ala Gly Ala Val Val Ile Ile Val Arg Ala Pro</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Arg Cys Arg Glu Leu Pro Ala Gln Lys Trp Trp His Thr Gly Ala Leu</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Tyr Arg Ile Gly Asp Leu Gln Ala Phe Gln Gly His Gly Ala Gly Asn</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Leu Ala Gly Leu Lys Gly Arg Leu Asp Tyr Leu Ser Ser Leu Lys Val</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Lys Gly Leu Val Leu Gly Pro Ile His Lys Asn Gln Lys Asp Asp Val</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Ala Gln Thr Asp Leu Leu Gln Ile Asp Pro Asn Phe Gly Ser Lys Glu</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Asp Phe Asp Ser Leu Leu Gln Ser Ala Lys Lys Lys Ser Ile Arg Val</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Ile Leu Asp Leu Thr Pro Asn Tyr Arg Gly Glu Asn Ser Trp Phe Ser</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Thr Gln Val Asp Thr Val Ala Thr Lys Val Lys Asp Ala Leu Glu Phe</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Trp Leu Gln Ala Gly Val Asp Gly Phe Gln Val Arg Asp Ile Glu Asn</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Leu Lys Asp Ala Ser Ser Phe Leu Ala Glu Trp Gln Asn Ile Thr Lys</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Gly Phe Ser Glu Asp Arg Leu Leu Ile Ala Gly Thr Asn Ser Ser Asp</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Leu Gln Gln Ile Leu Ser Leu Leu Glu Ser Asn Lys Asp Leu Leu Leu</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Thr Ser Ser Tyr Leu Ser Asp Ser Gly Ser Thr Gly Glu His Thr Lys</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Ser Leu Val Thr Gln Tyr Leu Asn Ala Thr Gly Asn Arg Trp Cys Ser</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Trp Ser Leu Ser Gln Ala Arg Leu Leu Thr Ser Phe Leu Pro Ala Gln</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Leu Leu Arg Leu Tyr Gln Leu Met Leu Phe Thr Leu Pro Gly Thr Pro</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Val Phe Ser Tyr Gly Asp Glu Ile Gly Leu Asp Ala Ala Ala Leu Pro</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Gly Gln Pro Met Glu Ala Pro Val Met Leu Trp Asp Glu Ser Ser Phe</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Pro Asp Ile Pro Gly Ala Val Ser Ala Asn Met Thr Val Lys Gly Gln</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Ser Glu Asp Pro Gly Ser Leu Leu Ser Leu Phe Arg Arg Leu Ser Asp</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Gln Arg Ser Lys Glu Arg Ser Leu Leu His Gly Asp Phe His Ala Phe</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Ser Ala Gly Pro Gly Leu Phe Ser Tyr Ile Arg His Trp Asp Gln Asn</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Glu Arg Phe Leu Val Val Leu Asn Phe Gly Asp Val Gly Leu Ser Ala</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Gly Leu Gln Ala Ser Asp Leu Pro Ala Ser Ala Ser Leu Pro Ala Lys</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Ala Asp Leu Leu Leu Ser Thr Gln Pro Gly Arg Glu Glu Gly Ser Pro</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Leu Glu Leu Glu Arg Leu Lys Leu Glu Pro His Glu Gly Leu Leu Leu</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Arg Phe Pro Tyr Ala Ala</entry></row><row><entry>625                 630</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 308</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 1021</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: IGSF2</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 308</entry></row><row><entry> </entry></row><row><entry>Met Ala Gly Ile Ser Tyr Val Ala Ser Phe Phe Leu Leu Leu Thr Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Ile Gly Gln Arg Glu Val Thr Val Gln Lys Gly Pro Leu Phe</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Arg Ala Glu Gly Tyr Pro Val Ser Ile Gly Cys Asn Val Thr Gly His</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Gln Gly Pro Ser Glu Gln His Phe Gln Trp Ser Val Tyr Leu Pro Thr</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Asn Pro Thr Gln Glu Val Gln Ile Ile Ser Thr Lys Asp Ala Ala Phe</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Ser Tyr Ala Val Tyr Thr Gln Arg Val Arg Ser Gly Asp Val Tyr Val</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Glu Arg Val Gln Gly Asn Ser Val Leu Leu His Ile Ser Lys Leu Gln</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Met Lys Asp Ala Gly Glu Tyr Glu Cys His Thr Pro Asn Thr Asp Glu</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Lys Tyr Tyr Gly Ser Tyr Ser Ala Lys Thr Asn Leu Ile Val Ile Pro</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Asp Thr Leu Ser Ala Thr Met Ser Ser Gln Thr Leu Gly Lys Glu Glu</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Gly Glu Pro Leu Ala Leu Thr Cys Glu Ala Ser Lys Ala Thr Ala Gln</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>His Thr His Leu Ser Val Thr Trp Tyr Leu Thr Gln Asp Gly Gly Gly</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Ser Gln Ala Thr Glu Ile Ile Ser Leu Ser Lys Asp Phe Ile Leu Val</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Pro Gly Pro Leu Tyr Thr Glu Arg Phe Ala Ala Ser Asp Val Gln Leu</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Asn Lys Leu Gly Pro Thr Thr Phe Arg Leu Ser Ile Glu Arg Leu Gln</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Ser Ser Asp Gln Gly Gln Leu Phe Cys Glu Ala Thr Glu Trp Ile Gln</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Asp Pro Asp Glu Thr Trp Met Phe Ile Thr Lys Lys Gln Thr Asp Gln</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Thr Thr Leu Arg Ile Gln Pro Ala Val Lys Asp Phe Gln Val Asn Ile</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Thr Ala Asp Ser Leu Phe Ala Glu Gly Lys Pro Leu Glu Leu Val Cys</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Leu Val Val Ser Ser Gly Arg Asp Pro Gln Leu Gln Gly Ile Trp Phe</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Phe Asn Gly Thr Glu Ile Ala His Ile Asp Ala Gly Gly Val Leu Gly</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Leu Lys Asn Asp Tyr Lys Glu Arg Ala Ser Gln Gly Glu Leu Gln Val</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Ser Lys Leu Gly Pro Lys Ala Phe Ser Leu Lys Ile Phe Ser Leu Gly</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Pro Glu Asp Glu Gly Ala Tyr Arg Cys Val Val Ala Glu Val Met Lys</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Thr Arg Thr Gly Ser Trp Gln Val Leu Gln Arg Lys Gln Ser Pro Asp</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Ser His Val His Leu Arg Lys Pro Ala Ala Arg Ser Val Val Met Ser</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Thr Lys Asn Lys Gln Gln Val Val Trp Glu Gly Glu Thr Leu Ala Phe</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Leu Cys Lys Ala Gly Gly Ala Glu Ser Pro Leu Ser Val Ser Trp Trp</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>His Ile Pro Arg Asp Gln Thr Gln Pro Glu Phe Val Ala Gly Met Gly</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Gln Asp Gly Ile Val Gln Leu Gly Ala Ser Tyr Gly Val Pro Ser Tyr</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>His Gly Asn Thr Arg Leu Glu Lys Met Asp Trp Ala Thr Phe Gln Leu</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Glu Ile Thr Phe Thr Ala Ile Thr Asp Ser Gly Thr Tyr Glu Cys Arg</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Val Ser Glu Lys Ser Arg Asn Gln Ala Arg Asp Leu Ser Trp Thr Gln</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Lys Ile Ser Val Thr Val Lys Ser Leu Glu Ser Ser Leu Gln Val Ser</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Leu Met Ser Arg Gln Pro Gln Val Met Leu Thr Asn Thr Phe Asp Leu</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Ser Cys Val Val Arg Ala Gly Tyr Ser Asp Leu Lys Val Pro Leu Thr</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Val Thr Trp Gln Phe Gln Pro Ala Ser Ser His Ile Phe His Gln Leu</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Ile Arg Ile Thr His Asn Gly Thr Ile Glu Trp Gly Asn Phe Leu Ser</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Arg Phe Gln Lys Lys Thr Lys Val Ser Gln Ser Leu Phe Arg Ser Gln</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Leu Leu Val His Asp Ala Thr Glu Glu Glu Thr Gly Val Tyr Gln Cys</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Glu Val Glu Val Tyr Asp Arg Asn Ser Leu Tyr Asn Asn Arg Pro Pro</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Arg Ala Ser Ala Ile Ser His Pro Leu Arg Ile Ala Val Thr Leu Pro</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Glu Ser Lys Leu Lys Val Asn Ser Arg Ser Gln Val Gln Glu Leu Ser</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Ile Asn Ser Asn Thr Asp Ile Glu Cys Ser Ile Leu Ser Arg Ser Asn</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry>Gly Asn Leu Gln Leu Ala Ile Ile Trp Tyr Phe Ser Pro Val Ser Thr</entry></row><row><entry>705                 710                 715                 720</entry></row><row><entry> </entry></row><row><entry>Asn Ala Ser Trp Leu Lys Ile Leu Glu Met Asp Gln Thr Asn Val Ile</entry></row><row><entry>                725                 730                 735</entry></row><row><entry> </entry></row><row><entry>Lys Thr Gly Asp Glu Phe His Thr Pro Gln Arg Lys Gln Lys Phe His</entry></row><row><entry>            740                 745                 750</entry></row><row><entry> </entry></row><row><entry>Thr Glu Lys Val Ser Gln Asp Leu Phe Gln Leu His Ile Leu Asn Val</entry></row><row><entry>        755                 760                 765</entry></row><row><entry> </entry></row><row><entry>Glu Asp Ser Asp Arg Gly Lys Tyr His Cys Ala Val Glu Glu Trp Leu</entry></row><row><entry>    770                 775                 780</entry></row><row><entry> </entry></row><row><entry>Leu Ser Thr Asn Gly Thr Trp His Lys Leu Gly Glu Lys Lys Ser Gly</entry></row><row><entry>785                 790                 795                 800</entry></row><row><entry> </entry></row><row><entry>Leu Thr Glu Leu Lys Leu Lys Pro Thr Gly Ser Lys Val Arg Val Ser</entry></row><row><entry>                805                 810                 815</entry></row><row><entry> </entry></row><row><entry>Lys Val Tyr Trp Thr Glu Asn Val Thr Glu His Arg Glu Val Ala Ile</entry></row><row><entry>            820                 825                 830</entry></row><row><entry> </entry></row><row><entry>Arg Cys Ser Leu Glu Ser Val Gly Ser Ser Ala Thr Leu Tyr Ser Val</entry></row><row><entry>        835                 840                 845</entry></row><row><entry> </entry></row><row><entry>Met Trp Tyr Trp Asn Arg Glu Asn Ser Gly Ser Lys Leu Leu Val His</entry></row><row><entry>    850                 855                 860</entry></row><row><entry> </entry></row><row><entry>Leu Gln His Asp Gly Leu Leu Glu Tyr Gly Glu Glu Gly Leu Arg Arg</entry></row><row><entry>865                 870                 875                 880</entry></row><row><entry> </entry></row><row><entry>His Leu His Cys Tyr Arg Ser Ser Ser Thr Asp Phe Val Leu Lys Leu</entry></row><row><entry>                885                 890                 895</entry></row><row><entry> </entry></row><row><entry>His Gln Val Glu Met Glu Asp Ala Gly Met Tyr Trp Cys Arg Val Ala</entry></row><row><entry>            900                 905                 910</entry></row><row><entry> </entry></row><row><entry>Glu Trp Gln Leu His Gly His Pro Ser Lys Trp Ile Asn Gln Ala Ser</entry></row><row><entry>        915                 920                 925</entry></row><row><entry> </entry></row><row><entry>Asp Glu Ser Gln Arg Met Val Leu Thr Val Leu Pro Ser Glu Pro Thr</entry></row><row><entry>    930                 935                 940</entry></row><row><entry> </entry></row><row><entry>Leu Pro Ser Arg Ile Cys Ser Ser Ala Pro Leu Leu Tyr Phe Leu Phe</entry></row><row><entry>945                 950                 955                 960</entry></row><row><entry> </entry></row><row><entry>Ile Cys Pro Phe Val Leu Leu Leu Leu Leu Leu Ile Ser Leu Leu Cys</entry></row><row><entry>                965                 970                 975</entry></row><row><entry> </entry></row><row><entry>Leu Tyr Trp Lys Ala Arg Lys Leu Ser Thr Leu Arg Ser Asn Thr Arg</entry></row><row><entry>            980                 985                 990</entry></row><row><entry> </entry></row><row><entry>Lys Glu Lys Ala Leu Trp Val Asp  Leu Lys Glu Ala Gly  Gly Val Thr</entry></row><row><entry>        995                 1000                 1005</entry></row><row><entry> </entry></row><row><entry>Thr Asn  Arg Arg Glu Asp Glu  Glu Glu Asp Glu Gly  Asn</entry></row><row><entry>    1010                 1015                 1020</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 309</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 1195</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: IGSF3</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 309</entry></row><row><entry> </entry></row><row><entry>Met Lys Cys Phe Phe Pro Val Leu Ser Cys Leu Ala Val Leu Gly Val</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Val Ser Ala Gln Arg Gln Val Thr Val Gln Glu Gly Pro Leu Tyr Arg</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Thr Glu Gly Ser His Ile Thr Ile Trp Cys Asn Val Ser Gly Tyr Gln</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Gly Pro Ser Glu Gln Asn Phe Gln Trp Ser Ile Tyr Leu Pro Ser Ser</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Pro Glu Arg Glu Val Gln Ile Val Ser Thr Met Asp Ser Ser Phe Pro</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Tyr Ala Ile Tyr Thr Gln Arg Val Arg Gly Gly Lys Ile Phe Ile Glu</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Arg Val Gln Gly Asn Ser Thr Leu Leu His Ile Thr Asp Leu Gln Ala</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Arg Asp Ala Gly Glu Tyr Glu Cys His Thr Pro Ser Thr Asp Lys Gln</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Tyr Phe Gly Ser Tyr Ser Ala Lys Met Asn Leu Val Val Ile Pro Asp</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ser Leu Gln Thr Thr Ala Met Pro Gln Thr Leu His Arg Val Glu Gln</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Asp Pro Leu Glu Leu Thr Cys Glu Val Ala Ser Glu Thr Ile Gln His</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Ser His Leu Ser Val Ala Trp Leu Arg Gln Lys Val Gly Glu Lys Pro</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Val Glu Val Ile Ser Leu Ser Arg Asp Phe Met Leu His Ser Ser Ser</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Glu Tyr Ala Gln Arg Gln Ser Leu Gly Glu Val Arg Leu Asp Lys Leu</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Gly Arg Thr Thr Phe Arg Leu Thr Ile Phe His Leu Gln Pro Ser Asp</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Gln Gly Glu Phe Tyr Cys Glu Ala Ala Glu Trp Ile Gln Asp Pro Asp</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Gly Ser Trp Tyr Ala Met Thr Arg Lys Arg Ser Glu Gly Ala Val Val</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Asn Val Gln Pro Thr Asp Lys Glu Phe Thr Val Arg Leu Glu Thr Glu</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Lys Arg Leu His Thr Val Gly Glu Pro Val Glu Phe Arg Cys Ile Leu</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Glu Ala Gln Asn Val Pro Asp Arg Tyr Phe Ala Val Ser Trp Ala Phe</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Asn Ser Ser Leu Ile Ala Thr Met Gly Pro Asn Ala Val Pro Val Leu</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Asn Ser Glu Phe Ala His Arg Glu Ala Arg Gly Gln Leu Lys Val Ala</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Lys Glu Ser Asp Ser Val Phe Val Leu Lys Ile Tyr His Leu Arg Gln</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Glu Asp Ser Gly Lys Tyr Asn Cys Arg Val Thr Glu Arg Glu Lys Thr</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Val Thr Gly Glu Phe Ile Asp Lys Glu Ser Lys Arg Pro Lys Asn Ile</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Pro Ile Ile Val Leu Pro Leu Lys Ser Ser Ile Ser Val Glu Val Ala</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Ser Asn Ala Ser Val Ile Leu Glu Gly Glu Asp Leu Arg Phe Ser Cys</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Ser Val Arg Thr Ala Gly Arg Pro Gln Gly Arg Phe Ser Val Ile Trp</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Gln Leu Val Asp Arg Gln Asn Arg Arg Ser Asn Ile Met Trp Leu Asp</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Arg Asp Gly Thr Val Gln Pro Gly Ser Ser Tyr Trp Glu Arg Ser Ser</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Phe Gly Gly Val Gln Met Glu Gln Val Gln Pro Asn Ser Phe Ser Leu</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Gly Ile Phe Asn Ser Arg Lys Glu Asp Glu Gly Gln Tyr Glu Cys His</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Val Thr Glu Trp Val Arg Ala Val Asp Gly Glu Trp Gln Ile Val Gly</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Glu Arg Arg Ala Ser Thr Pro Ile Ser Ile Thr Ala Leu Glu Met Gly</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Phe Ala Val Thr Ala Ile Ser Arg Thr Pro Gly Val Thr Tyr Ser Asp</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Ser Phe Asp Leu Gln Cys Ile Ile Lys Pro His Tyr Pro Ala Trp Val</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Pro Val Ser Val Thr Trp Arg Phe Gln Pro Val Gly Thr Val Glu Phe</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>His Asp Leu Val Thr Phe Thr Arg Asp Gly Gly Val Gln Trp Gly Asp</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Arg Ser Ser Ser Phe Arg Thr Arg Thr Ala Ile Glu Lys Ala Glu Ser</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Ser Asn Asn Val Arg Leu Ser Ile Ser Arg Ala Ser Asp Thr Glu Ala</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Gly Lys Tyr Gln Cys Val Ala Glu Leu Trp Arg Lys Asn Tyr Asn Asn</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Thr Trp Thr Arg Leu Ala Glu Arg Thr Ser Asn Leu Leu Glu Ile Arg</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Val Leu Gln Pro Val Thr Lys Leu Gln Val Ser Lys Ser Lys Arg Thr</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Leu Thr Leu Val Glu Asn Lys Pro Ile Gln Leu Asn Cys Ser Val Lys</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry>Ser Gln Thr Ser Gln Asn Ser His Phe Ala Val Leu Trp Tyr Val His</entry></row><row><entry>705                 710                 715                 720</entry></row><row><entry> </entry></row><row><entry>Lys Pro Ser Asp Ala Asp Gly Lys Leu Ile Leu Lys Thr Thr His Asn</entry></row><row><entry>                725                 730                 735</entry></row><row><entry> </entry></row><row><entry>Ser Ala Phe Glu Tyr Gly Thr Tyr Ala Glu Glu Glu Gly Leu Arg Ala</entry></row><row><entry>            740                 745                 750</entry></row><row><entry> </entry></row><row><entry>Arg Leu Gln Phe Glu Arg His Val Ser Gly Gly Leu Phe Ser Leu Thr</entry></row><row><entry>        755                 760                 765</entry></row><row><entry> </entry></row><row><entry>Val Gln Arg Ala Glu Val Ser Asp Ser Gly Ser Tyr Tyr Cys His Val</entry></row><row><entry>    770                 775                 780</entry></row><row><entry> </entry></row><row><entry>Glu Glu Trp Leu Leu Ser Pro Asn Tyr Ala Trp Tyr Lys Leu Ala Glu</entry></row><row><entry>785                 790                 795                 800</entry></row><row><entry> </entry></row><row><entry>Glu Val Ser Gly Arg Thr Glu Val Thr Val Lys Gln Pro Asp Ser Arg</entry></row><row><entry>                805                 810                 815</entry></row><row><entry> </entry></row><row><entry>Leu Arg Leu Ser Gln Ala Gln Gly Asn Leu Ser Val Leu Glu Thr Arg</entry></row><row><entry>            820                 825                 830</entry></row><row><entry> </entry></row><row><entry>Gln Val Gln Leu Glu Cys Val Val Leu Asn Arg Thr Ser Ile Thr Ser</entry></row><row><entry>        835                 840                 845</entry></row><row><entry> </entry></row><row><entry>Gln Leu Met Val Glu Trp Phe Val Trp Lys Pro Asn His Pro Glu Arg</entry></row><row><entry>    850                 855                 860</entry></row><row><entry> </entry></row><row><entry>Glu Thr Val Ala Arg Leu Ser Arg Asp Ala Thr Phe His Tyr Gly Glu</entry></row><row><entry>865                 870                 875                 880</entry></row><row><entry> </entry></row><row><entry>Gln Ala Ala Lys Asn Asn Leu Lys Gly Arg Leu His Leu Glu Ser Pro</entry></row><row><entry>                885                 890                 895</entry></row><row><entry> </entry></row><row><entry>Ser Pro Gly Val Tyr Arg Leu Phe Ile Gln Asn Val Ala Val Gln Asp</entry></row><row><entry>            900                 905                 910</entry></row><row><entry> </entry></row><row><entry>Ser Gly Thr Tyr Ser Cys His Val Glu Glu Trp Leu Pro Ser Pro Ser</entry></row><row><entry>        915                 920                 925</entry></row><row><entry> </entry></row><row><entry>Gly Met Trp Tyr Lys Arg Ala Glu Asp Thr Ala Gly Gln Thr Ala Leu</entry></row><row><entry>    930                 935                 940</entry></row><row><entry> </entry></row><row><entry>Thr Val Met Arg Pro Asp Ala Ser Leu Gln Val Asp Thr Val Val Pro</entry></row><row><entry>945                 950                 955                 960</entry></row><row><entry> </entry></row><row><entry>Asn Ala Thr Val Ser Glu Lys Ala Ala Phe Gln Leu Asp Cys Ser Ile</entry></row><row><entry>                965                 970                 975</entry></row><row><entry> </entry></row><row><entry>Val Ser Arg Ser Ser Gln Asp Ser Arg Phe Ala Val Ala Trp Tyr Ser</entry></row><row><entry>            980                 985                 990</entry></row><row><entry> </entry></row><row><entry>Leu Arg Thr Lys Ala Gly Gly Lys  Arg Ser Ser Pro Gly  Leu Glu Glu</entry></row><row><entry>        995                 1000                 1005</entry></row><row><entry> </entry></row><row><entry>Gln Glu  Glu Glu Arg Glu Glu  Glu Glu Glu Glu Glu  Glu Asp Asp</entry></row><row><entry>    1010                 1015                 1020</entry></row><row><entry> </entry></row><row><entry>Asp Asp  Asp Asp Pro Thr Glu  Arg Thr Ala Leu Leu  Ser Val Gly</entry></row><row><entry>    1025                 1030                 1035</entry></row><row><entry> </entry></row><row><entry>Pro Asp  Ala Val Phe Gly Pro  Glu Gly Ser Pro Trp  Glu Gly Arg</entry></row><row><entry>    1040                 1045                 1050</entry></row><row><entry> </entry></row><row><entry>Leu Arg  Phe Gln Arg Leu Ser  Pro Val Leu Tyr Arg  Leu Thr Val</entry></row><row><entry>    1055                 1060                 1065</entry></row><row><entry> </entry></row><row><entry>Leu Gln  Ala Ser Pro Gln Asp  Thr Gly Asn Tyr Ser  Cys His Val</entry></row><row><entry>    1070                 1075                 1080</entry></row><row><entry> </entry></row><row><entry>Glu Glu  Trp Leu Pro Ser Pro  Gln Lys Glu Trp Tyr  Arg Leu Thr</entry></row><row><entry>    1085                 1090                 1095</entry></row><row><entry> </entry></row><row><entry>Glu Glu  Glu Ser Ala Pro Ile  Gly Ile Arg Val Leu  Asp Thr Ser</entry></row><row><entry>    1100                 1105                 1110</entry></row><row><entry> </entry></row><row><entry>Pro Thr  Leu Gln Ser Ile Ile  Cys Ser Asn Asp Ala  Leu Phe Tyr</entry></row><row><entry>    1115                 1120                 1125</entry></row><row><entry> </entry></row><row><entry>Phe Val  Phe Phe Tyr Pro Phe  Pro Ile Phe Gly Ile  Leu Ile Ile</entry></row><row><entry>    1130                 1135                 1140</entry></row><row><entry> </entry></row><row><entry>Thr Ile  Leu Leu Val Arg Phe  Lys Ser Arg Asn Ser  Ser Lys Asn</entry></row><row><entry>    1145                 1150                 1155</entry></row><row><entry> </entry></row><row><entry>Ser Asp  Gly Lys Asn Gly Val  Pro Leu Leu Trp Ile  Lys Glu Pro</entry></row><row><entry>    1160                 1165                 1170</entry></row><row><entry> </entry></row><row><entry>His Leu  Asn Tyr Ser Pro Thr  Cys Leu Glu Pro Pro  Val Leu Ser</entry></row><row><entry>    1175                 1180                 1185</entry></row><row><entry> </entry></row><row><entry>Ile His  Pro Gly Ala Ile Asp</entry></row><row><entry>    1190                 1195</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 310</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 1023</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: ATP1A1</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 310</entry></row><row><entry> </entry></row><row><entry>Met Gly Lys Gly Val Gly Arg Asp Lys Tyr Glu Pro Ala Ala Val Ser</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Glu Gln Gly Asp Lys Lys Gly Lys Lys Gly Lys Lys Asp Arg Asp Met</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Asp Glu Leu Lys Lys Glu Val Ser Met Asp Asp His Lys Leu Ser Leu</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Asp Glu Leu His Arg Lys Tyr Gly Thr Asp Leu Ser Arg Gly Leu Thr</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ser Ala Arg Ala Ala Glu Ile Leu Ala Arg Asp Gly Pro Asn Ala Leu</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Thr Pro Pro Pro Thr Thr Pro Glu Trp Ile Lys Phe Cys Arg Gln Leu</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Phe Gly Gly Phe Ser Met Leu Leu Trp Ile Gly Ala Ile Leu Cys Phe</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Leu Ala Tyr Ser Ile Gln Ala Ala Thr Glu Glu Glu Pro Gln Asn Asp</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Asn Leu Tyr Leu Gly Val Val Leu Ser Ala Val Val Ile Ile Thr Gly</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Cys Phe Ser Tyr Tyr Gln Glu Ala Lys Ser Ser Lys Ile Met Glu Ser</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Phe Lys Asn Met Val Pro Gln Gln Ala Leu Val Ile Arg Asn Gly Glu</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Lys Met Ser Ile Asn Ala Glu Glu Val Val Val Gly Asp Leu Val Glu</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Val Lys Gly Gly Asp Arg Ile Pro Ala Asp Leu Arg Ile Ile Ser Ala</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Asn Gly Cys Lys Val Asp Asn Ser Ser Leu Thr Gly Glu Ser Glu Pro</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Gln Thr Arg Ser Pro Asp Phe Thr Asn Glu Asn Pro Leu Glu Thr Arg</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Asn Ile Ala Phe Phe Ser Thr Asn Cys Val Glu Gly Thr Ala Arg Gly</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Ile Val Val Tyr Thr Gly Asp Arg Thr Val Met Gly Arg Ile Ala Thr</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Leu Ala Ser Gly Leu Glu Gly Gly Gln Thr Pro Ile Ala Ala Glu Ile</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Glu His Phe Ile His Ile Ile Thr Gly Val Ala Val Phe Leu Gly Val</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Ser Phe Phe Ile Leu Ser Leu Ile Leu Glu Tyr Thr Trp Leu Glu Ala</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Val Ile Phe Leu Ile Gly Ile Ile Val Ala Asn Val Pro Glu Gly Leu</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Leu Ala Thr Val Thr Val Cys Leu Thr Leu Thr Ala Lys Arg Met Ala</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Arg Lys Asn Cys Leu Val Lys Asn Leu Glu Ala Val Glu Thr Leu Gly</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Ser Thr Ser Thr Ile Cys Ser Asp Lys Thr Gly Thr Leu Thr Gln Asn</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Arg Met Thr Val Ala His Met Trp Phe Asp Asn Gln Ile His Glu Ala</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Asp Thr Thr Glu Asn Gln Ser Gly Val Ser Phe Asp Lys Thr Ser Ala</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Thr Trp Leu Ala Leu Ser Arg Ile Ala Gly Leu Cys Asn Arg Ala Val</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Phe Gln Ala Asn Gln Glu Asn Leu Pro Ile Leu Lys Arg Ala Val Ala</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Gly Asp Ala Ser Glu Ser Ala Leu Leu Lys Cys Ile Glu Leu Cys Cys</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Gly Ser Val Lys Glu Met Arg Glu Arg Tyr Ala Lys Ile Val Glu Ile</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Pro Phe Asn Ser Thr Asn Lys Tyr Gln Leu Ser Ile His Lys Asn Pro</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Asn Thr Ser Glu Pro Gln His Leu Leu Val Met Lys Gly Ala Pro Glu</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Arg Ile Leu Asp Arg Cys Ser Ser Ile Leu Leu His Gly Lys Glu Gln</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Pro Leu Asp Glu Glu Leu Lys Asp Ala Phe Gln Asn Ala Tyr Leu Glu</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Leu Gly Gly Leu Gly Glu Arg Val Leu Gly Phe Cys His Leu Phe Leu</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Pro Asp Glu Gln Phe Pro Glu Gly Phe Gln Phe Asp Thr Asp Asp Val</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Asn Phe Pro Ile Asp Asn Leu Cys Phe Val Gly Leu Ile Ser Met Ile</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Asp Pro Pro Arg Ala Ala Val Pro Asp Ala Val Gly Lys Cys Arg Ser</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Ala Gly Ile Lys Val Ile Met Val Thr Gly Asp His Pro Ile Thr Ala</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Lys Ala Ile Ala Lys Gly Val Gly Ile Ile Ser Glu Gly Asn Glu Thr</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Val Glu Asp Ile Ala Ala Arg Leu Asn Ile Pro Val Ser Gln Val Asn</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Pro Arg Asp Ala Lys Ala Cys Val Val His Gly Ser Asp Leu Lys Asp</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Met Thr Ser Glu Gln Leu Asp Asp Ile Leu Lys Tyr His Thr Glu Ile</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Val Phe Ala Arg Thr Ser Pro Gln Gln Lys Leu Ile Ile Val Glu Gly</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry>Cys Gln Arg Gln Gly Ala Ile Val Ala Val Thr Gly Asp Gly Val Asn</entry></row><row><entry>705                 710                 715                 720</entry></row><row><entry> </entry></row><row><entry>Asp Ser Pro Ala Leu Lys Lys Ala Asp Ile Gly Val Ala Met Gly Ile</entry></row><row><entry>                725                 730                 735</entry></row><row><entry> </entry></row><row><entry>Ala Gly Ser Asp Val Ser Lys Gln Ala Ala Asp Met Ile Leu Leu Asp</entry></row><row><entry>            740                 745                 750</entry></row><row><entry> </entry></row><row><entry>Asp Asn Phe Ala Ser Ile Val Thr Gly Val Glu Glu Gly Arg Leu Ile</entry></row><row><entry>        755                 760                 765</entry></row><row><entry> </entry></row><row><entry>Phe Asp Asn Leu Lys Lys Ser Ile Ala Tyr Thr Leu Thr Ser Asn Ile</entry></row><row><entry>    770                 775                 780</entry></row><row><entry> </entry></row><row><entry>Pro Glu Ile Thr Pro Phe Leu Ile Phe Ile Ile Ala Asn Ile Pro Leu</entry></row><row><entry>785                 790                 795                 800</entry></row><row><entry> </entry></row><row><entry>Pro Leu Gly Thr Val Thr Ile Leu Cys Ile Asp Leu Gly Thr Asp Met</entry></row><row><entry>                805                 810                 815</entry></row><row><entry> </entry></row><row><entry>Val Pro Ala Ile Ser Leu Ala Tyr Glu Gln Ala Glu Ser Asp Ile Met</entry></row><row><entry>            820                 825                 830</entry></row><row><entry> </entry></row><row><entry>Lys Arg Gln Pro Arg Asn Pro Lys Thr Asp Lys Leu Val Asn Glu Arg</entry></row><row><entry>        835                 840                 845</entry></row><row><entry> </entry></row><row><entry>Leu Ile Ser Met Ala Tyr Gly Gln Ile Gly Met Ile Gln Ala Leu Gly</entry></row><row><entry>    850                 855                 860</entry></row><row><entry> </entry></row><row><entry>Gly Phe Phe Thr Tyr Phe Val Ile Leu Ala Glu Asn Gly Phe Leu Pro</entry></row><row><entry>865                 870                 875                 880</entry></row><row><entry> </entry></row><row><entry>Ile His Leu Leu Gly Leu Arg Val Asp Trp Asp Asp Arg Trp Ile Asn</entry></row><row><entry>                885                 890                 895</entry></row><row><entry> </entry></row><row><entry>Asp Val Glu Asp Ser Tyr Gly Gln Gln Trp Thr Tyr Glu Gln Arg Lys</entry></row><row><entry>            900                 905                 910</entry></row><row><entry> </entry></row><row><entry>Ile Val Glu Phe Thr Cys His Thr Ala Phe Phe Val Ser Ile Val Val</entry></row><row><entry>        915                 920                 925</entry></row><row><entry> </entry></row><row><entry>Val Gln Trp Ala Asp Leu Val Ile Cys Lys Thr Arg Arg Asn Ser Val</entry></row><row><entry>    930                 935                 940</entry></row><row><entry> </entry></row><row><entry>Phe Gln Gln Gly Met Lys Asn Lys Ile Leu Ile Phe Gly Leu Phe Glu</entry></row><row><entry>945                 950                 955                 960</entry></row><row><entry> </entry></row><row><entry>Glu Thr Ala Leu Ala Ala Phe Leu Ser Tyr Cys Pro Gly Met Gly Val</entry></row><row><entry>                965                 970                 975</entry></row><row><entry> </entry></row><row><entry>Ala Leu Arg Met Tyr Pro Leu Lys Pro Thr Trp Trp Phe Cys Ala Phe</entry></row><row><entry>            980                 985                 990</entry></row><row><entry> </entry></row><row><entry>Pro Tyr Ser Leu Leu Ile Phe Val  Tyr Asp Glu Val Arg  Lys Leu Ile</entry></row><row><entry>        995                 1000                 1005</entry></row><row><entry> </entry></row><row><entry>Ile Arg  Arg Arg Pro Gly Gly  Trp Val Glu Lys Glu  Thr Tyr Tyr</entry></row><row><entry>    1010                 1015                 1020</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 311</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 240</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: ATP1A2</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 311</entry></row><row><entry> </entry></row><row><entry>Met Gly Arg Gly Ala Gly Arg Glu Tyr Ser Pro Ala Ala Thr Thr Ala</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Glu Asn Gly Gly Gly Lys Lys Lys Gln Lys Glu Lys Glu Leu Asp Glu</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Leu Lys Lys Glu Val Ala Met Asp Asp His Lys Leu Ser Leu Asp Glu</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Leu Gly Arg Lys Tyr Gln Val Asp Leu Ser Lys Gly Leu Thr Asn Gln</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Arg Ala Gln Asp Val Leu Ala Arg Asp Gly Pro Asn Ala Leu Thr Pro</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Pro Pro Thr Thr Pro Glu Trp Val Lys Phe Cys Arg Gln Leu Phe Gly</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Gly Phe Ser Ile Leu Leu Trp Ile Gly Ala Ile Leu Cys Phe Leu Ala</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Tyr Gly Ile Gln Ala Ala Met Glu Asp Glu Pro Ser Asn Asp Asn Leu</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Tyr Leu Gly Val Val Leu Ala Ala Val Val Ile Val Thr Gly Cys Phe</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ser Tyr Tyr Gln Glu Ala Lys Ser Ser Lys Ile Met Asp Ser Phe Lys</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Asn Met Val Pro Gln Gln Ala Leu Val Ile Arg Glu Gly Glu Lys Met</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Gln Ile Asn Ala Glu Glu Val Val Val Gly Asp Leu Val Glu Val Lys</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Gly Gly Asp Arg Val Pro Ala Asp Leu Arg Ile Ile Ser Ser His Gly</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Cys Lys Val Asp Asn Ser Ser Leu Thr Gly Glu Ser Glu Pro Gln Thr</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Arg Ser Pro Glu Phe Thr His Glu Asn Pro Leu Glu Thr Arg Asn Ile</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 312</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 780</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: ATP1A3</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 312</entry></row><row><entry> </entry></row><row><entry>Cys Phe Phe Ser Thr Asn Cys Val Glu Gly Thr Ala Arg Gly Ile Val</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ile Ala Thr Gly Asp Arg Thr Val Met Gly Arg Ile Ala Thr Leu Ala</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Ser Gly Leu Glu Val Gly Arg Thr Pro Ile Ala Met Glu Ile Glu His</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Phe Ile Gln Leu Ile Thr Gly Val Ala Val Phe Leu Gly Val Ser Phe</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Phe Val Leu Ser Leu Ile Leu Gly Tyr Ser Trp Leu Glu Ala Val Ile</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Phe Leu Ile Gly Ile Ile Val Ala Asn Val Pro Glu Gly Leu Leu Ala</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Thr Val Thr Val Cys Leu Thr Leu Thr Ala Lys Arg Met Ala Arg Lys</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Asn Cys Leu Val Lys Asn Leu Glu Ala Val Glu Thr Leu Gly Ser Thr</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ser Thr Ile Cys Ser Asp Lys Thr Gly Thr Leu Thr Gln Asn Arg Met</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Thr Val Ala His Met Trp Phe Asp Asn Gln Ile His Glu Ala Asp Thr</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Thr Glu Asp Gln Ser Gly Ala Thr Phe Asp Lys Arg Ser Pro Thr Trp</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Thr Ala Leu Ser Arg Ile Ala Gly Leu Cys Asn Arg Ala Val Phe Lys</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Ala Gly Gln Glu Asn Ile Ser Val Ser Lys Arg Asp Thr Ala Gly Asp</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Ala Ser Glu Ser Ala Leu Leu Lys Cys Ile Glu Leu Ser Cys Gly Ser</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Val Arg Lys Met Arg Asp Arg Asn Pro Lys Val Ala Glu Ile Pro Phe</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Asn Ser Thr Asn Lys Tyr Gln Leu Ser Ile His Glu Arg Glu Asp Ser</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Pro Gln Ser His Val Leu Val Met Lys Gly Ala Pro Glu Arg Ile Leu</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Asp Arg Cys Ser Thr Ile Leu Val Gln Gly Lys Glu Ile Pro Leu Asp</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Lys Glu Met Gln Asp Ala Phe Gln Asn Ala Tyr Met Glu Leu Gly Gly</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Leu Gly Glu Arg Val Leu Gly Phe Cys Gln Leu Asn Leu Pro Ser Gly</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Lys Phe Pro Arg Gly Phe Lys Phe Asp Thr Asp Glu Leu Asn Phe Pro</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Thr Glu Lys Leu Cys Phe Val Gly Leu Met Ser Met Ile Asp Pro Pro</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Arg Ala Ala Val Pro Asp Ala Val Gly Lys Cys Arg Ser Ala Gly Ile</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Lys Val Ile Met Val Thr Gly Asp His Pro Ile Thr Ala Lys Ala Ile</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Ala Lys Gly Val Gly Ile Ile Ser Glu Gly Asn Glu Thr Val Glu Asp</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Ile Ala Ala Arg Leu Asn Ile Pro Met Ser Gln Val Asn Pro Arg Glu</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Ala Lys Ala Cys Val Val His Gly Ser Asp Leu Lys Asp Met Thr Ser</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Glu Gln Leu Asp Glu Ile Leu Lys Asn His Thr Glu Ile Val Phe Ala</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Arg Thr Ser Pro Gln Gln Lys Leu Ile Ile Val Glu Gly Cys Gln Arg</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Gln Gly Ala Ile Val Ala Val Thr Gly Asp Gly Val Asn Asp Ser Pro</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Ala Leu Lys Lys Ala Asp Ile Gly Ile Ala Met Gly Ile Ser Gly Ser</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Asp Val Ser Lys Gln Ala Ala Asp Met Ile Leu Leu Asp Asp Asn Phe</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Ala Ser Ile Val Thr Gly Val Glu Glu Gly Arg Leu Ile Phe Asp Asn</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Leu Lys Lys Ser Ile Ala Tyr Thr Leu Thr Ser Asn Ile Pro Glu Ile</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Thr Pro Phe Leu Leu Phe Ile Ile Ala Asn Ile Pro Leu Pro Leu Gly</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Thr Val Thr Ile Leu Cys Ile Asp Leu Gly Thr Asp Met Val Pro Ala</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Ile Ser Leu Ala Tyr Glu Ala Ala Glu Ser Asp Ile Met Lys Arg Gln</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Pro Arg Asn Ser Gln Thr Asp Lys Leu Val Asn Glu Arg Leu Ile Ser</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Met Ala Tyr Gly Gln Ile Gly Met Ile Gln Ala Leu Gly Gly Phe Phe</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Thr Tyr Phe Val Ile Leu Ala Glu Asn Gly Phe Leu Pro Ser Arg Leu</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Leu Gly Ile Arg Leu Asp Trp Asp Asp Arg Thr Met Asn Asp Leu Glu</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Asp Ser Tyr Gly Gln Glu Trp Thr Tyr Glu Gln Arg Lys Val Val Glu</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Phe Thr Cys His Thr Ala Phe Phe Ala Ser Ile Val Val Val Gln Trp</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Ala Asp Leu Ile Ile Cys Lys Thr Arg Arg Asn Ser Val Phe Gln Gln</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry>Gly Met Lys Asn Lys Ile Leu Ile Phe Gly Leu Leu Glu Glu Thr Ala</entry></row><row><entry>705                 710                 715                 720</entry></row><row><entry> </entry></row><row><entry>Leu Ala Ala Phe Leu Ser Tyr Cys Pro Gly Met Gly Val Ala Leu Arg</entry></row><row><entry>                725                 730                 735</entry></row><row><entry> </entry></row><row><entry>Met Tyr Pro Leu Lys Val Thr Trp Trp Phe Cys Ala Phe Pro Tyr Ser</entry></row><row><entry>            740                 745                 750</entry></row><row><entry> </entry></row><row><entry>Leu Leu Ile Phe Ile Tyr Asp Glu Val Arg Lys Leu Ile Leu Arg Arg</entry></row><row><entry>        755                 760                 765</entry></row><row><entry> </entry></row><row><entry>Tyr Pro Gly Gly Trp Val Glu Lys Glu Thr Tyr Tyr</entry></row><row><entry>    770                 775                 780</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 313</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 1026</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: ATP1A4</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 313</entry></row><row><entry> </entry></row><row><entry>Met Gly Ser Gly Gly Ser Asp Ser Tyr Arg Ile Ala Thr Ser Gln Asp</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Lys Asp Asp Lys Asp Ser Pro Lys Lys Asn Lys Gly Lys Glu Arg</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Arg Asp Leu Asp Asp Leu Lys Lys Glu Val Ala Met Thr Glu His Lys</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Met Ser Val Glu Glu Val Cys Arg Lys Tyr Asn Thr Asp Cys Val Gln</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Gly Leu Thr His Ser Lys Ala Gln Glu Ile Leu Ala Arg Asp Gly Pro</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Asn Ala Leu Thr Pro Pro Pro Thr Thr Pro Glu Trp Val Lys Phe Cys</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Arg Gln Leu Phe Gly Gly Phe Ser Ile Leu Leu Trp Ile Gly Ala Ile</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Leu Cys Phe Leu Ala Tyr Gly Ile Gln Ala Gly Thr Glu Asp Asp Pro</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ser Gly Asp Asn Leu Tyr Leu Gly Ile Val Leu Ala Ala Val Val Ile</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ile Thr Gly Cys Phe Ser Tyr Tyr Gln Glu Ala Lys Ser Ser Lys Ile</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Met Glu Ser Phe Lys Asn Met Val Pro Gln Gln Ala Leu Val Ile Arg</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Glu Gly Glu Lys Met Gln Val Asn Ala Glu Glu Val Val Val Gly Asp</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Leu Val Glu Ile Lys Gly Gly Asp Arg Val Pro Ala Asp Leu Arg Ile</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Ile Ser Ala His Gly Cys Lys Val Asp Asn Ser Ser Leu Thr Gly Glu</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Ser Glu Pro Gln Thr Arg Ser Pro Asp Cys Thr His Asp Asn Pro Leu</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Glu Thr Arg Asn Ile Thr Phe Phe Ser Thr Asn Cys Val Glu Gly Thr</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Ala Arg Gly Val Val Val Ala Thr Gly Asp Arg Thr Val Met Gly Arg</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Ile Ala Thr Leu Ala Ser Gly Leu Glu Val Gly Lys Thr Pro Ile Ala</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Ile Glu Ile Glu His Phe Ile Gln Leu Ile Thr Gly Val Ala Val Phe</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Leu Gly Val Ser Phe Phe Ile Leu Ser Leu Ile Leu Gly Tyr Thr Trp</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Leu Glu Ala Val Ile Phe Leu Ile Gly Ile Ile Val Ala Asn Val Pro</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Glu Gly Leu Leu Ala Thr Val Thr Val Cys Leu Thr Leu Thr Ala Lys</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Arg Met Ala Arg Lys Asn Cys Leu Val Lys Asn Leu Glu Ala Val Glu</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Thr Leu Gly Ser Thr Ser Thr Ile Cys Ser Asp Lys Thr Gly Thr Leu</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Thr Gln Asn Arg Met Thr Val Ala His Met Trp Phe Asp Asn Gln Ile</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>His Glu Ala Asp Thr Thr Glu Asp Gln Ser Gly Thr Ser Phe Asp Lys</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Ser Ser His Thr Trp Val Ala Leu Ser His Ile Ala Gly Leu Cys Asn</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Arg Ala Val Phe Lys Gly Gly Gln Asp Asn Ile Pro Val Leu Lys Arg</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Asp Val Ala Gly Asp Ala Ser Glu Ser Ala Leu Leu Lys Cys Ile Glu</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Leu Ser Ser Gly Ser Val Lys Leu Met Arg Glu Arg Asn Lys Lys Val</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Ala Glu Ile Pro Phe Asn Ser Thr Asn Lys Tyr Gln Leu Ser Ile His</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Glu Thr Glu Asp Pro Asn Asp Asn Arg Tyr Leu Leu Val Met Lys Gly</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Ala Pro Glu Arg Ile Leu Asp Arg Cys Ser Thr Ile Leu Leu Gln Gly</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Lys Glu Gln Pro Leu Asp Glu Glu Met Lys Glu Ala Phe Gln Asn Ala</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Tyr Leu Glu Leu Gly Gly Leu Gly Glu Arg Val Leu Gly Phe Cys His</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Tyr Tyr Leu Pro Glu Glu Gln Phe Pro Lys Gly Phe Ala Phe Asp Cys</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Asp Asp Val Asn Phe Thr Thr Asp Asn Leu Cys Phe Val Gly Leu Met</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Ser Met Ile Asp Pro Pro Arg Ala Ala Val Pro Asp Ala Val Gly Lys</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Cys Arg Ser Ala Gly Ile Lys Val Ile Met Val Thr Gly Asp His Pro</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Ile Thr Ala Lys Ala Ile Ala Lys Gly Val Gly Ile Ile Ser Glu Gly</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Asn Glu Thr Val Glu Asp Ile Ala Ala Arg Leu Asn Ile Pro Val Ser</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Gln Val Asn Pro Arg Asp Ala Lys Ala Cys Val Ile His Gly Thr Asp</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Leu Lys Asp Phe Thr Ser Glu Gln Ile Asp Glu Ile Leu Gln Asn His</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Thr Glu Ile Val Phe Ala Arg Thr Ser Pro Gln Gln Lys Leu Ile Ile</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry>Val Glu Gly Cys Gln Arg Gln Gly Ala Ile Val Ala Val Thr Gly Asp</entry></row><row><entry>705                 710                 715                 720</entry></row><row><entry> </entry></row><row><entry>Gly Val Asn Asp Ser Pro Ala Leu Lys Lys Ala Asp Ile Gly Val Ala</entry></row><row><entry>                725                 730                 735</entry></row><row><entry> </entry></row><row><entry>Met Gly Ile Ala Gly Ser Asp Val Ser Lys Gln Ala Ala Asp Met Ile</entry></row><row><entry>            740                 745                 750</entry></row><row><entry> </entry></row><row><entry>Leu Leu Asp Asp Asn Phe Ala Ser Ile Val Thr Gly Val Glu Glu Gly</entry></row><row><entry>        755                 760                 765</entry></row><row><entry> </entry></row><row><entry>Arg Leu Ile Phe Asp Asn Leu Lys Lys Ser Ile Ala Tyr Thr Leu Thr</entry></row><row><entry>    770                 775                 780</entry></row><row><entry> </entry></row><row><entry>Ser Asn Ile Pro Glu Ile Thr Pro Phe Leu Leu Phe Ile Met Ala Asn</entry></row><row><entry>785                 790                 795                 800</entry></row><row><entry> </entry></row><row><entry>Ile Pro Leu Pro Leu Gly Thr Ile Thr Ile Leu Cys Ile Asp Leu Gly</entry></row><row><entry>                805                 810                 815</entry></row><row><entry> </entry></row><row><entry>Thr Asp Met Val Pro Ala Ile Ser Leu Ala Tyr Glu Ala Ala Glu Ser</entry></row><row><entry>            820                 825                 830</entry></row><row><entry> </entry></row><row><entry>Asp Ile Met Lys Arg Gln Pro Arg Asn Pro Arg Thr Asp Lys Leu Val</entry></row><row><entry>        835                 840                 845</entry></row><row><entry> </entry></row><row><entry>Asn Glu Arg Leu Ile Ser Met Ala Tyr Gly Gln Ile Gly Met Ile Gln</entry></row><row><entry>    850                 855                 860</entry></row><row><entry> </entry></row><row><entry>Ala Leu Gly Gly Phe Phe Ser Tyr Phe Val Ile Leu Ala Glu Asn Gly</entry></row><row><entry>865                 870                 875                 880</entry></row><row><entry> </entry></row><row><entry>Phe Leu Pro Gly Asn Leu Val Gly Ile Arg Leu Asn Trp Asp Asp Arg</entry></row><row><entry>                885                 890                 895</entry></row><row><entry> </entry></row><row><entry>Thr Val Asn Asp Leu Glu Asp Ser Tyr Gly Gln Gln Trp Thr Tyr Glu</entry></row><row><entry>            900                 905                 910</entry></row><row><entry> </entry></row><row><entry>Gln Arg Lys Val Val Glu Phe Thr Cys His Thr Ala Phe Phe Val Ser</entry></row><row><entry>        915                 920                 925</entry></row><row><entry> </entry></row><row><entry>Ile Val Val Val Gln Trp Ala Asp Leu Ile Ile Cys Lys Thr Arg Arg</entry></row><row><entry>    930                 935                 940</entry></row><row><entry> </entry></row><row><entry>Asn Ser Val Phe Gln Gln Gly Met Lys Asn Lys Ile Leu Ile Phe Gly</entry></row><row><entry>945                 950                 955                 960</entry></row><row><entry> </entry></row><row><entry>Leu Phe Glu Glu Thr Ala Leu Ala Ala Phe Leu Ser Tyr Cys Pro Gly</entry></row><row><entry>                965                 970                 975</entry></row><row><entry> </entry></row><row><entry>Met Asp Val Ala Leu Arg Met Tyr Pro Leu Lys Pro Ser Trp Trp Phe</entry></row><row><entry>            980                 985                 990</entry></row><row><entry> </entry></row><row><entry>Cys Ala Phe Pro Tyr Ser Phe Leu  Ile Phe Val Tyr Asp  Glu Ile Arg</entry></row><row><entry>        995                 1000                 1005</entry></row><row><entry> </entry></row><row><entry>Lys Leu  Ile Leu Arg Arg Asn  Pro Gly Gly Trp Val  Glu Lys Glu</entry></row><row><entry>    1010                 1015                 1020</entry></row><row><entry> </entry></row><row><entry>Thr Tyr  Tyr</entry></row><row><entry>    1025</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 314</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 1029</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: ATP1B3</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 314</entry></row><row><entry> </entry></row><row><entry>Met Gly Leu Trp Gly Lys Lys Gly Thr Val Ala Pro His Asp Gln Ser</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Arg Arg Arg Pro Lys Lys Gly Leu Ile Lys Lys Lys Met Val Lys</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Arg Glu Lys Gln Lys Arg Asn Met Glu Glu Leu Lys Lys Glu Val Val</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Met Asp Asp His Lys Leu Thr Leu Glu Glu Leu Ser Thr Lys Tyr Ser</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Val Asp Leu Thr Lys Gly His Ser His Gln Arg Ala Lys Glu Ile Leu</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Thr Arg Gly Gly Pro Asn Thr Val Thr Pro Pro Pro Thr Thr Pro Glu</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Trp Val Lys Phe Cys Lys Gln Leu Phe Gly Gly Phe Ser Leu Leu Leu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Trp Thr Gly Ala Ile Leu Cys Phe Val Ala Tyr Ser Ile Gln Ile Tyr</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Phe Asn Glu Glu Pro Thr Lys Asp Asn Leu Tyr Leu Ser Ile Val Leu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ser Val Val Val Ile Val Thr Gly Cys Phe Ser Tyr Tyr Gln Glu Ala</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Lys Ser Ser Lys Ile Met Glu Ser Phe Lys Asn Met Val Pro Gln Gln</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Ala Leu Val Ile Arg Gly Gly Glu Lys Met Gln Ile Asn Val Gln Glu</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Val Val Leu Gly Asp Leu Val Glu Ile Lys Gly Gly Asp Arg Val Pro</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Ala Asp Leu Arg Leu Ile Ser Ala Gln Gly Cys Lys Val Asp Asn Ser</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Ser Leu Thr Gly Glu Ser Glu Pro Gln Ser Arg Ser Pro Asp Phe Thr</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>His Glu Asn Pro Leu Glu Thr Arg Asn Ile Cys Phe Phe Ser Thr Asn</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Cys Val Glu Gly Thr Ala Arg Gly Ile Val Ile Ala Thr Gly Asp Ser</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Thr Val Met Gly Arg Ile Ala Ser Leu Thr Ser Gly Leu Ala Val Gly</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Gln Thr Pro Ile Ala Ala Glu Ile Glu His Phe Ile His Leu Ile Thr</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Val Val Ala Val Phe Leu Gly Val Thr Phe Phe Ala Leu Ser Leu Leu</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Leu Gly Tyr Gly Trp Leu Glu Ala Ile Ile Phe Leu Ile Gly Ile Ile</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Val Ala Asn Val Pro Glu Gly Leu Leu Ala Thr Val Thr Val Cys Leu</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Thr Leu Thr Ala Lys Arg Met Ala Arg Lys Asn Cys Leu Val Lys Asn</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Leu Glu Ala Val Glu Thr Leu Gly Ser Thr Ser Thr Ile Cys Ser Asp</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Lys Thr Gly Thr Leu Thr Gln Asn Arg Met Thr Val Ala His Met Trp</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Phe Asp Met Thr Val Tyr Glu Ala Asp Thr Thr Glu Glu Gln Thr Gly</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Lys Thr Phe Thr Lys Ser Ser Asp Thr Trp Phe Met Leu Ala Arg Ile</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Ala Gly Leu Cys Asn Arg Ala Asp Phe Lys Ala Asn Gln Glu Ile Leu</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Pro Ile Ala Lys Arg Ala Thr Thr Gly Asp Ala Ser Glu Ser Ala Leu</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Leu Lys Phe Ile Glu Gln Ser Tyr Ser Ser Val Ala Glu Met Arg Glu</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Lys Asn Pro Lys Val Ala Glu Ile Pro Phe Asn Ser Thr Asn Lys Tyr</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Gln Met Ser Ile His Leu Arg Glu Asp Ser Ser Gln Thr His Val Leu</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Met Met Lys Gly Ala Pro Glu Arg Ile Leu Glu Phe Cys Ser Thr Phe</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Leu Leu Asn Gly Gln Glu Tyr Ser Met Asn Asp Glu Met Lys Glu Ala</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Phe Gln Asn Ala Tyr Leu Glu Leu Gly Gly Leu Gly Glu Arg Val Leu</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Gly Phe Cys Phe Leu Asn Leu Pro Ser Ser Phe Ser Lys Gly Phe Pro</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Phe Asn Thr Asp Glu Ile Asn Phe Pro Met Asp Asn Leu Cys Phe Val</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Gly Leu Ile Ser Met Ile Asp Pro Pro Arg Ala Ala Val Pro Asp Ala</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Val Ser Lys Cys Arg Ser Ala Gly Ile Lys Val Ile Met Val Thr Gly</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Asp His Pro Ile Thr Ala Lys Ala Ile Ala Lys Gly Val Gly Ile Ile</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Ser Glu Gly Thr Glu Thr Ala Glu Glu Val Ala Ala Arg Leu Lys Ile</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Pro Ile Ser Lys Val Asp Ala Ser Ala Ala Lys Ala Ile Val Val His</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Gly Ala Glu Leu Lys Asp Ile Gln Ser Lys Gln Leu Asp Gln Ile Leu</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Gln Asn His Pro Glu Ile Val Phe Ala Arg Thr Ser Pro Gln Gln Lys</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry>Leu Ile Ile Val Glu Gly Cys Gln Arg Leu Gly Ala Val Val Ala Val</entry></row><row><entry>705                 710                 715                 720</entry></row><row><entry> </entry></row><row><entry>Thr Gly Asp Gly Val Asn Asp Ser Pro Ala Leu Lys Lys Ala Asp Ile</entry></row><row><entry>                725                 730                 735</entry></row><row><entry> </entry></row><row><entry>Gly Ile Ala Met Gly Ile Ser Gly Ser Asp Val Ser Lys Gln Ala Ala</entry></row><row><entry>            740                 745                 750</entry></row><row><entry> </entry></row><row><entry>Asp Met Ile Leu Leu Asp Asp Asn Phe Ala Ser Ile Val Thr Gly Val</entry></row><row><entry>        755                 760                 765</entry></row><row><entry> </entry></row><row><entry>Glu Glu Gly Arg Leu Ile Phe Asp Asn Leu Lys Lys Ser Ile Met Tyr</entry></row><row><entry>    770                 775                 780</entry></row><row><entry> </entry></row><row><entry>Thr Leu Thr Ser Asn Ile Pro Glu Ile Thr Pro Phe Leu Met Phe Ile</entry></row><row><entry>785                 790                 795                 800</entry></row><row><entry> </entry></row><row><entry>Ile Leu Gly Ile Pro Leu Pro Leu Gly Thr Ile Thr Ile Leu Cys Ile</entry></row><row><entry>                805                 810                 815</entry></row><row><entry> </entry></row><row><entry>Asp Leu Gly Thr Asp Met Val Pro Ala Ile Ser Leu Ala Tyr Glu Ser</entry></row><row><entry>            820                 825                 830</entry></row><row><entry> </entry></row><row><entry>Ala Glu Ser Asp Ile Met Lys Arg Leu Pro Arg Asn Pro Lys Thr Asp</entry></row><row><entry>        835                 840                 845</entry></row><row><entry> </entry></row><row><entry>Asn Leu Val Asn His Arg Leu Ile Gly Met Ala Tyr Gly Gln Ile Gly</entry></row><row><entry>    850                 855                 860</entry></row><row><entry> </entry></row><row><entry>Met Ile Gln Ala Leu Ala Gly Phe Phe Thr Tyr Phe Val Ile Leu Ala</entry></row><row><entry>865                 870                 875                 880</entry></row><row><entry> </entry></row><row><entry>Glu Asn Gly Phe Arg Pro Val Asp Leu Leu Gly Ile Arg Leu His Trp</entry></row><row><entry>                885                 890                 895</entry></row><row><entry> </entry></row><row><entry>Glu Asp Lys Tyr Leu Asn Asp Leu Glu Asp Ser Tyr Gly Gln Gln Trp</entry></row><row><entry>            900                 905                 910</entry></row><row><entry> </entry></row><row><entry>Thr Tyr Glu Gln Arg Lys Val Val Glu Phe Thr Cys Gln Thr Ala Phe</entry></row><row><entry>        915                 920                 925</entry></row><row><entry> </entry></row><row><entry>Phe Val Thr Ile Val Val Val Gln Trp Ala Asp Leu Ile Ile Ser Lys</entry></row><row><entry>    930                 935                 940</entry></row><row><entry> </entry></row><row><entry>Thr Arg Arg Asn Ser Leu Phe Gln Gln Gly Met Arg Asn Lys Val Leu</entry></row><row><entry>945                 950                 955                 960</entry></row><row><entry> </entry></row><row><entry>Ile Phe Gly Ile Leu Glu Glu Thr Leu Leu Ala Ala Phe Leu Ser Tyr</entry></row><row><entry>                965                 970                 975</entry></row><row><entry> </entry></row><row><entry>Thr Pro Gly Met Asp Val Ala Leu Arg Met Tyr Pro Leu Lys Ile Thr</entry></row><row><entry>            980                 985                 990</entry></row><row><entry> </entry></row><row><entry>Trp Trp Leu Cys Ala Ile Pro Tyr  Ser Ile Leu Ile Phe  Val Tyr Asp</entry></row><row><entry>        995                 1000                 1005</entry></row><row><entry> </entry></row><row><entry>Glu Ile  Arg Lys Leu Leu Ile  Arg Gln His Pro Asp  Gly Trp Val</entry></row><row><entry>    1010                 1015                 1020</entry></row><row><entry> </entry></row><row><entry>Glu Arg  Glu Thr Tyr Tyr</entry></row><row><entry>    1025</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 315</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 279</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: ATP2B1</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 315</entry></row><row><entry> </entry></row><row><entry>Met Thr Lys Asn Glu Lys Lys Ser Leu Asn Gln Ser Leu Ala Glu Trp</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Leu Phe Ile Tyr Asn Pro Thr Thr Gly Glu Phe Leu Gly Arg Thr</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Ala Lys Ser Trp Gly Leu Ile Leu Leu Phe Tyr Leu Val Phe Tyr Gly</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Phe Leu Ala Ala Leu Phe Ser Phe Thr Met Trp Val Met Leu Gln Thr</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Leu Asn Asp Glu Val Pro Lys Tyr Arg Asp Gln Ile Pro Ser Pro Gly</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Leu Met Val Phe Pro Lys Pro Val Thr Ala Leu Glu Tyr Thr Phe Ser</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Arg Ser Asp Pro Thr Ser Tyr Ala Gly Tyr Ile Glu Asp Leu Lys Lys</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Phe Leu Lys Pro Tyr Thr Leu Glu Glu Gln Lys Asn Leu Thr Val Cys</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Pro Asp Gly Ala Leu Phe Glu Gln Lys Gly Pro Val Tyr Val Ala Cys</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Gln Phe Pro Ile Ser Leu Leu Gln Ala Cys Ser Gly Met Asn Asp Pro</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Asp Phe Gly Tyr Ser Gln Gly Asn Pro Cys Ile Leu Val Lys Met Asn</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Arg Ile Ile Gly Leu Lys Pro Glu Gly Val Pro Arg Ile Asp Cys Val</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Ser Lys Asn Glu Asp Ile Pro Asn Val Ala Val Tyr Pro His Asn Gly</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Met Ile Asp Leu Lys Tyr Phe Pro Tyr Tyr Gly Lys Lys Leu His Val</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Gly Tyr Leu Gln Pro Leu Val Ala Val Gln Val Ser Phe Ala Pro Asn</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Asn Thr Gly Lys Glu Val Thr Val Glu Cys Lys Ile Asp Gly Ser Ala</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Asn Leu Lys Ser Gln Asp Asp Arg Asp Lys Phe Leu Gly Arg Val Met</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Phe Lys Ile Thr Ala Arg Ala</entry></row><row><entry>        275</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 316</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 1258</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: ATP2B2</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 316</entry></row><row><entry> </entry></row><row><entry>Met Gly Asp Met Ala Asn Asn Ser Val Ala Tyr Ser Gly Val Lys Asn</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ser Leu Lys Glu Ala Asn His Asp Gly Asp Phe Gly Ile Thr Leu Ala</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Glu Leu Arg Ala Leu Met Glu Leu Arg Ser Thr Asp Ala Leu Arg Lys</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ile Gln Glu Ser Tyr Gly Asp Val Tyr Gly Ile Cys Thr Lys Leu Lys</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Thr Ser Pro Asn Glu Gly Leu Ser Gly Asn Pro Ala Asp Leu Glu Arg</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Arg Glu Ala Val Phe Gly Lys Asn Phe Ile Pro Pro Lys Lys Pro Lys</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Thr Phe Leu Gln Leu Val Trp Glu Ala Leu Gln Asp Val Thr Leu Ile</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Ile Leu Glu Ile Ala Ala Ile Val Ser Leu Gly Leu Ser Phe Tyr Gln</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Pro Pro Glu Gly Asp Asn Ala Leu Cys Gly Glu Val Ser Val Gly Glu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Glu Glu Gly Glu Gly Glu Thr Gly Trp Ile Glu Gly Ala Ala Ile Leu</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Leu Ser Val Val Cys Val Val Leu Val Thr Ala Phe Asn Asp Trp Ser</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Lys Glu Lys Gln Phe Arg Gly Leu Gln Ser Arg Ile Glu Gln Glu Gln</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Lys Phe Thr Val Ile Arg Gly Gly Gln Val Ile Gln Ile Pro Val Ala</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Asp Ile Thr Val Gly Asp Ile Ala Gln Val Lys Tyr Gly Asp Leu Leu</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Pro Ala Asp Gly Ile Leu Ile Gln Gly Asn Asp Leu Lys Ile Asp Glu</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Ser Ser Leu Thr Gly Glu Ser Asp His Val Lys Lys Ser Leu Asp Lys</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Asp Pro Leu Leu Leu Ser Gly Thr His Val Met Glu Gly Ser Gly Arg</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Met Val Val Thr Ala Val Gly Val Asn Ser Gln Thr Gly Ile Ile Phe</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Thr Leu Leu Gly Ala Gly Gly Glu Glu Glu Glu Lys Lys Asp Glu Lys</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Lys Lys Glu Lys Lys Asn Lys Lys Gln Asp Gly Ala Ile Glu Asn Arg</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Asn Lys Ala Lys Ala Gln Asp Gly Ala Ala Met Glu Met Gln Pro Leu</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Lys Ser Glu Glu Gly Gly Asp Gly Asp Glu Lys Asp Lys Lys Lys Ala</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Asn Leu Pro Lys Lys Glu Lys Ser Val Leu Gln Gly Lys Leu Thr Lys</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Leu Ala Val Gln Ile Gly Lys Ala Gly Leu Leu Met Ser Ala Ile Thr</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Val Ile Ile Leu Val Leu Tyr Phe Val Ile Asp Thr Phe Trp Val Gln</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Lys Arg Pro Trp Leu Ala Glu Cys Thr Pro Ile Tyr Ile Gln Tyr Phe</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Val Lys Phe Phe Ile Ile Gly Val Thr Val Leu Val Val Ala Val Pro</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Glu Gly Leu Pro Leu Ala Val Thr Ile Ser Leu Ala Tyr Ser Val Lys</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Lys Met Met Lys Asp Asn Asn Leu Val Arg His Leu Asp Ala Cys Glu</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Thr Met Gly Asn Ala Thr Ala Ile Cys Ser Asp Lys Thr Gly Thr Leu</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Thr Met Asn Arg Met Thr Val Val Gln Ala Tyr Ile Asn Glu Lys His</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Tyr Lys Lys Val Pro Glu Pro Glu Ala Ile Pro Pro Asn Ile Leu Ser</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Tyr Leu Val Thr Gly Ile Ser Val Asn Cys Ala Tyr Thr Ser Lys Ile</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Leu Pro Pro Glu Lys Glu Gly Gly Leu Pro Arg His Val Gly Asn Lys</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Thr Glu Cys Ala Leu Leu Gly Leu Leu Leu Asp Leu Lys Arg Asp Tyr</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Gln Asp Val Arg Asn Glu Ile Pro Glu Glu Ala Leu Tyr Lys Val Tyr</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Thr Phe Asn Ser Val Arg Lys Ser Met Ser Thr Val Leu Lys Asn Ser</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Asp Gly Ser Tyr Arg Ile Phe Ser Lys Gly Ala Ser Glu Ile Ile Leu</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Lys Lys Cys Phe Lys Ile Leu Ser Ala Asn Gly Glu Ala Lys Val Phe</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Arg Pro Arg Asp Arg Asp Asp Ile Val Lys Thr Val Ile Glu Pro Met</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Ala Ser Glu Gly Leu Arg Thr Ile Cys Leu Ala Phe Arg Asp Phe Pro</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Ala Gly Glu Pro Glu Pro Glu Trp Asp Asn Glu Asn Asp Ile Val Thr</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Gly Leu Thr Cys Ile Ala Val Val Gly Ile Glu Asp Pro Val Arg Pro</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Glu Val Pro Asp Ala Ile Lys Lys Cys Gln Arg Ala Gly Ile Thr Val</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry>Arg Met Val Thr Gly Asp Asn Ile Asn Thr Ala Arg Ala Ile Ala Thr</entry></row><row><entry>705                 710                 715                 720</entry></row><row><entry> </entry></row><row><entry>Lys Cys Gly Ile Leu His Pro Gly Glu Asp Phe Leu Cys Leu Glu Gly</entry></row><row><entry>                725                 730                 735</entry></row><row><entry> </entry></row><row><entry>Lys Asp Phe Asn Arg Arg Ile Arg Asn Glu Lys Gly Glu Ile Glu Gln</entry></row><row><entry>            740                 745                 750</entry></row><row><entry> </entry></row><row><entry>Glu Arg Ile Asp Lys Ile Trp Pro Lys Leu Arg Val Leu Ala Arg Ser</entry></row><row><entry>        755                 760                 765</entry></row><row><entry> </entry></row><row><entry>Ser Pro Thr Asp Lys His Thr Leu Val Lys Gly Ile Ile Asp Ser Thr</entry></row><row><entry>    770                 775                 780</entry></row><row><entry> </entry></row><row><entry>Val Ser Asp Gln Arg Gln Val Val Ala Val Thr Gly Asp Gly Thr Asn</entry></row><row><entry>785                 790                 795                 800</entry></row><row><entry> </entry></row><row><entry>Asp Gly Pro Ala Leu Lys Lys Ala Asp Val Gly Phe Ala Met Gly Ile</entry></row><row><entry>                805                 810                 815</entry></row><row><entry> </entry></row><row><entry>Ala Gly Thr Asp Val Ala Lys Glu Ala Ser Asp Ile Ile Leu Thr Asp</entry></row><row><entry>            820                 825                 830</entry></row><row><entry> </entry></row><row><entry>Asp Asn Phe Thr Ser Ile Val Lys Ala Val Met Trp Gly Arg Asn Val</entry></row><row><entry>        835                 840                 845</entry></row><row><entry> </entry></row><row><entry>Tyr Asp Ser Ile Ser Lys Phe Leu Gln Phe Gln Leu Thr Val Asn Val</entry></row><row><entry>    850                 855                 860</entry></row><row><entry> </entry></row><row><entry>Val Ala Val Ile Val Ala Phe Thr Gly Ala Cys Ile Thr Gln Asp Ser</entry></row><row><entry>865                 870                 875                 880</entry></row><row><entry> </entry></row><row><entry>Pro Leu Lys Ala Val Gln Met Leu Trp Val Asn Leu Ile Met Asp Thr</entry></row><row><entry>                885                 890                 895</entry></row><row><entry> </entry></row><row><entry>Leu Ala Ser Leu Ala Leu Ala Thr Glu Pro Pro Thr Glu Ser Leu Leu</entry></row><row><entry>            900                 905                 910</entry></row><row><entry> </entry></row><row><entry>Leu Arg Lys Pro Tyr Gly Arg Asn Lys Pro Leu Ile Ser Arg Thr Met</entry></row><row><entry>        915                 920                 925</entry></row><row><entry> </entry></row><row><entry>Met Lys Asn Ile Leu Gly His Ala Phe Tyr Gln Leu Val Val Val Phe</entry></row><row><entry>    930                 935                 940</entry></row><row><entry> </entry></row><row><entry>Thr Leu Leu Phe Ala Gly Glu Lys Phe Phe Asp Ile Asp Ser Gly Arg</entry></row><row><entry>945                 950                 955                 960</entry></row><row><entry> </entry></row><row><entry>Asn Ala Pro Leu His Ala Pro Pro Ser Glu His Tyr Thr Ile Val Phe</entry></row><row><entry>                965                 970                 975</entry></row><row><entry> </entry></row><row><entry>Asn Thr Phe Val Leu Met Gln Leu Phe Asn Glu Ile Asn Ala Arg Lys</entry></row><row><entry>            980                 985                 990</entry></row><row><entry> </entry></row><row><entry>Ile His Gly Glu Arg Asn Val Phe  Glu Gly Ile Phe Asn  Asn Ala Ile</entry></row><row><entry>        995                 1000                 1005</entry></row><row><entry> </entry></row><row><entry>Phe Cys  Thr Ile Val Leu Gly  Thr Phe Val Val Gln  Ile Ile Ile</entry></row><row><entry>    1010                 1015                 1020</entry></row><row><entry> </entry></row><row><entry>Val Gln  Phe Gly Gly Lys Pro  Phe Ser Cys Ser Glu  Leu Ser Ile</entry></row><row><entry>    1025                 1030                 1035</entry></row><row><entry> </entry></row><row><entry>Glu Gln  Trp Leu Trp Ser Ile  Phe Leu Gly Met Gly  Thr Leu Leu</entry></row><row><entry>    1040                 1045                 1050</entry></row><row><entry> </entry></row><row><entry>Trp Gly  Gln Leu Ile Ser Thr  Ile Pro Thr Ser Arg  Leu Lys Phe</entry></row><row><entry>    1055                 1060                 1065</entry></row><row><entry> </entry></row><row><entry>Leu Lys  Glu Ala Gly His Gly  Thr Gln Lys Glu Glu  Ile Pro Glu</entry></row><row><entry>    1070                 1075                 1080</entry></row><row><entry> </entry></row><row><entry>Glu Glu  Leu Ala Glu Asp Val  Glu Glu Ile Asp His  Ala Glu Arg</entry></row><row><entry>    1085                 1090                 1095</entry></row><row><entry> </entry></row><row><entry>Glu Leu  Arg Arg Gly Gln Ile  Leu Trp Phe Arg Gly  Leu Asn Arg</entry></row><row><entry>    1100                 1105                 1110</entry></row><row><entry> </entry></row><row><entry>Ile Gln  Thr Gln Met Asp Val  Val Asn Ala Phe Gln  Ser Gly Ser</entry></row><row><entry>    1115                 1120                 1125</entry></row><row><entry> </entry></row><row><entry>Ser Ile  Gln Gly Ala Leu Arg  Arg Gln Pro Ser Ile  Ala Ser Gln</entry></row><row><entry>    1130                 1135                 1140</entry></row><row><entry> </entry></row><row><entry>His His  Asp Val Thr Asn Ile  Ser Thr Pro Thr His  Ile Arg Val</entry></row><row><entry>    1145                 1150                 1155</entry></row><row><entry> </entry></row><row><entry>Val Asn  Ala Phe Arg Ser Ser  Leu Tyr Glu Gly Leu  Glu Lys Pro</entry></row><row><entry>    1160                 1165                 1170</entry></row><row><entry> </entry></row><row><entry>Glu Ser  Arg Ser Ser Ile His  Asn Phe Met Thr His  Pro Glu Phe</entry></row><row><entry>    1175                 1180                 1185</entry></row><row><entry> </entry></row><row><entry>Arg Ile  Glu Asp Ser Glu Pro  His Ile Pro Leu Ile  Asp Asp Thr</entry></row><row><entry>    1190                 1195                 1200</entry></row><row><entry> </entry></row><row><entry>Asp Ala  Glu Asp Asp Ala Pro  Thr Lys Arg Asn Ser  Ser Pro Pro</entry></row><row><entry>    1205                 1210                 1215</entry></row><row><entry> </entry></row><row><entry>Pro Ser  Pro Asn Lys Asn Asn  Asn Ala Val Asp Ser  Gly Ile His</entry></row><row><entry>    1220                 1225                 1230</entry></row><row><entry> </entry></row><row><entry>Leu Thr  Ile Glu Met Asn Lys  Ser Ala Thr Ser Ser  Ser Pro Gly</entry></row><row><entry>    1235                 1240                 1245</entry></row><row><entry> </entry></row><row><entry>Ser Pro  Leu His Ser Leu Glu  Thr Ser Leu</entry></row><row><entry>    1250                 1255</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 317</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 1272</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: ATP2B3</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 317</entry></row><row><entry> </entry></row><row><entry>Met Gly Asp Met Thr Asn Ser Asp Phe Tyr Ser Lys Asn Gln Arg Asn</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Glu Ser Ser His Gly Gly Glu Phe Gly Cys Thr Met Glu Glu Leu Arg</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Ser Leu Met Glu Leu Arg Gly Thr Glu Ala Val Val Lys Ile Lys Glu</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Thr Tyr Gly Asp Thr Glu Ala Ile Cys Arg Arg Leu Lys Thr Ser Pro</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Val Glu Gly Leu Pro Gly Thr Ala Pro Asp Leu Glu Lys Arg Lys Gln</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Ile Phe Gly Gln Asn Phe Ile Pro Pro Lys Lys Pro Lys Thr Phe Leu</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Gln Leu Val Trp Glu Ala Leu Gln Asp Val Thr Leu Ile Ile Leu Glu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Ile Ala Ala Ile Ile Ser Leu Gly Leu Ser Phe Tyr His Pro Pro Gly</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Glu Gly Asn Glu Gly Cys Ala Thr Ala Gln Gly Gly Ala Glu Asp Glu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Gly Glu Ala Glu Ala Gly Trp Ile Glu Gly Ala Ala Ile Leu Leu Ser</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Val Ile Cys Val Val Leu Val Thr Ala Phe Asn Asp Trp Ser Lys Glu</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Lys Gln Phe Arg Gly Leu Gln Ser Arg Ile Glu Gln Glu Gln Lys Phe</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Thr Val Val Arg Ala Gly Gln Val Val Gln Ile Pro Val Ala Glu Ile</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Val Val Gly Asp Ile Ala Gln Val Lys Tyr Gly Asp Leu Leu Pro Ala</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Asp Gly Leu Phe Ile Gln Gly Asn Asp Leu Lys Ile Asp Glu Ser Ser</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Leu Thr Gly Glu Ser Asp Gln Val Arg Lys Ser Val Asp Lys Asp Pro</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Met Leu Leu Ser Gly Thr His Val Met Glu Gly Ser Gly Arg Met Leu</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Val Thr Ala Val Gly Val Asn Ser Gln Thr Gly Ile Ile Phe Thr Leu</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Leu Gly Ala Gly Gly Glu Glu Glu Glu Lys Lys Asp Lys Lys Gly Val</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Lys Lys Gly Asp Gly Leu Gln Leu Pro Ala Ala Asp Gly Ala Ala Ala</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Ser Asn Ala Ala Asp Ser Ala Asn Ala Ser Leu Val Asn Gly Lys Met</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Gln Asp Gly Asn Val Asp Ala Ser Gln Ser Lys Ala Lys Gln Gln Asp</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Gly Ala Ala Ala Met Glu Met Gln Pro Leu Lys Ser Ala Glu Gly Gly</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Asp Ala Asp Asp Arg Lys Lys Ala Ser Met His Lys Lys Glu Lys Ser</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Val Leu Gln Gly Lys Leu Thr Lys Leu Ala Val Gln Ile Gly Lys Ala</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Gly Leu Val Met Ser Ala Ile Thr Val Ile Ile Leu Val Leu Tyr Phe</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Thr Val Asp Thr Phe Val Val Asn Lys Lys Pro Trp Leu Pro Glu Cys</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Thr Pro Val Tyr Val Gln Tyr Phe Val Lys Phe Phe Ile Ile Gly Val</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Thr Val Leu Val Val Ala Val Pro Glu Gly Leu Pro Leu Ala Val Thr</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Ile Ser Leu Ala Tyr Ser Val Lys Lys Met Met Lys Asp Asn Asn Leu</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Val Arg His Leu Asp Ala Cys Glu Thr Met Gly Asn Ala Thr Ala Ile</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Cys Ser Asp Lys Thr Gly Thr Leu Thr Thr Asn Arg Met Thr Val Val</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Gln Ala Tyr Val Gly Asp Val His Tyr Lys Glu Ile Pro Asp Pro Ser</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Ser Ile Asn Thr Lys Thr Met Glu Leu Leu Ile Asn Ala Ile Ala Ile</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Asn Ser Ala Tyr Thr Thr Lys Ile Leu Pro Pro Glu Lys Glu Gly Ala</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Leu Pro Arg Gln Val Gly Asn Lys Thr Glu Cys Gly Leu Leu Gly Phe</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Val Leu Asp Leu Lys Gln Asp Tyr Glu Pro Val Arg Ser Gln Met Pro</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Glu Glu Lys Leu Tyr Lys Val Tyr Thr Phe Asn Ser Val Arg Lys Ser</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Met Ser Thr Val Ile Lys Leu Pro Asp Glu Ser Phe Arg Met Tyr Ser</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Lys Gly Ala Ser Glu Ile Val Leu Lys Lys Cys Cys Lys Ile Leu Asn</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gly Glu Pro Arg Val Phe Arg Pro Arg Asp Arg Asp Glu Met</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Val Lys Lys Val Ile Glu Pro Met Ala Cys Asp Gly Leu Arg Thr Ile</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Cys Val Ala Tyr Arg Asp Phe Pro Ser Ser Pro Glu Pro Asp Trp Asp</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Asn Glu Asn Asp Ile Leu Asn Glu Leu Thr Cys Ile Cys Val Val Gly</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry>Ile Glu Asp Pro Val Arg Pro Glu Val Pro Glu Ala Ile Arg Lys Cys</entry></row><row><entry>705                 710                 715                 720</entry></row><row><entry> </entry></row><row><entry>Gln Arg Ala Gly Ile Thr Val Arg Met Val Thr Gly Asp Asn Ile Asn</entry></row><row><entry>                725                 730                 735</entry></row><row><entry> </entry></row><row><entry>Thr Ala Arg Ala Ile Ala Ile Lys Cys Gly Ile Ile His Pro Gly Glu</entry></row><row><entry>            740                 745                 750</entry></row><row><entry> </entry></row><row><entry>Asp Phe Leu Cys Leu Glu Gly Lys Glu Phe Asn Arg Arg Ile Arg Asn</entry></row><row><entry>        755                 760                 765</entry></row><row><entry> </entry></row><row><entry>Glu Lys Gly Glu Ile Glu Gln Glu Arg Ile Asp Lys Ile Trp Pro Lys</entry></row><row><entry>    770                 775                 780</entry></row><row><entry> </entry></row><row><entry>Leu Arg Val Leu Ala Arg Ser Ser Pro Thr Asp Lys His Thr Leu Val</entry></row><row><entry>785                 790                 795                 800</entry></row><row><entry> </entry></row><row><entry>Lys Gly Ile Ile Asp Ser Thr His Thr Glu Gln Arg Gln Val Val Ala</entry></row><row><entry>                805                 810                 815</entry></row><row><entry> </entry></row><row><entry>Val Thr Gly Asp Gly Thr Asn Asp Gly Pro Ala Leu Lys Lys Ala Asp</entry></row><row><entry>            820                 825                 830</entry></row><row><entry> </entry></row><row><entry>Val Gly Phe Ala Met Gly Ile Ala Gly Thr Asp Val Ala Lys Glu Ala</entry></row><row><entry>        835                 840                 845</entry></row><row><entry> </entry></row><row><entry>Ser Asp Ile Ile Leu Thr Asp Asp Asn Phe Ser Ser Ile Val Lys Ala</entry></row><row><entry>    850                 855                 860</entry></row><row><entry> </entry></row><row><entry>Val Met Trp Gly Arg Asn Val Tyr Asp Ser Ile Ser Lys Phe Leu Gln</entry></row><row><entry>865                 870                 875                 880</entry></row><row><entry> </entry></row><row><entry>Phe Gln Leu Thr Val Asn Val Val Ala Val Ile Val Ala Phe Thr Gly</entry></row><row><entry>                885                 890                 895</entry></row><row><entry> </entry></row><row><entry>Ala Cys Ile Thr Gln Asp Ser Pro Leu Lys Ala Val Gln Met Leu Trp</entry></row><row><entry>            900                 905                 910</entry></row><row><entry> </entry></row><row><entry>Val Asn Leu Ile Met Asp Thr Phe Ala Ser Leu Ala Leu Ala Thr Glu</entry></row><row><entry>        915                 920                 925</entry></row><row><entry> </entry></row><row><entry>Pro Pro Thr Glu Thr Leu Leu Leu Arg Lys Pro Tyr Gly Arg Asn Lys</entry></row><row><entry>    930                 935                 940</entry></row><row><entry> </entry></row><row><entry>Pro Leu Ile Ser Arg Thr Met Met Lys Asn Ile Leu Gly His Ala Val</entry></row><row><entry>945                 950                 955                 960</entry></row><row><entry> </entry></row><row><entry>Tyr Gln Leu Ala Leu Ile Phe Thr Leu Leu Phe Val Gly Glu Lys Met</entry></row><row><entry>                965                 970                 975</entry></row><row><entry> </entry></row><row><entry>Phe Gln Ile Asp Ser Gly Arg Asn Ala Pro Leu His Ser Pro Pro Ser</entry></row><row><entry>            980                 985                 990</entry></row><row><entry> </entry></row><row><entry>Glu His Tyr Thr Ile Ile Phe Asn  Thr Phe Val Met Met  Gln Leu Phe</entry></row><row><entry>        995                 1000                 1005</entry></row><row><entry> </entry></row><row><entry>Asn Glu  Ile Asn Ala Arg Lys  Ile His Gly Glu Arg  Asn Val Phe</entry></row><row><entry>    1010                 1015                 1020</entry></row><row><entry> </entry></row><row><entry>Asp Gly  Ile Phe Arg Asn Pro  Ile Phe Cys Thr Ile  Val Leu Gly</entry></row><row><entry>    1025                 1030                 1035</entry></row><row><entry> </entry></row><row><entry>Thr Phe  Ala Ile Gln Ile Val  Ile Val Gln Phe Gly  Gly Lys Pro</entry></row><row><entry>    1040                 1045                 1050</entry></row><row><entry> </entry></row><row><entry>Phe Ser  Cys Ser Pro Leu Gln  Leu Asp Gln Trp Met  Trp Cys Ile</entry></row><row><entry>    1055                 1060                 1065</entry></row><row><entry> </entry></row><row><entry>Phe Ile  Gly Leu Gly Glu Leu  Val Trp Gly Gln Val  Ile Ala Thr</entry></row><row><entry>    1070                 1075                 1080</entry></row><row><entry> </entry></row><row><entry>Ile Pro  Thr Ser Arg Leu Lys  Phe Leu Lys Glu Ala  Gly Arg Leu</entry></row><row><entry>    1085                 1090                 1095</entry></row><row><entry> </entry></row><row><entry>Thr Gln  Lys Glu Glu Ile Pro  Glu Glu Glu Leu Asn  Glu Asp Val</entry></row><row><entry>    1100                 1105                 1110</entry></row><row><entry> </entry></row><row><entry>Glu Glu  Ile Asp His Ala Glu  Arg Glu Leu Arg Arg  Gly Gln Ile</entry></row><row><entry>    1115                 1120                 1125</entry></row><row><entry> </entry></row><row><entry>Leu Trp  Phe Arg Gly Leu Asn  Arg Ile Gln Thr Gln  Ile Glu Val</entry></row><row><entry>    1130                 1135                 1140</entry></row><row><entry> </entry></row><row><entry>Val Asn  Thr Phe Lys Ser Gly  Ala Ser Phe Gln Gly  Ala Leu Arg</entry></row><row><entry>    1145                 1150                 1155</entry></row><row><entry> </entry></row><row><entry>Arg Gln  Ser Ser Val Thr Ser  Gln Ser Gln Asp Ile  Arg Val Val</entry></row><row><entry>    1160                 1165                 1170</entry></row><row><entry> </entry></row><row><entry>Lys Ala  Phe Arg Ser Ser Leu  Tyr Glu Gly Leu Glu  Lys Pro Glu</entry></row><row><entry>    1175                 1180                 1185</entry></row><row><entry> </entry></row><row><entry>Ser Arg  Thr Ser Ile His Asn  Phe Met Ala His Pro  Glu Phe Arg</entry></row><row><entry>    1190                 1195                 1200</entry></row><row><entry> </entry></row><row><entry>Ile Glu  Asp Ser Gln Pro His  Ile Pro Leu Ile Asp  Asp Thr Asp</entry></row><row><entry>    1205                 1210                 1215</entry></row><row><entry> </entry></row><row><entry>Leu Glu  Glu Asp Ala Ala Leu  Lys Gln Asn Ser Ser  Pro Pro Ser</entry></row><row><entry>    1220                 1225                 1230</entry></row><row><entry> </entry></row><row><entry>Ser Leu  Asn Lys Asn Asn Ser  Ala Ile Asp Ser Gly  Ile Asn Leu</entry></row><row><entry>    1235                 1240                 1245</entry></row><row><entry> </entry></row><row><entry>Thr Thr  Asp Thr Ser Lys Ser  Ala Thr Ser Ser Ser  Pro Gly Ser</entry></row><row><entry>    1250                 1255                 1260</entry></row><row><entry> </entry></row><row><entry>Pro Ile  His Ser Leu Glu Thr  Ser Leu</entry></row><row><entry>    1265                 1270</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 318</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 874</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: ATP2B4</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 318</entry></row><row><entry> </entry></row><row><entry>Met Gly Asp Met Ala Asn Ser Ser Ile Glu Phe His Pro Lys Pro Gln</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Gln Gln Arg Asp Val Pro Gln Ala Gly Gly Phe Gly Cys Thr Leu Ala</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Glu Leu Arg Thr Leu Met Glu Leu Arg Gly Ala Glu Ala Leu Gln Lys</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ile Glu Glu Ala Tyr Gly Asp Val Ser Gly Leu Cys Arg Arg Leu Lys</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Thr Ser Pro Thr Glu Gly Leu Ala Asp Asn Thr Asn Asp Leu Glu Lys</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Arg Arg Gln Ile Tyr Gly Gln Asn Phe Ile Pro Pro Lys Gln Pro Lys</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Thr Phe Leu Gln Leu Val Trp Glu Ala Leu Gln Asp Val Thr Leu Ile</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Ile Leu Glu Val Ala Ala Ile Val Ser Leu Gly Leu Ser Phe Tyr Ala</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Pro Pro Gly Glu Glu Ser Glu Ala Cys Gly Asn Val Ser Gly Gly Ala</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Glu Asp Glu Gly Glu Ala Glu Ala Gly Trp Ile Glu Gly Ala Ala Ile</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Leu Leu Ser Val Ile Cys Val Val Leu Val Thr Ala Phe Asn Asp Trp</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Ser Lys Glu Lys Gln Phe Arg Gly Leu Gln Ser Arg Ile Glu Gln Glu</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Gln Lys Phe Thr Val Ile Arg Asn Gly Gln Leu Leu Gln Val Pro Val</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Ala Ala Leu Val Val Gly Asp Ile Ala Gln Val Lys Tyr Gly Asp Leu</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Leu Pro Ala Asp Gly Val Leu Ile Gln Ala Asn Asp Leu Lys Ile Asp</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Glu Ser Ser Leu Thr Gly Glu Ser Asp His Val Arg Lys Ser Ala Asp</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Lys Asp Pro Met Leu Leu Ser Gly Thr His Val Met Glu Gly Ser Gly</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Arg Met Val Val Thr Ala Val Gly Val Asn Ser Gln Thr Gly Ile Ile</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Phe Thr Leu Leu Gly Ala Gly Gly Glu Glu Glu Glu Lys Lys Asp Lys</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Lys Gly Lys Gln Gln Asp Gly Ala Met Glu Ser Ser Gln Thr Lys Ala</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Lys Lys Gln Asp Gly Ala Val Ala Met Glu Met Gln Pro Leu Lys Ser</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Ala Glu Gly Gly Glu Met Glu Glu Arg Glu Lys Lys Lys Ala Asn Ala</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Pro Lys Lys Glu Lys Ser Val Leu Gln Gly Lys Leu Thr Lys Leu Ala</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Val Gln Ile Gly Lys Ala Gly Leu Val Met Ser Ala Ile Thr Val Ile</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Ile Leu Val Leu Tyr Phe Val Ile Glu Thr Phe Val Val Glu Gly Arg</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Thr Trp Leu Ala Glu Cys Thr Pro Val Tyr Val Gln Tyr Phe Val Lys</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Phe Phe Ile Ile Gly Val Thr Val Leu Val Val Ala Val Pro Glu Gly</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Leu Pro Leu Ala Val Thr Ile Ser Leu Ala Tyr Ser Val Lys Lys Met</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Met Lys Asp Asn Asn Leu Val Arg His Leu Asp Ala Cys Glu Thr Met</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Gly Asn Ala Thr Ala Ile Cys Ser Asp Lys Thr Gly Thr Leu Thr Thr</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Asn Arg Met Thr Val Val Gln Ser Tyr Leu Gly Asp Thr His Tyr Lys</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Glu Ile Pro Ala Pro Ser Ala Leu Thr Pro Lys Ile Leu Asp Leu Leu</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Val His Ala Ile Ser Ile Asn Ser Ala Tyr Thr Thr Lys Ile Leu Pro</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Pro Glu Lys Glu Gly Ala Leu Pro Arg Gln Val Gly Asn Lys Thr Glu</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Cys Ala Leu Leu Gly Phe Val Leu Asp Leu Lys Arg Asp Phe Gln Pro</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Val Arg Glu Gln Ile Pro Glu Asp Lys Leu Tyr Lys Val Tyr Thr Phe</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Asn Ser Val Arg Lys Ser Met Ser Thr Val Ile Arg Met Pro Asp Gly</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Gly Phe Arg Leu Phe Ser Lys Gly Ala Ser Glu Ile Leu Leu Lys Lys</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Cys Thr Asn Ile Leu Asn Ser Asn Gly Glu Leu Arg Gly Phe Arg Pro</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Arg Asp Arg Asp Asp Met Val Arg Lys Ile Ile Glu Pro Met Ala Cys</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Asp Gly Leu Arg Thr Ile Cys Ile Ala Tyr Arg Asp Phe Ser Ala Gly</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Gln Glu Pro Asp Trp Asp Asn Glu Asn Glu Val Val Gly Asp Leu Thr</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Cys Ile Ala Val Val Gly Ile Glu Asp Pro Val Arg Pro Glu Val Pro</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Glu Ala Ile Arg Lys Cys Gln Arg Ala Gly Ile Thr Val Arg Met Val</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry>Thr Gly Asp Asn Ile Asn Thr Ala Arg Ala Ile Ala Ala Lys Cys Gly</entry></row><row><entry>705                 710                 715                 720</entry></row><row><entry> </entry></row><row><entry>Ile Ile Gln Pro Gly Glu Asp Phe Leu Cys Leu Glu Gly Lys Glu Phe</entry></row><row><entry>                725                 730                 735</entry></row><row><entry> </entry></row><row><entry>Asn Arg Arg Ile Arg Asn Glu Lys Gly Glu Ile Glu Gln Glu Arg Leu</entry></row><row><entry>            740                 745                 750</entry></row><row><entry> </entry></row><row><entry>Asp Lys Val Trp Pro Lys Leu Arg Val Leu Ala Arg Ser Ser Pro Thr</entry></row><row><entry>        755                 760                 765</entry></row><row><entry> </entry></row><row><entry>Asp Lys His Thr Leu Val Lys Gly Ile Ile Asp Ser Thr Thr Gly Glu</entry></row><row><entry>    770                 775                 780</entry></row><row><entry> </entry></row><row><entry>Gln Arg Gln Val Val Ala Val Thr Gly Asp Gly Thr Asn Asp Gly Pro</entry></row><row><entry>785                 790                 795                 800</entry></row><row><entry> </entry></row><row><entry>Ala Leu Lys Lys Ala Asp Val Gly Phe Ala Met Gly Ile Ala Gly Thr</entry></row><row><entry>                805                 810                 815</entry></row><row><entry> </entry></row><row><entry>Asp Val Ala Lys Glu Ala Ser Asp Ile Ile Leu Thr Asp Asp Asn Phe</entry></row><row><entry>            820                 825                 830</entry></row><row><entry> </entry></row><row><entry>Thr Ser Ile Val Lys Ala Val Met Trp Gly Arg Asn Val Tyr Asp Ser</entry></row><row><entry>        835                 840                 845</entry></row><row><entry> </entry></row><row><entry>Ile Ser Lys Phe Leu Gln Phe Gln Leu Thr Val Asn Val Val Ala Val</entry></row><row><entry>    850                 855                 860</entry></row><row><entry> </entry></row><row><entry>Ile Val Ala Phe Thr Gly Ala Cys Ile Thr</entry></row><row><entry>865                 870</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 319</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 731</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: PTGFRN Protein Fragment #1</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 319</entry></row><row><entry> </entry></row><row><entry>Pro Ser Ala Arg Pro Pro Pro Ser Leu Ser Leu Arg Glu Gly Glu Pro</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Phe Glu Leu Arg Cys Thr Ala Ala Ser Ala Ser Pro Leu His Thr His</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Leu Ala Leu Leu Trp Glu Val His Arg Gly Pro Ala Arg Arg Ser Val</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Leu Ala Leu Thr His Glu Gly Arg Phe His Pro Gly Leu Gly Tyr Glu</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Gln Arg Tyr His Ser Gly Asp Val Arg Leu Asp Thr Val Gly Ser Asp</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Ala Tyr Arg Leu Ser Val Ser Arg Ala Leu Ser Ala Asp Gln Gly Ser</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Tyr Arg Cys Ile Val Ser Glu Trp Ile Ala Glu Gln Gly Asn Trp Gln</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Glu Ile Gln Glu Lys Ala Val Glu Val Ala Thr Val Val Ile Gln Pro</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ser Val Leu Arg Ala Ala Val Pro Lys Asn Val Ser Val Ala Glu Gly</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Lys Glu Leu Asp Leu Thr Cys Asn Ile Thr Thr Asp Arg Ala Asp Asp</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Val Arg Pro Glu Val Thr Trp Ser Phe Ser Arg Met Pro Asp Ser Thr</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Leu Pro Gly Ser Arg Val Leu Ala Arg Leu Asp Arg Asp Ser Leu Val</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>His Ser Ser Pro His Val Ala Leu Ser His Val Asp Ala Arg Ser Tyr</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>His Leu Leu Val Arg Asp Val Ser Lys Glu Asn Ser Gly Tyr Tyr Tyr</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Cys His Val Ser Leu Trp Ala Pro Gly His Asn Arg Ser Trp His Lys</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Val Ala Glu Ala Val Ser Ser Pro Ala Gly Val Gly Val Thr Trp Leu</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Glu Pro Asp Tyr Gln Val Tyr Leu Asn Ala Ser Lys Val Pro Gly Phe</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Ala Asp Asp Pro Thr Glu Leu Ala Cys Arg Val Val Asp Thr Lys Ser</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Gly Glu Ala Asn Val Arg Phe Thr Val Ser Trp Tyr Tyr Arg Met Asn</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Arg Arg Ser Asp Asn Val Val Thr Ser Glu Leu Leu Ala Val Met Asp</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Gly Asp Trp Thr Leu Lys Tyr Gly Glu Arg Ser Lys Gln Arg Ala Gln</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Asp Gly Asp Phe Ile Phe Ser Lys Glu His Thr Asp Thr Phe Asn Phe</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Arg Ile Gln Arg Thr Thr Glu Glu Asp Arg Gly Asn Tyr Tyr Cys Val</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Val Ser Ala Trp Thr Lys Gln Arg Asn Asn Ser Trp Val Lys Ser Lys</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Asp Val Phe Ser Lys Pro Val Asn Ile Phe Trp Ala Leu Glu Asp Ser</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Val Leu Val Val Lys Ala Arg Gln Pro Lys Pro Phe Phe Ala Ala Gly</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Asn Thr Phe Glu Met Thr Cys Lys Val Ser Ser Lys Asn Ile Lys Ser</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Pro Arg Tyr Ser Val Leu Ile Met Ala Glu Lys Pro Val Gly Asp Leu</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Ser Ser Pro Asn Glu Thr Lys Tyr Ile Ile Ser Leu Asp Gln Asp Ser</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Val Val Lys Leu Glu Asn Trp Thr Asp Ala Ser Arg Val Asp Gly Val</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Val Leu Glu Lys Val Gln Glu Asp Glu Phe Arg Tyr Arg Met Tyr Gln</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Thr Gln Val Ser Asp Ala Gly Leu Tyr Arg Cys Met Val Thr Ala Trp</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Ser Pro Val Arg Gly Ser Leu Trp Arg Glu Ala Ala Thr Ser Leu Ser</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Asn Pro Ile Glu Ile Asp Phe Gln Thr Ser Gly Pro Ile Phe Asn Ala</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Ser Val His Ser Asp Thr Pro Ser Val Ile Arg Gly Asp Leu Ile Lys</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Leu Phe Cys Ile Ile Thr Val Glu Gly Ala Ala Leu Asp Pro Asp Asp</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Met Ala Phe Asp Val Ser Trp Phe Ala Val His Ser Phe Gly Leu Asp</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Lys Ala Pro Val Leu Leu Ser Ser Leu Asp Arg Lys Gly Ile Val Thr</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Thr Ser Arg Arg Asp Trp Lys Ser Asp Leu Ser Leu Glu Arg Val Ser</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Val Leu Glu Phe Leu Leu Gln Val His Gly Ser Glu Asp Gln Asp Phe</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Gly Asn Tyr Tyr Cys Ser Val Thr Pro Trp Val Lys Ser Pro Thr Gly</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Ser Trp Gln Lys Glu Ala Glu Ile His Ser Lys Pro Val Phe Ile Thr</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Val Lys Met Asp Val Leu Asn Ala Phe Lys Tyr Pro Leu Leu Ile Gly</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Val Gly Leu Ser Thr Val Ile Gly Leu Leu Ser Cys Leu Ile Gly Tyr</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry>Cys Ser Ser His Trp Cys Cys Lys Lys Glu Val Gln Glu Thr Arg Arg</entry></row><row><entry>705                 710                 715                 720</entry></row><row><entry> </entry></row><row><entry>Glu Arg Arg Arg Leu Met Ser Met Glu Met Asp</entry></row><row><entry>                725                 730</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 320</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 611</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: PTGFRN Protein Fragment #2</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 320</entry></row><row><entry> </entry></row><row><entry>Val Ala Thr Val Val Ile Gln Pro Ser Val Leu Arg Ala Ala Val Pro</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Asn Val Ser Val Ala Glu Gly Lys Glu Leu Asp Leu Thr Cys Asn</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Ile Thr Thr Asp Arg Ala Asp Asp Val Arg Pro Glu Val Thr Trp Ser</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Phe Ser Arg Met Pro Asp Ser Thr Leu Pro Gly Ser Arg Val Leu Ala</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Arg Leu Asp Arg Asp Ser Leu Val His Ser Ser Pro His Val Ala Leu</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Ser His Val Asp Ala Arg Ser Tyr His Leu Leu Val Arg Asp Val Ser</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Lys Glu Asn Ser Gly Tyr Tyr Tyr Cys His Val Ser Leu Trp Ala Pro</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Gly His Asn Arg Ser Trp His Lys Val Ala Glu Ala Val Ser Ser Pro</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ala Gly Val Gly Val Thr Trp Leu Glu Pro Asp Tyr Gln Val Tyr Leu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Asn Ala Ser Lys Val Pro Gly Phe Ala Asp Asp Pro Thr Glu Leu Ala</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Cys Arg Val Val Asp Thr Lys Ser Gly Glu Ala Asn Val Arg Phe Thr</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Val Ser Trp Tyr Tyr Arg Met Asn Arg Arg Ser Asp Asn Val Val Thr</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Ser Glu Leu Leu Ala Val Met Asp Gly Asp Trp Thr Leu Lys Tyr Gly</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Glu Arg Ser Lys Gln Arg Ala Gln Asp Gly Asp Phe Ile Phe Ser Lys</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Glu His Thr Asp Thr Phe Asn Phe Arg Ile Gln Arg Thr Thr Glu Glu</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Asp Arg Gly Asn Tyr Tyr Cys Val Val Ser Ala Trp Thr Lys Gln Arg</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Asn Asn Ser Trp Val Lys Ser Lys Asp Val Phe Ser Lys Pro Val Asn</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Ile Phe Trp Ala Leu Glu Asp Ser Val Leu Val Val Lys Ala Arg Gln</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Pro Lys Pro Phe Phe Ala Ala Gly Asn Thr Phe Glu Met Thr Cys Lys</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Val Ser Ser Lys Asn Ile Lys Ser Pro Arg Tyr Ser Val Leu Ile Met</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Ala Glu Lys Pro Val Gly Asp Leu Ser Ser Pro Asn Glu Thr Lys Tyr</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Ile Ile Ser Leu Asp Gln Asp Ser Val Val Lys Leu Glu Asn Trp Thr</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Asp Ala Ser Arg Val Asp Gly Val Val Leu Glu Lys Val Gln Glu Asp</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Glu Phe Arg Tyr Arg Met Tyr Gln Thr Gln Val Ser Asp Ala Gly Leu</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Tyr Arg Cys Met Val Thr Ala Trp Ser Pro Val Arg Gly Ser Leu Trp</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Arg Glu Ala Ala Thr Ser Leu Ser Asn Pro Ile Glu Ile Asp Phe Gln</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Thr Ser Gly Pro Ile Phe Asn Ala Ser Val His Ser Asp Thr Pro Ser</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Val Ile Arg Gly Asp Leu Ile Lys Leu Phe Cys Ile Ile Thr Val Glu</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Gly Ala Ala Leu Asp Pro Asp Asp Met Ala Phe Asp Val Ser Trp Phe</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Ala Val His Ser Phe Gly Leu Asp Lys Ala Pro Val Leu Leu Ser Ser</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Leu Asp Arg Lys Gly Ile Val Thr Thr Ser Arg Arg Asp Trp Lys Ser</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Asp Leu Ser Leu Glu Arg Val Ser Val Leu Glu Phe Leu Leu Gln Val</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>His Gly Ser Glu Asp Gln Asp Phe Gly Asn Tyr Tyr Cys Ser Val Thr</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Pro Trp Val Lys Ser Pro Thr Gly Ser Trp Gln Lys Glu Ala Glu Ile</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>His Ser Lys Pro Val Phe Ile Thr Val Lys Met Asp Val Leu Asn Ala</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Phe Lys Tyr Pro Leu Leu Ile Gly Val Gly Leu Ser Thr Val Ile Gly</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Leu Leu Ser Cys Leu Ile Gly Tyr Cys Ser Ser His Trp Cys Cys Lys</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Lys Glu Val Gln Glu Thr Arg Arg Glu Arg Arg Arg Leu Met Ser Met</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Glu Met Asp</entry></row><row><entry>    610</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 321</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 485</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: PTGFRN Protein Fragment #3</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 321</entry></row><row><entry> </entry></row><row><entry>Ser Pro Ala Gly Val Gly Val Thr Trp Leu Glu Pro Asp Tyr Gln Val</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Tyr Leu Asn Ala Ser Lys Val Pro Gly Phe Ala Asp Asp Pro Thr Glu</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Leu Ala Cys Arg Val Val Asp Thr Lys Ser Gly Glu Ala Asn Val Arg</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Phe Thr Val Ser Trp Tyr Tyr Arg Met Asn Arg Arg Ser Asp Asn Val</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Val Thr Ser Glu Leu Leu Ala Val Met Asp Gly Asp Trp Thr Leu Lys</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Tyr Gly Glu Arg Ser Lys Gln Arg Ala Gln Asp Gly Asp Phe Ile Phe</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Ser Lys Glu His Thr Asp Thr Phe Asn Phe Arg Ile Gln Arg Thr Thr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Glu Glu Asp Arg Gly Asn Tyr Tyr Cys Val Val Ser Ala Trp Thr Lys</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Gln Arg Asn Asn Ser Trp Val Lys Ser Lys Asp Val Phe Ser Lys Pro</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Val Asn Ile Phe Trp Ala Leu Glu Asp Ser Val Leu Val Val Lys Ala</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Arg Gln Pro Lys Pro Phe Phe Ala Ala Gly Asn Thr Phe Glu Met Thr</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Cys Lys Val Ser Ser Lys Asn Ile Lys Ser Pro Arg Tyr Ser Val Leu</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Ile Met Ala Glu Lys Pro Val Gly Asp Leu Ser Ser Pro Asn Glu Thr</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Lys Tyr Ile Ile Ser Leu Asp Gln Asp Ser Val Val Lys Leu Glu Asn</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Trp Thr Asp Ala Ser Arg Val Asp Gly Val Val Leu Glu Lys Val Gln</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Glu Asp Glu Phe Arg Tyr Arg Met Tyr Gln Thr Gln Val Ser Asp Ala</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Gly Leu Tyr Arg Cys Met Val Thr Ala Trp Ser Pro Val Arg Gly Ser</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Leu Trp Arg Glu Ala Ala Thr Ser Leu Ser Asn Pro Ile Glu Ile Asp</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Phe Gln Thr Ser Gly Pro Ile Phe Asn Ala Ser Val His Ser Asp Thr</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Pro Ser Val Ile Arg Gly Asp Leu Ile Lys Leu Phe Cys Ile Ile Thr</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Val Glu Gly Ala Ala Leu Asp Pro Asp Asp Met Ala Phe Asp Val Ser</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Trp Phe Ala Val His Ser Phe Gly Leu Asp Lys Ala Pro Val Leu Leu</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Ser Ser Leu Asp Arg Lys Gly Ile Val Thr Thr Ser Arg Arg Asp Trp</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Lys Ser Asp Leu Ser Leu Glu Arg Val Ser Val Leu Glu Phe Leu Leu</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Gln Val His Gly Ser Glu Asp Gln Asp Phe Gly Asn Tyr Tyr Cys Ser</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Val Thr Pro Trp Val Lys Ser Pro Thr Gly Ser Trp Gln Lys Glu Ala</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Glu Ile His Ser Lys Pro Val Phe Ile Thr Val Lys Met Asp Val Leu</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Asn Ala Phe Lys Tyr Pro Leu Leu Ile Gly Val Gly Leu Ser Thr Val</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Ile Gly Leu Leu Ser Cys Leu Ile Gly Tyr Cys Ser Ser His Trp Cys</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Cys Lys Lys Glu Val Gln Glu Thr Arg Arg Glu Arg Arg Arg Leu Met</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Ser Met Glu Met Asp</entry></row><row><entry>                485</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 322</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 343</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: PTGFRN Protein Fragment #4</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 322</entry></row><row><entry> </entry></row><row><entry>Lys Pro Val Asn Ile Phe Trp Ala Leu Glu Asp Ser Val Leu Val Val</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ala Arg Gln Pro Lys Pro Phe Phe Ala Ala Gly Asn Thr Phe Glu</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Met Thr Cys Lys Val Ser Ser Lys Asn Ile Lys Ser Pro Arg Tyr Ser</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Val Leu Ile Met Ala Glu Lys Pro Val Gly Asp Leu Ser Ser Pro Asn</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Glu Thr Lys Tyr Ile Ile Ser Leu Asp Gln Asp Ser Val Val Lys Leu</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Glu Asn Trp Thr Asp Ala Ser Arg Val Asp Gly Val Val Leu Glu Lys</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Val Gln Glu Asp Glu Phe Arg Tyr Arg Met Tyr Gln Thr Gln Val Ser</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Asp Ala Gly Leu Tyr Arg Cys Met Val Thr Ala Trp Ser Pro Val Arg</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Gly Ser Leu Trp Arg Glu Ala Ala Thr Ser Leu Ser Asn Pro Ile Glu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ile Asp Phe Gln Thr Ser Gly Pro Ile Phe Asn Ala Ser Val His Ser</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Asp Thr Pro Ser Val Ile Arg Gly Asp Leu Ile Lys Leu Phe Cys Ile</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Ile Thr Val Glu Gly Ala Ala Leu Asp Pro Asp Asp Met Ala Phe Asp</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Val Ser Trp Phe Ala Val His Ser Phe Gly Leu Asp Lys Ala Pro Val</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Leu Leu Ser Ser Leu Asp Arg Lys Gly Ile Val Thr Thr Ser Arg Arg</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Asp Trp Lys Ser Asp Leu Ser Leu Glu Arg Val Ser Val Leu Glu Phe</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Leu Leu Gln Val His Gly Ser Glu Asp Gln Asp Phe Gly Asn Tyr Tyr</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Cys Ser Val Thr Pro Trp Val Lys Ser Pro Thr Gly Ser Trp Gln Lys</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Glu Ala Glu Ile His Ser Lys Pro Val Phe Ile Thr Val Lys Met Asp</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Val Leu Asn Ala Phe Lys Tyr Pro Leu Leu Ile Gly Val Gly Leu Ser</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Thr Val Ile Gly Leu Leu Ser Cys Leu Ile Gly Tyr Cys Ser Ser His</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Trp Cys Cys Lys Lys Glu Val Gln Glu Thr Arg Arg Glu Arg Arg Arg</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Leu Met Ser Met Glu Met Asp</entry></row><row><entry>            340</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 323</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 217</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: PTGFRN Protein Fragment #5</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 323</entry></row><row><entry> </entry></row><row><entry>Val Arg Gly Ser Leu Trp Arg Glu Ala Ala Thr Ser Leu Ser Asn Pro</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ile Glu Ile Asp Phe Gln Thr Ser Gly Pro Ile Phe Asn Ala Ser Val</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>His Ser Asp Thr Pro Ser Val Ile Arg Gly Asp Leu Ile Lys Leu Phe</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Cys Ile Ile Thr Val Glu Gly Ala Ala Leu Asp Pro Asp Asp Met Ala</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Phe Asp Val Ser Trp Phe Ala Val His Ser Phe Gly Leu Asp Lys Ala</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Pro Val Leu Leu Ser Ser Leu Asp Arg Lys Gly Ile Val Thr Thr Ser</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Arg Arg Asp Trp Lys Ser Asp Leu Ser Leu Glu Arg Val Ser Val Leu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Glu Phe Leu Leu Gln Val His Gly Ser Glu Asp Gln Asp Phe Gly Asn</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Tyr Tyr Cys Ser Val Thr Pro Trp Val Lys Ser Pro Thr Gly Ser Trp</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Gln Lys Glu Ala Glu Ile His Ser Lys Pro Val Phe Ile Thr Val Lys</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Met Asp Val Leu Asn Ala Phe Lys Tyr Pro Leu Leu Ile Gly Val Gly</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Leu Ser Thr Val Ile Gly Leu Leu Ser Cys Leu Ile Gly Tyr Cys Ser</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Ser His Trp Cys Cys Lys Lys Glu Val Gln Glu Thr Arg Arg Glu Arg</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Arg Arg Leu Met Ser Met Glu Met Asp</entry></row><row><entry>    210                 215</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 324</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 66</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: PTGFRN Protein Fragment #6</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 324</entry></row><row><entry> </entry></row><row><entry>Ser Lys Pro Val Phe Ile Thr Val Lys Met Asp Val Leu Asn Ala Phe</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Tyr Pro Leu Leu Ile Gly Val Gly Leu Ser Thr Val Ile Gly Leu</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Leu Ser Cys Leu Ile Gly Tyr Cys Ser Ser His Trp Cys Cys Lys Lys</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Glu Val Gln Glu Thr Arg Arg Glu Arg Arg Arg Leu Met Ser Met Glu</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Met Asp</entry></row><row><entry>65</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 325</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 21</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: PTGFRN Protein - Signal Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 325</entry></row><row><entry> </entry></row><row><entry>Met Gly Arg Leu Ala Ser Arg Pro Leu Leu Leu Ala Leu Leu Ser Leu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ala Leu Cys Arg Gly</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 326</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 247</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: BSG Protein Fragment #1</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 326</entry></row><row><entry> </entry></row><row><entry>Pro Gly Thr Val Phe Thr Thr Val Glu Asp Leu Gly Ser Lys Ile Leu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Thr Cys Ser Leu Asn Asp Ser Ala Thr Glu Val Thr Gly His Arg</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Trp Leu Lys Gly Gly Val Val Leu Lys Glu Asp Ala Leu Pro Gly Gln</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Lys Thr Glu Phe Lys Val Asp Ser Asp Asp Gln Trp Gly Glu Tyr Ser</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Cys Val Phe Leu Pro Glu Pro Met Gly Thr Ala Asn Ile Gln Leu His</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Gly Pro Pro Arg Val Lys Ala Val Lys Ser Ser Glu His Ile Asn Glu</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Gly Glu Thr Ala Met Leu Val Cys Lys Ser Glu Ser Val Pro Pro Val</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Thr Asp Trp Ala Trp Tyr Lys Ile Thr Asp Ser Glu Asp Lys Ala Leu</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Met Asn Gly Ser Glu Ser Arg Phe Phe Val Ser Ser Ser Gln Gly Arg</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ser Glu Leu His Ile Glu Asn Leu Asn Met Glu Ala Asp Pro Gly Gln</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Tyr Arg Cys Asn Gly Thr Ser Ser Lys Gly Ser Asp Gln Ala Ile Ile</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Thr Leu Arg Val Arg Ser His Leu Ala Ala Leu Trp Pro Phe Leu Gly</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Ile Val Ala Glu Val Leu Val Leu Val Thr Ile Ile Phe Ile Tyr Glu</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Lys Arg Arg Lys Pro Glu Asp Val Leu Asp Asp Asp Asp Ala Gly Ser</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Ala Pro Leu Lys Ser Ser Gly Gln His Gln Asn Asp Lys Gly Lys Asn</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Val Arg Gln Arg Asn Ser Ser</entry></row><row><entry>                245</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 327</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 168</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: BSG Protein Fragment #2</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 327</entry></row><row><entry> </entry></row><row><entry>His Gly Pro Pro Arg Val Lys Ala Val Lys Ser Ser Glu His Ile Asn</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Glu Gly Glu Thr Ala Met Leu Val Cys Lys Ser Glu Ser Val Pro Pro</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Val Thr Asp Trp Ala Trp Tyr Lys Ile Thr Asp Ser Glu Asp Lys Ala</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Leu Met Asn Gly Ser Glu Ser Arg Phe Phe Val Ser Ser Ser Gln Gly</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Arg Ser Glu Leu His Ile Glu Asn Leu Asn Met Glu Ala Asp Pro Gly</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Gln Tyr Arg Cys Asn Gly Thr Ser Ser Lys Gly Ser Asp Gln Ala Ile</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Ile Thr Leu Arg Val Arg Ser His Leu Ala Ala Leu Trp Pro Phe Leu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Gly Ile Val Ala Glu Val Leu Val Leu Val Thr Ile Ile Phe Ile Tyr</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Glu Lys Arg Arg Lys Pro Glu Asp Val Leu Asp Asp Asp Asp Ala Gly</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ser Ala Pro Leu Lys Ser Ser Gly Gln His Gln Asn Asp Lys Gly Lys</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Asn Val Arg Gln Arg Asn Ser Ser</entry></row><row><entry>                165</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 328</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 66</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: BSG Protein Fragment #3</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 328</entry></row><row><entry> </entry></row><row><entry>Ser His Leu Ala Ala Leu Trp Pro Phe Leu Gly Ile Val Ala Glu Val</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Val Leu Val Thr Ile Ile Phe Ile Tyr Glu Lys Arg Arg Lys Pro</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Glu Asp Val Leu Asp Asp Asp Asp Ala Gly Ser Ala Pro Leu Lys Ser</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ser Gly Gln His Gln Asn Asp Lys Gly Lys Asn Val Arg Gln Arg Asn</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ser Ser</entry></row><row><entry>65</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 329</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 18</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: BSG Protein - Signal Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 329</entry></row><row><entry> </entry></row><row><entry>Met Ala Ala Ala Leu Phe Val Leu Leu Gly Phe Ala Leu Leu Gly Thr</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>His Gly</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 330</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 456</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: IGSF8 Protein Fragment #1</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 330</entry></row><row><entry> </entry></row><row><entry>Ala Pro Pro Gly Pro Arg Gly Arg Gln Ala Pro Thr Ser Pro Pro Arg</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Met Thr Val His Glu Gly Gln Glu Leu Ala Leu Gly Cys Leu Ala Arg</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Thr Ser Thr Gln Lys His Thr His Leu Ala Val Ser Phe Gly Arg Ser</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Val Pro Glu Ala Pro Val Gly Arg Ser Thr Leu Gln Glu Val Val Gly</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ile Arg Ser Asp Leu Ala Val Glu Ala Gly Ala Pro Tyr Ala Glu Arg</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Leu Ala Ala Gly Glu Leu Arg Leu Gly Lys Glu Gly Thr Asp Arg Tyr</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Arg Met Val Val Gly Gly Ala Gln Ala Gly Asp Ala Gly Thr Tyr His</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Cys Thr Ala Ala Glu Trp Ile Gln Asp Pro Asp Gly Ser Trp Ala Gln</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ile Ala Glu Lys Arg Ala Val Leu Ala His Val Asp Val Gln Thr Leu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ser Ser Gln Leu Ala Val Thr Val Gly Pro Gly Glu Arg Arg Ile Gly</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Pro Gly Glu Pro Leu Glu Leu Leu Cys Asn Val Ser Gly Ala Leu Pro</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Pro Ala Gly Arg His Ala Ala Tyr Ser Val Gly Trp Glu Met Ala Pro</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Ala Gly Ala Pro Gly Pro Gly Arg Leu Val Ala Gln Leu Asp Thr Glu</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Gly Val Gly Ser Leu Gly Pro Gly Tyr Glu Gly Arg His Ile Ala Met</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Glu Lys Val Ala Ser Arg Thr Tyr Arg Leu Arg Leu Glu Ala Ala Arg</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Pro Gly Asp Ala Gly Thr Tyr Arg Cys Leu Ala Lys Ala Tyr Val Arg</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gly Thr Arg Leu Arg Glu Ala Ala Ser Ala Arg Ser Arg Pro</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Leu Pro Val His Val Arg Glu Glu Gly Val Val Leu Glu Ala Val Ala</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Trp Leu Ala Gly Gly Thr Val Tyr Arg Gly Glu Thr Ala Ser Leu Leu</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Cys Asn Ile Ser Val Arg Gly Gly Pro Pro Gly Leu Arg Leu Ala Ala</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Ser Trp Trp Val Glu Arg Pro Glu Asp Gly Glu Leu Ser Ser Val Pro</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Ala Gln Leu Val Gly Gly Val Gly Gln Asp Gly Val Ala Glu Leu Gly</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Val Arg Pro Gly Gly Gly Pro Val Ser Val Glu Leu Val Gly Pro Arg</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Ser His Arg Leu Arg Leu His Ser Leu Gly Pro Glu Asp Glu Gly Val</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Tyr His Cys Ala Pro Ser Ala Trp Val Gln His Ala Asp Tyr Ser Trp</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Tyr Gln Ala Gly Ser Ala Arg Ser Gly Pro Val Thr Val Tyr Pro Tyr</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Met His Ala Leu Asp Thr Leu Phe Val Pro Leu Leu Val Gly Thr Gly</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Val Ala Leu Val Thr Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Phe Met Lys Arg Leu Arg Lys Arg</entry></row><row><entry>    450                 455</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 331</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 320</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: IGSF8 Protein Fragment #2</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 331</entry></row><row><entry> </entry></row><row><entry>Ala His Val Asp Val Gln Thr Leu Ser Ser Gln Leu Ala Val Thr Val</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Gly Pro Gly Glu Arg Arg Ile Gly Pro Gly Glu Pro Leu Glu Leu Leu</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Cys Asn Val Ser Gly Ala Leu Pro Pro Ala Gly Arg His Ala Ala Tyr</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ser Val Gly Trp Glu Met Ala Pro Ala Gly Ala Pro Gly Pro Gly Arg</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Leu Val Ala Gln Leu Asp Thr Glu Gly Val Gly Ser Leu Gly Pro Gly</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Tyr Glu Gly Arg His Ile Ala Met Glu Lys Val Ala Ser Arg Thr Tyr</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Arg Leu Arg Leu Glu Ala Ala Arg Pro Gly Asp Ala Gly Thr Tyr Arg</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Cys Leu Ala Lys Ala Tyr Val Arg Gly Ser Gly Thr Arg Leu Arg Glu</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ala Ala Ser Ala Arg Ser Arg Pro Leu Pro Val His Val Arg Glu Glu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Gly Val Val Leu Glu Ala Val Ala Trp Leu Ala Gly Gly Thr Val Tyr</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Arg Gly Glu Thr Ala Ser Leu Leu Cys Asn Ile Ser Val Arg Gly Gly</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Pro Pro Gly Leu Arg Leu Ala Ala Ser Trp Trp Val Glu Arg Pro Glu</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Asp Gly Glu Leu Ser Ser Val Pro Ala Gln Leu Val Gly Gly Val Gly</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Gln Asp Gly Val Ala Glu Leu Gly Val Arg Pro Gly Gly Gly Pro Val</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Ser Val Glu Leu Val Gly Pro Arg Ser His Arg Leu Arg Leu His Ser</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Leu Gly Pro Glu Asp Glu Gly Val Tyr His Cys Ala Pro Ser Ala Trp</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Val Gln His Ala Asp Tyr Ser Trp Tyr Gln Ala Gly Ser Ala Arg Ser</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Gly Pro Val Thr Val Tyr Pro Tyr Met His Ala Leu Asp Thr Leu Phe</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Val Pro Leu Leu Val Gly Thr Gly Val Ala Leu Val Thr Gly Ala Thr</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Val Leu Gly Thr Ile Thr Cys Cys Phe Met Lys Arg Leu Arg Lys Arg</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 332</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 179</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: IGSF8 Protein Fragment #3</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 332</entry></row><row><entry> </entry></row><row><entry>Arg Glu Glu Gly Val Val Leu Glu Ala Val Ala Trp Leu Ala Gly Gly</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Thr Val Tyr Arg Gly Glu Thr Ala Ser Leu Leu Cys Asn Ile Ser Val</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Arg Gly Gly Pro Pro Gly Leu Arg Leu Ala Ala Ser Trp Trp Val Glu</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Arg Pro Glu Asp Gly Glu Leu Ser Ser Val Pro Ala Gln Leu Val Gly</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Gly Val Gly Gln Asp Gly Val Ala Glu Leu Gly Val Arg Pro Gly Gly</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Gly Pro Val Ser Val Glu Leu Val Gly Pro Arg Ser His Arg Leu Arg</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Leu His Ser Leu Gly Pro Glu Asp Glu Gly Val Tyr His Cys Ala Pro</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Ser Ala Trp Val Gln His Ala Asp Tyr Ser Trp Tyr Gln Ala Gly Ser</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ala Arg Ser Gly Pro Val Thr Val Tyr Pro Tyr Met His Ala Leu Asp</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Thr Leu Phe Val Pro Leu Leu Val Gly Thr Gly Val Ala Leu Val Thr</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys Phe Met Lys Arg Leu</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Arg Lys Arg</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 333</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 24</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: IGSF8 Protein Fragment #4</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 333</entry></row><row><entry> </entry></row><row><entry>Val Ala Leu Val Thr Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Phe Met Lys Arg Leu Arg Lys Arg</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 334</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 27</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: IGSF8 Protein - Signal Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 334</entry></row><row><entry> </entry></row><row><entry>Met Gly Ala Leu Arg Pro Thr Leu Leu Pro Pro Ser Leu Pro Leu Leu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Leu Leu Met Leu Gly Met Gly Cys Trp Ala</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 335</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 335</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 336</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 336</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 337</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 337</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 338</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 338</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 339</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 339</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 340</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 340</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 341</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 341</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 342</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 342</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 343</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 343</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 344</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 344</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 345</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 345</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 346</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 346</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 347</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 347</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 348</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 348</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 349</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 349</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 350</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 350</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 351</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 351</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 352</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 352</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 353</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 353</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 354</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 354</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 355</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 355</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 356</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 356</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 357</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 357</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 358</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 358</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 359</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 359</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 360</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 360</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 361</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 361</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 362</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 362</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 363</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 363</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 364</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 364</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 365</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 365</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 366</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 366</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 367</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 367</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 368</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 368</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 369</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 369</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 370</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 370</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 371</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 371</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 372</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 372</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 373</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 373</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 374</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 374</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 375</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 375</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 376</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 376</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 377</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 377</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 378</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 378</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 379</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 379</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 380</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 380</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 381</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 381</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 382</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 382</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 383</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 383</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 384</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 384</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 385</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 385</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 386</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 386</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 387</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 387</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 388</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 388</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 389</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 389</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 390</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 390</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 391</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 391</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 392</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 392</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 393</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 393</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 394</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 394</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 395</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 395</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 396</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 396</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 397</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 397</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 398</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 398</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 399</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 399</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 400</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 400</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 401</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 332</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: The MARCKS protein</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 401</entry></row><row><entry> </entry></row><row><entry>Met Gly Ala Gln Phe Ser Lys Thr Ala Ala Lys Gly Glu Ala Ala Ala</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Glu Arg Pro Gly Glu Ala Ala Val Ala Ser Ser Pro Ser Lys Ala Asn</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Gly Gln Glu Asn Gly His Val Lys Val Asn Gly Asp Ala Ser Pro Ala</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ala Ala Glu Ser Gly Ala Lys Glu Glu Leu Gln Ala Asn Gly Ser Ala</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Pro Ala Ala Asp Lys Glu Glu Pro Ala Ala Ala Gly Ser Gly Ala Ala</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Ser Pro Ser Ala Ala Glu Lys Gly Glu Pro Ala Ala Ala Ala Ala Pro</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Glu Ala Gly Ala Ser Pro Val Glu Lys Glu Ala Pro Ala Glu Gly Glu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Ala Ala Glu Pro Gly Ser Pro Thr Ala Ala Glu Gly Glu Ala Ala Ser</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ala Ala Ser Ser Thr Ser Ser Pro Lys Ala Glu Asp Gly Ala Thr Pro</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ser Pro Ser Asn Glu Thr Pro Lys Lys Lys Lys Lys Arg Phe Ser Phe</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Lys Lys Ser Phe Lys Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Glu Ala Gly Glu Gly Gly Glu Ala Glu Ala Pro Ala Ala Glu Gly Gly</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Lys Asp Glu Ala Ala Gly Gly Ala Ala Ala Ala Ala Ala Glu Ala Gly</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Ala Ala Ser Gly Glu Gln Ala Ala Ala Pro Gly Glu Glu Ala Ala Ala</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Gly Glu Glu Gly Ala Ala Gly Gly Asp Pro Gln Glu Ala Lys Pro Gln</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Glu Ala Ala Val Ala Pro Glu Lys Pro Pro Ala Ser Asp Glu Thr Lys</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Ala Ala Glu Glu Pro Ser Lys Val Glu Glu Lys Lys Ala Glu Glu Ala</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Gly Ala Ser Ala Ala Ala Cys Glu Ala Pro Ser Ala Ala Gly Pro Gly</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Ala Pro Pro Glu Gln Glu Ala Ala Pro Ala Glu Glu Pro Ala Ala Ala</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Ala Ala Ser Ser Ala Cys Ala Ala Pro Ser Gln Glu Ala Gln Pro Glu</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Cys Ser Pro Glu Ala Pro Pro Ala Glu Ala Ala Glu</entry></row><row><entry>                325                 330</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 402</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 195</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: The MARCKSL1 protein</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 402</entry></row><row><entry> </entry></row><row><entry>Met Gly Ser Gln Ser Ser Lys Ala Pro Arg Gly Asp Val Thr Ala Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Glu Ala Ala Gly Ala Ser Pro Ala Lys Ala Asn Gly Gln Glu Asn Gly</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>His Val Lys Ser Asn Gly Asp Leu Ser Pro Lys Gly Glu Gly Glu Ser</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Pro Pro Val Asn Gly Thr Asp Glu Ala Ala Gly Ala Thr Gly Asp Ala</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ile Glu Pro Ala Pro Pro Ser Gln Gly Ala Glu Ala Lys Gly Glu Val</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Pro Pro Lys Glu Thr Pro Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Pro Phe Lys Leu Ser Gly Leu Ser Phe Lys Arg Asn Arg Lys Glu Gly</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Gly Gly Asp Ser Ser Ala Ser Ser Pro Thr Glu Glu Glu Gln Glu Gln</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Gly Glu Ile Gly Ala Cys Ser Asp Glu Gly Thr Ala Gln Glu Gly Lys</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ala Ala Ala Thr Pro Glu Ser Gln Glu Pro Gln Ala Lys Gly Ala Glu</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Ala Ser Ala Ala Ser Glu Glu Glu Ala Gly Pro Gln Ala Thr Glu Pro</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Ser Thr Pro Ser Gly Pro Glu Ser Gly Pro Thr Pro Ala Ser Ala Glu</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Gln Asn Glu</entry></row><row><entry>        195</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 403</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 227</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: The BASP1 protein</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 403</entry></row><row><entry> </entry></row><row><entry>Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala Thr Glu</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Glu Glu Gly Thr Pro Lys Glu Ser Glu Pro Gln Ala Ala Ala Glu Pro</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ala Glu Ala Lys Glu Gly Lys Glu Lys Pro Asp Gln Asp Ala Glu Gly</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Lys Ala Glu Glu Lys Glu Gly Glu Lys Asp Ala Ala Ala Ala Lys Glu</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Glu Ala Pro Lys Ala Glu Pro Glu Lys Thr Glu Gly Ala Ala Glu Ala</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Lys Ala Glu Pro Pro Lys Ala Pro Glu Gln Glu Gln Ala Ala Pro Gly</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Pro Ala Ala Gly Gly Glu Ala Pro Lys Ala Ala Glu Ala Ala Ala Ala</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Pro Ala Glu Ser Ala Ala Pro Ala Ala Gly Glu Glu Pro Ser Lys Glu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Glu Gly Glu Pro Lys Lys Thr Glu Ala Pro Ala Ala Pro Ala Ala Gln</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Glu Thr Lys Ser Asp Gly Ala Pro Ala Ser Asp Ser Lys Pro Gly Ser</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Ser Glu Ala Ala Pro Ser Ser Lys Glu Thr Pro Ala Ala Thr Glu Ala</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Pro Ser Ser Thr Pro Lys Ala Gln Gly Pro Ala Ala Ser Ala Glu Glu</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Pro Lys Pro Val Glu Ala Pro Ala Ala Asn Ser Asp Gln Thr Val Thr</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Val Lys Glu</entry></row><row><entry>225</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 404</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: misc_feature</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (2)..(2)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: wherein Xaa is alanine or any other amino acid</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 404</entry></row><row><entry> </entry></row><row><entry>Gly Xaa Lys Leu Ser Lys Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 405</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 4</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 405</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Lys</entry></row><row><entry>1</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 406</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 5</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 406</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 407</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 4</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 407</entry></row><row><entry> </entry></row><row><entry>Arg Arg Arg Arg</entry></row><row><entry>1</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 408</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 5</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 408</entry></row><row><entry> </entry></row><row><entry>Arg Arg Arg Arg Arg</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 409</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 4</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: misc_feature</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (1)..(1)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Wherein Xaa can be either Lys or Arg</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: misc_feature</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (2)..(2)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Wherein Xaa can be either Lys or Arg</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: misc_feature</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (3)..(3)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Wherein Xaa can be either Lys or Arg</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: misc_feature</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (4)..(4)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Wherein Xaa can be either Lys or Arg</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 409</entry></row><row><entry> </entry></row><row><entry>Xaa Xaa Xaa Xaa</entry></row><row><entry>1</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 410</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 10</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: Misc_feature</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (1)..(1)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Wherein Xaa can be either Lys or Arg</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: Misc_feature</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (2)..(2)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Wherein Xaa can be either Lys or Arg</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: Misc_feature</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (3)..(3)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Wherein Xaa can be either Lys or Arg</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: Misc_feature</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (4)..(4)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Wherein Xaa can be either Lys or Arg</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: Misc_feature</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (5)..(5)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Wherein Xaa can be either Lys or Arg</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 410</entry></row><row><entry> </entry></row><row><entry>Lys Arg Lys Arg Lys Arg Lys Arg Lys Arg</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 411</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 411</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 412</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 412</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Leu Ser Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 413</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 413</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Gln Ser Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 414</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 414</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ala Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 415</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 6</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 415</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 416</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 6</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 416</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Leu Ser Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 417</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 6</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 417</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Gln Ser Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 418</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 6</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 418</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ala Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 419</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 4</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 419</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Gly</entry></row><row><entry>1</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 420</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 5</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 420</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Gly Tyr</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 421</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 6</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 421</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Gly Tyr Asn</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 422</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 422</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Gly Tyr Asn Val</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 423</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 423</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Gly Tyr Asn Val Asn</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 424</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 6</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 424</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Gly Tyr Ser</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 425</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 6</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 425</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Gly Tyr Gly</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 426</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 426</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Gly Tyr Gly Gly</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 427</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 5</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 427</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Gly Ser</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 428</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 6</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 428</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Gly Ser Gly</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 429</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 429</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Gly Ser Gly Ser</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 430</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 4</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 430</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Ser</entry></row><row><entry>1</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 431</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 5</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 431</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Ser Gly</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 432</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 6</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 432</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Ser Gly Gly</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 433</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 433</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Ser Gly Gly Ser</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 434</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 434</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Ser Gly Gly Ser Gly</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 435</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 435</entry></row><row><entry> </entry></row><row><entry>Lys Lys Ser Gly Gly Ser Gly Gly</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 436</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 10</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 436</entry></row><row><entry> </entry></row><row><entry>Lys Lys Lys Ser Gly Gly Ser Gly Gly Ser</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 437</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 437</entry></row><row><entry> </entry></row><row><entry>Lys Arg Phe Ser Phe Lys Lys Ser</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 438</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 438</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 439</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 439</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Ser</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 440</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 440</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Leu Ser Lys Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 441</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 441</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Leu Ser Lys Lys Ser</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 442</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 442</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Gln Ser Lys Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 443</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 443</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Gln Ser Lys Lys Ser</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 444</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 444</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ala Lys Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 445</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 445</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ala Lys Lys Ser</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 446</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 446</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 447</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 447</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 448</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 448</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Gln Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 449</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 449</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ala Lys Lys Lys Lys Gly Tyr Asn Val Asn</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 450</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 450</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Ser Gly Gly</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 451</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 451</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Ser Gly Gly Ser</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 452</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 452</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Ser Gly Gly Ser Gly</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 453</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 453</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Ser Gly Gly Ser Gly Gly</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 454</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 454</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Ser Gly Gly Ser Gly Gly Ser</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 455</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 455</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Ser Gly Gly Ser Gly Gly Ser Val</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 456</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 456</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 457</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 29</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 457</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 458</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 28</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 458</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 459</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 27</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 459</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 460</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 26</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 460</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 461</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 25</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 461</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ala Lys Glu Lys Asp Lys Lys Ala</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 462</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 24</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 462</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ala Lys Glu Lys Asp Lys Lys</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 463</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 23</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 463</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ala Lys Glu Lys Asp Lys</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 464</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 22</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 464</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ala Lys Glu Lys Asp</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 465</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 21</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 465</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ala Lys Glu Lys</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 466</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 466</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ala Lys Glu</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 467</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 19</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 467</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ala Lys</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 468</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 18</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 468</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ala</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 469</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 469</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 470</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 470</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 471</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 471</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 472</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 13</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 472</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 473</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 12</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 473</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 474</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 11</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 474</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 475</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 10</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 475</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 476</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 476</entry></row><row><entry> </entry></row><row><entry>Gly Gly Lys Leu Ser Lys Lys Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 477</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 29</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 477</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys Glu Ala</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 478</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 28</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 478</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys Glu</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 479</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 27</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 479</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 480</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 26</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 480</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 481</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 25</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 481</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys Lys Asn</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 482</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 24</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 482</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys Lys</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 483</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 23</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 483</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 484</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 22</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 484</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 485</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 21</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 485</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 486</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 486</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 487</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 19</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 487</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 488</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 18</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 488</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 489</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 489</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 490</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 490</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 491</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 491</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 492</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 13</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 492</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 493</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 12</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 493</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 494</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 11</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 494</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 495</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 10</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 495</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 496</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 496</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg Phe</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 497</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 497</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys Arg</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 498</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 498</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ser Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 499</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 29</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 499</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys Glu Ala</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 500</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 28</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 500</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys Glu</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 501</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 27</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 501</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 502</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 26</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 502</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 503</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 25</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 503</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys Lys Asn</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 504</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 24</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 504</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys Lys</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 505</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 23</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 505</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe Lys</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 506</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 22</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 506</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser Phe</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 507</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 21</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 507</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe Ser</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 508</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 508</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly Phe</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 509</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 19</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 509</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser Gly</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 510</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 18</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 510</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Ser</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 511</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 511</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 512</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 512</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 513</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 513</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 514</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 514</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 515</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 13</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 515</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 516</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 12</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 516</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 517</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 11</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 517</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 518</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 10</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 518</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 519</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 519</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg Phe</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 520</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 520</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys Arg</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 521</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 521</entry></row><row><entry> </entry></row><row><entry>Gly Ala Lys Lys Ala Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 522</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 28</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 522</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ser Phe Lys Leu Ser Gly Phe Ser Phe Lys Lys</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 523</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 27</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 523</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ser Phe Lys Leu Ser Gly Phe Ser Phe Lys</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 524</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 26</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 524</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ser Phe Lys Leu Ser Gly Phe Ser Phe</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 525</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 25</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 525</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ser Phe Lys Leu Ser Gly Phe Ser</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 526</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 24</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 526</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ser Phe Lys Leu Ser Gly Phe</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 527</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 23</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 527</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ser Phe Lys Leu Ser Gly</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 528</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 22</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 528</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ser Phe Lys Leu Ser</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 529</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 21</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 529</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ser Phe Lys Leu</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 530</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 530</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ser Phe Lys</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 531</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 19</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 531</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ser Phe</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 532</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 18</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 532</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Ser</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 533</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 533</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 534</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 534</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 535</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 535</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 536</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 536</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 537</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 13</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 537</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 538</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 12</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 538</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 539</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 11</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 539</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 540</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 10</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 540</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 541</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 541</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 542</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 542</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 543</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 543</entry></row><row><entry> </entry></row><row><entry>Gly Ala Gln Glu Ser Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 544</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 30</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 544</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Phe Lys Leu Ser Gly Leu Ser Phe Lys Arg Asn Arg Lys</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 545</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 29</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 545</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Phe Lys Leu Ser Gly Leu Ser Phe Lys Arg Asn Arg</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 546</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 28</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 546</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Phe Lys Leu Ser Gly Leu Ser Phe Lys Arg Asn</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 547</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 27</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 547</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Phe Lys Leu Ser Gly Leu Ser Phe Lys Arg</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 548</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 26</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 548</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Phe Lys Leu Ser Gly Leu Ser Phe Lys</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 549</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 25</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 549</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Phe Lys Leu Ser Gly Leu Ser Phe</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 550</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 24</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 550</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Phe Lys Leu Ser Gly Leu Ser</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 551</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 23</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 551</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Phe Lys Leu Ser Gly Leu</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 552</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 22</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 552</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Phe Lys Leu Ser Gly</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 553</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 21</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 553</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Phe Lys Leu Ser</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 554</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 20</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 554</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Phe Lys Leu</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 555</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 19</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 555</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Phe Lys</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 556</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 18</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 556</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro Phe</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 557</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 557</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Pro</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 558</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 558</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 559</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 15</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 559</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 560</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 560</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 561</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 13</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 561</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 562</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 12</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 562</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 563</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 11</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 563</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 564</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 10</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 564</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 565</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 565</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 566</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 566</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 567</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 567</entry></row><row><entry> </entry></row><row><entry>Gly Ser Gln Ser Ser Lys Lys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 568</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 568</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 569</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 569</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 570</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 570</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 571</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 571</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 572</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 572</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 573</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 573</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 574</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 574</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 575</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 575</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 576</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 576</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 577</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 577</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 578</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 578</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 579</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 579</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 580</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 580</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 581</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 581</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 582</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 582</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 583</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 583</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 584</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 584</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 585</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 585</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 586</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 586</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 587</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 587</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 588</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 588</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 589</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 589</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 590</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 590</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 591</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 591</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 592</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 592</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 593</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 593</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 594</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 594</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 595</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 595</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 596</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 596</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 597</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 597</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 598</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 598</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 599</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 599</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 600</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 600</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 601</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 29</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 601</entry></row><row><entry> </entry></row><row><entry>Tyr Thr Ile Trp Met Pro Glu Asn Pro Arg Pro Gly Thr Pro Cys Asp</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ile Phe Thr Asn Ser Arg Gly Lys Arg Ala Ser Asn Gly</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 602</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Targeted Axonal Import (TAxI) peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 602</entry></row><row><entry> </entry></row><row><entry>Ser Ala Cys Gln Ser Gln Ser Gln Met Arg Cys Gly Gly Gly</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 603</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Targeted Axonal Import (TAxI) peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 603</entry></row><row><entry> </entry></row><row><entry>Gln Ser Gln Ser Gln Met Arg</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 604</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Targeted Axonal Import (TAxI) peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 604</entry></row><row><entry> </entry></row><row><entry>Ala Ser Gly Ala Gln Ala Arg</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 605</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Targeted Axonal Import (TAxI) peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 605</entry></row><row><entry> </entry></row><row><entry>Thr Ser Thr Ala Pro His Leu Arg Leu Arg Leu Thr Ser Arg</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 606</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: nuclear localizing signal (NLS)</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 606</entry></row><row><entry> </entry></row><row><entry>Pro Pro Lys Lys Arg Lys Val</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 607</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 6</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: nuclear localizing signal (NLS)</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 607</entry></row><row><entry> </entry></row><row><entry>Pro Lys Lys Arg Lys Val</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 608</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 19</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Angiopep-2</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 608</entry></row><row><entry> </entry></row><row><entry>Thr Phe Phe Tyr Gly Gly Ser Arg Gly Lys Arg Asn Asn Phe Lys Thr</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Glu Glu Tyr</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 609</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 39</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: ApoB</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 609</entry></row><row><entry> </entry></row><row><entry>Ser Ser Val Ile Asp Ala Leu Gln Tyr Lys Leu Glu Gly Thr Thr Arg</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu Thr Arg Lys Arg Gly Leu Lys Leu Ala Thr Ala Leu Ser Leu Ser</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Asn Lys Phe Val Glu Gly Ser</entry></row><row><entry>        35</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 610</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: ApoE</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 610</entry></row><row><entry> </entry></row><row><entry>Leu Arg Lys Leu Arg Lys Arg Leu Leu</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 611</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Peptide-22</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 611</entry></row><row><entry> </entry></row><row><entry>Cys Met Pro Arg Leu Arg Gly Cys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 612</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 12</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: CRT</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 612</entry></row><row><entry> </entry></row><row><entry>Thr His Arg Pro Pro Met Trp Ser Pro Val Trp Pro</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 613</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 12</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: THR retro-enantio</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 613</entry></row><row><entry> </entry></row><row><entry>Pro Trp Val Pro Ser Trp Met Pro Pro Arg His Thr</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 614</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: CRT</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 614</entry></row><row><entry> </entry></row><row><entry>Cys Arg Thr Ile Gly Pro Ser Val Cys</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 615</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 30</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Leptin30</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 615</entry></row><row><entry> </entry></row><row><entry>Tyr Gln Gln Ile Leu Thr Ser Met Pro Ser Arg Asn Val Ile Gln Ile</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ser Asn Asp Leu Glu Asn Leu Arg Asp Leu Leu His Val Leu</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 616</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 29</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: RVG29</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 616</entry></row><row><entry> </entry></row><row><entry>Tyr Thr Ile Trp Met Pro Glu Asn Pro Arg Pro Gly Thr Pro Cys Asp</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ile Phe Thr Asn Ser Arg Gly Lys Arg Ala Ser Asn Gly</entry></row><row><entry>            20                  25</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 617</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 16</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: CDX</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 617</entry></row><row><entry> </entry></row><row><entry>Gly Arg Glu Ile Arg Thr Gly Arg Ala Glu Arg Trp Ser Glu Lys Phe</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 618</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 18</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Apamin</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 618</entry></row><row><entry> </entry></row><row><entry>Cys Asn Cys Lys Ala Pro Glu Thr Ala Leu Cys Ala Arg Arg Cys Gln</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Gln His</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 619</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: MiniAp-4</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 619</entry></row><row><entry> </entry></row><row><entry>Lys Ala Pro Glu Thr Ala Leu Asp</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 620</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 2</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: GSH</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 620</entry></row><row><entry> </entry></row><row><entry>Cys Gly</entry></row><row><entry>1</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 621</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 13</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: G23</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 621</entry></row><row><entry> </entry></row><row><entry>His Leu Asn Ile Leu Ser Thr Leu Trp Lys Tyr Arg Cys</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 622</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: g7</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 622</entry></row><row><entry> </entry></row><row><entry>Gly Phe Thr Gly Phe Leu Ser</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 623</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 12</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: TGN</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 623</entry></row><row><entry> </entry></row><row><entry>Thr Gly Asn Tyr Lys Ala Leu His Pro His Asn Gly</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 624</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 11</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: HIV transactivator protein</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 624</entry></row><row><entry> </entry></row><row><entry>Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 625</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 18</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: SynB1</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 625</entry></row><row><entry> </entry></row><row><entry>Arg Gly Gly Arg Leu Ser Tyr Ser Arg Arg Arg Phe Ser Thr Ser Thr</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Gly Arg</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 626</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 6</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Diketopiperazines</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 626</entry></row><row><entry> </entry></row><row><entry>Asn Met Phe Asn Met Phe</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 627</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 4</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: PhPro</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 627</entry></row><row><entry> </entry></row><row><entry>Pro Pro Pro Pro</entry></row><row><entry>1</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 628</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 21</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Self peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 628</entry></row><row><entry> </entry></row><row><entry>Gly Asn Tyr Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ile Ile Glu Leu Lys</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 629</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 323</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Canonical CD47</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 629</entry></row><row><entry> </entry></row><row><entry>Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Ile Ala Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Met Lys Phe Val Ala Ser Asn Gln Lys Thr Ile Gln Pro Pro Arg Lys</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Ala Val Glu Glu Pro Leu Asn Ala Phe Lys Glu Ser Lys Gly Met Met</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Asn Asp Glu</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 630</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 292</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: CD47 HUMAN Isoform OA3-293</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 630</entry></row><row><entry> </entry></row><row><entry>Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Ile Ala Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Met Lys Phe Val</entry></row><row><entry>    290</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 631</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 305</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: CD47 HUMAN Isoform OA3-305</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 631</entry></row><row><entry> </entry></row><row><entry>Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Ile Ala Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Met Lys Phe Val Ala Ser Asn Gln Lys Thr Ile Gln Pro Pro Arg Asn</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Asn</entry></row><row><entry>305</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 632</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 311</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: CD47 HUMAN Isoform OA3-312</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 632</entry></row><row><entry> </entry></row><row><entry>Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Ile Ala Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Met Lys Phe Val Ala Ser Asn Gln Lys Thr Ile Gln Pro Pro Arg Lys</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Ala Val Glu Glu Pro Leu Asn</entry></row><row><entry>305                 310</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 633</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 4</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: Synthetic Peptide</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 633</entry></row><row><entry> </entry></row><row><entry>Gly Gly Gly Gly</entry></row><row><entry>1</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></tbody></tgroup></table></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002765A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002765</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17743498</doc-number><date>20220513</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>113</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>113</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>351</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2320</main-group><subgroup>35</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>PCT/US2020/059265</doc-number><date>20201106</date></document-id><parent-status>PENDING</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>17743498</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>63017854</doc-number><date>20200430</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>62934695</doc-number><date>20191113</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Alnylam Pharmaceuticals, Inc.</orgname><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Foster</last-name><first-name>Donald</first-name><address><city>Attleboro</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Agarwal</last-name><first-name>Sagar</first-name><address><city>Lexington</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Huang</last-name><first-name>Stephen Albert</first-name><address><city>Lexington</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Kim</last-name><first-name>Jae</first-name><address><city>Lexington</city><state>MA</state><country>US</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present invention relates to methods of inhibiting the expression of an AGT gene in a subject, as well as methods for treating subjects having an AGT-associated disorder, e.g., hypertension, using RNAi agents, e.g., double stranded RNAi agents, targeting the AGT gene. The invention also relates to methods of decreasing blood pressure levels in a subject using such RNAi agents to inhibit expression of an AGT gene.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="80.09mm" wi="158.75mm" file="US20230002765A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="238.84mm" wi="123.19mm" orientation="landscape" file="US20230002765A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="224.45mm" wi="128.02mm" orientation="landscape" file="US20230002765A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">RELATED APPLICATIONS</heading><p id="p-0002" num="0001">This application is a 35 &#xa7; U.S.C. 111(a) continuation application of International Application No. PCT/US2020/059265, filed on Nov. 6, 2020, which claims the benefit of priority to U.S. Provisional Patent Application No. 63/017,854, filed on Apr. 30, 2020, and U.S. Provisional Patent Application No. 62/934,695, filed on Nov. 13, 2019. The entire contents of each of the foregoing applications are incorporated herein by reference.</p><p id="p-0003" num="0002">This application is related to U.S. Pat. No. 11,015,201, issued on May 25, 2021, the entire contents of which are incorporated herein by reference.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">SEQUENCE LISTING</heading><p id="p-0004" num="0003">The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Apr. 28, 2022, is named 121301-11103_SL.txt and is 24,680 bytes in size.</p><heading id="h-0003" level="1">BACKGROUND OF THE INVENTION</heading><p id="p-0005" num="0004">The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in the regulation of blood pressure. The RAAS cascade begins with the release of renin by the juxtaglomerular cells of the kidney into the circulation. Renin secretion is stimulated by several factors, including Na+ load in the distal tubule, &#x3b2;-sympathetic stimulation, or reduced renal perfusion. Active renin in the plasma cleaves angiotensinogen (produced by the liver) to angiotensin I, which is then converted by circulating and locally expressed angiotensin-converting enzyme (ACE) to angiotensin II. Most of the effects of angiotensin II on the RAAS are exerted by its binding to angiotensin II type 1 receptors (AT<sub>1</sub>R), leading to arterial vasoconstriction, tubular and glomerular effects, such as enhanced Na+ reabsorption or modulation of glomerular filtration rate. In addition, together with other stimuli such as adrenocorticotropin, anti-diuretic hormone, catecholamines, endothelin, serotonin, and levels of Mg2+ and K+, AT<sub>1</sub>R stimulation leads to aldosterone release which, in turn, promotes Na+ and K+ excretion in the renal distal convoluted tubule.</p><p id="p-0006" num="0005">Dysregulation of the RAAS leading to, for example, excessive angiotensin II production or AT<sub>1</sub>R stimulation results in hypertension which can lead to, e.g., increased oxidative stress, promotion of inflammation, hypertrophy, and fibrosis in the heart, kidneys, and arteries, and result in, e.g., left ventricular fibrosis, arterial remodeling, and glomerulosclerosis.</p><p id="p-0007" num="0006">Hypertension is the most prevalent, controllable disease in developed countries, affecting 20-50% of adult populations. Hypertension is a major risk factor for various diseases, disorders and conditions such as, shortened life expectancy, chronic kidney disease, stroke, myocardial infarction, heart failure, aneurysms (e.g. aortic aneurysm), peripheral artery disease, heart damage (e.g., heart enlargement or hypertrophy) and other cardiovascular related diseases, disorders, or conditions. In addition, hypertension has been shown to be an important risk factor for cardiovascular morbidity and mortality accounting for, or contributing to, 62% of all strokes and 49% of all cases of heart disease. In 2017, changes in the guidelines for diagnosis, prevention, and treatment of hypertension were developed providing goals for even lower blood pressure to further decrease risk of development of diseases and disorders associated with hypertension (see, e.g., Reboussin et al.</p><p id="p-0008" num="0007">Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol. </i>2017 Nov. 7. pii: S0735-1097(17)41517-8. doi: 10.1016/j.jacc.2017.11.004; and Whelton et al. (2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol. </i>2017 Nov. 7. pii: S0735-1097(17)41519-1. doi: 10.1016/j.jacc.2017.11.006).</p><p id="p-0009" num="0008">Despite the number of anti-hypertensive drugs available for treating hypertension, more than two-thirds of subjects are not controlled with one anti-hypertensive agent and require two or more anti-hypertensive agents selected from different drug classes. This further reduces the number of subjects with controlled blood pressure as adherence is reduced and side-effects are increased with increasing numbers of medications. Furthermore, several studies have suggested a potential relationship between chronic use of antihypertensive medications and deterioration in kidney function finding that antihypertensive agents to control blood pressure also impact kidney function independently of their effect on blood pressure (Tomlinson, et al (2013) PLoS ONE 8(11) Article ID e78465; The SPRINT Research Group (2015) NEJM 373(22):2103-2116, ClinicalTrials.gov number, NCT01206062; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) <i>Kidney International Supplements </i>3:1-150; Kamaroff, et al. (2018(<i>Hindawi International J Chron Dis </i>Article ID 1382705 | https://doi.org/10.1155/2018/1382705).</p><p id="p-0010" num="0009">Accordingly, there is a need in the art for additional methods and therapies to treat subjects having hypertension.</p><heading id="h-0004" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0011" num="0010">The invention provides methods and compositions for inhibiting the expression of an angiotensinogen (AGT) gene, for treating a subject having a disorder that would benefit from reduction in AGT expression, for treating a subject having an AGT-associated disorder, and for decreasing blood pressure in a subject. The methods include administering to the subject a fixed dose of an RNAi agent, e.g., a double stranded RNAi agent, targeting an AGT gene.</p><p id="p-0012" num="0011">In one aspect, the present invention provides a method for inhibiting the expression of an angiotensinogen (AGT) gene in a subject. The method includes administering to the subject a fixed dose of about 50 mg to about 800 mg (e.g., about 50 to about 200 mg, about 50 mg to about 500 mg, about 100 mg to about 800 mg, about 100 mg to about 500 mg, about 100 mg to about 300 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 500 mg, about 200 mg to about 800 mg, about 300 mg to about 800 mg, about 300 mg to about 500 mg, about 300 mg to about 4000 mg, about 400 mg to about 800 mg, about 400 mg to about 500 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg) of a double-stranded ribonucleic acid (RNAi) agent, or salt thereof, wherein the double-stranded RNAi agent, or salt thereof, comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10); wherein the double-stranded RNAi agent, or salt thereof, comprises at least one modified nucleotide; and wherein at least one of the modifications on the nucleotides is a thermally destabilizing nucleotide modification, thereby inhibiting the expression of the AGT gene in the subject.</p><p id="p-0013" num="0012">In another aspect, the present invention provides a method for treating a subject that would benefit from reduction in angiotensinogen (AGT) expression, e.g., a subject at risk of developing an AGT-associated disorder, e.g., hypertension. The method includes administering to the subject a fixed dose of about 50 mg to about 800 mg (e.g., about 50 to about 200 mg, about 50 mg to about 500 mg, about 100 mg to about 800 mg, about 100 mg to about 500 mg, about 100 mg to about 300 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 500 mg, about 200 mg to about 800 mg, about 300 mg to about 800 mg, about 300 mg to about 500 mg, about 300 mg to about 4000 mg, about 400 mg to about 800 mg, about 400 mg to about 500 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg) of a double-stranded ribonucleic acid (RNAi) agent, or salt thereof, wherein the double-stranded RNAi agent, or salt thereof, comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10); wherein the double-stranded RNAi agent, or salt thereof, comprises at least one modified nucleotide; and wherein at least one of the modifications on the nucleotides is a thermally destabilizing nucleotide modification, thereby treating the subject that would benefit from reduction in AGT expression.</p><p id="p-0014" num="0013">In one aspect, the present invention provides a method for treating a subject having an angiotensinogen- (AGT-) associated disorder, e.g., hypertension. The method includes administering to the subject a fixed dose of about 50 mg to about 800 mg (e.g., about 50 to about 200 mg, about 50 mg to about 500 mg, about 100 mg to about 800 mg, about 100 mg to about 500 mg, about 100 mg to about 300 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 500 mg, about 200 mg to about 800 mg, about 300 mg to about 800 mg, about 300 mg to about 500 mg, about 300 mg to about 4000 mg, about 400 mg to about 800 mg, about 400 mg to about 500 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg) of a double-stranded ribonucleic acid (RNAi) agent, or salt thereof, wherein the double-stranded RNAi agent, or salt thereof, comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10); wherein the double-stranded RNAi agent, or salt thereof, comprises at least one modified nucleotide; wherein at least one of the modifications on the nucleotides is a thermally destabilizing nucleotide modification, thereby treating the subject having the AGT-associated disorder.</p><p id="p-0015" num="0014">In another aspect, the present invention provides a method for decreasing blood pressure level in a subject, such as a subject having an AGT-associated disorder, e.g., hypertension. The method includes administering to the subject a fixed dose of about 50 mg to about 800 mg (e.g., about 50 to about 200 mg, about 50 mg to about 500 mg, about 100 mg to about 800 mg, about 100 mg to about 500 mg, about 100 mg to about 300 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 500 mg, about 200 mg to about 800 mg, about 300 mg to about 800 mg, about 300 mg to about 500 mg, about 300 mg to about 4000 mg, about 400 mg to about 800 mg, about 400 mg to about 500 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg) of a double-stranded ribonucleic acid (RNAi) agent, or salt thereof, wherein the double-stranded RNAi agent, or salt thereof, comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10); wherein the double-stranded RNAi agent, or salt thereof, comprises at least one modified nucleotide; wherein at least one of the modifications on the nucleotides is a thermally destabilizing nucleotide modification, thereby decreasing the blood pressure level in the subject.</p><p id="p-0016" num="0015">In some embodiments, the fixed dose is administered to the subject at an interval of once a month. In other embodiments, the fixed dose is administered to the subject at an interval of once a quarter. In some embodiments, the fixed dose is administered to the subject at an interval of bianually.</p><p id="p-0017" num="0016">In some embodiments, the subject is administered a fixed dose of about 50 mg to about 200 mg. In other embodiments, the subject is administered a fixed dose of about 200 mg to about 400 mg.</p><p id="p-0018" num="0017">In some embodiments, the subject is administered a fixed dose of about 400 mg to about 800 mg.</p><p id="p-0019" num="0018">In some embodiments, the subject is administered a fixed dose of about 100 mg. In some embodiments, the subject is administered a fixed dose of about 200 mg. In some embodiments, the subject is administered a fixed dose of about 300 mg. In some embodiments, the subject is administered a fixed dose of about 400 mg. In some embodiments, the subject is administered a fixed dose of about 500 mg. In other embodiments, the subject is administered a fixed dose of about 600 mg. In some embodiments, the subject is administered a fixed dose of about 800 mg.</p><p id="p-0020" num="0019">In some embodiments, the double stranded RNAi agent, or salt thereof, is administered to the subject subcutaneously or intravenously. In some embodiments, the subcutaneous administration is subcutaneous injection, e.g., subcutaneous self-administration. In other embodiments, the intravenous administration is intravenous injection.</p><p id="p-0021" num="0020">In some embodiments, the antisense strand comprises a nucleotide sequence comprising at least 20 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand comprises a nucleotide sequence comprising at least 20 contiguous nucleotides of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10).</p><p id="p-0022" num="0021">In other embodiments, the antisense strand comprises a nucleotide sequence comprising at least 21 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand comprises a nucleotide sequence comprising at least 20 contiguous nucleotides of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10).</p><p id="p-0023" num="0022">In some embodiments, the antisense strand comprises a nucleotide sequence comprising at least 22 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand comprises a nucleotide sequence comprising at least 20 contiguous nucleotides of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10).</p><p id="p-0024" num="0023">In some embodiments, the antisense strand comprises the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand comprises the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10).</p><p id="p-0025" num="0024">In some embodiments, the antisense strand consists of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand consists of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10).</p><p id="p-0026" num="0025">In some embodiments, substantially all of the nucleotides of the sense strand are modified nucleotides. In other embodiments, substantially all of the nucleotides of the antisense strand are modified nucleotides.</p><p id="p-0027" num="0026">In some embodiments, all of the nucleotides of the sense strand are modified nucleotides. In some embodiments, all of the nucleotides of the antisense strand are modified nucleotides.</p><p id="p-0028" num="0027">In some embodiments, at least one of the nucleotide modifications is selected from the group consisting of a deoxy-nucleotide, a 3&#x2032;-terminal deoxy-thymine (dT) nucleotide, a 2&#x2032;-O-methyl modified nucleotide, a 2&#x2032;-fluoro modified nucleotide, a 2&#x2032;-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2&#x2032;-amino-modified nucleotide, a 2&#x2032;-O-allyl-modified nucleotide, 2&#x2032;-C-alkyl-modified nucleotide, 2&#x2032;-hydroxly-modified nucleotide, a 2&#x2032;-methoxyethyl modified nucleotide, a 2&#x2032;-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5&#x2032;-phosphate, a nucleotide comprising a 5&#x2032;-phosphate mimic, a thermally destabilizing nucleotide, a glycol modified nucleotide (GNA), and a 2-O&#x2014;(N-methylacetamide) modified nucleotide; and combinations thereof.</p><p id="p-0029" num="0028">In some embodiments, at least one of the nucleotide modifications is selected from the group consisting of a deoxy-nucleotide, a 2&#x2032;-O-methyl modified nucleotide, a 2&#x2032;-fluoro modified nucleotide, a 2&#x2032;-deoxy-modified nucleotide, a glycol modified nucleotide (GNA), and a 2-O&#x2014;(N-methylacetamide) modified nucleotide; and combinations thereof.</p><p id="p-0030" num="0029">In some embodiments, the double stranded region is 19-23 nucleotide pairs in length, 19-21 nucleotide pairs in length, 21-23 nucleotide pairs in length, or 21 nucleotide pairs in length.</p><p id="p-0031" num="0030">In some embodiments, each strand is independently 19-23 nucleotides in length, 19-25 nucleotides in length, or 21-23 nucleotides in length. In some embodiments, the sense strand is 21 nucleotides in length, and the antisense strand is 23 nucleotides in length.</p><p id="p-0032" num="0031">In some embodiments, at least one strand comprises a 3&#x2032; overhang of at least 1 nucleotide or a 3&#x2032; overhang of at least 2 nucleotides.</p><p id="p-0033" num="0032">In some embodiments, the double-stranded RNAi agent, or salt thereof, further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage. In some embodiments, the phosphorothioate or methylphosphonate internucleotide linkage is at the 3&#x2032;-terminus of one strand. In some embodiments, the strand is the antisense strand. In other embodiments, the strand is the sense strand.</p><p id="p-0034" num="0033">In some embodiments, the phosphorothioate or methylphosphonate internucleotide linkage is at the 5&#x2032;-terminus of one strand. In some embodiments, the strand is the antisense strand. In other embodiments, the strand is the sense strand.</p><p id="p-0035" num="0034">In some embodiments, the phosphorothioate or methylphosphonate internucleotide linkage is at the both the 5&#x2032;- and 3&#x2032;-terminus of one strand. In some embodiments, the strand is the antisense strand.</p><p id="p-0036" num="0035">In one aspect, the present invention provides a method for inhibiting the expression of an angiotensinogen (AGT) gene in a subject. The method includes administering to the subject a fixed dose of about 50 mg to about 800 mg (e.g., about 50 to about 200 mg, about 50 mg to about 500 mg, about 100 mg to about 800 mg, about 100 mg to about 500 mg, about 100 mg to about 300 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 500 mg, about 200 mg to about 800 mg, about 300 mg to about 800 mg, about 300 mg to about 500 mg, about 300 mg to about 4000 mg, about 400 mg to about 800 mg, about 400 mg to about 500 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg) of a double-stranded ribonucleic acid (RNAi) agent, or salt thereof, wherein the double-stranded RNAi agent, or salt thereof, comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a modified nucleotide sequence comprising at least 19 contiguous nucleotides of the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11) and the sense strand comprises a modified nucleotide sequence comprising at least 19 contiguous nucleotides of the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12); wherein the chemical modifications are defined as follows: a is 2&#x2032;-O-methyladenosine-3&#x2032;-phosphate, c is 2&#x2032;-O-methylcytidine-3&#x2032;-phosphate, g is 2&#x2032;-O-methylguanosine-3&#x2032;-phosphate, u is 2&#x2032;-O-methyluridine-3&#x2032;-phosphate, Af is 2&#x2032;-fluoroadenosine-3&#x2032;-phosphate, Cf is 2&#x2032;-fluorocytidine-3&#x2032;-phosphate, Gf is 2&#x2032;-fluoroguanosine-3&#x2032;-phosphate, Uf is 2&#x2032;-fluorouridine-3&#x2032;-phosphate, (Tgn) is thymidine-glycol nucleic acid (GNA)S-Isomer, and s is phosphorothioate linkage, thereby inhibiting the expression of the AGT gene in the subject.</p><p id="p-0037" num="0036">In another aspect, the present invention provides a method for treating a subject that would benefit from reduction in AGT expression, e.g., a subject at risk of developing an AGT-associated disorder, e.g., hypertension. The method includes administering to the subject a fixed dose of about 50 mg to about 800 mg (e.g., about 50 to about 200 mg, about 50 mg to about 500 mg, about 100 mg to about 800 mg, about 100 mg to about 500 mg, about 100 mg to about 300 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 500 mg, about 200 mg to about 800 mg, about 300 mg to about 800 mg, about 300 mg to about 500 mg, about 300 mg to about 4000 mg, about 400 mg to about 800 mg, about 400 mg to about 500 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg) of a double-stranded ribonucleic acid (RNAi) agent, or salt thereof, wherein the double-stranded RNAi, or salt thereof, agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a modified nucleotide sequence comprising at least 19 contiguous nucleotides of the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11) and the sense strand comprises a modified nucleotide sequence comprising at least 19 contiguous nucleotides of the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12); wherein chemical modifications are defined as follows: a is 2&#x2032;-O-methyladenosine-3&#x2032;-phosphate, c is 2&#x2032;-O-methylcytidine-3&#x2032;-phosphate, g is 2&#x2032;-O-methylguanosine-3&#x2032;-phosphate, u is 2&#x2032;-O-methyluridine-3&#x2032;-phosphate, Af is 2&#x2032;-fluoroadenosine-3&#x2032;-phosphate, Cf is 2&#x2032;-fluorocytidine-3&#x2032;-phosphate, Gf is 2&#x2032;-fluoroguanosine-3&#x2032;-phosphate, Uf is 2&#x2032;-fluorouridine-3&#x2032;-phosphate, (Tgn) is thymidine-glycol nucleic acid (GNA)S-Isomer, and s is phosphorothioate linkage, thereby treating the subject that would benefit from reduction in AGT expression.</p><p id="p-0038" num="0037">In one aspect, the present invention provides a method for treating a subject having an AGT-associated disorder, e.g., hypertension. The method includes administering to the subject a fixed dose of about 50 mg to about 800 mg (e.g., about 50 to about 200 mg, about 50 mg to about 500 mg, about 100 mg to about 800 mg, about 100 mg to about 500 mg, about 100 mg to about 300 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 500 mg, about 200 mg to about 800 mg, about 300 mg to about 800 mg, about 300 mg to about 500 mg, about 300 mg to about 4000 mg, about 400 mg to about 800 mg, about 400 mg to about 500 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg) of a double-stranded ribonucleic acid (RNAi) agent, or salt thereof, wherein the double-stranded RNAi agent, or salt thereof, comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a modified nucleotide sequence comprising at least 19 contiguous nucleotides of the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11) and the sense strand comprises a modified nucleotide sequence comprising at least 19 contiguous nucleotides of the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12); wherein chemical modifications are defined as follows: a is 2&#x2032;-O-methyladenosine-3&#x2032;-phosphate, c is 2&#x2032;-O-methylcytidine-3&#x2032;-phosphate, g is 2&#x2032;-O-methylguanosine-3&#x2032;-phosphate, u is 2&#x2032;-O-methyluridine-3&#x2032;-phosphate, Af is 2&#x2032;-fluoroadenosine-3&#x2032;-phosphate, Cf is 2&#x2032;-fluorocytidine-3&#x2032;-phosphate, Gf is 2&#x2032;-fluoroguanosine-3&#x2032;-phosphate, Uf is 2&#x2032;-fluorouridine-3&#x2032;-phosphate, (Tgn) is thymidine-glycol nucleic acid (GNA)S-Isomer, and s is phosphorothioate linkage, thereby treating the subject having the AGT-associated disorder.</p><p id="p-0039" num="0038">In another aspect, the present invention provides a method for decreasing blood pressure level in a subject. The method includes administering to the subject a fixed dose of about 50 mg to about 800 mg (e.g., about 50 to about 200 mg, about 50 mg to about 500 mg, about 100 mg to about 800 mg, about 100 mg to about 500 mg, about 100 mg to about 300 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 500 mg, about 200 mg to about 800 mg, about 300 mg to about 800 mg, about 300 mg to about 500 mg, about 300 mg to about 4000 mg, about 400 mg to about 800 mg, about 400 mg to about 500 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg) of a double-stranded ribonucleic acid (RNAi) agent, or salt thereof, wherein the double-stranded RNAi agent, or salt thereof, comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a modified nucleotide sequence comprising at least 19 contiguous nucleotides of the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11) and the sense strand comprises a modified nucleotide sequence comprising at least 19 contiguous nucleotides of the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12); wherein chemical modifications are defined as follows: a is 2&#x2032;-O-methyladenosine-3&#x2032;-phosphate, c is 2&#x2032;-O-methylcytidine-3&#x2032;-phosphate, g is 2&#x2032;-O-methylguanosine-3&#x2032;-phosphate, u is 2&#x2032;-O-methyluridine-3&#x2032;-phosphate, Af is 2&#x2032;-fluoroadenosine-3&#x2032;-phosphate, Cf is 2&#x2032;-fluorocytidine-3&#x2032;-phosphate, Gf is 2&#x2032;-fluoroguanosine-3&#x2032;-phosphate, Uf is 2&#x2032;-fluorouridine-3&#x2032;-phosphate, (Tgn) is thymidine-glycol nucleic acid (GNA)S-Isomer, and s is phosphorothioate linkage, thereby decreasing the blood pressure level in the subject.</p><p id="p-0040" num="0039">In some embodiments, the fixed dose is administered to the subject at an interval of once a month. In other embodiments, the fixed dose is administered to the subject at an interval of once a quarter. In some embodiments, the fixed dose is administered to the subject at an interval of bianually.</p><p id="p-0041" num="0040">In some embodiments, the subject is administered a fixed dose of about 50 mg to about 200 mg. In other embodiments, the subject is administered a fixed dose of about 200 mg to about 400 mg.</p><p id="p-0042" num="0041">In some embodiments, the subject is administered a fixed dose of about 400 mg to about 800 mg.</p><p id="p-0043" num="0042">In some embodiments, the subject is administered a fixed dose of about 100 mg. In some embodiments, the subject is administered a fixed dose of about 200 mg. In some embodiments, the subject is administered a fixed dose of about 300 mg. In some embodiments, the subject is administered a fixed dose of about 400 mg. In some embodiments, the subject is administered a fixed dose of about 500 mg. In other embodiments, the subject is administered a fixed dose of about 600 mg. In some embodiments, the subject is administered a fixed dose of about 800 mg.</p><p id="p-0044" num="0043">In some embodiments, the double stranded RNAi agent, or salt thereof, is administered to the subject subcutaneously or intravenously. In some embodiments, the subcutaneous administration is subcutaneous injection, e.g., subcutaneous self-administration. In other embodiments, the intravenous administration is intravenous injection.</p><p id="p-0045" num="0044">In some embodiments, the antisense strand comprises a modified nucleotide sequence comprising at least 20 contiguous nucleotides of the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11) and the sense strand comprises a modified nucleotide sequence comprising at least 20 contiguous nucleotides of the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12).</p><p id="p-0046" num="0045">In some embodiments, the antisense strand comprises a modified nucleotide sequence comprising at least 21 contiguous nucleotides of the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11) and the sense strand comprises a modified nucleotide sequence comprising at least 20 contiguous nucleotides of the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12).</p><p id="p-0047" num="0046">In some embodiments, the antisense strand comprises a modified nucleotide sequence comprising at least 22 contiguous nucleotides of the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11) and the sense strand comprises a modified nucleotide sequence comprising at least 20 contiguous nucleotides of the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12).</p><p id="p-0048" num="0047">In some embodiments, the antisense strand comprises a modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11) and the sense strand comprises a modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12).</p><p id="p-0049" num="0048">In other embodiments, the antisense strand consists of a modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11) and the sense strand consists of a modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12).</p><p id="p-0050" num="0049">In some embodiments, the double stranded RNAi agent, or salt thereof, further comprises a ligand. In other embodiments, the ligand is conjugated to the 3&#x2032; end of the sense strand.</p><p id="p-0051" num="0050">In some embodiments, the ligand is an N-acetylgalactosamine (GalNAc) derivative. In other embodiments, the GalNAc derivative comprises one or more GalNAc derivatives attached through a monovalent, bivalent, or trivalent branched linker.</p><p id="p-0052" num="0051">In some embodiments, the ligand is</p><p id="p-0053" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="67.99mm" wi="108.80mm" file="US20230002765A1-20230105-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0054" num="0052">In other embodiments, the 3&#x2032; end of the sense strand is conjugated to the ligand as shown in the following schematic</p><p id="p-0055" num="0000"><chemistry id="CHEM-US-00002" num="00002"><img id="EMI-C00002" he="88.98mm" wi="141.73mm" file="US20230002765A1-20230105-C00002.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0056" num="0000">and, wherein X is O or S.</p><p id="p-0057" num="0053">In some embodiments, the subject is a human. In some embodiments, the subject has a systolic blood pressure of at least 130 mm Hg or a diastolic blood pressure of at least 80 mm Hg. In other embodiments, the subject has a systolic blood pressure of at least 140 mm Hg or a diastolic blood pressure of at least 80 mm Hg.</p><p id="p-0058" num="0054">In some embodiments, the subject is part of a group susceptible to salt sensitivity, is overweight, is obese, is pregnant, is planning to become pregnant, has type 2 diabetes, has type 1 diabetes, or has reduced kidney function.</p><p id="p-0059" num="0055">In some embodiments, the disorder that would benefit from reduction in AGT expression is an AGT-associated disorder. In one embodiment, the AGT-associated disorder is hypertension. In other embodiments, the AGT-associated disorder is selected from the group consisting of high blood pressure, hypertension, borderline hypertension, primary hypertension, secondary hypertension isolated systolic or diastolic hypertension, pregnancy-associated hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt hypertension, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, labile hypertension; hypertensive heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis, vasculopathy, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiac myopathy, nocturnal hypotension, glomerulosclerosis, coarctation of the aorta, aortic aneurism, ventricular fibrosis, heart failure, myocardial infarction, angina, stroke, renal disease, renal failure, systemic sclerosis, intrauterine growth restriction (IUGR), fetal growth restriction, obesity, liver steatosis/fatty liver, non-alcoholic Steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD); glucose intolerance, type 2 diabetes, and metabolic syndrome. In one embodiment, the AGT-associated disorder is hypertension. In one embodiment, the hypertension is selected from the group consisting of high blood pressure, hypertension, borderline hypertension, primary hypertension, secondary hypertension isolated systolic or diastolic hypertension, pregnancy-associated hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt hypertension, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, labile hypertension; hypertensive heart disease, and hypertensive nephropathy.</p><p id="p-0060" num="0056">In some embodiments, the blood pressure comprises systolic blood pressure and/or diastolic blood pressure.</p><p id="p-0061" num="0057">In some embodiments, administering results in a decrease in AGT expression by at least 30%, 40% 50%, 60%, 70%, 80%, 90%, or 95%. In some embodiments, the AGT protein level in blood or serum sample of the subject is decreased by at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%.</p><p id="p-0062" num="0058">In some embodiments, administering results in a decrease in systolic blood pressure and/or diastolic blood pressure. In some embodiments, the systolic blood pressure and/or diastolic blood pressure is decreased by at least 4 mmHg, 5 mmHg, 6 mmHg, 7 mmHg, 8 mmHg, 9 mmHg or 10 mmHg.</p><p id="p-0063" num="0059">In some embodiments, the methods further comprise administering to the subject an additional therapeutic agent for treatment of hypertension. In some embodiments, the additional therapeutic agent is selected from the group consisting of a diuretic, an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, a beta-blocker, a vasodialator, a calcium channel blocker, an aldosterone antagonist, an alpha2-agonist, a renin inhibitor, an alpha-blocker, a peripheral acting adrenergic agent, a selective D1 receptor partial agonist, a nonselective alpha-adrenergic antagonist, a synthetic, a steroidal antimineralocorticoid agent; a combination of any of the foregoing; and a hypertension therapeutic agent formulated as a combination of agents. In some embodiments, the additional therapeutic agent comprises an angiotensin II receptor antagonist. In other embodiments, the angiotensin II receptor antagonist is selected from the group consisting of losartan, valsartan, olmesartan, eprosartan, and azilsartan.</p><p id="p-0064" num="0060">In some embodiments, the RNAi agent is administered as a pharmaceutical composition.</p><p id="p-0065" num="0061">In some embodiments, the RNAi agent is administered in an unbuffered solution. In some embodiments, the unbuffered solution is saline or water.</p><p id="p-0066" num="0062">In some embodiments, the RNAi agent is administered with a buffer solution. In some embodiments, the buffer solution comprises acetate, citrate, prolamine, carbonate, or phosphate or any combination thereof. In some embodiments, the buffer solution is phosphate buffered saline (PBS).</p><p id="p-0067" num="0063">The present invention also provides a kit for performing the methods of the invention, as described herein. The kit comprises a) the RNAi agent, and b) instructions for use, and c) optionally, means for administering the RNAi agent to the subject.</p><p id="p-0068" num="0064">In another aspect, the present invention also provides a pharmaceutical composition for treating an AGT-associated disorder comprising a double stranded ribonucleic acid (RNAi) agent, or salt thereof, for inhibiting expression of angiotensinogen (AGT). The pharmaceutical composition comprises a dsRNA agent comprising a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence of UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence of GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10); wherein no more than five of the nucleotides do not comprise a modification; wherein at least one of the nucleotide modifications is a thermally destabilizing nucleotide modification; wherein the double stranded RNAi agent is administered at a dose of at least 50 mg/dose no more than once per month, e.g. a dose of about 50 mg to about 800 mg about once per month (e.g., about 50 to about 200 mg, about 50 mg to about 500 mg, about 100 mg to about 800 mg, about 100 mg to about 500 mg, about 100 mg to about 300 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 500 mg, about 200 mg to about 800 mg, about 300 mg to about 800 mg, about 300 mg to about 500 mg, about 300 mg to about 4000 mg, about 400 mg to about 800 mg, about 400 mg to about 500 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg).</p><p id="p-0069" num="0065">In certain embodiments, the antisense strand comprises a nucleotide sequence comprising at least 20 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9), In certain embodiments, the sense strand further comprises a nucleotide sequence comprising at least 20 contiguous nucleotides of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10).</p><p id="p-0070" num="0066">In certain embodiments, the antisense strand comprises a nucleotide sequence comprising at least 21 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9). In certain embodiments, the sense strand further comprises the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10).</p><p id="p-0071" num="0067">In certain embodiments, the antisense strand a nucleotide sequence comprising comprises at least 22 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9), In certain embodiments, the sense strand further comprises the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10)</p><p id="p-0072" num="0068">In certain embodiments, antisense strand comprises the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9). In certain embodiments, the sense strand further comprises the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO:10).</p><p id="p-0073" num="0069">In certain embodiments, the nucleotide sequence of the antisense strand consists of UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9). In certain embodiments, the nucleotide sequence of the sense strand further consists of GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10).</p><p id="p-0074" num="0070">In certain embodiments, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a nucleotide modification.</p><p id="p-0075" num="0071">In certain embodiments, at least one of the nucleotide modifications is selected from the group consisting of a deoxy-nucleotide, a 3&#x2032;-terminal deoxy-thymine (dT) nucleotide, a 2&#x2032;-O-methyl modified nucleotide, a 2&#x2032;-fluoro modified nucleotide, a 2&#x2032;-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2&#x2032;-amino-modified nucleotide, a 2&#x2032;-O-allyl-modified nucleotide, 2&#x2032;-C-alkyl-modified nucleotide, 2&#x2032;-hydroxly-modified nucleotide, a 2&#x2032;-methoxyethyl modified nucleotide, a 2&#x2032;-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5&#x2032;-phosphate, a nucleotide comprising a 5&#x2032;-phosphate mimic, a thermally destabilizing nucleotide, a glycol modified nucleotide (GNA), and a 2-O&#x2014;(N-methylacetamide) modified nucleotide; and combinations thereof. In certain embodiments, at least one of the nucleotide modifications is selected from the group consisting of a deoxy-nucleotide, a 2&#x2032;-O-methyl modified nucleotide, a 2&#x2032;-fluoro modified nucleotide, a 2&#x2032;-deoxy-modified nucleotide, a glycol modified nucleotide (GNA), and a 2-O&#x2014;(N-methylacetamide) modified nucleotide; and combinations thereof.</p><p id="p-0076" num="0072">In certain embodiments, the nucleotide modifications are selected from the group consisting of 2&#x2032;-methoxyethyl, 2&#x2032;-fluoro, a 2&#x2032;-deoxy-modified nucleotide, and GNA; and combinations thereof.</p><p id="p-0077" num="0073">In certain embodiments, the double stranded region is of a length selected from: 19-23 nucleotide pairs in length, 19-21 nucleotide pairs in length, 21-23 nucleotide pairs in length, 21 nucleotide pairs in length, 19-30 nucleotide pairs in length, 19-25 nucleotide pairs in length, 23-27 nucleotide pairs in length. In certain embodiments, the double stranded region has a length of 19-21 nucleotide pairs in length.</p><p id="p-0078" num="0074">In certain embodiments, each strand of the double stranded RNAi or salt thereof, is independently of a length selected from 19-30 nucleotides in length 19-23 nucleotides in length, and 21-23 nucleotides in length. In certain embodiments, each strand is independently 21-23 nucleotides in length. In certain embodiments, the sense strand is 21 nucleotides in length, and the antisense strand is 23 nucleotides in length.</p><p id="p-0079" num="0075">In certain embodiments, at least one strand comprises a 3&#x2032; overhang of at least 1 nucleotide. In certain embodiments, at least one strand comprises a 3&#x2032; overhang of at least 2 nucleotides.</p><p id="p-0080" num="0076">In certain embodiments, the agent further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage. In certain embodiments, the phosphorothioate or methylphosphonate internucleotide linkage is at the 3&#x2032;-terminus of one strand. In certain embodiments, the strand is the antisense strand. In certain embodiments, the strand is the sense strand.</p><p id="p-0081" num="0077">In certain embodiments, the phosphorothioate or methylphosphonate internucleotide linkage is at the 5&#x2032;-terminus of one strand. In certain embodiments, the strand is the antisense strand. In certain embodiments, the strand is the sense strand.</p><p id="p-0082" num="0078">In certain embodiments, the phosphorothioate or methylphosphonate internucleotide linkage is at the both the 5&#x2032;- and 3&#x2032;-terminus of one strand. In certain embodiments, the strand is the antisense strand.</p><p id="p-0083" num="0079">The invention provides a pharmaceutical composition for treating an AGT-associated disorder comprising a double stranded ribonucleic acid (RNAi) agent, or salt thereof, for inhibiting expression of angiotensinogen (AGT). The pharmaceutical composition comprises a double stranded RNAi agent, or salt thereof, agent comprising a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a modified nucleotide sequence comprising at least 19 contiguous nucleotides of the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11) and the sense strand comprises a modified nucleotide sequence comprising at least 19 contiguous nucleotides of the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12); wherein chemical modifications are defined as follows: a is 2&#x2032;-O-methyladenosine-3&#x2032;-phosphate, c is 2&#x2032;-O-methylcytidine-3&#x2032;-phosphate, g is 2&#x2032;-O-methylguanosine-3&#x2032;-phosphate, u is 2&#x2032;-O-methyluridine-3&#x2032;-phosphate, Af is 2&#x2032;-fluoroadenosine-3&#x2032;-phosphate, Cf is 2&#x2032;-fluorocytidine-3&#x2032;-phosphate, Gf is 2&#x2032;-fluoroguanosine-3&#x2032;-phosphate, Uf is 2&#x2032;-fluorouridine-3&#x2032;-phosphate, (Tgn) is thymidine-glycol nucleic acid (GNA)S-Isomer, and s is phosphorothioate linkage; and wherein the pharmaceutical composition is administered at a dose of at least 50 mg/dose no more than once per month.</p><p id="p-0084" num="0080">In certain embodiments, the antisense strand comprises a modified nucleotide sequence comprising at least 20 contiguous nucleotides of the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11). In certain embodiments, the sense strand further comprises a modified nucleotide sequence comprising at least 20 contiguous nucleotides of the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12).</p><p id="p-0085" num="0081">In certain embodiments, the antisense strand comprises a modified nucleotide sequence comprising at least 21 contiguous nucleotides of the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11). In certain embodiments, the sense strand further comprises the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO:12).</p><p id="p-0086" num="0082">In certain embodiments, the antisense strand comprises a modified nucleotide sequence comprising at least 22 contiguous nucleotides of the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11). In certain embodiments, the sense strand further comprises the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12).</p><p id="p-0087" num="0083">In certain embodiments, the antisense strand comprises the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11). In certain embodiments, the sense strand further comprises the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12).</p><p id="p-0088" num="0084">In certain embodiments, the modified nucleotide sequence of the antisense strand consists of usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11). In certain embodiments, the modified nucleotide sequence of the sense strand consists of gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12).</p><p id="p-0089" num="0085">In certain embodiments, the double stranded RNAi agent, or salt thereof, further comprises a ligand. In certain embodiments, the ligand is conjugated to the 3&#x2032; end of the sense strand. In certain embodiments, the ligand is an N-acetylgalactosamine (GalNAc) derivative. In certain embodiments, the GalNAc derivative comprises one or more GalNAc derivatives attached through a monovalent, bivalent, or trivalent branched linker.</p><p id="p-0090" num="0086">In certain embodiments, ligand is</p><p id="p-0091" num="0000"><chemistry id="CHEM-US-00003" num="00003"><img id="EMI-C00003" he="67.99mm" wi="108.80mm" file="US20230002765A1-20230105-C00003.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0092" num="0087">In certain embodiments, the 3&#x2032; end of the sense strand is conjugated to the ligand as shown in the following schematic</p><p id="p-0093" num="0000"><chemistry id="CHEM-US-00004" num="00004"><img id="EMI-C00004" he="88.98mm" wi="141.73mm" file="US20230002765A1-20230105-C00004.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0094" num="0000">and, wherein X is O or S. In certain embodiments, the X is O.</p><p id="p-0095" num="0088">In certain embodiments, the sense strand comprises the nucleotide sequence gsuscaucCfaCfAfAfugagaguaca wherein the 3&#x2032; end of the sense strand is conjugated to L96 (N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol Hyp-(GalNAc-alkyl)3) and the antisense strand comprises the nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa; wherein chemical modifications are defined as follows: a is 2&#x2032;-O-methyladenosine-3&#x2032;-phosphate, c is 2&#x2032;-O-methylcytidine-3&#x2032;-phosphate, g is 2&#x2032;-O-methylguanosine-3&#x2032;-phosphate, u is 2&#x2032;-O-methyluridine-3&#x2032;-phosphate, Af is 2&#x2032;-fluoroadenosine-3&#x2032;-phosphate, Cf is 2&#x2032;-fluorocytidine-3&#x2032;-phosphate, Gf is 2&#x2032;-fluoroguanosine-3&#x2032;-phosphate, Uf is 2&#x2032;-fluorouridine-3&#x2032;-phosphate, (Tgn) is thymidine-glycol nucleic acid (GNA)S-Isomer, and s is phosphorothioate linkage.</p><p id="p-0096" num="0089">In certain embodiments, the double stranded RNAi agent, or salt thereof, is administered at a dose of 50 mg to 500 mg per dose. In certain embodiments, the double stranded RNAi agent, or salt thereof, is administered at a dose of 50 to 400 mg per dose. In certain embodiments double stranded RNAi, the double stranded RNAi agent, or salt thereof, is administered at a dose of 50 to 300 mg per dose.</p><p id="p-0097" num="0090">In some embodiments, the double stranded RNAi agent, or salt thereof, is administered at fixed dose of about 50 mg to about 200 mg. In other embodiments, the double stranded RNAi agent, or salt thereof, is administered at a fixed dose of about 200 mg to about 400 mg. In some embodiments, the double stranded RNAi agent, or salt thereof, is administered at a fixed dose of about 400 mg to about 800 mg.</p><p id="p-0098" num="0091">In some embodiments, the double stranded RNAi agent, or salt thereof, is administered at a fixed dose of about 100 mg. In some embodiments, the double stranded RNAi agent, or salt thereof, is administered at a fixed dose of about 200 mg. In some embodiments, the double stranded RNAi agent, or salt thereof, is administered at a fixed dose of about 300 mg. In some embodiments, the double stranded RNAi agent, or salt thereof, is administered at a fixed dose of about 400 mg. In some embodiments, the double stranded RNAi agent, or salt thereof, is administered at a fixed dose of about 500 mg. In other embodiments, the double stranded RNAi agent, or salt thereof, is administered at fixed dose of about 600 mg. In some embodiments, the double stranded RNAi agent, or salt thereof, is administered at a fixed dose of about 800 mg.</p><p id="p-0099" num="0092">In certain embodiments, the pharmaceutical composition is administered at a frequency of once per month to once per six months. In certain embodiments, the pharmaceutical composition is administered at a frequency of once per month to once per three months. In certain embodiments, the pharmaceutical composition is administered at a frequency of once per three months to once per six months.</p><p id="p-0100" num="0093">In some embodiments, the pharmaceutical composition is administered to the subject at an interval of once a month. In other embodiments, the pharmaceutical composition is administered to the subject at an interval of once a quarter. In some embodiments, the pharmaceutical composition is administered to the subject at an interval of biannually.</p><p id="p-0101" num="0094">In certain embodiments, the double stranded RNAi agent is administered at a dose of 50 to 400 mg per dose at a frequency of once per month to once per six months.</p><p id="p-0102" num="0095">In certain embodiments, the AGT-associated disorder is selected from the group consisting of high blood pressure, hypertension, borderline hypertension, primary hypertension, secondary hypertension isolated systolic or diastolic hypertension, pregnancy-associated hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt hypertension, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, labile hypertension; hypertensive heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis, vasculopathy, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiac myopathy, nocturnal hypotension, glomerulosclerosis, coarctation of the aorta, aortic aneurism, ventricular fibrosis, heart failure, myocardial infarction, angina, stroke, renal disease, renal failure, systemic sclerosis, intrauterine growth restriction (IUGR), fetal growth restriction, obesity, liver steatosis/fatty liver, non-alcoholic Steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD); glucose intolerance, type 2 diabetes, and metabolic syndrome.</p><p id="p-0103" num="0096">In certain embodiments, the subject has a systolic blood pressure of at least 130 mm Hg or a diastolic blood pressure of at least 80 mm Hg. In certain embodiments, the subject has a systolic blood pressure of at least 140 mm Hg and a diastolic blood pressure of at least 80 mm Hg.</p><p id="p-0104" num="0097">In certain embodiments, the subject is part of a group susceptible to salt sensitivity, is overweight, is obese, is pregnant, is planning to become pregnant, has type 2 diabetes, or has type 1 diabetes.</p><p id="p-0105" num="0098">In certain embodiments, the subject has an AGT-associated disorder and is further part of a group susceptible to salt sensitivity, is overweight, is obese, is pregnant, is planning to become pregnant, has type 2 diabetes, or has type 1 diabetes.</p><p id="p-0106" num="0099">In certain embodiments, subject has reduced kidney function. In certain embodiments, the subject has an AGT-associated disorder and is further has reduced kidney function.</p><p id="p-0107" num="0100">In certain embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.</p><p id="p-0108" num="0101">In certain embodiments, the pharmaceutical composition is for administration by subcutaneous or intravenous injection.</p><p id="p-0109" num="0102">The invention further provides for the use of a pharmaceutical composition of any in a method of treating an AGT-associated disorder or for use in the method of preparation of a medicament for use in a method of treating an AGT-associated disorder.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0005" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0110" num="0103"><figref idref="DRAWINGS">FIG. <b>1</b></figref> is a graph showing percent change in serum AGT relative to AGT baseline at day 0 after a single placebo, 10 mg, 25 mg, 50 mg, 100 mg, or 200 mg subcutaneous dose of AD-85481.</p><p id="p-0111" num="0104"><figref idref="DRAWINGS">FIG. <b>2</b></figref> is a graph showing changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Week 8 relative to baseline after a single placebo, 10 mg, 25 mg, 50 mg, 100 mg, or 200 mg subcutaneous dose of AD-85481. The number of subjects in each group are shown along the x axis.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0006" level="1">DETAILED DESCRIPTION OF THE INVENTION</heading><p id="p-0112" num="0105">The present invention provides methods for inhibiting the expression of an angiotensinogen (AGT) gene. The present invention also provides methods for treating a subject having a disorder that would benefit from reduction in AGT expression, or treating an AGT-associated disorder in a subject. In addition, the present invention provides methods for decreasing blood pressure level in a subject. The methods include administering to the subject a fixed dose, e.g., about 50 mg to about 800 mg, of a double stranded RNAi agent, or salt thereof, targeting AGT, as described herein.</p><p id="p-0113" num="0106">The following detailed description discloses methods for inhibiting the expression of an AGT gene, methods for treating subjects that would benefit from reduction of the expression of an AGT gene, e.g., subjects susceptible to or diagnosed with an AGT-associated disorder, e.g., hypertension, using an double stranded RNAi agent, or salt thereof, targeting AGT, and pharmaceutical compositions comprising fixed doses of such RNAi agents, or salt thereof, for inhibiting the expression of an AGT gene.</p><heading id="h-0007" level="1">I. Definitions</heading><p id="p-0114" num="0107">In order that the present invention may be more readily understood, certain terms are first defined. In addition, it should be noted that whenever a value or range of values of a parameter are recited, it is intended that values and ranges intermediate to the recited values are also intended to be part of this invention.</p><p id="p-0115" num="0108">The articles &#x201c;a&#x201d; and &#x201c;an&#x201d; are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, &#x201c;an element&#x201d; means one element or more than one element, e.g., a plurality of elements.</p><p id="p-0116" num="0109">The term &#x201c;including&#x201d; is used herein to mean, and is used interchangeably with, the phrase &#x201c;including but not limited to&#x201d;.</p><p id="p-0117" num="0110">The term &#x201c;or&#x201d; is used herein to mean, and is used interchangeably with, the term &#x201c;and/or,&#x201d; unless context clearly indicates otherwise. For example, &#x201c;sense strand or antisense strand&#x201d; is understood as &#x201c;sense strand or antisense strand or sense strand and antisense strand.&#x201d;</p><p id="p-0118" num="0111">The term &#x201c;about&#x201d; is used herein to mean within the typical ranges of tolerances in the art. For example, &#x201c;about&#x201d; can be understood as about 2 standard deviations from the mean. In certain embodiments, about means+10%. In certain embodiments, about means+5%. When about is present before a series of numbers or a range, it is understood that &#x201c;about&#x201d; can modify each of the numbers in the series or range. The term &#x201c;at least&#x201d; prior to a number or series of numbers is understood to include the number adjacent to the term &#x201c;at least&#x201d;, and all subsequent numbers or integers that could logically be included, as clear from context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, &#x201c;at least 19 nucleotides of a 21 nucleotide nucleic acid molecule&#x201d; means that 19, 20, or 21 nucleotides have the indicated property.</p><p id="p-0119" num="0112">When at least is present before a series of numbers or a range, it is understood that &#x201c;at least&#x201d; can modify each of the numbers in the series or range.</p><p id="p-0120" num="0113">As used herein, &#x201c;no more than&#x201d; or &#x201c;less than&#x201d; is understood as the value adjacent to the phrase and logical lower values or integers, as logical from context, to zero. For example, a duplex with an overhang of &#x201c;no more than 2 nucleotides&#x201d; has a 2, 1, or 0 nucleotide overhang. When &#x201c;no more than&#x201d; is present before a series of numbers or a range, it is understood that &#x201c;no more than&#x201d; can modify each of the numbers in the series or range. As used herein, ranges include both the upper and lower limit.</p><p id="p-0121" num="0114">In the event of a conflict between a sequence and its indicated site on a transcript or other sequence, the nucleotide sequence recited in the specification takes precedence.</p><p id="p-0122" num="0115">In the event of a conflict between a chemical structure and a chemical name, the chemical structure takes precedence.</p><p id="p-0123" num="0116">As used herein, &#x201c;angiotensinogen,&#x201d; used interchangeably with the term &#x201c;AGT&#x201d; refers to the well-known gene and polypeptide, also known in the art as Serpin Peptidase Inhibitor, Clade A, Member 8; Alpha-1 Antiproteinase; Antitrypsin; SERPINA8; Angiotensin I; Serpin A8; Angiotensin II; Alpha-1 Antiproteinase angiotensinogen; antitrypsin; pre-angiotensinogen2; ANHU; Serine Proteinase Inhibitor; and Cysteine Proteinase Inhibitor.</p><p id="p-0124" num="0117">The term &#x201c;AGT&#x201d; includes human AGT, the amino acid and complete coding sequence of which may be found in for example, GenBank Accession No. GI:188595658 (NM_000029.3; SEQ ID NO:1); <i>Macaca fascicularis </i>AGT, the amino acid and complete coding sequence of which may be found in for example, GenBank Accession No. GI: 90075391 (AB170313.1: SEQ ID NO:3); mouse (<i>Mus musculus</i>) AGT, the amino acid and complete coding sequence of which may be found in for example, GenBank Accession No. GI: 113461997 (NM_007428.3; SEQ ID NO:5); and rat AGT (<i>Rattus norvegicus</i>) AGT the amino acid and complete coding sequence of which may be found in for example, for example GenBank Accession No. GI:51036672 (NM_134432; SEQ ID NO:7).</p><p id="p-0125" num="0118">Additional examples of AGT mRNA sequences are readily available using publicly available databases, e.g., GenBank, UniProt, OMIM, and the <i>Macaca </i>genome project web site.</p><p id="p-0126" num="0119">The term &#x201c;AGT,&#x201d; as used herein, also refers to naturally occurring DNA sequence variations of the AGT gene, such as a single nucleotide polymorphism (SNP) in the AGT gene. Exemplary SNPs may be found in the dbSNP database available at www.ncbi.nlm.nih.gov/projects/SNP/snp-_ref.cgi?geneId=183. Non-limiting examples of sequence variations within the AGT gene include, for example, those described in U.S. Pat. No. 5,589,584, the entire contents of which are incorporated herein by reference. For example, sequence variations within the AGT gene may include as a C&#x2192;T at position &#x2212;532 (relative to the transcription start site); a G&#x2192;A at position &#x2212;386; a G&#x2192;A at position &#x2212;218; a C&#x2192;T at position &#x2212;18; a G&#x2192;A and a A&#x2192;C at position &#x2212;6 and &#x2212;10; a C&#x2192;T at position +10 (untanslated); a C&#x2192;T at position +521 (T174M); a T&#x2192;C at position +597 (P199P); a T&#x2192;C at position+704 (M235T; also see, e.g., Reference SNP (refSNP) Cluster Report: rs699, available at www.ncbi.nlm.nih.gov/SNP); a A&#x2192;G at position +743 (Y248C); a C&#x2192;T at position +813 (N271N); a G&#x2192;A at position +1017 (L339L); a C&#x2192;A at position +1075 (L359M); and/or a G&#x2192;A at position +1162 (V388M).</p><p id="p-0127" num="0120">As used herein, &#x201c;target sequence&#x201d; refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an AGT gene, including mRNA that is a product of RNA processing of a primary transcription product. The target portion of the sequence will be at least long enough to serve as a substrate for iRNA-directed cleavage at or near that portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an AGT gene. In one embodiment, the target sequence is within the protein coding region of AGT.</p><p id="p-0128" num="0121">The target sequence may be from about 19-36 nucleotides in length, e.g., preferably about 19-30 nucleotides in length. For example, the target sequence can be about 19-30 nucleotides, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.</p><p id="p-0129" num="0122">As used herein, the term &#x201c;strand comprising a sequence&#x201d; refers to an oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.</p><p id="p-0130" num="0123">&#x201c;G,&#x201d; &#x201c;C,&#x201d; &#x201c;A,&#x201d; &#x201c;T,&#x201d; and &#x201c;U&#x201d; each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine, and uracil as a base, respectively. However, it will be understood that the term &#x201c;ribonucleotide&#x201d; or &#x201c;nucleotide&#x201d; can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety (see, e.g., Table 2). The skilled person is well aware that guanine, cytosine, adenine, and uracil can be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base can base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of dsRNA featured in the invention by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the invention.</p><p id="p-0131" num="0124">The terms &#x201c;iRNA&#x201d;, &#x201c;RNAi agent,&#x201d; &#x201c;iRNA agent,&#x201d;, &#x201c;RNA interference agent&#x201d; as used interchangeably herein, refer to an agent that contains RNA as that term is defined herein, and which mediates the targeted cleavage of an RNA transcript via an RNA-induced silencing complex (RISC) pathway. iRNA directs the sequence-specific degradation of mRNA through a process known as RNA interference (RNAi). The iRNA modulates, e.g., inhibits, the expression of an AGT gene in a cell, e.g., a cell within a subject, such as a mammalian subject, preferably a human subject.</p><p id="p-0132" num="0125">In one embodiment, an RNAi agent of the invention includes a single stranded RNA that interacts with a target RNA sequence, e.g., an AGT target mRNA sequence, to direct the cleavage of the target RNA. Without wishing to be bound by theory it is believed that long double stranded RNA introduced into cells is broken down into siRNA by a Type III endonuclease known as Dicer (Sharp et al. (2001) <i>Genes Dev. </i>15:485). Dicer, a ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3&#x2032; overhangs (Bernstein, et al., (2001) <i>Nature </i>409:363). The siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition (Nykanen, et al., (2001) Cell 107:309). Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleave the target to induce silencing (Elbashir, et al., (2001) <i>Genes Dev. </i>15:188). Thus, in one aspect the invention relates to a single stranded RNA (siRNA) generated within a cell and which promotes the formation of a RISC complex to effect silencing of the target gene, i.e., an AGT gene. Accordingly, the term &#x201c;siRNA&#x201d; is also used herein to refer to an iRNA as described above.</p><p id="p-0133" num="0126">In certain embodiments, the RNAi agent may be a single-stranded siRNA (ssRNAi) that is introduced into a cell or organism to inhibit a target mRNA. Single-stranded RNAi agents bind to the RISC endonuclease, Argonaute 2, which then cleaves the target mRNA. The single-stranded siRNAs are generally 15-30 nucleotides and are chemically modified. The design and testing of single-stranded siRNAs are described in U.S. Pat. No. 8,101,348 and in Lima et al., (2012) Cell 150:883-894, the entire contents of each of which are hereby incorporated herein by reference. Any of the antisense nucleotide sequences described herein may be used as a single-stranded siRNA as described herein or as chemically modified by the methods described in Lima et al., (2012) Cell 150:883-894.</p><p id="p-0134" num="0127">In certain embodiments, an &#x201c;iRNA&#x201d; for use in the compositions, uses, and methods of the invention is a double stranded RNA and is referred to herein as a &#x201c;double stranded RNA agent,&#x201d; &#x201c;double stranded RNA (dsRNA) molecule,&#x201d; &#x201c;dsRNA agent,&#x201d; or &#x201c;dsRNA&#x201d;. The term &#x201c;dsRNA&#x201d;, refers to a complex of ribonucleic acid molecules, having a duplex structure comprising two anti-parallel and substantially complementary nucleic acid strands, referred to as having &#x201c;sense&#x201d; and &#x201c;antisense&#x201d; orientations with respect to a target RNA, i.e., an AGT gene. In some embodiments of the invention, a double stranded RNA (dsRNA) triggers the degradation of a target RNA, e.g., an mRNA, through a post-transcriptional gene-silencing mechanism referred to herein as RNA interference or RNAi.</p><p id="p-0135" num="0128">In general, the majority of nucleotides of each strand of a dsRNA molecule are non-ribonucleotides, e.g., a deoxyribonucleotide or a modified nucleotide. In addition, as used in this specification, an &#x201c;iRNA&#x201d; may include ribonucleotides with chemical modifications; an iRNA may include substantial modifications at multiple nucleotides. As used herein, the term &#x201c;modified nucleotide&#x201d; refers to a nucleotide having, independently, a modified sugar moiety, a modified internucleotide linkage, or modified nucleobase, or any combination thereof. Thus, the term modified nucleotide encompasses substitutions, additions, or removal of, e.g., a functional group or atom, to internucleoside linkages, sugar moieties, or nucleobases. The modifications suitable for use in the agents of the invention include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a siRNA type molecule, are encompassed by &#x201c;iRNA&#x201d; or &#x201c;RNAi agent&#x201d; for the purposes of this specification and claims.</p><p id="p-0136" num="0129">The duplex region may be of any length that permits specific degradation of a desired target RNA through a RISC pathway, and may range from about 19 to 36 base pairs in length, e.g., about 19-30 base pairs in length, for example, about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 base pairs in length, such as about 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. In certain embodiments, the duplex region is 19-21 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.</p><p id="p-0137" num="0130">The two strands forming the duplex structure may be different portions of one larger RNA molecule, or they may be separate RNA molecules. Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3&#x2032;-end of one strand and the 5&#x2032;-end of the respective other strand forming the duplex structure, the connecting RNA chain is referred to as a &#x201c;hairpin loop.&#x201d; A hairpin loop can comprise at least one unpaired nucleotide. In some embodiments, the hairpin loop can comprise at least 4, 5, 6, 7, 8, 9, 10, 20, 23, or more unpaired nucleotides. In some embodiments, the hairpin loop can be 10 or fewer nucleotides. In some embodiments, the hairpin loop can be 8 or fewer unpaired nucleotides. In some embodiments, the hairpin loop can be 4-10 unpaired nucleotides. In some embodiments, the hairpin loop can be 4-8 nucleotides.</p><p id="p-0138" num="0131">Where the two substantially complementary strands of a dsRNA are comprised by separate RNA molecules, those molecules need not be, but can be covalently connected. Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3&#x2032;-end of one strand and the 5&#x2032;-end of the respective other strand forming the duplex structure, the connecting structure is referred to as a &#x201c;linker.&#x201d; The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest strand of the dsRNA minus any overhangs that are present in the duplex. In addition to the duplex structure, an RNAi may comprise one or more nucleotide overhangs.</p><p id="p-0139" num="0132">In certain embodiments, an iRNA agent of the invention is a dsRNA, each strand of which comprises 19-23 nucleotides, that interacts with a target RNA sequence, e.g., an AGT gene, to direct cleavage of the target RNA.</p><p id="p-0140" num="0133">In some embodiments, an iRNA of the invention is a dsRNA of 24-30 nucleotides that interacts with a target RNA sequence, e.g., an AGT target mRNA sequence, to direct the cleavage of the target RNA.</p><p id="p-0141" num="0134">As used herein, the term &#x201c;nucleotide overhang&#x201d; refers to at least one unpaired nucleotide that protrudes from the duplex structure of a double stranded iRNA. For example, when a 3&#x2032;-end of one strand of a dsRNA extends beyond the 5&#x2032;-end of the other strand, or vice versa, there is a nucleotide overhang. A dsRNA can comprise an overhang of at least one nucleotide; alternatively, the overhang can comprise at least two nucleotides, at least three nucleotides, at least four nucleotides, at least five nucleotides or more. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand, or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5&#x2032;-end, 3&#x2032;-end, or both ends of either an antisense or sense strand of a dsRNA.</p><p id="p-0142" num="0135">In certain embodiments, the antisense strand of a dsRNA has a 1-10 nucleotide, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3&#x2032;-end or the 5&#x2032;-end. In certain embodiments, the overhang on the sense strand or the antisense strand, or both, can include extended lengths longer than 10 nucleotides, e.g., 1-30 nucleotides, 2-30 nucleotides, 10-30 nucleotides, 10-25 nucleotides, 10-20 nucleotides, or 10-15 nucleotides in length. In certain embodiments, an extended overhang is on the sense strand of the duplex. In certain embodiments, an extended overhang is present on the 3&#x2032;end of the sense strand of the duplex. In certain embodiments, an extended overhang is present on the 5&#x2032;end of the sense strand of the duplex. In certain embodiments, an extended overhang is on the antisense strand of the duplex. In certain embodiments, an extended overhang is present on the 3&#x2032;end of the antisense strand of the duplex. In certain embodiments, an extended overhang is present on the 5&#x2032;end of the antisense strand of the duplex. In certain embodiments, one or more of the nucleotides in the extended overhang is replaced with a nucleoside thiophosphate. In certain embodiments, the overhang includes a self-complementary portion such that the overhang is capable of forming a hairpin structure that is stable under physiological conditions.</p><p id="p-0143" num="0136">&#x201c;Blunt&#x201d; or &#x201c;blunt end&#x201d; means that there are no unpaired nucleotides at that end of the double stranded RNA agent, i.e., no nucleotide overhang. A &#x201c;blunt ended&#x201d; double stranded RNA agent is double stranded over its entire length, i.e., no nucleotide overhang at either end of the molecule. The RNAi agents of the invention include RNAi agents with no nucleotide overhang at one end (i.e., agents with one overhang and one blunt end) or with no nucleotide overhangs at either end. Most often such a molecule will be double-stranded over its entire length.</p><p id="p-0144" num="0137">The term &#x201c;antisense strand&#x201d; or &#x201c;guide strand&#x201d; refers to the strand of an iRNA, e.g., a dsRNA, which includes a region that is substantially complementary to a target sequence, e.g., an AGT mRNA. As used herein, the term &#x201c;region of complementarity&#x201d; refers to the region on the antisense strand that is substantially complementary to a sequence, for example a target sequence, e.g., an AGT nucleotide sequence, as defined herein. Where the region of complementarity is not fully complementary to the target sequence, the mismatches can be in the internal or terminal regions of the molecule. Generally, the most tolerated mismatches are in the terminal regions, e.g., within 5, 4, or 3 nucleotides of the 5&#x2032;- or 3&#x2032;-end of the iRNA. In some embodiments, a double stranded RNA agent of the invention includes a nucleotide mismatch in the antisense strand. In some embodiments, a double stranded RNA agent of the invention includes a nucleotide mismatch in the sense strand. In some embodiments, the nucleotide mismatch is, for example, within 5, 4, 3 nucleotides from the 3&#x2032;-end of the iRNA. In another embodiment, the nucleotide mismatch is, for example, in the 3&#x2032;-terminal nucleotide of the iRNA.</p><p id="p-0145" num="0138">The term &#x201c;sense strand&#x201d; or &#x201c;passenger strand&#x201d; as used herein, refers to the strand of an iRNA that includes a region that is substantially complementary to a region of the antisense strand as that term is defined herein.</p><p id="p-0146" num="0139">As used herein, &#x201c;substantially all of the nucleotides are modified&#x201d; are largely but not wholly modified and can include not more than 5, 4, 3, 2, or 1 unmodified nucleotides.</p><p id="p-0147" num="0140">As used herein, the term &#x201c;cleavage region&#x201d; refers to a region that is located immediately adjacent to the cleavage site. The cleavage site is the site on the target at which cleavage occurs. In some embodiments, the cleavage region comprises three bases on either end of, and immediately adjacent to, the cleavage site. In some embodiments, the cleavage region comprises two bases on either end of, and immediately adjacent to, the cleavage site. In some embodiments, the cleavage site specifically occurs at the site bound by nucleotides 10 and 11 of the antisense strand, and the cleavage region comprises nucleotides 11, 12 and 13.</p><p id="p-0148" num="0141">Complementary sequences within an iRNA, e.g., within a dsRNA as described herein, include base-pairing of the oligonucleotide or polynucleotide comprising a first nucleotide sequence to an oligonucleotide or polynucleotide comprising a second nucleotide sequence over the entire length of one or both nucleotide sequences. Such sequences can be referred to as &#x201c;fully complementary&#x201d; with respect to each other herein. However, where a first sequence is referred to as &#x201c;substantially complementary&#x201d; with respect to a second sequence herein, the two sequences can be fully complementary, or they can form one or more, but generally not more than 5, 4, 3, or 2 mismatched base pairs upon hybridization for a duplex up to 30 base pairs, while retaining the ability to hybridize under the conditions most relevant to their ultimate application, e.g., inhibition of gene expression via a RISC pathway. However, where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs shall not be regarded as mismatches with regard to the determination of complementarity. For example, a dsRNA comprising one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is fully complementary to the shorter oligonucleotide, can yet be referred to as &#x201c;fully complementary&#x201d; for the purposes described herein.</p><p id="p-0149" num="0142">&#x201c;Complementary&#x201d; sequences, as used herein, can also include, or be formed entirely from, non-Watson-Crick base pairs or base pairs formed from non-natural and modified nucleotides, in so far as the above requirements with respect to their ability to hybridize are fulfilled. Such non-Watson-Crick base pairs include, but are not limited to, G:U Wobble or Hoogstein base pairing.</p><p id="p-0150" num="0143">The terms &#x201c;complementary,&#x201d; &#x201c;fully complementary&#x201d; and &#x201c;substantially complementary&#x201d; herein can be used with respect to the base matching between the sense strand and the antisense strand of a dsRNA, or between the antisense strand of a double stranded RNA agent and a target sequence, as will be understood from the context of their use.</p><p id="p-0151" num="0144">As used herein, a polynucleotide that is &#x201c;substantially complementary to at least part of&#x201d; a messenger RNA (mRNA) refers to a polynucleotide that is substantially complementary to a contiguous portion of the mRNA of interest (e.g., an mRNA encoding an AGT gene). For example, a polynucleotide is complementary to at least a part of an AGT mRNA if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding an AGT gene.</p><p id="p-0152" num="0145">Accordingly, in some embodiments, the sense strand polynucleotides and the antisense polynucleotides disclosed herein are fully complementary to the target AGT sequence. In other embodiments, the sense strand polynucleotides or the antisense polynucleotides disclosed herein are substantially complementary to the target AGT sequence and comprise a contiguous nucleotide sequence which is at least 80% complementary over its entire length to the equivalent region of the nucleotide sequence of any one of SEQ ID NOs:1 and 2, or a fragment of any one of SEQ ID NOs:1 and 2, such as at least 90%, or 95% complementary; or 100% complementary.</p><p id="p-0153" num="0146">Accordingly, in some embodiments, the antisense strand polynucleotides disclosed herein are fully complementary to the target AGT sequence. In other embodiments, the antisense strand polynucleotides disclosed herein are substantially complementary to the target AGT sequence and comprise a contiguous nucleotide sequence which is at least about 90% complementary over its entire length to the equivalent region of the nucleotide sequence of SEQ ID NO:1, or a fragment of SEQ ID NO:1, such as about 90%, or about 95%, complementary. In certain embodiments, the fragment of SEQ ID NO: 1 is nucleotides 638-658 of SEQ ID NO: 1.</p><p id="p-0154" num="0147">In certain embodiments, the nucleotide sequence of the antisense strand of an iRNA of the invention comprises at least 19 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9). In certain embodiments, the iRNA of the invention further comprises a sense strand comprising at least 19 contiguous nucleotides of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10).</p><p id="p-0155" num="0148">In certain embodiments, the nucleotide sequence of the antisense strand of an iRNA of the invention comprises the nucleotides sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9). In certain embodiments, the iRNA of the invention further comprises a sense strand comprising the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10).</p><p id="p-0156" num="0149">In certain embodiments, the nucleotide sequence of the antisense strand of an iRNA of the invention consists of UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9). In certain embodiments, the iRNA of the invention further comprises a sense strand wherein the nucleotide sequence of the strand consists of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10).</p><p id="p-0157" num="0150">In certain embodiments, the modified nucleotide sequence of the antisense strand of an iRNA of the invention comprises at least 19 contiguous nucleotides of the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11). In certain embodiments the iRNA of the invention further comprises a sense strand comprising a modified nucleotide sequence comprising at least 19 contiguous nucleotides of gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12). The chemical modifications are defined as follows: a is 2&#x2032;-O-methyladenosine-3&#x2032;-phosphate, c is 2&#x2032;-O-methylcytidine-3&#x2032;-phosphate, g is 2&#x2032;-O-methylguanosine-3&#x2032;-phosphate, u is 2&#x2032;-O-methyluridine-3&#x2032;-phosphate, Af is 2&#x2032;-fluoroadenosine-3&#x2032;-phosphate, Cf is 2&#x2032;-fluorocytidine-3&#x2032;-phosphate, Gf is 2&#x2032;-fluoroguanosine-3&#x2032;-phosphate, Uf is 2&#x2032;-fluorouridine-3&#x2032;-phosphate, (Tgn) is thymidine-glycol nucleic acid (GNA)S-isomer, and s is phosphorothioate linkage; and wherein the 3&#x2032;end of the sense strand is optionally covalently linked to a ligand, e.g., an N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol (also referred to as Hyp-(GalNAc-alkyl)3 or L96).</p><p id="p-0158" num="0151">In certain embodiments, the modified nucleotide sequence of the antisense strand of an iRNA of the invention comprises the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11). In certain embodiments the iRNA of the invention further comprises a sense strand comprising the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12).</p><p id="p-0159" num="0152">In certain embodiments, the modified nucleotide sequence of the antisense strand of an iRNA of the invention consists of usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11). In certain embodiments, the iRNA of the invention further comprises a sense strand wherein the modified nucleotide sequence of the sense strand consists of the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12).</p><p id="p-0160" num="0153">In general, an &#x201c;iRNA&#x201d; includes ribonucleotides with chemical modifications. Such modifications may include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a dsRNA molecule, are encompassed by &#x201c;iRNA&#x201d; for the purposes of this specification and claims.</p><p id="p-0161" num="0154">In an aspect of the invention, an agent for use in the methods and compositions of the invention is a single-stranded antisense oligonucleotide molecule that inhibits a target mRNA via an antisense inhibition mechanism. The single-stranded antisense oligonucleotide molecule is complementary to a sequence within the target mRNA. The single-stranded antisense oligonucleotides can inhibit translation in a stoichiometric manner by base pairing to the mRNA and physically obstructing the translation machinery, see Dias, N. et al., (2002) Mol Cancer Ther 1:347-355. The single-stranded antisense oligonucleotide molecule may be about 14 to about 30 nucleotides in length and have a sequence that is complementary to a target sequence. For example, the single-stranded antisense oligonucleotide molecule may comprise a sequence that is at least about 14, 15, 16, 17, 18, 19, 20, or more contiguous nucleotides from any one of the antisense sequences described herein.</p><p id="p-0162" num="0155">The phrase &#x201c;contacting a cell with an iRNA,&#x201d; such as a dsRNA, as used herein, includes contacting a cell by any possible means. Contacting a cell with an iRNA includes contacting a cell in vitro with the iRNA or contacting a cell in vivo with the iRNA. The contacting may be done directly or indirectly. Thus, for example, the iRNA may be put into physical contact with the cell by the individual performing the method, or alternatively, the iRNA may be put into a situation that will permit or cause it to subsequently come into contact with the cell.</p><p id="p-0163" num="0156">Contacting a cell in vitro may be done, for example, by incubating the cell with the iRNA. Contacting a cell in vivo may be done, for example, by injecting the iRNA into or near the tissue where the cell is located, or by injecting the iRNA into another area, e.g., the bloodstream or the subcutaneous space, such that the agent will subsequently reach the tissue where the cell to be contacted is located. For example, the iRNA may contain or be coupled to a ligand, e.g., GalNAc, that directs the iRNA to a site of interest, e.g., the liver. Combinations of in vitro and in vivo methods of contacting are also possible. For example, a cell may also be contacted in vitro with an iRNA and subsequently transplanted into a subject.</p><p id="p-0164" num="0157">In certain embodiments, contacting a cell with an iRNA includes &#x201c;introducing&#x201d; or &#x201c;delivering the iRNA into the cell&#x201d; by facilitating or effecting uptake or absorption into the cell. Absorption or uptake of an iRNA can occur through unaided diffusion or active cellular processes, or by auxiliary agents or devices. Introducing an iRNA into a cell may be in vitro or in vivo. For example, for in vivo introduction, iRNA can be injected into a tissue site or administered systemically. In vitro introduction into a cell includes methods known in the art such as electroporation and lipofection. Further approaches are described herein below or are known in the art.</p><p id="p-0165" num="0158">The term &#x201c;lipid nanoparticle&#x201d; or &#x201c;LNP&#x201d; is a vesicle comprising a lipid layer encapsulating a pharmaceutically active molecule, such as a nucleic acid molecule, e.g., an iRNA or a plasmid from which an iRNA is transcribed. LNPs are described in, for example, U.S. Pat. Nos. 6,858,225, 6,815,432, 8,158,601, and 8,058,069, the entire contents of which are hereby incorporated herein by reference.</p><p id="p-0166" num="0159">As used herein, a &#x201c;subject&#x201d; is an animal, such as a mammal, including a primate (such as a human, a non-human primate, e.g., a monkey, and a chimpanzee), or a non-primate (such as a cow, a pig, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, or a mouse) that expresses the target gene, either endogenously or heterologously. In an embodiment, the subject is a human, such as a human being treated or assessed for a disease or disorder that would benefit from reduction in AGT expression; a human at risk for a disease or disorder that would benefit from reduction in AGT expression; a human having a disease or disorder that would benefit from reduction in AGT expression; or human being treated for a disease or disorder that would benefit from reduction in AGT expression as described herein. The diagnostic criteria for an AGT-associated disorder, e.g., hypertension, are provided below. In some embodiments, the subject is a female human. In other embodiments, the subject is a male human. In certain embodiments, the subject is part of a group susceptible to salt sensitivity, e.g., black or an older adult (&#x2265;65 years of age). In certain embodiments, the subject is overweight or obese, e.g., a subject that suffers from central obesity. In certain embodiments, the subject is sedentary. In certain embodiments, the subject is pregnant or planning to become pregnant. In certain embodiments, the subject has reduced kidney function. In certain embodiments the subject has type 1 diabetes. In certain embodiments, the subject has type 2 diabetes.</p><p id="p-0167" num="0160">As used herein, the terms &#x201c;treating&#x201d; or &#x201c;treatment&#x201d; refer to a beneficial or desired result, such as reducing at least one sign or symptom of an AGT-associated disorder, e.g., hypertension in a subject. Treatment also includes a reduction of one or more sign or symptoms associated with unwanted AGT expression, e.g., angiotensin II type 1 receptor activation (AT<sub>1</sub>R) (e.g., hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, aneurysms, peripheral artery disease, heart disease, increased oxidative stress, e.g., increased superoxide formation, inflammation, vasoconstriction, sodium and water retention, potassium and magnesium loss, renin suppression, myocyte and smooth muscle hypertrophy, increased collagen synthesis, stimulation of vascular, myocardial and renal fibrosis, increased rate and force of cardiac contractions, altered heart rate, e.g., increased arrhythmia, stimulation of plasminogen activator inhibitor 1 (PAI1), activation of the sympathetic nervous system, and increased endothelin secretion), symptoms of pregnancy-associated hypertension (e.g., preeclampsia, and eclampsia), including, but not limited to intrauterine growth restriction (IUGR) or fetal growth restriction, symptoms associated with malignant hypertension, symptoms associated with hyperaldosteronism; diminishing the extent of unwanted AT<sub>1</sub>R activation; stabilization (i.e., not worsening) of the state of chronic AT<sub>1</sub>R activation; amelioration or palliation of unwanted AT<sub>1</sub>R activation (e.g., hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, aneurysms, peripheral artery disease, heart disease, increased oxidative stress, e.g., increased superoxide formation, inflammation, vasoconstriction, sodium and water retention, potassium and magnesium loss, renin suppression, myocyte and smooth muscle hypertrophy, increased collagen synthesis, stimulation of vascular, myocardial and renal fibrosis, increased rate and force of cardiac contractions, altered heart rate, e.g., increased arrhythmia, stimulation of plasminogen activator inhibitor 1 (PAI1), activation of the sympathetic nervous system, and increased endothelin secretion) whether detectable or undetectable. AGT-associated disorders can also include obesity, liver steatosis/fatty liver, e.g., non-alcoholic Steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD); glucose intolerance, type 2 diabetes, and metabolic syndrome. &#x201c;Treatment&#x201d; can also mean prolonging survival as compared to expected survival in the absence of treatment.</p><p id="p-0168" num="0161">As used herein, &#x201c;reduced kidney function&#x201d; and the like can be diagnosed using any of a number of recognized criteria, e.g., glomerular filtration rate (GFR), albuminuria, creatinine, or BUN. As used herein, reduced kidney function can be transient or chronic. A GFR of at least 60 is considered to be normal. A GFR of 60 or less is indicative of reduced kidney function with a GFR of &#x3e;15-60 being indicative of kidney disease, and a GFR of less than 15 is indicative of kidney failure. GFR is typically determined based on urine creatinine levels, with a higher level of creatinine indicative of lower kidney function. The presence of albumin in the urine is also indicative of decreased kidney function. The absolute level of albumin can be determined to diagnose decreased kidney function. The ratio of albumin to creatinine can also be determined to assess kidney function. A urine albumin to creatinine ratio of 30 mg/g or less is indicative of normal kidney function. A urine albumin to creatinine ratio greater than 30 mg/g is indicative of reduced kidney function.</p><p id="p-0169" num="0162">The term &#x201c;lower&#x201d; in the context of the level of AGT gene expression or agt protein production in a subject, or a disease marker or symptom refers to a statistically significant decrease in such level. The decrease can be, for example, at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or below the level of detection for the detection method in a relevant cell or tissue, e.g., a liver cell, or other subject sample, e.g., blood or serum derived therefrom, urine. In certain embodiments, &#x201c;lower&#x201d; is a reduction of AGT protein in the serum after administration of one or more doses of an iRNA agent provided herein relative to AGT protein level in serum prior to administration of any doses of an iRNA agent provided herein.</p><p id="p-0170" num="0163">As used herein, &#x201c;prevention&#x201d; or &#x201c;preventing,&#x201d; when used in reference to a disease or disorder, that would benefit from a reduction in expression of an AGT gene or production of agt protein, e.g., in a subject susceptible to an AGT-associated disorder due to, e.g., aging, genetic factors, hormone changes, diet, and a sedentary lifestyle, wherein the subject does not yet meet the diagnostic criteria for the AGT-associated disorder. As used herein, prevention can be understood as administration of an agent to a subject who does not yet meet the diagnostic criteria for the AGT-associated disorder to delay or reduce the likelihood that the subject will develop the AGT-associated disorder. As the agent is a pharmaceutical agent, it is understood that administration typically would be under the direction of a health care professional capable of identifying a subject who does not yet meet the diagnostic criteria for an AGT-associated disorder as being susceptible to developing an AGT-associated disorder. Diagnosic criteria for hypertension and risk factors for hypertension are provided below. In certain embodiments, the disease or disorder is e.g., a symptom of unwanted AT<sub>1</sub>R activation, such as a hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, aneurysms, peripheral artery disease, heart disease, increased oxidative stress, e.g., increased superoxide formation, inflammation, vasoconstriction, sodium and water retention, potassium and magnesium loss, renin suppression, myocyte and smooth muscle hypertrophy, increased collagen synthesis, stimulation of vascular, myocardial and renal fibrosis, increased rate and force of cardiac contractions, altered heart rate, e.g., increased arrhythmia, stimulation of plasminogen activator inhibitor 1 (PAI1), activation of the sympathetic nervous system, and increased endothelin secretion. AGT-associated disorders can also include obesity, liver steatosis/fatty liver, e.g., non-alcoholic Steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD); glucose intolerance, type 2 diabetes, and metabolic syndrome. The likelihood of developing, e.g., hypertension, is reduced, for example, when an individual having one or more risk factors for a hypertension either fails to develop hypertension or develops hypertension with less severity relative to a population having the same risk factors and not receiving treatment as described herein. The failure to develop an AGT-associated disorder, e.g., hypertension or a delay in the time to develop hypertension by months or years is considered effective prevention. Prevention may require administration of more than one dose if the iRNA agent. Provided with appropriate methods to identify subjects at risk to develop any of the AGT-associated diseases above, the iRNA agents provided herein can be used as pharmaceutical agents for or in methods of prevention of AGT-associated diseases. Risk factors for various AGT-associated diseases are discussed below.</p><p id="p-0171" num="0164">As used herein, the term &#x201c;angiotensinogen-associated disease&#x201d; or &#x201c;AGT-associated disease,&#x201d; is a disease or disorder that is caused by, or associated with, renin-angiotensin-aldosterone system (RAAS) activation, or a disease or disorder the symptoms of which or progression of which responds to RAAS inactivation. The term &#x201c;angiotensinogen-associated disease&#x201d; includes a disease, disorder, or condition that would benefit from reduction in AGT expression. Such diseases are typically associated with high blood pressure. Non-limiting examples of angiotensinogen-associated diseases include hypertension, e.g., borderline hypertension (also known as prehypertension), primary hypertension (also known as essential hypertension or idiopathic hypertension), secondary hypertension (also known as inessential hypertension), isolated systolic or diastolic hypertension, pregnancy-associated hypertension (e.g., preeclampsia, eclampsia, and post-partum preelampsia), diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension (also known as renal hypertension), Goldblatt hypertension, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venouss hypertension, systolic hypertension, labile hypertension; hypertensive heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis, vasculopathy (including peripheral vascular disease), diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiac myopathy, glomerulosclerosis, coarctation of the aorta, aortic aneurism, ventricular fibrosis, sleep apnea, heart failure (e.g., left ventricular systolic dysfunction, heart failure with decreased ejection fraction), myocardial infarction, angina, stroke, renal disease e.g., chronic kidney disease or diabetic nephropathy optionally in the context of pregnancy, renal failure, e.g., chronic renal failure, and systemic sclerosis (e.g., scleroderma renal crisis). In certain embodiments, AGT-associated disease includes intrauterine growth restriction (IUGR) or fetal growth restriction. In certain embodiments, AGT-associated disorders can also include obesity, liver steatosis/fatty liver, e.g., non-alcoholic Steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD); glucose intolerance, type 2 diabetes, and metabolic syndrome, and nocturnal hypotension.</p><p id="p-0172" num="0165">Thresholds for high blood pressure and stages of hypertension are discussed in detail below.</p><p id="p-0173" num="0166">In one embodiment, an angiotensinogen-associated disease is primary hypertension. &#x201c;Primary hypertension&#x201d; is a result of environmental or genetic causes (e.g., a result of no obvious underlying medical cause).</p><p id="p-0174" num="0167">In one embodiment, an angiotensinogen-associated disease is secondary hypertension. &#x201c;Secondary hypertension&#x201d; has an identifiable underlying disorder which can be of multiple etiologies, including renal, vascular, and endocrine causes, e.g., renal parenchymal disease (e.g., polycystic kidneys, glomerular or interstitial disease), renal vascular disease (e.g., renal artery stenosis, fibromuscular dysplasia), endocrine disorders (e.g., adrenocorticosteroid or mineralocorticoid excess, pheochromocytoma, hyperthyroidism or hypothyroidism, growth hormone excess, hyperparathyroidism), coarctation of the aorta, or oral contraceptive use.</p><p id="p-0175" num="0168">In one embodiment, an angiotensinogen-associated disease is pregnancy-associated hypertension, e.g., chronic hypertension of pregnancy, gestational hypertension, preeclampsia, eclampsia, preeclampsia superimposed on chronic hypertension, HELLP syndrome, and gestational hypertension (also known as transient hypertension of pregnancy, chronic hypertension identified in the latter half of pregnancy, and pregnancy-induced hypertension (PIH)). Diagnostic criteria for pregnancy-associated hypertension are provided below.</p><p id="p-0176" num="0169">In one embodiment, an angiotensinogen-associated disease is resistant hypertension. &#x201c;Resistant hypertension&#x201d; is blood pressure that remains above goal (e.g., above 130 mm Hg systolic or above 90 diastolic) in spite of concurrent use of three antihypertensive agents of different classes, one of which is a thiazide diuretic. Subjects whose blood pressure is controlled with four or more medications are also considered to have resistant hypertension.</p><p id="p-0177" num="0170">A &#x201c;therapeutically-effective amount&#x201d; or &#x201c;prophylactically effective amount&#x201d; also includes an amount of an RNAi agent that produces some desired effect at a reasonable benefit/risk ratio applicable to any treatment. The iRNA employed in the methods of the present invention may be administered in a sufficient amount to produce a reasonable benefit/risk ratio applicable to such treatment.</p><p id="p-0178" num="0171">The phrase &#x201c;pharmaceutically acceptable&#x201d; is employed herein to refer to those compounds, materials, compositions, or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human subjects and animal subjects without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.</p><p id="p-0179" num="0172">The phrase &#x201c;pharmaceutically-acceptable carrier&#x201d; as used herein means a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be &#x201c;acceptable&#x201d; in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject being treated. Such carriers are known in the art. Pharmaceutically acceptable carriers include carriers for administration by injection.</p><p id="p-0180" num="0173">The term &#x201c;sample,&#x201d; as used herein, includes a collection of similar fluids, cells, or tissues isolated from a subject, as well as fluids, cells, or tissues present within a subject. Examples of biological fluids include blood, serum and serosal fluids, plasma, cerebrospinal fluid, ocular fluids, lymph, urine, saliva, and the like. Tissue samples may include samples from tissues, organs, or localized regions. For example, samples may be derived from particular organs, parts of organs, or fluids or cells within those organs. In certain embodiments, samples may be derived from the liver (e.g., whole liver or certain segments of liver or certain types of cells in the liver, such as, e.g., hepatocytes). In some embodiments, a &#x201c;sample derived from a subject&#x201d; refers to urine obtained from the subject. A &#x201c;sample derived from a subject&#x201d; can refer to blood or blood derived serum or plasma from the subject.</p><heading id="h-0008" level="1">II. Methods of the Invention</heading><p id="p-0181" num="0174">The present invention provides methods for inhibiting the expression of an angiotensinogen (AGT) gene. The present invention also provides methods for treating a subject that would benefit from reduction in AGT expression (such as a subject at risk of developing an AGT-associated disorder, e.g., hypertension), or treating an AGT-associated disorder, e.g., hypertension, in a subject. In addition, the present invention provides methods for decreasing blood pressure level in a subject, such as a subject having an AGT-associate disorder, e.g., hypertension. The methods include administering to the subject a fixed dose, e.g., about 50 mg to about 800 mg, of a double stranded RNAi agent targeting AGT, as described herein.</p><p id="p-0182" num="0175">Accordingly, in one aspect, the present invention provides a methods of inhibiting the expression of an angiotensinogen (AGT) gene in a subject. The method comprises administering to the subject a fixed dose of about 50 mg to about 800 mg, e.g., about 50 to about 200 mg, about 50 mg to about 500 mg, about 100 mg to about 800 mg, about 100 mg to about 500 mg, about 100 mg to about 300 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 500 mg, about 200 mg to about 800 mg, about 300 mg to about 800 mg, about 300 mg to about 500 mg, about 300 mg to about 4000 mg, about 400 mg to about 800 mg, about 400 mg to about 500 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg, of a double-stranded ribonucleic acid (RNAi) agent that inhibits expression of AGT. Values and ranges intermediate to the foregoing recited values are also intended to be part of this invention.</p><p id="p-0183" num="0176">The term &#x201c;inhibiting,&#x201d; as used herein, is used interchangeably with &#x201c;reducing,&#x201d; &#x201c;silencing,&#x201d; &#x201c;downregulating&#x201d;, &#x201c;suppressing&#x201d;, and other similar terms, and includes any level of inhibition.</p><p id="p-0184" num="0177">The phrase &#x201c;inhibiting expression of an AGT&#x201d; is intended to refer to inhibition of expression of any AGT gene (such as, e.g., a mouse AGT gene, a rat AGT gene, a monkey AGT gene, or a human AGT gene) as well as variants or mutants of an AGTgene. Thus, the AGT gene may be a wild-type AGT gene, a mutant AGT gene, or a transgenic AGT gene in the context of a genetically manipulated cell, group of cells, or organism.</p><p id="p-0185" num="0178">&#x201c;Inhibiting expression of an AGT gene&#x201d; includes any level of inhibition of an AGT gene, e.g., at least partial suppression of the expression of an AGT gene. The expression of the AGT gene may be assessed based on the level, or the change in the level, of any variable associated with AGT gene expression, e.g., AGT mRNA level or AGT protein level. This level may be assessed in an individual cell or in a group of cells, including, for example, a sample derived from a subject. It is understood that AGT is expressed predominantly in the liver, but also in the brain, gall bladder, heart, and kidney, and is present in circulation.</p><p id="p-0186" num="0179">Inhibition may be assessed by a decrease in an absolute or relative level of one or more variables that are associated with AGT expression compared with a control level. The control level may be any type of control level that is utilized in the art, e.g., a pre-dose baseline level, or a level determined from a similar subject, cell, or sample that is untreated or treated with a control (such as, e.g., buffer only control or inactive agent control).</p><p id="p-0187" num="0180">In some embodiments of the methods of the invention, expression of an AGT gene is inhibited by at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or to below the level of detection of the assay. In preferred embodiments, expression of an AGT gene is inhibited by at least 50%. It is further understood that inhibition of AGT expression in certain tissues, e.g., in liver, without a significant inhibition of expression in other tissues, e.g., brain, may be desirable. In preferred embodiments, expression level is determined using the assay method provided in Example 2 of PCT Application No. PCT/US2019/032150 with a 10 nM siRNA concentration in the appropriate species matched cell line.</p><p id="p-0188" num="0181">In certain embodiments, inhibition of expression in vivo is determined by knockdown of the human gene in a rodent expressing the human gene, e.g., an AAV-infected mouse expressing the human target gene (i.e., AGT), e.g., when administered a single dose at 3 mg/kg at the nadir of RNA expression. Knockdown of expression of an endogenous gene in a model animal system can also be determined, e.g., after administration of a single dose at 3 mg/kg at the nadir of RNA expression. Such systems are useful when the nucleic acid sequence of the human gene and the model animal gene are sufficiently close such that the human iRNA provides effective knockdown of the model animal gene. RNA expression in liver is determined using the PCR methods provided in Example 2 of PCT Application No. PCT/US2019/032150.</p><p id="p-0189" num="0182">Inhibition of the expression of an AGT gene may be manifested by a reduction of the amount of mRNA expressed by a first cell or group of cells (such cells may be present, for example, in a sample derived from a subject) in which an AGT gene is transcribed and which has or have been treated (e.g., by contacting the cell or cells with an iRNA of the invention, or by administering an iRNA of the invention to a subject in which the cells are or were present) such that the expression of an AGT gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has not or have not been so treated (control cell(s) not treated with an iRNA or not treated with an iRNA targeted to the gene of interest). In preferred embodiments, the inhibition is assessed by the method provided in Example 2 of PCT Application No. PCT/US2019/032150 using a 10 nM siRNA concentration in the species matched cell line and expressing the level of mRNA in treated cells as a percentage of the level of mRNA in control cells, using the following formula:</p><p id="p-0190" num="0000"><maths id="MATH-US-00001" num="00001"><math overflow="scroll"> <mrow>  <mrow>   <mfrac>    <mrow>     <mrow>      <mo>(</mo>      <mrow>       <mi>mRNA</mi>       <mo>&#x2062;</mo>       <mtext>   </mtext>       <mi>in</mi>       <mo>&#x2062;</mo>       <mtext>   </mtext>       <mi>control</mi>       <mo>&#x2062;</mo>       <mtext>   </mtext>       <mi>cells</mi>      </mrow>      <mo>)</mo>     </mrow>     <mo>-</mo>     <mrow>      <mo>(</mo>      <mrow>       <mi>mRNA</mi>       <mo>&#x2062;</mo>       <mtext>   </mtext>       <mi>in</mi>       <mo>&#x2062;</mo>       <mtext>   </mtext>       <mi>treated</mi>       <mo>&#x2062;</mo>       <mtext>   </mtext>       <mi>cells</mi>      </mrow>      <mo>)</mo>     </mrow>    </mrow>    <mrow>     <mo>(</mo>     <mrow>      <mi>mRNA</mi>      <mo>&#x2062;</mo>      <mtext>   </mtext>      <mi>in</mi>      <mo>&#x2062;</mo>      <mtext>   </mtext>      <mi>control</mi>      <mo>&#x2062;</mo>      <mtext>   </mtext>      <mi>cells</mi>     </mrow>     <mo>)</mo>    </mrow>   </mfrac>   <mo>&#xb7;</mo>   <mn>100</mn>  </mrow>  <mo>&#x2062;</mo>  <mi>%</mi> </mrow></math></maths></p><p id="p-0191" num="0183">In other embodiments, inhibition of the expression of an AGT gene may be assessed in terms of a reduction of a parameter that is functionally linked to AGT gene expression, e.g., AGT protein level in blood or serum from a subject. AGT gene silencing may be determined in any cell expressing AGT, either endogenous or heterologous from an expression construct, and by any assay known in the art.</p><p id="p-0192" num="0184">Inhibition of the expression of an AGT protein may be manifested by a reduction in the level of the AGT protein that is expressed by a cell or group of cells or in a subject sample (e.g., the level of protein in a blood sample derived from a subject). As explained above, for the assessment of mRNA suppression, the inhibition of protein expression levels in a treated cell or group of cells may similarly be expressed as a percentage of the level of protein in a control cell or group of cells, or the change in the level of protein in a subject sample, e.g., blood or serum derived therefrom.</p><p id="p-0193" num="0185">A control cell, a group of cells, or subject sample that may be used to assess the inhibition of the expression of an AGT gene includes a cell, group of cells, or subject sample that has not yet been contacted with an RNAi agent of the invention. For example, the control cell, group of cells, or subject sample may be derived from an individual subject (e.g., a human or animal subject) prior to treatment of the subject with an RNAi agent or an appropriately matched population control.</p><p id="p-0194" num="0186">The level of AGT mRNA that is expressed by a cell or group of cells may be determined using any method known in the art for assessing mRNA expression. In one embodiment, the level of expression of AGT in a sample is determined by detecting a transcribed polynucleotide, or portion thereof, e.g., mRNA of the AGT gene. RNA may be extracted from cells using RNA extraction techniques including, for example, using acid phenol/guanidine isothiocyanate extraction (RNAzol B; Biogenesis), RNeasy&#x2122; RNA preparation kits (Qiagen&#xae;) or PAXgene&#x2122; (PreAnalytix&#x2122;, Switzerland). Typical assay formats utilizing ribonucleic acid hybridization include nuclear run-on assays, RT-PCR, RNase protection assays, northern blotting, in situ hybridization, and microarray analysis.</p><p id="p-0195" num="0187">In some embodiments, the level of expression of AGT is determined using a nucleic acid probe. The term &#x201c;probe&#x201d;, as used herein, refers to any molecule that is capable of selectively binding to a specific AGT. Probes can be synthesized by one of skill in the art or derived from appropriate biological preparations. Probes may be specifically designed to be labeled. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.</p><p id="p-0196" num="0188">Isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or northern analyses, polymerase chain reaction (PCR) analyses and probe arrays. One method for the determination of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to AGT mRNA. In one embodiment, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative embodiment, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix&#xae; gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in determining the level of AGT mRNA.</p><p id="p-0197" num="0189">An alternative method for determining the level of expression of AGT in a sample involves the process of nucleic acid amplification or reverse transcriptase (to prepare cDNA) of for example mRNA in the sample, e.g., by RT-PCR (the experimental embodiment set forth in Mullis, 1987, U.S. Pat. No. 4,683,202), ligase chain reaction (Barany (1991) <i>Proc. Nat. Acad. Sci. USA </i>88:189-193), self sustained sequence replication (Guatelli et al. (1990) <i>Proc. Nat. Acad. Sci. USA </i>87:1874-1878), transcriptional amplification system (Kwoh et al. (1989) <i>Proc. Nat. Acad. Sci. USA </i>86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) <i>Bio/Technology </i>6:1197), rolling circle replication (Lizardi et al., U.S. Pat. No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In particular aspects of the invention, the level of expression of AGT is determined by quantitative fluorogenic RT-PCR (i.e., the TaqMan&#x2122; System). In preferred embodiments, expression level is determined by the method provided in Example 2 of PCT Application No. PCT/US2019/032150 using a 10 nM siRNA concentration in the species matched cell line.</p><p id="p-0198" num="0190">The level of AGT protein expression may be determined using any method known in the art for the measurement of protein levels. Such methods include, for example, high performance liquid chromatography (HPLC), absorption spectroscopy, a colorimetric assays, spectrophotometric assays, flow cytometry, immunoelectrophoresis, western blotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, electrochemiluminescence assays, and the like.</p><p id="p-0199" num="0191">In some embodiments, the efficacy of the methods of the invention are assessed by a decrease in AGT mRNA or protein level (e.g., in a liver biopsy). In certain embodiments, a puncture liver biopsy sample serves as the tissue material for monitoring the reduction in the AGT gene or protein expression. In other embodiments, a blood sample serves as the subject sample for monitoring the reduction in the agt protein expression.</p><p id="p-0200" num="0192">In some embodiments of the methods of the invention, the iRNA is administered to a subject such that the iRNA is delivered to a specific site within the subject. The inhibition of expression of AGT may be assessed using measurements of the level or change in the level of AGT mRNA or agt protein in a sample derived from fluid or tissue from the specific site within the subject (e.g., liver or blood).</p><p id="p-0201" num="0193">As used herein, the terms detecting or determining a level of an analyte are understood to mean performing the steps to determine if a material, e.g., protein, RNA, is present. As used herein, methods of detecting or determining include detection or determination of an analyte level that is below the level of detection for the method used.</p><p id="p-0202" num="0194">In another aspect, the present invention provides a method of treating a subject having an AGT-associated disorder, e.g., high blood pressure, e.g., hypertension. The method comprises administering to the subject a fixed dose of about 50 mg to about 800 mg, e.g., about 50-200 mg, about 200-400 mg, about 400-800 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg, of a double-stranded ribonucleic acid (RNAi) agent that inhibits expression of AGT. Values and ranges intermediate to the foregoing recited values are also intended to be part of this invention.</p><p id="p-0203" num="0195">In some embodiments, the AGT-associated disorder is selected from the group consisting of high blood pressure, hypertension, borderline hypertension, primary hypertension, secondary hypertension isolated systolic or diastolic hypertension, pregnancy-associated hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt hypertension, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, labile hypertension; hypertensive heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis, vasculopathy, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiac myopathy, nocturnal hypotension, glomerulosclerosis, coarctation of the aorta, aortic aneurism, ventricular fibrosis, heart failure, myocardial infarction, angina, stroke, renal disease, renal failure, systemic sclerosis, intrauterine growth restriction (IUGR), fetal growth restriction, obesity, liver steatosis/fatty liver, non-alcoholic Steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD); glucose intolerance, type 2 diabetes, and metabolic syndrome.</p><p id="p-0204" num="0196">In one embodiment, the AGT-associate disorder is hypertension. In one embodiment, the hypertension is borderline hypertension, primary hypertension, secondary hypertension isolated systolic or diastolic hypertension, pregnancy-associated hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt hypertension, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, labile hypertension; hypertensive heart disease, or hypertensive nephropathy.</p><p id="p-0205" num="0197">In a further aspect, the present invention provides a method of treating a subject that would benefit from reduction in AGT expression. The method comprises administering to the subject a fixed dose of about 50 mg to about 800 mg, e.g., about 50-200 mg, about 200-400 mg, about 400-800 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg, of a double-stranded ribonucleic acid (RNAi) agent that inhibits expression of AGT. Values and ranges intermediate to the foregoing recited values are also intended to be part of this invention.</p><p id="p-0206" num="0198">In a further aspect, the present invention provides a method of decreasing blood pressure level, e.g., systolic blood pressure and/or diastolic blood pressure, in a subject. The method comprises administering to the subject a fixed dose of about 50 mg to about 800 mg, e.g., about 50-200 mg, about 200-400 mg, about 400-800 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg, of a double-stranded ribonucleic acid (RNAi) agent that inhibits expression of AGT. Values and ranges intermediate to the foregoing recited values are also intended to be part of this invention.</p><p id="p-0207" num="0199">In the methods of the invention, a cell, e.g., a cell within a subject, such as a human subject (e.g., a subject in need thereof, such as subject having an AGT-associated disorder), may be contacted with the siRNA in vitro or in vivo, i.e., the cell may be within a subject.</p><p id="p-0208" num="0200">A cell suitable for treatment using the methods of the invention may be any cell that expresses an AGT gene, e.g., a liver cell, a brain cell, a gall bladder cell, a heart cell, or a kidney cell, but preferably a liver cell. A cell suitable for use in the methods of the invention may be a mammalian cell, e.g., a primate cell (such as a human cell, including human cell in a chimeric non-human animal, or a non-human primate cell, e.g., a monkey cell or a chimpanzee cell), or a non-primate cell. In certain embodiments, the cell is a human cell, e.g., a human liver cell. In the methods of the invention, AGT expression is inhibited in the cell by at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or to a level below the level of detection of the assay.</p><p id="p-0209" num="0201">In one embodiment, a dsRNA agent targeting AGT is administered to a subject such that AGT levels, e.g., in a cell, tissue, blood, urine or other tissue or fluid of the subject are reduced by at least about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 62%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% or more.</p><p id="p-0210" num="0202">In another embodiment, a dsRNA agent targeting AGT is administered to a subject such that the blood pressure levels, e.g., systolic blood pressure and/or diastolic blood pressure, of the subject are reduced by at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mmHg or more.</p><p id="p-0211" num="0203">Administration of the dsRNA agent according to the methods and uses of the invention may result in a reduction of the severity, signs, symptoms, and/or markers of such diseases or disorders in a patient with primary hyperoxaluria. By &#x201c;reduction&#x201d; in this context is meant a statistically significant decrease in such level. The reduction can be, for example, at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or about 100%.</p><p id="p-0212" num="0204">Efficacy of treatment or prevention of disease can be assessed, for example by measuring disease progression, disease remission, symptom severity, reduction in pain, quality of life, dose of a medication required to sustain a treatment effect, level of a disease marker or any other measurable parameter appropriate for a given disease being treated or targeted for prevention. It is well within the ability of one skilled in the art to monitor efficacy of treatment or prevention by measuring any one of such parameters, or any combination of parameters. For example, efficacy of treatment of primary hyperoxaluria may be assessed, for example, by periodic monitoring of oxalate levels in the subject being treated. Comparisons of the later measurements with the initial measurements provide a physician an indication of whether the treatment is effective. It is well within the ability of one skilled in the art to monitor efficacy of treatment or prevention by measuring such a parameter, or any combination of parameters. In connection with the administration of a dsRNA agent targeting AGT or pharmaceutical composition thereof, &#x201c;effective against&#x201d; primary hyperoxaluria indicates that administration in a clinically appropriate manner results in a beneficial effect for at least a statistically significant fraction of patients, such as improvement of symptoms, a cure, a reduction in disease, extension of life, improvement in quality of life, or other effect generally recognized as positive by medical doctors familiar with treating primary hyperoxaluria and the related causes.</p><p id="p-0213" num="0205">A treatment or preventive effect is evident when there is a statistically significant improvement in one or more parameters of disease status, or by a failure to worsen or to develop symptoms where they would otherwise be anticipated. As an example, a favorable change of at least 10% in a measurable parameter of disease, and preferably at least 20%, 30%, 40%, 50% or more can be indicative of effective treatment. Efficacy for a given dsRNA agent drug or formulation of that drug can also be judged using an experimental animal model for the given disease as known in the art. When using an experimental animal model, efficacy of treatment is evidenced when a statistically significant reduction in a marker or symptom is observed.</p><p id="p-0214" num="0206">Any positive change resulting in e.g., lessening of severity of disease measured using the appropriate scale, represents adequate treatment using a dsRNA agent or dsRNA agent formulation as described herein.</p><p id="p-0215" num="0207">The in vivo methods of the invention may include administering to a subject a composition containing an iRNA, where the iRNA includes a nucleotide sequence that is complementary to at least a part of an RNA transcript of the AGT gene of the mammal to which the RNAi agent is to be administered. The composition can be administered by any means known in the art including, but not limited to oral, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal, and intrathecal), intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), nasal, rectal, and topical (including buccal and sublingual) administration. In certain embodiments, the compositions are administered by intravenous infusion or injection. In certain embodiments, the compositions are administered by subcutaneous injection. In certain embodiments, the compositions are administered by intramuscular injection.</p><p id="p-0216" num="0208">In some embodiments, the administration is via a depot injection. A depot injection may release the dsRNA agent in a consistent way over a prolonged time period. Thus, a depot injection may reduce the frequency of dosing needed to obtain a desired effect, e.g., a desired inhibition of AGT, or a therapeutic or prophylactic effect. A depot injection may also provide more consistent serum concentrations. Depot injections may include subcutaneous injections or intramuscular injections. In preferred embodiments, the depot injection is a subcutaneous injection.</p><p id="p-0217" num="0209">In some embodiments, the administration is via a pump. The pump may be an external pump or a surgically implanted pump. In certain embodiments, the pump is a subcutaneously implanted osmotic pump. In other embodiments, the pump is an infusion pump. An infusion pump may be used for intravenous, subcutaneous, arterial, or epidural infusions. In preferred embodiments, the infusion pump is a subcutaneous infusion pump. In other embodiments, the pump is a surgically implanted pump that delivers the dsRNA agent to the liver.</p><p id="p-0218" num="0210">Other modes of administration include epidural, intracerebral, intracerebroventricular, nasal administration, intraarterial, intracardiac, intraosseous infusion, intrathecal, and intravitreal, and pulmonary. The mode of administration may be chosen based upon whether local or systemic treatment is desired and based upon the area to be treated. The route and site of administration may be chosen to enhance targeting.</p><p id="p-0219" num="0211">The iRNA is preferably administered subcutaneously, i.e., by subcutaneous injection. One or more injections may be used to deliver the desired dose of iRNA to a subject. The injections may be repeated over a period of time.</p><p id="p-0220" num="0212">The administration may be repeated on a regular basis. In certain embodiments, the iRNA is administered about once per month to about once per quarter, i.e., about every three months, or about once per quarter to about twice per year, i.e., about once every six months. In certain embodiments, the iRNA is administered once per month. In other embodiments, the iRNA is administered every three months, or once per quarter. In yet another embodiment, the iRNA is administered every six months or biannually.</p><p id="p-0221" num="0213">A dsRNA agent of the invention may be administered in &#x201c;naked&#x201d; form, or as a &#x201c;free dsRNA agent.&#x201d; A naked dsRNA agent is administered in the absence of a pharmaceutical composition. The naked dsRNA agent may be in a suitable buffer solution. The buffer solution may comprise acetate, citrate, prolamine, carbonate, or phosphate, or any combination thereof. In one embodiment, the buffer solution is phosphate buffered saline (PBS). The pH and osmolarity of the buffer solution containing the dsRNA agent can be adjusted such that it is suitable for administering to a subject.</p><p id="p-0222" num="0214">Alternatively, an iRNA of the invention may be administered as a pharmaceutical composition, such as a dsRNA liposomal formulation. The RNAi agent may be administered as a pharmaceutical composition in an unbuffered solution. The unbuffered solution may comprise saline or water. Alternatively, the RNAi agent may be administered as a pharmaceutical composition in a buffer solution. The buffer solution may comprise acetate, citrate, prolamine, carbonate, or phosphate or any combination thereof. In one embodiment, the buffer solution is phosphate buffered saline (PBS).</p><p id="p-0223" num="0215">Subjects that would benefit from an inhibition of AGT gene expression are subjects susceptible to or diagnosed with an AGT-associated disease or disorder, e.g., high blood pressure, e.g., hypertension. The subjects may have a systolic blood pressure of at least 130, 135, 140, 145, 150, 155 or 160 mmHg or a diastolic blood pressure of at least 80, 85, 90, 95, 100, 105, 110 mmHg. The subject may be susceptible to salt sensitivity, overweight, obese, pregnant, or planning to become pregnant. The subject may have type 2 diabetes, type 1 diabetes, or have reduced kidney function.</p><p id="p-0224" num="0216">The method further comprises administering to the subject an additional therapeutic agent for treatment of hypertension. Exemplary therapeutic agents for use as a combination therapy may include, but are not limited to, a diuretic, an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, a beta-blocker, a vasodialator, a calcium channel blocker, an aldosterone antagonist, an alpha2-agonist, a renin inhibitor, an alpha-blocker, a peripheral acting adrenergic agent, a selective D1 receptor partial agonist, a nonselective alpha-adrenergic antagonist, a synthetic, a steroidal antimineralocorticoid agent; a combination of any of the foregoing; and a hypertension therapeutic agent formulated as a combination of agents. In some embodiments, the additional therapeutic agent comprises an angiotensin II receptor antagonist, e.g., losartan, valsartan, olmesartan, eprosartan, and azilsartan.</p><p id="p-0225" num="0217">Administration of the iRNA according to the methods of the invention may result prevention or treatment of an AGT associated disorder, e.g., high blood pressure, e.g., hypertension. Diagnostic criteria for various types of high blood pressure are provided below.</p><heading id="h-0009" level="1">III. Diagnostic Criteria, Risk Factors, and Treatments for Hypertension</heading><p id="p-0226" num="0218">Recently practice guidelines for prevention and treatment of hypertension were revised. Extensive reports were published by Reboussin et al. (Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Nov. 7. pii: S0735-1097(17)41517-8. doi: 10.1016/j.jacc.2017.11.004.) and Whelton et al. (2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Nov. 7. pii: S0735-1097(17)41519-1. doi: 10.1016/j.jacc.2017.11.006). Some highlights of the new Guidelines are provided below. However, the Guidelines should be understood as providing the knowledge of those of skill in the art regarding diagnostic and monitoring criteria and treatment for hypertension at the time of filing of this application and are incorporated herein by reference.</p><p id="p-0227" num="0219">A. Diagnostic Criteria</p><p id="p-0228" num="0220">Although a continuous association exists between higher blood pressure and increased cardiovascular disease risk, it is useful to categorize blood pressure levels for clinical and public health decision making. Blood pressure can be categorized into 4 levels on the basis of average blood pressure measured in a healthcare setting (office pressures): normal, elevated, and stage 1 or 2 hypertension as shown in the table below (from Whelton et al., 2017).</p><p id="p-0229" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="70pt" align="center"/><colspec colname="3" colwidth="14pt" align="center"/><colspec colname="4" colwidth="77pt" align="center"/><thead><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>Systolic Blood Pressure</entry><entry/><entry>Diastolic Blood Pressure</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>Blood Pressure</entry><entry/><entry/><entry/></row><row><entry>Category</entry><entry/><entry/><entry/></row><row><entry>Normal</entry><entry>&#x3c;120 mm Hg</entry><entry>and</entry><entry>&#x3c;80 mm Hg</entry></row><row><entry>Elevated</entry><entry>120-129 mm Hg</entry><entry>and</entry><entry>&#x3c;80 mm Hg</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="161pt" align="center"/><tbody valign="top"><row><entry>Hypertension*</entry><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="70pt" align="center"/><colspec colname="3" colwidth="14pt" align="center"/><colspec colname="4" colwidth="77pt" align="center"/><tbody valign="top"><row><entry>Stage 1</entry><entry>130-139 mm Hg</entry><entry>or</entry><entry>80-89 mm Hg</entry></row><row><entry>Stage 2</entry><entry>&#x2265;140 mm Hg</entry><entry>or</entry><entry>&#x2265;90 mm Hg</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry namest="1" nameend="4" align="left" id="FOO-00001">*Individuals with systolic blood pressure and diastolic blood pressure in 2 categories should be designated to the higher blood pressure category.</entry></row></tbody></tgroup></table></tables></p><p id="p-0230" num="0221">Blood pressure indicates blood pressure based on an average of &#x2265;2 careful readings obtained on &#x2265;2 occasions. Best practices for obtaining careful blood pressure readings are detailed in Whelton et al., 2017 and are known in the art.</p><p id="p-0231" num="0222">This categorization differs from that previously recommended in the JNC 7 report (Chobanian et al; the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42:1206-52) with stage 1 hypertension now defined as a systolic blood pressure (SBP) of 130-139 or a diastolic blood pressure (DBP) of 80-89 mm Hg, and with stage 2 hypertension in the present document corresponding to stages 1 and 2 in the JNC 7 report. The rationale for this categorization is based on observational data related to the association between SBP/DBP and cardiovascular disease risk, randomized clinical trials of lifestyle modification to lower blood pressure, and randomized clinical trials of treatment with antihypertensive medication to prevent cardiovascular disease.</p><p id="p-0232" num="0223">The increased risk of cardiovascular disease among adults with stage 2 hypertension is well established. An increasing number of individual studies and meta-analyses of observational data have reported a gradient of progressively higher cardiovascular disease risk going from normal blood pressure to elevated blood pressure and stage 1 hypertension. In many of these meta-analyses, the hazard ratios for coronary heart disease and stroke were between 1.1 and 1.5 for the comparison of SBP/DBP of 120-129/80-84 mm Hg versus &#x3c;120/80 mm Hg and between 1.5 and 2.0 for the comparison of SBP/DBP of 130-139/85-89 mm Hg versus &#x3c;120/80 mm Hg. This risk gradient was consistent across subgroups defined by sex and race/ethnicity. The relative increase in cardiovascular disease risk associated with higher blood pressure was attenuated but still present among older adults. Lifestyle modification and pharmacological antihypertensive treatment are recommended for individuals with elevated blood pressure and stages 1 and 2 hypertension. Clinical benefit can be obtained by a reduction of the stage of elevated blood pressure, even if blood pressure is not normalized by a treatment.</p><p id="p-0233" num="0224">B. Risk Factors</p><p id="p-0234" num="0225">Hypertension is a complex disease that results from a combination of factors including, but not limited to, genetics, lifestyle, diet, and secondary risk factors. Hypertension can also be associated with pregnancy. It is understood that due to the complex nature of hypertension, it is understood that multiple interventions may be required for treatment of hypertension. Moreover, non-pharmacological interventions, including modification of diet and lifestyle, can be useful for the prevention and treatment of hypertension. Further, an intervention may provide a clinical benefit without fully normalizing blood pressure in an individual.</p><p id="p-0235" num="0226">1. Genetic Risk Factors</p><p id="p-0236" num="0227">Several monogenic forms of hypertension have been identified, such as glucocorticoid-remediable aldosteronism, Liddle's syndrome, Gordon's syndrome, and others in which single-gene mutations fully explain the pathophysiology of hypertension, these disorders are rare. The current tabulation of known genetic variants contributing to blood pressure and hypertension includes more than 25 rare mutations and 120 single nucleotide polymorphisms. However, although genetic factors may contribute to hypertension in some individuals, it is estimated that genetic variation accounts for only about 3.5% of blood pressure variability.</p><p id="p-0237" num="0228">2. Diet and Alcohol Consumption</p><p id="p-0238" num="0229">Common environmental and lifestyle risk factors leading to hypertension include poor diet, insufficient physical activity, and excess alcohol consumption. These factors can lead to a person to become overweight or obese, further increasing the likelihood of developing or exacerbating hypertension. Elevated blood pressure is even more strongly correlated with increased waist-to-hip ratio or other measures of central fat distribution. Obesity at a young age and ongoing obesity is strongly correlated with hypertension later in life. Achieving a normal weight can reduce the risk of developing high blood pressure to that of a person who has never been obese.</p><p id="p-0239" num="0230">Intake of sodium, potassium, magnesium, and calcium can also have a significant effect on blood pressure. Sodium intake is positively correlated with blood pressure and accounts for much of the age-related increase in blood pressure. Certain groups are more sensitive to increased sodium consumption than others including black and older adults (&#x2265;65 years old), and those with a higher level of blood pressure or comorbidities such as chronic kidney disease, diabetes mellitus, or metabolic syndrome. In aggregate, these groups constitute more than half of all US adults. Salt sensitivity may be a marker for increased cardiovascular disease and all-cause mortality, independent of blood pressure. Currently, techniques for recognition of salt sensitivity are impractical in a clinical setting. Therefore, salt sensitivity is best considered as a group characteristic.</p><p id="p-0240" num="0231">Potassium intake is inversely related to blood pressure and stroke, and a higher level of potassium seems to blunt the effect of sodium on blood pressure. A lower sodium-potassium ratio is associated with a lower blood pressure than that noted for corresponding levels of sodium or potassium on their own. A similar observation has been made for risk of cardiovascular disease.</p><p id="p-0241" num="0232">Alcohol consumption has long been associated with high blood pressure. In the US, it has been estimated that alcohol consumption accounts for about 10% of the population burden of hypertension, with the burden being greater in men than women.</p><p id="p-0242" num="0233">It is understood that changes in diet or alcohol consumption can be an aspect of prevention or treatment of hypertension.</p><p id="p-0243" num="0234">3. Physical Activity</p><p id="p-0244" num="0235">There is a well-established inverse correlation between physical activity/physical fitness and blood pressure levels. Even modest levels of physical activity have been demonstrated to be beneficial in decreasing hypertension.</p><p id="p-0245" num="0236">It is understood that an increase in physical activity can be an aspect of prevention or treatment of hypertension.</p><p id="p-0246" num="0237">4. Secondary Risk Factors</p><p id="p-0247" num="0238">Secondary hypertension can underlie severe elevation of blood pressure, pharmacologically resistant hypertension, sudden onset of hypertension, increased blood pressure in patients with hypertension previously controlled on drug therapy, onset of diastolic hypertension in older adults, and target organ damage disproportionate to the duration or severity of the hypertension. Although secondary hypertension should be suspected in younger patients (&#x3c;30 years of age) with elevated blood pressure, it is not uncommon for primary hypertension to manifest at a younger age, especially in blacks, and some forms of secondary hypertension, such as renovascular disease, are more common at older age (&#x2265;65 years of age). Many of the causes of secondary hypertension are strongly associated with clinical findings or groups of findings that suggest a specific disorder. In such cases, treatment of the underlying condition may resolve the findings of elevated blood pressure without administering agents typically used for the treatment of hypertension.</p><p id="p-0248" num="0239">5. Pregnancy</p><p id="p-0249" num="0240">Pregnancy is a risk factor for high blood pressure, and high blood pressure during pregnancy is a risk factor for cardiovascular disease and hypertension later in life. A Report on pregnancy associated hypertension was published in 2013 by the American College of Obstetrics and Gynecology (ACOG) (American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013; 122:1122-31). Some highlights of the Report are provided below. However, the Report should be understood as providing the knowledge of those of skill in the art regarding diagnostic and monitoring criteria and treatment for hypertension in pregnancy at the time of filing of this application and are incorporated herein by reference.'</p><p id="p-0250" num="0241">The diagnostic criteria for preeclampsia are provided in the table below (from Table 1 of the ACOG report, 2013).</p><p id="p-0251" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="224pt" align="left"/><thead><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>Blood Pressure</entry><entry>&#x2265;140 mm Hg diastolic or &#x2265;90 mm Hg diastolic on two occasions at least 4</entry></row><row><entry/><entry>hours apart after 20 weeks of gestation in a woman with a previously normal</entry></row><row><entry/><entry>blood pressure</entry></row><row><entry/><entry>&#x2265;160 mm Hg systolic or &#x2265;110 mm Hg diastolic, hypertension can be</entry></row><row><entry/><entry>confirmed within a short interval (minutes) to facilitate timely</entry></row><row><entry/><entry>antihypertensive therapy</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="287pt" align="center"/><tbody valign="top"><row><entry>and</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="224pt" align="left"/><tbody valign="top"><row><entry>Proteinurea</entry><entry>&#x2265;300 mg per 24-hour urine collection (or this amount extrapolated for a</entry></row><row><entry/><entry>timed collection)</entry></row><row><entry/><entry>Or</entry></row><row><entry/><entry>Protein/creatinine ratio &#x2265; 0.3 (each measured as mg/dL)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="287pt" align="center"/><tbody valign="top"><row><entry>Or in the absence of proteinurea, new onset of hypertension with the new onset of an of the</entry></row><row><entry>following:</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="224pt" align="left"/><tbody valign="top"><row><entry>Thrombocytopenia</entry><entry>Platelet count &#x2264; 100,000/microliter</entry></row><row><entry>Renal insufficiency</entry><entry>Serum creatinine concentration &#x2265; 1.1 mg/dL or a doubling of the serum</entry></row><row><entry/><entry>creatinine concentration in the absence of other renal disease</entry></row><row><entry>Impaired liver</entry><entry>Elevated blood concentrations if liver transaminases to twice normal</entry></row><row><entry>function</entry><entry>concentration</entry></row><row><entry>Pulmonary edema</entry><entry/></row><row><entry>Cerebral or visual</entry><entry/></row><row><entry>symptoms</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0252" num="0242">Blood Pressure management during pregnancy is complicated by the fact that many commonly used antihypertensive agents, including ACE inhibitors and ARBs, are contraindicated during pregnancy because of potential harm to the fetus. The goal of antihypertensive treatment during pregnancy includes prevention of severe hypertension and the possibility of prolonging gestation to allow the fetus more time to mature before delivery. A review of treatment for pregnancy-associated severe hypertension found insufficient evidence to recommend specific agents; rather, clinician experience was recommended in this setting (Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013; 7:CD001449).</p><p id="p-0253" num="0243">C. Treatments</p><p id="p-0254" num="0244">Treatment of high blood pressure is complex as it is frequently present with other comorbidities, often including reduced renal function, for which the subject may also be undergoing treatment. Clinicians managing adults with high blood pressure should focus on overall patient health, with a particular emphasis on reducing the risk of future adverse cardiovascular disease outcomes. All patient risk factors need to be managed in an integrated fashion with a comprehensive set of nonpharmacological and pharmacological strategies. As patient blood pressure and risk of future cardiovascular disease events increase, blood pressure management should be intensified.</p><p id="p-0255" num="0245">Whereas treatment of high blood pressure with blood pressure-lowering medications on the basis of blood pressure level alone is considered cost effective, use of a combination of absolute cardiovascular disease risk and blood pressure level to guide such treatment is more efficient and cost effective at reducing risk of cardiovascular disease than is use of blood pressure level alone. Many patients started on a single agent will subsequently require &#x2265;2 drugs from different pharmacological classes to reach their blood pressure goals. Knowledge of the pharmacological mechanisms of action of each agent is important. Drug regimens with complementary activity, where a second antihypertensive agent is used to block compensatory responses to the initial agent or affect a different pressor mechanism, can result in additive lowering of blood pressure. For example, thiazide diuretics may stimulate the renin-angiotensin-aldosterone system. By adding an ACE inhibitor or ARB to the thiazide, an additive blood pressure lowering effect may be obtained. Use of combination therapy may also improve adherence. Several 2- and 3-fixed-dose drug combinations of antihypertensive drug therapy are available, with complementary mechanisms of action among the components.</p><p id="p-0256" num="0246">Table 18 from Whelton et al. 2017 listing oral antihypertensive drugs is provided below. Classes of therapeutic agents for the treatment of high blood pressure and drugs that fall within those classes are provided. Dose ranges, frequencies, and comments are also provided.</p><p id="p-0257" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="105pt" align="center"/><thead><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry/><entry/><entry>Usual Dose.</entry><entry/><entry/></row><row><entry/><entry/><entry>Range</entry><entry>Daily </entry><entry/></row><row><entry>Class</entry><entry>Drug</entry><entry>(mg/d)*</entry><entry>Frequency</entry><entry>Comments</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="308pt" align="center"/><tbody valign="top"><row><entry>Primary agents</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="105pt" align="center"/><tbody valign="top"><row><entry>Thiazide or thiazide-</entry><entry>Chlorthalidone</entry><entry>12.5-25&#x2009;&#x2002;</entry><entry>1</entry><entry>Chlorthalidone is preferred on the</entry></row><row><entry>type diuretics</entry><entry>Hydrochlorothiazide</entry><entry>25-50</entry><entry>1</entry><entry>basis of prolonged half-life and</entry></row><row><entry/><entry>Indapamide</entry><entry>1.25-2.5</entry><entry>1</entry><entry>proven trial reduction of CVD.</entry></row><row><entry/><entry>Metolazone</entry><entry>2.5-10&#x2009;</entry><entry>1</entry><entry>Monitor for hyponatremia and</entry></row><row><entry/><entry/><entry/><entry/><entry>hypokalemia, uric acid and</entry></row><row><entry/><entry/><entry/><entry/><entry>calcium levels.</entry></row><row><entry/><entry/><entry/><entry/><entry>Use with caution in patients with</entry></row><row><entry/><entry/><entry/><entry/><entry>history of acute gout unless</entry></row><row><entry/><entry/><entry/><entry/><entry>patient is on uric acid-lowering</entry></row><row><entry/><entry/><entry/><entry/><entry>therapy.</entry></row><row><entry>ACE inhibitors</entry><entry>Benazepril</entry><entry>10-40</entry><entry>1 or 2</entry><entry>Do not use in combination with</entry></row><row><entry/><entry>Captopril</entry><entry>12.5-150&#x2009;</entry><entry>2 or 3</entry><entry>ARBs or direct renin inhibitor</entry></row><row><entry/><entry>Enalapril</entry><entry>&#x2002;5-40</entry><entry>1 or 2</entry><entry>There is an increased risk of</entry></row><row><entry/><entry>Fosinopril</entry><entry>10-40</entry><entry>1</entry><entry>hyperkalemia, especially in</entry></row><row><entry/><entry>Lisinopril</entry><entry>10-40</entry><entry>1</entry><entry>patents with CKD or in those on</entry></row><row><entry/><entry>Moexipril</entry><entry>7.5-30&#x2009;</entry><entry>1 or 2</entry><entry>K<sup>+</sup> supplements or K<sup>+</sup>-sparing</entry></row><row><entry/><entry>Perindopril</entry><entry>&#x2002;4-16</entry><entry>1</entry><entry>drugs.</entry></row><row><entry/><entry>Quinapril</entry><entry>10-80</entry><entry>1 or 2</entry><entry>There is a risk of acute renal</entry></row><row><entry/><entry>Ramipril</entry><entry>2.5-10&#x2009;</entry><entry>1 or 2</entry><entry>failure in patients with severe</entry></row><row><entry/><entry>Trandolapril</entry><entry>1-4</entry><entry>1</entry><entry>bilateral renal artery stenosis.</entry></row><row><entry/><entry/><entry/><entry/><entry>Do no use if patient has history of</entry></row><row><entry/><entry/><entry/><entry/><entry>angioedema with ACE inhibitors.</entry></row><row><entry/><entry/><entry/><entry/><entry>Avoid in pregnancy.</entry></row><row><entry>ARBs</entry><entry>Azilsartan</entry><entry>40-80</entry><entry>1</entry><entry>Do not use in combination with</entry></row><row><entry/><entry>Candesartan</entry><entry>&#x2002;8-32</entry><entry>1</entry><entry>ACE inhibitors or direct renin</entry></row><row><entry/><entry>Eprosartan</entry><entry>600-800</entry><entry>1 or 2</entry><entry>inhibitors.</entry></row><row><entry/><entry>Irbesartan</entry><entry>150-300</entry><entry>1</entry><entry>There is an increased risk of</entry></row><row><entry/><entry>Losartan</entry><entry>&#x2002;50-100</entry><entry>1 or 2</entry><entry>hyperkalemia in CKD or in those</entry></row><row><entry/><entry>Olmesartan</entry><entry>20-40</entry><entry>1</entry><entry>on K<sup>+</sup> supplements or K<sup>+</sup>-sparing</entry></row><row><entry/><entry>Telmisartan</entry><entry>20-80</entry><entry>1</entry><entry>drugs.</entry></row><row><entry/><entry>Valsartan</entry><entry>&#x2002;80-320</entry><entry>1</entry><entry>There is a risk of acute renal</entry></row><row><entry/><entry/><entry/><entry/><entry>failure in patients with severe</entry></row><row><entry/><entry/><entry/><entry/><entry>bilateral renal artery stenosis.</entry></row><row><entry/><entry/><entry/><entry/><entry>Do not use if patient has history of</entry></row><row><entry/><entry/><entry/><entry/><entry>angioedema with ARBs. Patients</entry></row><row><entry/><entry/><entry/><entry/><entry>with a history of angioedema with</entry></row><row><entry/><entry/><entry/><entry/><entry>an ACE inhibitor can receive an</entry></row><row><entry/><entry/><entry/><entry/><entry>ARB beginning 6 weeks after</entry></row><row><entry/><entry/><entry/><entry/><entry>ACE inhibitor is discontinued.</entry></row><row><entry/><entry/><entry/><entry/><entry>Avoid in pregnancy.</entry></row><row><entry>CCB-</entry><entry>Amlodipine</entry><entry>2.5-10&#x2009;</entry><entry>1</entry><entry>Avoid use in patients with</entry></row><row><entry>dihydropyridines</entry><entry>Felodipine</entry><entry>&#x2002;5-10</entry><entry>1</entry><entry>HFrEF; amlodipine or felodipine</entry></row><row><entry/><entry>Isradipine</entry><entry>&#x2002;5-10</entry><entry>2</entry><entry>may be used if required</entry></row><row><entry/><entry>Nicardipine SR</entry><entry>&#x2002;5-20</entry><entry>1</entry><entry>They are associated with dose-</entry></row><row><entry/><entry>Nifedipine LA</entry><entry>&#x2002;60-120</entry><entry>1</entry><entry>related pedal edema, which is</entry></row><row><entry/><entry>Nisoldipine</entry><entry>30-90</entry><entry>1</entry><entry>more common in women than</entry></row><row><entry/><entry/><entry/><entry/><entry>men.</entry></row><row><entry>CCB-</entry><entry>Diltiazem SR</entry><entry>180-360</entry><entry>2</entry><entry>Avoid routine use with beta</entry></row><row><entry>nondihydropyridines</entry><entry>Diltiazem ER</entry><entry>120-480</entry><entry>1</entry><entry>blockers because of increased risk</entry></row><row><entry/><entry>Verapamil IR</entry><entry>40-80</entry><entry>3</entry><entry>of bradycardia and heart block.</entry></row><row><entry/><entry>Verapamil SR</entry><entry>120-480</entry><entry>1 or 2</entry><entry>Do not use in patients with</entry></row><row><entry/><entry>Verapamil-delayed</entry><entry>100-480</entry><entry>1 (in the</entry><entry>HFrEF.</entry></row><row><entry/><entry>onset ER (various</entry><entry/><entry>evening)</entry><entry>There are drug interactions with</entry></row><row><entry/><entry>forms)</entry><entry/><entry/><entry>diltiazem and verapamil (CYP3A4</entry></row><row><entry/><entry/><entry/><entry/><entry>major substrate and moderate</entry></row><row><entry/><entry/><entry/><entry/><entry>inhibitor).</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="308pt" align="center"/><tbody valign="top"><row><entry>Secondary agents</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="105pt" align="center"/><tbody valign="top"><row><entry>Diuretics-loop</entry><entry>Bumetanide</entry><entry>0.5-4&#x2002;&#x2009;</entry><entry>2</entry><entry>There are preferred diuretics in</entry></row><row><entry/><entry>Furosemide</entry><entry>20-80</entry><entry>2</entry><entry>patients with symptomatic HF.</entry></row><row><entry/><entry>Torsemide</entry><entry>&#x2002;5-10</entry><entry>1</entry><entry>They are preferred over thiazides</entry></row><row><entry/><entry/><entry/><entry/><entry>in patients with moderate-to-</entry></row><row><entry/><entry/><entry/><entry/><entry>severe CKD (e.g., GFR &#x3c; 30</entry></row><row><entry/><entry/><entry/><entry/><entry>mL/min).</entry></row><row><entry>Diuretics-potassium</entry><entry>Amiloride</entry><entry>&#x2002;5-10</entry><entry>1 or 2</entry><entry>These are monotherapy agents</entry></row><row><entry>sparing</entry><entry>Triamterene</entry><entry>&#x2002;50-100</entry><entry>1 or 2</entry><entry>and minimally effective</entry></row><row><entry/><entry/><entry/><entry/><entry>antihypertensive agents.</entry></row><row><entry/><entry/><entry/><entry/><entry>Combination therapy of</entry></row><row><entry/><entry/><entry/><entry/><entry>potassium-sparing diuretic with a</entry></row><row><entry/><entry/><entry/><entry/><entry>thiazide can be considered in</entry></row><row><entry/><entry/><entry/><entry/><entry>patients with hypokalemia on</entry></row><row><entry/><entry/><entry/><entry/><entry>thiazide monotherapy.</entry></row><row><entry/><entry/><entry/><entry/><entry>Avoid in patients with significate</entry></row><row><entry/><entry/><entry/><entry/><entry>CKD (e.g. GFR &#x3c; 45 mL/min).</entry></row><row><entry>Diuretics-</entry><entry>Eplerenone</entry><entry>&#x2002;50-100</entry><entry>12&#x2002;</entry><entry>These are preferred agents in</entry></row><row><entry>aldosterone</entry><entry>Spironolactone</entry><entry>&#x2002;25-100</entry><entry>1</entry><entry>primary aldosteronism and</entry></row><row><entry>antagonists</entry><entry/><entry/><entry/><entry>resistant hypertension.</entry></row><row><entry/><entry/><entry/><entry/><entry>Spironolactone is associated with</entry></row><row><entry/><entry/><entry/><entry/><entry>greater risk of gynecomastia and</entry></row><row><entry/><entry/><entry/><entry/><entry>impotence as compared with</entry></row><row><entry/><entry/><entry/><entry/><entry>eplerenone.</entry></row><row><entry/><entry/><entry/><entry/><entry>This is common add-on therapy in</entry></row><row><entry/><entry/><entry/><entry/><entry>resistant hypertension.</entry></row><row><entry/><entry/><entry/><entry/><entry>Avoid use with K<sup>+</sup> supplements,</entry></row><row><entry/><entry/><entry/><entry/><entry>other K<sup>+</sup>-sparing diuretics, or</entry></row><row><entry/><entry/><entry/><entry/><entry>significant renal dysfunction.</entry></row><row><entry/><entry/><entry/><entry/><entry>Eplerenone often requires twice-</entry></row><row><entry/><entry/><entry/><entry/><entry>daily dosing for adequate BP</entry></row><row><entry/><entry/><entry/><entry/><entry>lowering.</entry></row><row><entry>Beta blockers-</entry><entry>Atenolol</entry><entry>&#x2002;25-100</entry><entry>12&#x2002;</entry><entry>Beta blockers are not</entry></row><row><entry>cardioselective</entry><entry>Betaxolol</entry><entry>&#x2002;5-20</entry><entry>1</entry><entry>recommended as first-line agents</entry></row><row><entry/><entry>Bisoprolol</entry><entry>2.5-10&#x2009;</entry><entry>1</entry><entry>unless the patient has IHD or HF.</entry></row><row><entry/><entry>Metoprolol tartrate</entry><entry>100-400</entry><entry>2</entry><entry>These are preferred in patients</entry></row><row><entry/><entry>Metoprolol</entry><entry>&#x2002;50-200</entry><entry>1</entry><entry>with bronchospastic airway</entry></row><row><entry/><entry>succinate</entry><entry/><entry/><entry>disease requiring a beta blocker.</entry></row><row><entry/><entry/><entry/><entry/><entry>Bisoprolol and metoprolol</entry></row><row><entry/><entry/><entry/><entry/><entry>succinate are preferred in patients</entry></row><row><entry/><entry/><entry/><entry/><entry>with HFrEF.</entry></row><row><entry/><entry/><entry/><entry/><entry>Avoid abrupt cessation.</entry></row><row><entry>Beta blockers-</entry><entry>Nebivolol</entry><entry>&#x2002;5-40</entry><entry>1</entry><entry>Nebivolol induces nitric oxide-</entry></row><row><entry>cardioselective and</entry><entry/><entry/><entry/><entry>inducesd vasodilation.</entry></row><row><entry>vasodilatory</entry><entry/><entry/><entry/><entry>Avoid abrupt cessation.</entry></row><row><entry>Beta blockers-</entry><entry>Nadolol</entry><entry>&#x2002;40-120</entry><entry>1</entry><entry>Avoid in patients with reactive</entry></row><row><entry>noncardioselective</entry><entry>Propranolol IR</entry><entry>160-480</entry><entry>2</entry><entry>airways disease.</entry></row><row><entry/><entry>Propranolol LA</entry><entry>&#x2002;80-320</entry><entry>1</entry><entry>Avoid abrupt cessation.</entry></row><row><entry>Beta blockers-</entry><entry>Acebutolol</entry><entry>200-800</entry><entry>2</entry><entry>Generally avoid, especially in</entry></row><row><entry>intrinsic</entry><entry>Carteolol</entry><entry>2.5-10&#x2009;</entry><entry>1</entry><entry>patients with IHD or HF.</entry></row><row><entry>sympathomimetic</entry><entry>Penbutolol</entry><entry>10-40</entry><entry>1</entry><entry>Avoid abrupt cessation.</entry></row><row><entry>activity</entry><entry>Pindolol</entry><entry>10-60</entry><entry>2</entry><entry/></row><row><entry>Beta blockers-</entry><entry>Carvedilol</entry><entry>12.5-50&#x2009;&#x2002;</entry><entry>2</entry><entry>Carvedilol is preferred in patients</entry></row><row><entry>combined alpha-and</entry><entry>Carvedilol</entry><entry>20-80</entry><entry>1</entry><entry>with HFrEF.</entry></row><row><entry>beta receptor</entry><entry>phosphate</entry><entry/><entry/><entry>Avoid abrupt cessation.</entry></row><row><entry/><entry>Labetalol</entry><entry>200-800</entry><entry>2</entry><entry/></row><row><entry>Direct renin</entry><entry>Aliskiren</entry><entry>150-300</entry><entry>1</entry><entry>Do not use in combination with</entry></row><row><entry>inhibitor</entry><entry/><entry/><entry/><entry>ACE inhibitors or ARBs.</entry></row><row><entry/><entry/><entry/><entry/><entry>Aliskiren is very long acting.</entry></row><row><entry/><entry/><entry/><entry/><entry>There is an increased risk of</entry></row><row><entry/><entry/><entry/><entry/><entry>hyperkalemina in CKD or in those</entry></row><row><entry/><entry/><entry/><entry/><entry>on K<sup>+</sup> supplements or K<sup>+</sup>-sparing</entry></row><row><entry/><entry/><entry/><entry/><entry>drugs.</entry></row><row><entry/><entry/><entry/><entry/><entry>Aliskiren may cause acute renal</entry></row><row><entry/><entry/><entry/><entry/><entry>failure in patients with severe</entry></row><row><entry/><entry/><entry/><entry/><entry>bilateral renal artery stenosis.</entry></row><row><entry/><entry/><entry/><entry/><entry>Avoid in pregnancy.</entry></row><row><entry>Alpha-1-blockers</entry><entry>Doxazosin</entry><entry>1-8</entry><entry>1</entry><entry>These are associated with</entry></row><row><entry/><entry>Prazosin</entry><entry>&#x2002;2-20</entry><entry>2 or 3</entry><entry>orthostatic hypotension, especially</entry></row><row><entry/><entry>Terazosin</entry><entry>&#x2002;1-20</entry><entry>1 or 2</entry><entry>in older adults.</entry></row><row><entry/><entry/><entry/><entry/><entry>They may be considered as</entry></row><row><entry/><entry/><entry/><entry/><entry>second-line agent in patients with</entry></row><row><entry/><entry/><entry/><entry/><entry>concomitant BPH.</entry></row><row><entry>Central alpha-</entry><entry>Clonidine oral</entry><entry>0.1-0.8</entry><entry>2</entry><entry>These are generally reserved as</entry></row><row><entry>agonist and other</entry><entry>Clonidine patch</entry><entry>0.1-0.3</entry><entry>1 weekly</entry><entry>last-line because of significant</entry></row><row><entry>centrally acting</entry><entry>Methyldopa</entry><entry>&#x2002;250-1000</entry><entry>2</entry><entry>CNS adverse effects, especially in</entry></row><row><entry>drugs</entry><entry>Guanfacine</entry><entry>0.5-2&#x2009;&#x2002;</entry><entry>1</entry><entry>older adults.</entry></row><row><entry/><entry/><entry/><entry/><entry>Avoid abrupt discontinuation of</entry></row><row><entry/><entry/><entry/><entry/><entry>clonidine, which may induce</entry></row><row><entry/><entry/><entry/><entry/><entry>hypertensive crisis; clonidine</entry></row><row><entry/><entry/><entry/><entry/><entry>must be tapered to avoid rebound</entry></row><row><entry/><entry/><entry/><entry/><entry>hypertension.</entry></row><row><entry>Direct vasodilators</entry><entry>Hydralazine</entry><entry>250-200</entry><entry>2 or 3</entry><entry>These are associated with sodium</entry></row><row><entry/><entry>Minoxidil</entry><entry>&#x2003;5-100</entry><entry>1-3</entry><entry>and water retention and reflex</entry></row><row><entry/><entry/><entry/><entry/><entry>tachycardia; use with a diuretic</entry></row><row><entry/><entry/><entry/><entry/><entry>and beta blocker.</entry></row><row><entry/><entry/><entry/><entry/><entry>Hydralazine is associated with</entry></row><row><entry/><entry/><entry/><entry/><entry>drug-induced lupus-like syndrome</entry></row><row><entry/><entry/><entry/><entry/><entry>at higher doses.</entry></row><row><entry/><entry/><entry/><entry/><entry>Minoxidil is associated with</entry></row><row><entry/><entry/><entry/><entry/><entry>hirsutism and required a loop</entry></row><row><entry/><entry/><entry/><entry/><entry>diurestic. Minoxidil can induce</entry></row><row><entry/><entry/><entry/><entry/><entry>pericardial effusion.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry namest="1" nameend="5" align="left" id="FOO-00002">*Dosages may vary from those listed in the FDA approved labeling (available at https://dailymed.nlm.nih.gov/dailymed/). ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; BPH, benign prostatic hyperplasia; CCB, calcium channel blocker; CKD, chronic kidney disease; CNS, central nervous system; CVD, cardiovascular disease; ER, extended release; GFR, glomerular filtration rate; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; IHD, ischemic heart disease; IR, immediate release; LA, long-acting; and SR, sustained release.</entry></row><row><entry namest="1" nameend="5" align="left" id="FOO-00003">From, Chobanian et al. (2003) The JNC 7 Report. <i>JAMA</i> 289(19): 2560.</entry></row></tbody></tgroup></table></tables></p><heading id="h-0010" level="1">IV. Delivery of an iRNA Agent for Use in the Methods of the Invention</heading><p id="p-0258" num="0247">The delivery of an iRNA agent to a cell e.g., a cell within a subject, such as a human subject (e.g., a subject in need thereof, such as a subject having an ACT-associated disorder, e.g., hypertension), for use in the methods of the invention, can be achieved in a number of different ways. For example, delivery may be performed by contacting a cell with an iRNA of the invention either in vitro or in vivo. In vivo delivery may also be performed directly by administering a composition comprising an iRNA, e.g., a dsRNA, to a subject. Alternatively, in vivo delivery may be performed indirectly by administering one or more vectors that encode and direct the expression of the iRNA. These alternatives are discussed further below.</p><p id="p-0259" num="0248">In general, any method of delivering a nucleic acid molecule (in vitro or in vivo) can be adapted for use with an iRNA of the invention (see e.g., Akhtar S. and Julian R L. (1992) <i>Trends Cell. Biol. </i>2(5):139-144 and WO94/02595, which are incorporated herein by reference in their entireties). For in vivo delivery, factors to consider in order to deliver an iRNA molecule include, for example, biological stability of the delivered molecule, prevention of non-specific effects, and accumulation of the delivered molecule in the target tissue. The non-specific effects of an iRNA can be minimized by local administration, for example, by direct injection or implantation into a tissue or topically administering the preparation. Local administration to a treatment site maximizes local concentration of the agent, limits the exposure of the agent to systemic tissues that can otherwise be harmed by the agent or that can degrade the agent, and permits a lower total dose of the iRNA molecule to be administered. Several studies have shown successful knockdown of gene products when an iRNA is administered locally. For example, intraocular delivery of a VEGF dsRNA by intravitreal injection in cynomolgus monkeys (Tolentino, M J., et al (2004) <i>Retina </i>24:132-138) and subretinal injections in mice (Reich, S J., et al (2003) <i>Mol. Vis. </i>9:210-216) were both shown to prevent neovascularization in an experimental model of age-related macular degeneration. In addition, direct intratumoral injection of a dsRNA in mice reduces tumor volume (Pille, J., et al (2005) <i>Mol. Ther. </i>11:267-274) and can prolong survival of tumor-bearing mice (Kim, W J., et al (2006) <i>Mol. Ther. </i>14:343-350; Li, S., et al (2007) <i>Mol. Ther. </i>15:515-523). RNA interference has also shown success with local delivery to the CNS by direct injection (Dorn, G., et al. (2004) <i>Nucleic Acids </i>32:e49; Tan, P H., et al (2005) <i>Gene Ther. </i>12:59-66; Makimura, H., et al (2002) <i>BMC Neurosci. </i>3:18; Shishkina, G T., et al (2004) <i>Neuroscience </i>129:521-528; Thakker, E R., et al (2004) <i>Proc. Natl. Acad. Sci. U.S.A. </i>101:17270-17275; Akaneya, Y., et al (2005) <i>J. Neurophysiol. </i>93:594-602) and to the lungs by intranasal administration (Howard, K A., et al (2006) <i>Mol. Ther. </i>14:476-484; Zhang, X., et al (2004) <i>J. Biol. Chem. </i>279:10677-10684; Bitko, V., et al (2005) <i>Nat. Med. </i>11:50-55). For administering an iRNA systemically for the treatment of a disease, the RNA can be modified or alternatively delivered using a drug delivery system; both methods act to prevent the rapid degradation of the dsRNA by endo- and exo-nucleases in vivo. Modification of the RNA or the pharmaceutical carrier can also permit targeting of the iRNA composition to the target tissue and avoid undesirable off-target effects. iRNA molecules can be modified by chemical conjugation to lipophilic groups such as cholesterol to enhance cellular uptake and prevent degradation. For example, an iRNA directed against ApoB conjugated to a lipophilic cholesterol moiety was injected systemically into mice and resulted in knockdown of apoB mRNA in both the liver and jejunum (Soutschek, J., et al (2004) <i>Nature </i>432:173-178). Conjugation of an iRNA to an aptamer has been shown to inhibit tumor growth and mediate tumor regression in a mouse model of prostate cancer (McNamara, J O., et al (2006) <i>Nat. Biotechnol. </i>24:1005-1015). In an alternative embodiment, the iRNA can be delivered using drug delivery systems such as a nanoparticle, a dendrimer, a polymer, liposomes, or a cationic delivery system. Positively charged cationic delivery systems facilitate binding of an iRNA molecule (negatively charged) and also enhance interactions at the negatively charged cell membrane to permit efficient uptake of an iRNA by the cell. Cationic lipids, dendrimers, or polymers can either be bound to an iRNA, or induced to form a vesicle or micelle (see e.g., Kim S H., et al (2008) <i>Journal of Controlled Release </i>129(2):107-116) that encases an iRNA. The formation of vesicles or micelles further prevents degradation of the iRNA when administered systemically. Methods for making and administering cationic-iRNA complexes are well within the abilities of one skilled in the art (see e.g., Sorensen, D R., et al (2003) <i>J. Mol. Biol </i>327:761-766; Verma, U N., et al (2003) <i>Clin. Cancer Res. </i>9:1291-1300; Arnold, A S et al (2007) <i>J. Hypertens. </i>25:197-205, which are incorporated herein by reference in their entirety). Some non-limiting examples of drug delivery systems useful for systemic delivery of iRNAs include DOTAP (Sorensen, D R., et al (2003), supra; Verma, U N., et al (2003), supra), Oligofectamine, &#x201c;solid nucleic acid lipid particles&#x201d; (Zimmermann, T S., et al (2006) <i>Nature </i>441:111-114), cardiolipin (Chien, P Y., et al (2005) <i>Cancer Gene Ther. </i>12:321-328; Pal, A., et al (2005) <i>Int J. Oncol. </i>26:1087-1091), polyethyleneimine (Bonnet M E., et al (2008) <i>Pharm. Res</i>. Aug. 16 Epub ahead of print; <i>Aigner, A</i>. (2006) <i>J. Biomed. Biotechnol. </i>71659), Arg-Gly-Asp (RGD) peptides (Liu, S. (2006) <i>Mol. Pharm. </i>3:472-487), and polyamidoamines (Tomalia, D A., et al (2007) <i>Biochem. Soc. Trans. </i>35:61-67; Yoo, H., et al (1999) <i>Pharm. Res. </i>16:1799-1804). In some embodiments, an iRNA forms a complex with cyclodextrin for systemic administration. Methods for administration and pharmaceutical compositions of iRNAs and cyclodextrins can be found in U.S. Pat. No. 7,427,605, which is herein incorporated by reference in its entirety.</p><p id="p-0260" num="0249">A. Vector Encoded iRNAs for Use in the Methods of the Invention</p><p id="p-0261" num="0250">iRNA targeting the AGT gene can be expressed from transcription units inserted into DNA or RNA vectors (see, e.g., Couture, A, et al., <i>TIG</i>. (1996), 12:5-10; Skillern, A., et al., International PCT Publication No. WO 00/22113, Conrad, International PCT Publication No. WO 00/22114, and Conrad, U.S. Pat. No. 6,054,299). Expression can be transient (on the order of hours to weeks) or sustained (weeks to months or longer), depending upon the specific construct used and the target tissue or cell type. These transgenes can be introduced as a linear construct, a circular plasmid, or a viral vector, which can be an integrating or non-integrating vector. The transgene can also be constructed to permit it to be inherited as an extrachromosomal plasmid (Gassmann, et al., <i>Proc. Natl. Acad. Sci. USA </i>(1995) 92:1292).</p><p id="p-0262" num="0251">The individual strand or strands of an iRNA can be transcribed from a promoter on an expression vector. Where two separate strands are to be expressed to generate, for example, a dsRNA, two separate expression vectors can be co-introduced (e.g., by transfection or infection) into a target cell. Alternatively each individual strand of a dsRNA can be transcribed by promoters both of which are located on the same expression plasmid. In one embodiment, a dsRNA is expressed as inverted repeat polynucleotides joined by a linker polynucleotide sequence such that the dsRNA has a stem and loop structure.</p><p id="p-0263" num="0252">iRNA expression vectors are generally DNA plasmids or viral vectors. Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can be used to produce recombinant constructs for the expression of an iRNA as described herein. Eukaryotic cell expression vectors are well known in the art and are available from a number of commercial sources. Typically, such vectors are provided containing convenient restriction sites for insertion of the desired nucleic acid segment. Delivery of iRNA expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that allows for introduction into a desired target cell.</p><p id="p-0264" num="0253">iRNA expression plasmids can be transfected into target cells as a complex with cationic lipid carriers (e.g., Oligofectamine) or non-cationic lipid-based carriers (e.g., Transit-TKO&#x2122;). Multiple lipid transfections for iRNA-mediated knockdowns targeting different regions of a target RNA over a period of a week or more are also contemplated by the invention. Successful introduction of vectors into host cells can be monitored using various known methods. For example, transient transfection can be signaled with a reporter, such as a fluorescent marker, such as Green Fluorescent Protein (GFP). Stable transfection of cells ex vivo can be ensured using markers that provide the transfected cell with resistance to specific environmental factors (e.g., antibiotics and drugs), such as hygromycin B resistance.</p><p id="p-0265" num="0254">Viral vector systems which can be utilized with the methods and compositions described herein include, but are not limited to, (a) adenovirus vectors; (b) retrovirus vectors, including but not limited to lentiviral vectors, moloney murine leukemia virus, etc.; (c) adeno-associated virus vectors; (d) herpes simplex virus vectors; (e) SV 40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; (i) pox virus vectors such as an orthopox, e.g., vaccinia virus vectors or avipox, e.g. canary pox or fowl pox; and (j) a helper-dependent or gutless adenovirus. Replication-defective viruses can also be advantageous. Different vectors will or will not become incorporated into the cells' genome. The constructs can include viral sequences for transfection, if desired. Alternatively, the construct can be incorporated into vectors capable of episomal replication, e.g. EPV and EBV vectors. Constructs for the recombinant expression of an iRNA will generally require regulatory elements, e.g., promoters, enhancers, etc., to ensure the expression of the iRNA in target cells. Other aspects to consider for vectors and constructs are further described below.</p><p id="p-0266" num="0255">Vectors useful for the delivery of an iRNA will include regulatory elements (promoter, enhancer, etc.) sufficient for expression of the iRNA in the desired target cell or tissue. The regulatory elements can be chosen to provide either constitutive or regulated/inducible expression.</p><p id="p-0267" num="0256">Expression of the iRNA can be precisely regulated, for example, by using an inducible regulatory sequence that is sensitive to certain physiological regulators, e.g., circulating glucose levels, or hormones (Docherty et al., 1994<i>, FASEB J. </i>8:20-24). Such inducible expression systems, suitable for the control of dsRNA expression in cells or in mammals include, for example, regulation by ecdysone, by estrogen, progesterone, tetracycline, chemical inducers of dimerization, and isopropyl-beta-D1-thiogalactopyranoside (IPTG). A person skilled in the art would be able to choose the appropriate regulatory/promoter sequence based on the intended use of the iRNA transgene.</p><p id="p-0268" num="0257">Viral vectors that contain nucleic acid sequences encoding an iRNA can be used. For example, a retroviral vector can be used (see Miller et al., <i>Meth. Enzymol. </i>217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding an iRNA are cloned into one or more vectors, which facilitate delivery of the nucleic acid into a patient. More detail about retroviral vectors can be found, for example, in Boesen et al., <i>Biotherapy </i>6:291-302 (1994), which describes the use of a retroviral vector to deliver the mdr1 gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., <i>J. Clin. Invest. </i>93:644-651 (1994); Kiem et al., <i>Blood </i>83:1467-1473 (1994); <i>Salmons and Gunzberg, Human Gene Therapy </i>4:129-141 (1993); and Grossman and Wilson, <i>Curr. Opin</i>. in Genetics and Devel. 3:110-114 (1993). Lentiviral vectors contemplated for use include, for example, the HIV based vectors described in U.S. Pat. Nos. 6,143,520; 5,665,557; and 5,981,276, which are herein incorporated by reference.</p><p id="p-0269" num="0258">Adenoviruses are also contemplated for use in delivery of iRNAs of the invention. Adenoviruses are especially attractive vehicles, e.g., for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, <i>Current Opinion in Genetics and Development </i>3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., <i>Human Gene Therapy </i>5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., <i>Science </i>252:431-434 (1991); Rosenfeld et al., <i>Cell </i>68:143-155 (1992); Mastrangeli et al., <i>J. Clin. Invest. </i>91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., <i>Gene Therapy </i>2:775-783 (1995). A suitable AV vector for expressing an iRNA featured in the invention, a method for constructing the recombinant AV vector, and a method for delivering the vector into target cells, are described in Xia H et al. (2002), <i>Nat. Biotech. </i>20: 1006-1010.</p><p id="p-0270" num="0259">Adeno-associated virus (AAV) vectors may also be used to delivery an iRNA of the invention (Walsh et al., <i>Proc. Soc. Exp. Biol. Med. </i>204:289-300 (1993); U.S. Pat. No. 5,436,146). In one embodiment, the iRNA can be expressed as two separate, complementary single-stranded RNA molecules from a recombinant AAV vector having, for example, either the U6 or H1 RNA promoters, or the cytomegalovirus (CMV) promoter. Suitable AAV vectors for expressing the dsRNA featured in the invention, methods for constructing the recombinant AV vector, and methods for delivering the vectors into target cells are described in Samulski R et al. (1987), <i>J. Virol. </i>61: 3096-3101; Fisher K J et al. (1996), <i>J. Virol, </i>70: 520-532; Samulski R et al. (1989), <i>J. Virol. </i>63: 3822-3826; U.S. Pat. Nos. 5,252,479; 5,139,941; International Patent Application No. WO 94/13788; and International Patent Application No. WO 93/24641, the entire disclosures of which are herein incorporated by reference.</p><p id="p-0271" num="0260">Another viral vector suitable for delivery of an iRNA of the invention is a pox virus such as a vaccinia virus, for example an attenuated vaccinia such as Modified Virus Ankara (MVA) or NYVAC, an avipox such as fowl pox or canary pox.</p><p id="p-0272" num="0261">The tropism of viral vectors can be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses, or by substituting different viral capsid proteins, as appropriate. For example, lentiviral vectors can be pseudotyped with surface proteins from vesicular stomatitis virus (VSV), rabies, Ebola, Mokola, and the like. AAV vectors can be made to target different cells by engineering the vectors to express different capsid protein serotypes; see, e.g., Rabinowitz J E et al. (2002), <i>J Virol </i>76:791-801, the entire disclosure of which is herein incorporated by reference.</p><p id="p-0273" num="0262">The pharmaceutical preparation of a vector can include the vector in an acceptable diluent, or can include a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.</p><heading id="h-0011" level="1">V. Double Stranded iRNAs Agents for Use in the Methods of the Invention</heading><p id="p-0274" num="0263">Suitable double-stranded RNAi agentes for use in the methods of the invention include an antisense strand having a region of complementarity which is complementary to at least a part of an mRNA formed in the expression of an AGT gene. The region of complementarity is about 19-30 nucleotides in length (e.g., about 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, or 19 nucleotides in length). Upon contact with a cell expressing the AGT gene, the iRNA inhibits the expression of the AGT gene (e.g., a human, a primate, a non-primate, or a rat AGT gene) by at least 50% as assayed by, for example, a PCR or branched DNA (bDNA)-based method, or by a protein-based method, such as by immunofluorescence analysis, using, for example, western blotting or flow cytometric techniques. In preferred embodiments, inhibition of expression is determined by the qPCR method provided in the examples, especially in Example 2 of PCT Application No. PCT/US2019/032150 with the siRNA at a 10 nM concentration in an appropriate organism cell line provided therein. In preferred embodiments, inhibition of expression in vivo is determined by knockdown of the human gene in a rodent expressing the human gene, e.g., a mouse or an AAV-infected mouse expressing the human target gene, e.g., when administered a single dose at 3 mg/kg at the nadir of RNA expression. RNA expression in liver is determined using the PCR methods provided in Example 2 of PCT Application No. PCT/US2019/032150.</p><p id="p-0275" num="0264">A dsRNA includes two RNA strands that are complementary and hybridize to form a duplex structure under conditions in which the dsRNA will be used. One strand of a dsRNA (the antisense strand) includes a region of complementarity that is substantially complementary, and generally fully complementary, to a target sequence. The target sequence can be derived from the sequence of an mRNA formed during the expression of an AGT gene. The other strand (the sense strand) includes a region that is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. As described elsewhere herein and as known in the art, the complementary sequences of a dsRNA can also be contained as self-complementary regions of a single nucleic acid molecule, as opposed to being on separate oligonucleotides.</p><p id="p-0276" num="0265">Generally, the duplex structure is 19 to 30 base pairs in length. Similarly, the region of complementarity to the target sequence is 19 to 30 nucleotides in length.</p><p id="p-0277" num="0266">In some embodiments, the dsRNA is about 19 to about 23 nucleotides in length, or about 25 to about 30 nucleotides in length. In general, the dsRNA is long enough to serve as a substrate for the Dicer enzyme. For example, it is well-known in the art that dsRNAs longer than about 21-23 nucleotides in length may serve as substrates for Dicer. As the ordinarily skilled person will also recognize, the region of an RNA targeted for cleavage will most often be part of a larger RNA molecule, often an mRNA molecule. Where relevant, a &#x201c;part&#x201d; of an mRNA target is a contiguous sequence of an mRNA target of sufficient length to allow it to be a substrate for RNAi-directed cleavage (i.e., cleavage through a RISC pathway).</p><p id="p-0278" num="0267">One of skill in the art will also recognize that the duplex region is a primary functional portion of a dsRNA, e.g., a duplex region of about 19 to about 30 base pairs, e.g., about 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs. In certain embodiments, the duplex region is 19-21 base pairs. Thus, in one embodiment, to the extent that it becomes processed to a functional duplex, of e.g., 15-30 base pairs, that targets a desired RNA for cleavage, an RNA molecule or complex of RNA molecules having a duplex region greater than 30 base pairs is a dsRNA. Thus, an ordinarily skilled artisan will recognize that in one embodiment, a miRNA is a dsRNA. In another embodiment, a dsRNA is not a naturally occurring miRNA. In another embodiment, an iRNA agent useful to target AGT gene expression is not generated in the target cell by cleavage of a larger dsRNA.</p><p id="p-0279" num="0268">A dsRNA as described herein can further include one or more single-stranded nucleotide overhangs e.g., 1-4, 2-4, 1-3, 2-3, 1, 2, 3, or 4 nucleotides. dsRNAs having at least one nucleotide overhang can have superior inhibitory properties relative to their blunt-ended counterparts. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand, or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5&#x2032;-end, 3&#x2032;-end, or both ends of an antisense or sense strand of a dsRNA.</p><p id="p-0280" num="0269">The overhangs can be the result of one strand being longer than the other, or the result of two strands of the same length being staggered. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence. The first and second strands can also be joined, e.g., by additional bases to form a hairpin, or by other non-base linkers.</p><p id="p-0281" num="0270">In one embodiment, the nucleotides in the overhang region of the RNAi agent can each independently be a modified or unmodified nucleotide including, but not limited to 2&#x2032;-sugar modified, such as, 2-F, 2&#x2032;-O-methyl, thymidine (T), 2&#x2032;-O-methoxyethyl-5-methyluridine (Teo), 2&#x2032;-O-methoxyethyladenosine (Aeo), 2&#x2032;-O-methoxyethyl-5-methylcytidine (m5Ceo), and any combinations thereof. For example, TT can be an overhang sequence for either end on either strand. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence.</p><p id="p-0282" num="0271">The 5&#x2032;- or 3&#x2032;-overhangs at the sense strand, antisense strand or both strands of the RNAi agent may be phosphorylated. In some embodiments, the overhang region(s) contains two nucleotides having a phosphorothioate between the two nucleotides, where the two nucleotides can be the same or different. In one embodiment, the overhang is present at the 3&#x2032;-end of the sense strand, antisense strand, or both strands. In one embodiment, this 3&#x2032;-overhang is present in the antisense strand. In one embodiment, this 3&#x2032;-overhang is present in the sense strand.</p><p id="p-0283" num="0272">The RNAi agent may contain only a single overhang, which can strengthen the interference activity of the RNAi, without affecting its overall stability. For example, the single-stranded overhang may be located at the 3&#x2032;-terminal end of the sense strand or, alternatively, at the 3&#x2032;-terminal end of the antisense strand. The RNAi may also have a blunt end, located at the 5&#x2032;-end of the antisense strand (or the 3&#x2032;-end of the sense strand) or vice versa. Generally, the antisense strand of the RNAi has a nucleotide overhang at the 3&#x2032;-end, and the 5&#x2032;-end is blunt. While not wishing to be bound by theory, the asymmetric blunt end at the 5&#x2032;-end of the antisense strand and 3&#x2032;-end overhang of the antisense strand favor the guide strand loading into RISC process.</p><p id="p-0284" num="0273">In some embodiments, the double-stranded RNAi agents for use in the methods of the present invention are unmodified. In other embodiments, the double-stranded RNAi agents for use in the methods of the present invention are modified, e.g., comprise chemical modifications capable of inhibiting the expression of a target gene (i.e., an AGT gene) in vivo, or enhancing stability or other beneficial characteristic of the agents. In some embodiment, the double-stranded RNAi agents comprises a thermally destabilizing nucleotide modification.</p><p id="p-0285" num="0274">As described in more detail below, in certain aspects of the invention, substantially all of the nucleotides of an iRNA of the invention are modified. In other embodiments of the invention, all of the nucleotides of an iRNA of the invention are modified. iRNAs of the invention in which &#x201c;substantially all of the nucleotides are modified&#x201d; are largely but not wholly modified and can include not more than 5, 4, 3, 2, or 1 unmodified nucleotides.</p><p id="p-0286" num="0275">A dsNA can be synthesized by standard methods known in the art. Double stranded RNAi compounds of the invention may be prepared using a two-step procedure. First, the individual strands of the double stranded RNA molecule are prepared separately. Then, the component strands are annealed. The individual strands of the siRNA compound can be prepared using solution-phase or solid-phase organic synthesis or both. Organic synthesis offers the advantage that the oligonucleotide strands comprising unnatural or modified nucleotides can be easily prepared. Similarly, single-stranded oligonucleotides of the invention can be prepared using solution-phase or solid-phase organic synthesis or both.</p><heading id="h-0012" level="1">VI. Modified iRNAs of the Invention</heading><p id="p-0287" num="0276">In certain embodiments, the RNA of the iRNA of the invention e.g., a dsRNA, is unmodified, and does not comprise, e.g., chemical modifications or conjugations known in the art and described herein. In other embodiments, the RNA of an iRNA of the invention, e.g., a dsRNA, is chemically modified to enhance stability or other beneficial characteristics. In certain embodiments of the invention, substantially all of the nucleotides of an iRNA of the invention are modified. In other embodiments of the invention, all of the nucleotides of an iRNA or substantially all of the nucleotides of an iRNA are modified, i.e., not more than 5, 4, 3, 2, or 1 unmodified nucleotides are present in a strand of the iRNA.</p><p id="p-0288" num="0277">The nucleic acids featured in the invention can be synthesized or modified by methods well established in the art, such as those described in &#x201c;Current protocols in nucleic acid chemistry,&#x201d; Beaucage, S. L. et al. (Edrs), John Wiley &#x26; Sons, Inc., New York, N.Y., USA, which is hereby incorporated herein by reference. Modifications include, for example, end modifications, e.g., 5&#x2032;-end modifications (phosphorylation, conjugation, inverted linkages) or 3&#x2032;-end modifications (conjugation, DNA nucleotides, inverted linkages, etc.); base modifications, e.g., replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases; sugar modifications (e.g., at the 2&#x2032;-position or 4&#x2032;-position) or replacement of the sugar; or backbone modifications, including modification or replacement of the phosphodiester linkages. Specific examples of iRNA compounds useful in the embodiments described herein include, but are not limited to, RNAs containing modified backbones or no natural internucleoside linkages. RNAs having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. In some embodiments, a modified iRNA will have a phosphorus atom in its internucleoside backbone.</p><p id="p-0289" num="0278">Modified RNA backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3&#x2032;-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3&#x2032;-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3&#x2032;-5&#x2032; linkages, 2&#x2032;-5&#x2032;-linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3&#x2032;-5&#x2032; to 5&#x2032;-3&#x2032; or 2&#x2032;-5&#x2032; to 5&#x2032;-2&#x2032;. Various salts, e.g., sodium salts, mixed salts and free acid forms are also included.</p><p id="p-0290" num="0279">Representative U.S. patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170; 6,172,209; 6,239,265; 6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,534,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and U.S. Pat. RE39464, the entire contents of each of which are hereby incorporated herein by reference.</p><p id="p-0291" num="0280">Modified RNA backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S, and CH<sub>2 </sub>component parts.</p><p id="p-0292" num="0281">Representative U.S. patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and, 5,677,439, the entire contents of each of which are hereby incorporated herein by reference.</p><p id="p-0293" num="0282">Suitable RNA mimetics are contemplated for use in iRNAs provided herein, in which both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound in which an RNA mimetic that has been shown to have excellent hybridization properties is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of an RNA is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative US patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, the entire contents of each of which are hereby incorporated herein by reference. Additional PNA compounds suitable for use in the iRNAs of the invention are described in, for example, in Nielsen et al., <i>Science, </i>1991, 254, 1497-1500.</p><p id="p-0294" num="0283">Some embodiments featured in the invention include RNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular &#x2014;CH<sub>2</sub>&#x2014;NH&#x2014;CH<sub>2</sub>&#x2014;, &#x2014;CH<sub>2</sub>&#x2014;N(CH<sub>3</sub>)&#x2014;O&#x2014;CH<sub>2</sub>-[known as a methylene (methylimino) or MMI backbone], &#x2014;CH<sub>2</sub>&#x2014;O&#x2014;N(CH<sub>3</sub>)&#x2014;CH<sub>2</sub>&#x2014;, &#x2014;CH<sub>2</sub>&#x2014;N(CH<sub>3</sub>)&#x2014;N(CH<sub>3</sub>)&#x2014;CH<sub>2</sub>&#x2014; and &#x2014;N(CH<sub>3</sub>)&#x2014;CH<sub>2</sub>&#x2014;CH<sub>2</sub>&#x2014;[wherein the native phosphodiester backbone is represented as &#x2014;O&#x2014;P&#x2014;O&#x2014;CH<sub>2</sub>&#x2014;] of the above-referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above-referenced U.S. Pat. No. 5,602,240. In some embodiments, the RNAs featured herein have morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.</p><p id="p-0295" num="0284">Modified RNAs can also contain one or more substituted sugar moieties. The iRNAs, e.g., dsRNAs, featured herein can include one of the following at the 2&#x2032;-position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted C<sub>1 </sub>to C<sub>10 </sub>alkyl or C<sub>2 </sub>to C<sub>10 </sub>alkenyl and alkynyl. Exemplary suitable modifications include O[(CH<sub>2</sub>)<sub>n</sub>O]<sub>m</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>OCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>ONH<sub>2</sub>, and O(CH<sub>2</sub>)<sub>n</sub>ON[(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>)]<sub>2</sub>, where n and m are from 1 to about 10. In other embodiments, dsRNAs include one of the following at the 2&#x2032; position: C<sub>1 </sub>to C<sub>10 </sub>lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH<sub>3</sub>, OCN, Cl, Br, CN, CF<sub>3</sub>, OCF<sub>3</sub>, SOCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an iRNA, or a group for improving the pharmacodynamic properties of an iRNA, and other substituents having similar properties. In some embodiments, the modification includes a 2&#x2032;-methoxyethoxy (2&#x2032;-O&#x2014;CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2&#x2032;-O-(2-methoxyethyl) or 2&#x2032;-MOE) (Martin et al., <i>Helv. Chim. Acta, </i>1995, 78:486-504) i.e., an alkoxy-alkoxy group. Another exemplary modification is 2&#x2032;-dimethylaminooxyethoxy, i.e., a O(CH<sub>2</sub>)20N(CH<sub>3</sub>)<sub>2 </sub>group, also known as 2&#x2032;-DMAOE, as described in examples herein below, and 2&#x2032;-dimethylaminoethoxyethoxy (also known in the art as 2&#x2032;-O-dimethylaminoethoxyethyl or 2&#x2032;-DMAEOE), i.e., 2&#x2032;-O&#x2014;CH<sub>2</sub>&#x2014;O&#x2014;CH<sub>2</sub>&#x2014;N(CH<sub>2</sub>)2. Further exemplary modifications include: 5&#x2032;-Me-2&#x2032;-F nucleotides, 5&#x2032;-Me-2&#x2032;-OMe nucleotides, 5&#x2032;-Me-2&#x2032;-deoxynucleotides, (both R and S isomers in these three families); 2&#x2032;-alkoxyalkyl; and 2&#x2032;-NMA (N-methylacetamide).</p><p id="p-0296" num="0285">Other modifications include 2&#x2032;-methoxy (2&#x2032;-OCH<sub>3</sub>), 2&#x2032;-aminopropoxy (2&#x2032;-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>) and 2&#x2032;-fluoro (2&#x2032;-F). Similar modifications can also be made at other positions on the RNA of an iRNA, particularly the 3&#x2032; position of the sugar on the 3&#x2032; terminal nucleotide or in 2&#x2032;-5&#x2032; linked dsRNAs and the 5&#x2032; position of 5&#x2032; terminal nucleotide. iRNAs can also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.</p><p id="p-0297" num="0286">An iRNA can also include nucleobase (often referred to in the art simply as &#x201c;base&#x201d;) modifications or substitutions. As used herein, &#x201c;unmodified&#x201d; or &#x201c;natural&#x201d; nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as deoxy-thymine (dT), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl anal other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008; those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. L, ed. John Wiley &#x26; Sons, 1990, these disclosed by Englisch et al., <i>Angewandte Chemie, International Edition, </i>1991, 30, 613, and those disclosed by Sanghvi, Y S., Chapter 15, dsRNA Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., Ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2&#xb0; C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., dsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are exemplary base substitutions, even more particularly when combined with 2&#x2032;-O-methoxyethyl sugar modifications.</p><p id="p-0298" num="0287">Representative U.S. patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. Nos. 3,687,808, 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,681,941; 5,750,692; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, the entire contents of each of which are hereby incorporated herein by reference.</p><p id="p-0299" num="0288">The RNA of an iRNA can also be modified to include one or more locked nucleic acids (LNA). A locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2&#x2032; and 4&#x2032; carbons. This structure effectively &#x201c;locks&#x201d; the ribose in the 3&#x2032;-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, and to reduce off-target effects (Elmen, J. et al., (2005) <i>Nucleic Acids Research </i>33(1):439-447; Mook, O R. et al., (2007) <i>Mol Canc Ther </i>6(3):833-843; Grunweller, A. et al., (2003) <i>Nucleic Acids Research </i>31(12):3185-3193).</p><p id="p-0300" num="0289">Representative U.S. Patents that teach the preparation of locked nucleic acid nucleotides include, but are not limited to, the following: U.S. Pat. Nos. 6,268,490; 6,670,461; 6,794,499; 6,998,484; 7,053,207; 7,084,125; and 7,399,845, the entire contents of each of which are hereby incorporated herein by reference.</p><p id="p-0301" num="0290">In some embodiments, the RNA of an iRNA can also be modified to include one or more bicyclic sugar moieties. A &#x201c;biyclic sugar&#x201d; is a furanosyl ring modified by the bridging of two atoms. A &#x201c;bicyclic nucleoside&#x201d; (&#x201c;BNA&#x201d;) is a nucleoside having a sugar moiety comprising a bridge connecting two carbon atoms of the sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the bridge connects the 4&#x2032;-carbon and the 2&#x2032;-carbon of the sugar ring. Thus, in some embodiments an agent of the invention may include one or more locked nucleic acids (LNA). A locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2&#x2032; and 4&#x2032; carbons. In other words, an LNA is a nucleotide comprising a bicyclic sugar moiety comprising a 4&#x2032;-CH<sub>2</sub>&#x2014;O-2&#x2032; bridge. This structure effectively &#x201c;locks&#x201d; the ribose in the 3&#x2032;-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, and to reduce off-target effects (Elmen, J. et al., (2005) <i>Nucleic Acids Research </i>33(1):439-447; Mook, O R. et al., (2007) <i>Mol Canc Ther </i>6(3):833-843; Grunweller, A. et al., (2003) <i>Nucleic Acids Research </i>31(12):3185-3193). Examples of bicyclic nucleosides for use in the polynucleotides of the invention include without limitation nucleosides comprising a bridge between the 4&#x2032; and the 2&#x2032; ribosyl ring atoms. In certain embodiments, the antisense polynucleotide agents of the invention include one or more bicyclic nucleosides comprising a 4&#x2032; to 2&#x2032; bridge. Examples of such 4&#x2032; to 2&#x2032; bridged bicyclic nucleosides, include but are not limited to 4&#x2032;-(CH<sub>2</sub>)&#x2014;O-2&#x2032; (LNA); 4&#x2032;-(CH<sub>2</sub>)&#x2014;S-2&#x2032;; 4&#x2032;-(CH<sub>2</sub>)<sub>2</sub>&#x2014;O-2&#x2032; (ENA); 4&#x2032;-CH(CH<sub>3</sub>)&#x2014;O-2&#x2032; (also referred to as &#x201c;constrained ethyl&#x201d; or &#x201c;cEt&#x201d;) and 4&#x2032;-CH(CH<sub>2</sub>OCH<sub>3</sub>)&#x2014;O-2&#x2032; (and analogs thereof; see, e.g., U.S. Pat. No. 7,399,845); 4&#x2032;-C(CH<sub>3</sub>)(CH<sub>3</sub>)&#x2014;O-2&#x2032; (and analogs thereof; see e.g., U.S. Pat. No. 8,278,283); 4&#x2032;-CH<sub>2</sub>&#x2014;N(OCH<sub>3</sub>)-2&#x2032; (and analogs thereof; see e.g., U.S. Pat. No. 8,278,425); 4&#x2032;-CH<sub>2</sub>&#x2014;O&#x2014;N(CH<sub>3</sub>)-2&#x2032; (see, e.g., U.S. Patent Publication No. 2004/0171570); 4&#x2032;-CH<sub>2</sub>&#x2014;N(R)&#x2014;O-2&#x2032;, wherein R is H, C1-C12 alkyl, or a protecting group (see, e.g., U.S. Pat. No. 7,427,672); 4&#x2032;-CH<sub>2</sub>&#x2014;C(H)(CH<sub>3</sub>)-2&#x2032; (see, e.g., Chattopadhyaya et al., <i>J. Org. Chem., </i>2009, 74, 118-134); and 4&#x2032;-CH<sub>2</sub>&#x2014;C(&#x2550;CH<sub>2</sub>)-2&#x2032; (and analogs thereof; see, e.g., U.S. Pat. No. 8,278,426).</p><p id="p-0302" num="0291">Any of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example &#x3b1;-L-ribofuranose and &#x3b2;-D-ribofuranose (see WO 99/14226).</p><p id="p-0303" num="0292">The RNA of an iRNA can also be modified to include one or more constrained ethyl nucleotides. As used herein, a &#x201c;constrained ethyl nucleotide&#x201d; or &#x201c;cEt&#x201d; is a locked nucleic acid comprising a bicyclic sugar moiety comprising a 4&#x2032;-CH(CH<sub>3</sub>)&#x2014;O-2&#x2032; bridge. In one embodiment, a constrained ethyl nucleotide is in the S conformation referred to herein as &#x201c;S-cEt.&#x201d;</p><p id="p-0304" num="0293">An iRNA of the invention may also include one or more &#x201c;conformationally restricted nucleotides&#x201d; (&#x201c;CRN&#x201d;). CRN are nucleotide analogs with a linker connecting the C2&#x2032; and C4&#x2032; carbons of ribose or the C3 and &#x2014;C5&#x2032; carbons of ribose. CRN lock the ribose ring into a stable conformation and increase the hybridization affinity to mRNA. The linker is of sufficient length to place the oxygen in an optimal position for stability and affinity resulting in less ribose ring puckering.</p><p id="p-0305" num="0294">In some embodiments, an iRNA of the invention comprises one or more monomers that are UNA (unlocked nucleic acid) nucleotides. UNA is unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked &#x201c;sugar&#x201d; residue. In one example, UNA also encompasses monomer with bonds between C1&#x2032;-C4&#x2032; have been removed (i.e. the covalent carbon-oxygen-carbon bond between the C1&#x2032; and C4&#x2032; carbons). In another example, the C2&#x2032;-C3&#x2032; bond (i.e. the covalent carbon-carbon bond between the C2&#x2032; and C3&#x2032; carbons) of the sugar has been removed (see Nuc. Acids Symp. Series, 52, 133-134 (2008) and Fluiter et al., <i>Mol. Biosyst., </i>2009, 10, 1039 hereby incorporated by reference).</p><p id="p-0306" num="0295">Potentially stabilizing modifications to the ends of RNA molecules can include N-(acetylaminocaproyl)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(caproyl-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2&#x2032;-O-deoxythymidine (ether), N-(aminocaproyl)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyl-uridine-3&#x2033;-phosphate, inverted base dT(idT) and others. Disclosure of this modification can be found in PCT Publication No. WO 2011/005861.</p><p id="p-0307" num="0296">Other modifications of the nucleotides of an iRNA of the invention include a 5&#x2032; phosphate or 5&#x2032; phosphate mimic, e.g., a 5&#x2032;-terminal phosphate or phosphate mimic on the antisense strand of an iRNA. Suitable phosphate mimics are disclosed in, for example U.S. Patent Publication No. 2012/0157511, the entire contents of which are incorporated herein by reference.</p><p id="p-0308" num="0297">A. Modified iRNAs Comprising Motifs of the Invention</p><p id="p-0309" num="0298">In certain aspects of the invention, the double stranded RNA agents of the invention include agents with chemical modifications as disclosed, for example, in WO2013/075035, the entire contents of each of which are incorporated herein by reference. WO2013/075035 provides motifs of three identical modifications on three consecutive nucleotides into a sense strand or antisense strand of a dsRNAi agent, particularly at or near the cleavage site. In some embodiments, the sense strand and antisense strand of the dsRNAi agent may otherwise be completely modified. The introduction of these motifs interrupts the modification pattern, if present, of the sense or antisense strand. The dsRNAi agent may be optionally conjugated with a GalNAc derivative ligand, for instance on the sense strand.</p><p id="p-0310" num="0299">More specifically, when the sense strand and antisense strand of the double stranded RNA agent are completely modified to have one or more motifs of three identical modifications on three consecutive nucleotides at or near the cleavage site of at least one strand of a dsRNAi agent, the gene silencing activity of the dsRNAi agent was observed.</p><p id="p-0311" num="0300">Accordingly, the invention provides double stranded RNA agents capable of inhibiting the expression of a target gene (i.e., AGT gene) in vivo. The RNAi agent comprises a sense strand and an antisense strand. Each strand of the RNAi agent may be, for example, 17-30 nucleotides in length, 25-30 nucleotides in length, 27-30 nucleotides in length, 19-25 nucleotides in length, 19-23 nucleotides in length, 19-21 nucleotides in length, 21-25 nucleotides in length, or 21-23 nucleotides in length.</p><p id="p-0312" num="0301">The sense strand and antisense strand typically form a duplex double stranded RNA (&#x201c;dsRNA&#x201d;), also referred to herein as &#x201c;dsRNAi agent.&#x201d; The duplex region of a dsRNAi agent may be, for example, the duplex region can be 27-30 nucleotide pairs in length, 19-25 nucleotide pairs in length, 19-23 nucleotide pairs in length, 19-21 nucleotide pairs in length, 21-25 nucleotide pairs in length, or 21-23 nucleotide pairs in length. In another example, the duplex region is selected from 19, 20, 21, 22, 23, 24, 25, 26, and 27 nucleotides in length.</p><p id="p-0313" num="0302">In certain embodiments, the dsRNAi agent may contain one or more overhang regions or capping groups at the 3&#x2032;-end, 5&#x2032;-end, or both ends of one or both strands. The overhang can be, independently, 1-6 nucleotides in length, for instance 2-6 nucleotides in length, 1-5 nucleotides in length, 2-5 nucleotides in length, 1-4 nucleotides in length, 2-4 nucleotides in length, 1-3 nucleotides in length, 2-3 nucleotides in length, or 1-2 nucleotides in length. In certain embodiments, the overhang regions can include extended overhang regions as provided above. The overhangs can be the result of one strand being longer than the other, or the result of two strands of the same length being staggered. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence. The first and second strands can also be joined, e.g., by additional bases to form a hairpin, or by other non-base linkers.</p><p id="p-0314" num="0303">In certain embodiments, the nucleotides in the overhang region of the dsRNAi agent can each independently be a modified or unmodified nucleotide including, but no limited to 2&#x2032;-sugar modified, such as, 2&#x2032;-F, 2&#x2032;-O-methyl, thymidine (T), 2&#x2032;-O-methoxyethyl-5-methyluridine (Teo), 2&#x2032;-O-methoxyethyladenosine (Aeo), 2&#x2032;-O-methoxyethyl-5-methylcytidine (m5Ceo), and any combinations thereof. For example, TT can be an overhang sequence for either end on either strand. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence.</p><p id="p-0315" num="0304">The 5&#x2032;- or 3&#x2032;-overhangs at the sense strand, antisense strand, or both strands of the dsRNAi agent may be phosphorylated. In some embodiments, the overhang region(s) contains two nucleotides having a phosphorothioate between the two nucleotides, where the two nucleotides can be the same or different. In some embodiments, the overhang is present at the 3&#x2032;-end of the sense strand, antisense strand, or both strands. In some embodiments, this 3&#x2032;-overhang is present in the antisense strand. In some embodiments, this 3&#x2032;-overhang is present in the sense strand.</p><p id="p-0316" num="0305">The dsRNAi agent may contain only a single overhang, which can strengthen the interference activity of the RNAi, without affecting its overall stability. For example, the single-stranded overhang may be located at the 3&#x2032;-end of the sense strand or, alternatively, at the 3-end of the antisense strand. The RNAi may also have a blunt end, located at the 5&#x2032;-end of the antisense strand (or the 3&#x2032;-end of the sense strand) or vice versa. Generally, the antisense strand of the dsRNAi agent has a nucleotide overhang at the 3&#x2032;-end, and the 5&#x2032;-end is blunt. While not wishing to be bound by theory, the asymmetric blunt end at the 5&#x2032;-end of the antisense strand and 3&#x2032;-end overhang of the antisense strand favor the guide strand loading into RISC process.</p><p id="p-0317" num="0306">In certain embodiments, the dsRNAi agent is a double ended bluntmer of 19 nucleotides in length, wherein the sense strand contains at least one motif of three 2&#x2032;-F modifications on three consecutive nucleotides at positions 7, 8, 9 from the 5&#x2032;end. The antisense strand contains at least one motif of three 2&#x2032;-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5&#x2032;end.</p><p id="p-0318" num="0307">In other embodiments, the dsRNAi agent is a double ended bluntmer of 20 nucleotides in length, wherein the sense strand contains at least one motif of three 2&#x2032;-F modifications on three consecutive nucleotides at positions 8, 9, 10 from the 5&#x2032;end. The antisense strand contains at least one motif of three 2&#x2032;-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5&#x2032;end.</p><p id="p-0319" num="0308">In yet other embodiments, the dsRNAi agent is a double ended bluntmer of 21 nucleotides in length, wherein the sense strand contains at least one motif of three 2&#x2032;-F modifications on three consecutive nucleotides at positions 9, 10, 11 from the 5&#x2032;end. The antisense strand contains at least one motif of three 2&#x2032;-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5&#x2032;end.</p><p id="p-0320" num="0309">In certain embodiments, the dsRNAi agent comprises a 21 nucleotide sense strand and a 23 nucleotide antisense strand, wherein the sense strand contains at least one motif of three 2&#x2032;-F modifications on three consecutive nucleotides at positions 9, 10, 11 from the 5&#x2032;end; the antisense strand contains at least one motif of three 2&#x2032;-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5&#x2032;end, wherein one end of the RNAi agent is blunt, while the other end comprises a 2 nucleotide overhang. Preferably, the 2 nucleotide overhang is at the 3&#x2032;-end of the antisense strand.</p><p id="p-0321" num="0310">When the 2 nucleotide overhang is at the 3&#x2032;-end of the antisense strand, there may be two phosphorothioate internucleotide linkages between the terminal three nucleotides, wherein two of the three nucleotides are the overhang nucleotides, and the third nucleotide is a paired nucleotide next to the overhang nucleotide. In one embodiment, the RNAi agent additionally has two phosphorothioate internucleotide linkages between the terminal three nucleotides at both the 5&#x2032;-end of the sense strand and at the 5&#x2032;-end of the antisense strand. In certain embodiments, every nucleotide in the sense strand and the antisense strand of the dsRNAi agent, including the nucleotides that are part of the motifs are modified nucleotides. In certain embodiments each residue is independently modified with a 2&#x2032;-O-methyl or 3&#x2032;-fluoro, e.g., in an alternating motif. Optionally, the dsRNAi agent further comprises a ligand (preferably GalNAc<sub>3</sub>).</p><p id="p-0322" num="0311">In certain embodiments, the dsRNAi agent comprises a sense and an antisense strand, wherein the sense strand is 25-30 nucleotide residues in length, wherein starting from the 5&#x2032; terminal nucleotide (position 1) positions 1 to 23 of the first strand comprise at least 8 ribonucleotides; the antisense strand is 36-66 nucleotide residues in length and, starting from the 3&#x2032; terminal nucleotide, comprises at least 8 ribonucleotides in the positions paired with positions 1-23 of sense strand to form a duplex; wherein at least the 3&#x2032; terminal nucleotide of antisense strand is unpaired with sense strand, and up to 6 consecutive 3&#x2032; terminal nucleotides are unpaired with sense strand, thereby forming a 3&#x2032; single stranded overhang of 1-6 nucleotides; wherein the 5&#x2032; terminus of antisense strand comprises from 10-30 consecutive nucleotides which are unpaired with sense strand, thereby forming a 10-30 nucleotide single stranded 5&#x2032; overhang; wherein at least the sense strand 5&#x2032; terminal and 3&#x2032; terminal nucleotides are base paired with nucleotides of antisense strand when sense and antisense strands are aligned for maximum complementarity, thereby forming a substantially duplexed region between sense and antisense strands; and antisense strand is sufficiently complementary to a target RNA along at least 19 ribonucleotides of antisense strand length to reduce target gene expression when the double stranded nucleic acid is introduced into a mammalian cell; and wherein the sense strand contains at least one motif of three 2&#x2032;-F modifications on three consecutive nucleotides, where at least one of the motifs occurs at or near the cleavage site. The antisense strand contains at least one motif of three 2&#x2032;-O-methyl modifications on three consecutive nucleotides at or near the cleavage site.</p><p id="p-0323" num="0312">In certain embodiments, the dsRNAi agent comprises sense and antisense strands, wherein the dsRNAi agent comprises a first strand having a length which is at least 25 and at most 29 nucleotides and a second strand having a length which is at most 30 nucleotides with at least one motif of three 2&#x2032;-O-methyl modifications on three consecutive nucleotides at position 11, 12, 13 from the 5&#x2032; end; wherein the 3&#x2032; end of the first strand and the 5&#x2032; end of the second strand form a blunt end and the second strand is 1-4 nucleotides longer at its 3&#x2032; end than the first strand, wherein the duplex region which is at least 25 nucleotides in length, and the second strand is sufficiently complementary to a target mRNA along at least 19 nucleotide of the second strand length to reduce target gene expression when the RNAi agent is introduced into a mammalian cell, and wherein Dicer cleavage of the dsRNAi agent preferentially results in an siRNA comprising the 3&#x2032;-end of the second strand, thereby reducing expression of the target gene in the mammal. Optionally, the dsRNAi agent further comprises a ligand.</p><p id="p-0324" num="0313">In certain embodiments, the sense strand of the dsRNAi agent contains at least one motif of three identical modifications on three consecutive nucleotides, where one of the motifs occurs at the cleavage site in the sense strand.</p><p id="p-0325" num="0314">In certain embodiments, the antisense strand of the dsRNAi agent can also contain at least one motif of three identical modifications on three consecutive nucleotides, where one of the motifs occurs at or near the cleavage site in the antisense strand.</p><p id="p-0326" num="0315">For a dsRNAi agent having a duplex region of 19-23 nucleotide in length, the cleavage site of the antisense strand is typically around the 10, 11, and 12 positions from the 5&#x2032;-end. Thus the motifs of three identical modifications may occur at the 9, 10, 11 positions; the 10, 11, 12 positions; the 11, 12, 13 positions; the 12, 13, 14 positions; or the 13, 14, 15 positions of the antisense strand, the count starting from the first nucleotide from the 5&#x2032;-end of the antisense strand, or, the count starting from the first paired nucleotide within the duplex region from the 5&#x2032;-end of the antisense strand. The cleavage site in the antisense strand may also change according to the length of the duplex region of the dsRNAi agent from the 5&#x2032;-end.</p><p id="p-0327" num="0316">The sense strand of the dsRNAi agent may contain at least one motif of three identical modifications on three consecutive nucleotides at the cleavage site of the strand; and the antisense strand may have at least one motif of three identical modifications on three consecutive nucleotides at or near the cleavage site of the strand. When the sense strand and the antisense strand form a dsRNA duplex, the sense strand and the antisense strand can be so aligned that one motif of the three nucleotides on the sense strand and one motif of the three nucleotides on the antisense strand have at least one nucleotide overlap, i.e., at least one of the three nucleotides of the motif in the sense strand forms a base pair with at least one of the three nucleotides of the motif in the antisense strand. Alternatively, at least two nucleotides may overlap, or all three nucleotides may overlap.</p><p id="p-0328" num="0317">In some embodiments, the sense strand of the dsRNAi agent may contain more than one motif of three identical modifications on three consecutive nucleotides. The first motif may occur at or near the cleavage site of the strand and the other motifs may be a wing modification. The term &#x201c;wing modification&#x201d; herein refers to a motif occurring at another portion of the strand that is separated from the motif at or near the cleavage site of the same strand. The wing modification is either adjacent to the first motif or is separated by at least one or more nucleotides. When the motifs are immediately adjacent to each other then the chemistries of the motifs are distinct from each other, and when the motifs are separated by one or more nucleotide than the chemistries can be the same or different. Two or more wing modifications may be present. For instance, when two wing modifications are present, each wing modification may occur at one end relative to the first motif which is at or near cleavage site or on either side of the lead motif.</p><p id="p-0329" num="0318">Like the sense strand, the antisense strand of the dsRNAi agent may contain more than one motif of three identical modifications on three consecutive nucleotides, with at least one of the motifs occurring at or near the cleavage site of the strand. This antisense strand may also contain one or more wing modifications in an alignment similar to the wing modifications that may be present on the sense strand.</p><p id="p-0330" num="0319">In some embodiments, the wing modification on the sense strand or antisense strand of the dsRNAi agent typically does not include the first one or two terminal nucleotides at the 3&#x2032;-end, 5&#x2032;-end, or both ends of the strand.</p><p id="p-0331" num="0320">In other embodiments, the wing modification on the sense strand or antisense strand of the dsRNAi agent typically does not include the first one or two paired nucleotides within the duplex region at the 3&#x2032;-end, 5&#x2032;-end, or both ends of the strand.</p><p id="p-0332" num="0321">When the sense strand and the antisense strand of the dsRNAi agent each contain at least one wing modification, the wing modifications may fall on the same end of the duplex region, and have an overlap of one, two, or three nucleotides.</p><p id="p-0333" num="0322">When the sense strand and the antisense strand of the dsRNAi agent each contain at least two wing modifications, the sense strand and the antisense strand can be so aligned that two modifications each from one strand fall on one end of the duplex region, having an overlap of one, two, or three nucleotides; two modifications each from one strand fall on the other end of the duplex region, having an overlap of one, two or three nucleotides; two modifications one strand fall on each side of the lead motif, having an overlap of one, two or three nucleotides in the duplex region.</p><p id="p-0334" num="0323">In some embodiments, every nucleotide in the sense strand and antisense strand of the dsRNAi agent, including the nucleotides that are part of the motifs, may be modified. Each nucleotide may be modified with the same or different modification which can include one or more alteration of one or both of the non-linking phosphate oxygens or of one or more of the linking phosphate oxygens; alteration of a constituent of the ribose sugar, e.g., of the 2&#x2032;-hydroxyl on the ribose sugar; wholesale replacement of the phosphate moiety with &#x201c;dephospho&#x201d; linkers; modification or replacement of a naturally occurring base; and replacement or modification of the ribose-phosphate backbone.</p><p id="p-0335" num="0324">As nucleic acids are polymers of subunits, many of the modifications occur at a position which is repeated within a nucleic acid, e.g., a modification of a base, or a phosphate moiety, or a non-linking O of a phosphate moiety. In some cases, the modification will occur at all of the subject positions in the nucleic acid but in many cases it will not. By way of example, a modification may only occur at a 3&#x2032;- or 5&#x2032; terminal position, may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand. A modification may occur in a double strand region, a single strand region, or in both. A modification may occur only in the double strand region of an RNA or may only occur in a single strand region of a RNA. For example, a phosphorothioate modification at a non-linking O position may only occur at one or both termini, may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand, or may occur in double strand and single strand regions, particularly at termini. The 5&#x2032;-end or ends can be phosphorylated.</p><p id="p-0336" num="0325">It may be possible, e.g., to enhance stability, to include particular bases in overhangs, or to include modified nucleotides or nucleotide surrogates, in single strand overhangs, e.g., in a 5&#x2032;- or 3&#x2032;-overhang, or in both. For example, it can be desirable to include purine nucleotides in overhangs. In some embodiments all or some of the bases in a 3&#x2032;- or 5&#x2032;-overhang may be modified, e.g., with a modification described herein. Modifications can include, e.g., the use of modifications at the 2&#x2032; position of the ribose sugar with modifications that are known in the art, e.g., the use of deoxyribonucleotides, 2&#x2032;-deoxy-2&#x2032;-fluoro (2&#x2032;-F) or 2&#x2032;-O-methyl modified instead of the ribosugar of the nucleobase, and modifications in the phosphate group, e.g., phosphorothioate modifications. Overhangs need not be homologous with the target sequence.</p><p id="p-0337" num="0326">In some embodiments, each residue of the sense strand and antisense strand is independently modified with LNA, CRN, cET, UNA, HNA, CeNA, 2&#x2032;-methoxyethyl, 2&#x2032;-O-methyl, 2&#x2032;-O-allyl, 2&#x2032;-C-allyl, 2&#x2032;-deoxy, 2&#x2032;-hydroxyl, or 2&#x2032;-fluoro. The strands can contain more than one modification. In one embodiment, each residue of the sense strand and antisense strand is independently modified with 2&#x2032;-O-methyl or 2&#x2032;-fluoro.</p><p id="p-0338" num="0327">At least two different modifications are typically present on the sense strand and antisense strand. Those two modifications may be the 2&#x2032;-O-methyl or 2&#x2032;-fluoro modifications, or others.</p><p id="p-0339" num="0328">In certain embodiments, the N<sub>a </sub>or N<sub>b </sub>comprise modifications of an alternating pattern. The term &#x201c;alternating motif&#x201d; as used herein refers to a motif having one or more modifications, each modification occurring on alternating nucleotides of one strand. The alternating nucleotide may refer to one per every other nucleotide or one per every three nucleotides, or a similar pattern. For example, if A, B and C each represent one type of modification to the nucleotide, the alternating motif can be &#x201c;ABABABABABAB . . . ,&#x201d; &#x201c;AABBAABBAABB . . . ,&#x201d; &#x201c;AABAABAABAAB . . . ,&#x201d; &#x201c;AAABAAABAAAB . . . ,&#x201d; &#x201c;AAABBBAAABBB . . . ,&#x201d; or &#x201c;ABCABCABCABC . . . ,&#x201d; etc.</p><p id="p-0340" num="0329">The type of modifications contained in the alternating motif may be the same or different. For example, if A, B, C, D each represent one type of modification on the nucleotide, the alternating pattern, i.e., modifications on every other nucleotide, may be the same, but each of the sense strand or antisense strand can be selected from several possibilities of modifications within the alternating motif such as &#x201c;ABABAB . . . &#x201d;, &#x201c;ACACAC . . . &#x201d; &#x201c;BDBDBD . . . &#x201d; or &#x201c;CDCDCD . . . ,&#x201d; etc.</p><p id="p-0341" num="0330">In some embodiments, the dsRNAi agent of the invention comprises the modification pattern for the alternating motif on the sense strand relative to the modification pattern for the alternating motif on the antisense strand is shifted. The shift may be such that the modified group of nucleotides of the sense strand corresponds to a differently modified group of nucleotides of the antisense strand and vice versa. For example, the sense strand when paired with the antisense strand in the dsRNA duplex, the alternating motif in the sense strand may start with &#x201c;ABABAB&#x201d; from 5&#x2032; to 3&#x2032; of the strand and the alternating motif in the antisense strand may start with &#x201c;BABABA&#x201d; from 5&#x2032; to 3&#x2032; of the strand within the duplex region. As another example, the alternating motif in the sense strand may start with &#x201c;AABBAABB&#x201d; from 5&#x2032; to 3&#x2032; of the strand and the alternating motif in the antisense strand may start with &#x201c;BBAABBAA&#x201d; from 5&#x2032; to 3&#x2032; of the strand within the duplex region, so that there is a complete or partial shift of the modification patterns between the sense strand and the antisense strand.</p><p id="p-0342" num="0331">In some embodiments, the dsRNAi agent comprises the pattern of the alternating motif of 2&#x2032;-O-methyl modification and 2&#x2032;-F modification on the sense strand initially has a shift relative to the pattern of the alternating motif of 2&#x2032;-O-methyl modification and 2&#x2032;-F modification on the antisense strand initially, i.e., the 2&#x2032;-O-methyl modified nucleotide on the sense strand base pairs with a 2&#x2032;-F modified nucleotide on the antisense strand and vice versa. The 1 position of the sense strand may start with the 2&#x2032;-F modification, and the 1 position of the antisense strand may start with the 2&#x2032;-O-methyl modification.</p><p id="p-0343" num="0332">The introduction of one or more motifs of three identical modifications on three consecutive nucleotides to the sense strand or antisense strand interrupts the initial modification pattern present in the sense strand or antisense strand. This interruption of the modification pattern of the sense or antisense strand by introducing one or more motifs of three identical modifications on three consecutive nucleotides to the sense or antisense strand may enhance the gene silencing activity against the target gene.</p><p id="p-0344" num="0333">In some embodiments, when the motif of three identical modifications on three consecutive nucleotides is introduced to any of the strands, the modification of the nucleotide next to the motif is a different modification than the modification of the motif. For example, the portion of the sequence containing the motif is &#x201c; . . . N<sub>a</sub>YYYN<sub>b </sub>. . . ,&#x201d; where &#x201c;Y&#x201d; represents the modification of the motif of three identical modifications on three consecutive nucleotides, and &#x201c;N<sub>a</sub>&#x201d; and &#x201c;N<sub>b</sub>&#x201d; represent a modification to the nucleotide next to the motif &#x201c;YYY&#x201d; that is different than the modification of Y, and where N<sub>a </sub>and N<sub>b </sub>can be the same or different modifications. Alternatively, N<sub>a </sub>or N<sub>b </sub>may be present or absent when there is a wing modification present.</p><p id="p-0345" num="0334">The iRNA may further comprise at least one phosphorothioate or methylphosphonate internucleotide linkage. The phosphorothioate or methylphosphonate internucleotide linkage modification may occur on any nucleotide of the sense strand, antisense strand, or both strands in any position of the strand. For instance, the internucleotide linkage modification may occur on every nucleotide on the sense strand or antisense strand; each internucleotide linkage modification may occur in an alternating pattern on the sense strand or antisense strand; or the sense strand or antisense strand may contain both internucleotide linkage modifications in an alternating pattern. The alternating pattern of the internucleotide linkage modification on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the internucleotide linkage modification on the sense strand may have a shift relative to the alternating pattern of the internucleotide linkage modification on the antisense strand. In one embodiment, a double-stranded RNAi agent comprises 6-8 phosphorothioate internucleotide linkages. In some embodiments, the antisense strand comprises two phosphorothioate internucleotide linkages at the 5&#x2032;-end and two phosphorothioate internucleotide linkages at the 3&#x2032;-end, and the sense strand comprises at least two phosphorothioate internucleotide linkages at either the 5&#x2032;-end or the 3&#x2032;-end.</p><p id="p-0346" num="0335">In some embodiments, the dsRNAi agent comprises a phosphorothioate or methylphosphonate internucleotide linkage modification in the overhang region. For example, the overhang region may contain two nucleotides having a phosphorothioate or methylphosphonate internucleotide linkage between the two nucleotides. Internucleotide linkage modifications also may be made to link the overhang nucleotides with the terminal paired nucleotides within the duplex region. For example, at least 2, 3, 4, or all the overhang nucleotides may be linked through phosphorothioate or methylphosphonate internucleotide linkage, and optionally, there may be additional phosphorothioate or methylphosphonate internucleotide linkages linking the overhang nucleotide with a paired nucleotide that is next to the overhang nucleotide. For instance, there may be at least two phosphorothioate internucleotide linkages between the terminal three nucleotides, in which two of the three nucleotides are overhang nucleotides, and the third is a paired nucleotide next to the overhang nucleotide. These terminal three nucleotides may be at the 3&#x2032;-end of the antisense strand, the 3&#x2032;-end of the sense strand, the 5&#x2032;-end of the antisense strand, or the 5&#x2032;end of the antisense strand.</p><p id="p-0347" num="0336">In some embodiments, the 2-nucleotide overhang is at the 3&#x2032;-end of the antisense strand, and there are two phosphorothioate internucleotide linkages between the terminal three nucleotides, wherein two of the three nucleotides are the overhang nucleotides, and the third nucleotide is a paired nucleotide next to the overhang nucleotide. Optionally, the dsRNAi agent may additionally have two phosphorothioate internucleotide linkages between the terminal three nucleotides at both the 5&#x2032;-end of the sense strand and at the 5&#x2032;-end of the antisense strand.</p><p id="p-0348" num="0337">In one embodiment, the dsRNAi agent comprises mismatch(es) with the target, within the duplex, or combinations thereof. The mismatch may occur in the overhang region or the duplex region. The base pair may be ranked on the basis of their propensity to promote dissociation or melting (e.g., on the free energy of association or dissociation of a particular pairing, the simplest approach is to examine the pairs on an individual pair basis, though next neighbor or similar analysis can also be used). In terms of promoting dissociation: A:U is preferred over G:C; G:U is preferred over G:C; and I:C is preferred over G:C (I=inosine). Mismatches, e.g., non-canonical or other than canonical pairings (as described elsewhere herein) are preferred over canonical (A:T, A:U, G:C) pairings; and pairings which include a universal base are preferred over canonical pairings.</p><p id="p-0349" num="0338">In certain embodiments, the dsRNAi agent comprises at least one of the first 1, 2, 3, 4, or 5 base pairs within the duplex regions from the 5&#x2032;-end of the antisense strand independently selected from the group of: A:U, G:U, I:C, and mismatched pairs, e.g., non-canonical or other than canonical pairings or pairings which include a universal base, to promote the dissociation of the antisense strand at the 5&#x2032;-end of the duplex.</p><p id="p-0350" num="0339">In certain embodiments, the nucleotide at the 1 position within the duplex region from the 5&#x2032;-end in the antisense strand is selected from A, dA, dU, U, and dT. Alternatively, at least one of the first 1, 2, or 3 base pair within the duplex region from the 5&#x2032;-end of the antisense strand is an AU base pair. For example, the first base pair within the duplex region from the 5&#x2032;-end of the antisense strand is an AU base pair.</p><p id="p-0351" num="0340">In other embodiments, the nucleotide at the 3&#x2032;-end of the sense strand is deoxy-thymine (dT) or the nucleotide at the 3&#x2032;-end of the antisense strand is deoxy-thymine (dT). For example, there is a short sequence of deoxy-thymine nucleotides, for example, two dT nucleotides on the 3&#x2032;-end of the sense, antisense strand, or both strands.</p><p id="p-0352" num="0341">In certain embodiments, the sense strand sequence may be represented by formula (I):</p><p id="p-0353" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>p</sub>-N<sub>a</sub>-(XXX)<sub>i</sub>-N<sub>b</sub>-YYY-N<sub>b</sub>-(ZZZ)<sub>j</sub>-N<sub>a</sub>-<i>n</i><sub>q</sub>3&#x2032;&#x2003;&#x2003;(I)<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0354" num="0342">wherein:</p><p id="p-0355" num="0343">i and j are each independently 0 or 1;</p><p id="p-0356" num="0344">p and q are each independently 0-6;</p><p id="p-0357" num="0345">each N<sub>a </sub>independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;</p><p id="p-0358" num="0346">each N<sub>b </sub>independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;</p><p id="p-0359" num="0347">each n<sub>p </sub>and n<sub>q </sub>independently represent an overhang nucleotide;</p><p id="p-0360" num="0348">wherein Nb and Y do not have the same modification; and</p><p id="p-0361" num="0349">XXX, YYY, and ZZZ each independently represent one motif of three identical modifications on three consecutive nucleotides. Preferably YYY is all 2&#x2032;-F modified nucleotides.</p><p id="p-0362" num="0350">In some embodiments, the N<sub>a </sub>or N<sub>b </sub>comprises modifications of alternating pattern.</p><p id="p-0363" num="0351">In some embodiments, the YYY motif occurs at or near the cleavage site of the sense strand. For example, when the dsRNAi agent has a duplex region of 17-23 nucleotides in length, the YYY motif can occur at or the vicinity of the cleavage site (e.g.: can occur at positions 6, 7, 8; 7, 8, 9; 8, 9, 10; 9, 10, 11; 10, 11, 12; or 11, 12, 13) of the sense strand, the count starting from the first nucleotide, from the 5&#x2032;-end; or optionally, the count starting at the first paired nucleotide within the duplex region, from the 5&#x2032;-end.</p><p id="p-0364" num="0352">In one embodiment, i is 1 and j is 0, or i is 0 and j is 1, or both i and j are 1. The sense strand can therefore be represented by the following formulas:</p><p id="p-0365" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>p</sub>-N<sub>a</sub>-YYY-N<sub>b</sub>-ZZZ-N<sub>a</sub>-<i>n</i><sub>q</sub>3&#x2032;&#x2003;&#x2003;(Ib);<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0366" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>p</sub>-N<sub>a</sub>-XXX-N<sub>b</sub>-YYY-N<sub>a</sub>-<i>n</i><sub>q</sub>3&#x2032;&#x2003;&#x2003;(Ic); or<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0367" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>p</sub>-N<sub>a</sub>-XXX-N<sub>b</sub>-YYY-N<sub>b</sub>-ZZZ-N<sub>a</sub>-<i>n</i><sub>q</sub>3&#x2032;&#x2003;&#x2003;(Id).<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0368" num="0353">When the sense strand is represented by formula (Ib), N<sub>b </sub>represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N<sub>a </sub>independently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.</p><p id="p-0369" num="0354">When the sense strand is represented as formula (Ic), N<sub>b </sub>represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N<sub>a </sub>can independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.</p><p id="p-0370" num="0355">When the sense strand is represented as formula (Id), each N<sub>b </sub>independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Preferably, N<sub>b </sub>is 0, 1, 2, 3, 4, 5, or 6 Each N<sub>a </sub>can independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.</p><p id="p-0371" num="0356">Each of X, Y and Z may be the same or different from each other.</p><p id="p-0372" num="0357">In other embodiments, i is 0 and j is 0, and the sense strand may be represented by the formula:</p><p id="p-0373" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>p</sub>-N<sub>a</sub>-YYY-N<sub>a</sub>-<i>n</i><sub>q</sub>3&#x2032;&#x2003;&#x2003;(Ia).<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0374" num="0358">When the sense strand is represented by formula (Ia), each N<sub>a </sub>independently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.</p><p id="p-0375" num="0359">In one embodiment, the antisense strand sequence of the RNAi may be represented by formula (II):</p><p id="p-0376" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>q&#x2032;</sub>-N<sub>a</sub>&#x2032;-(Z&#x2032;Z&#x2032;Z&#x2032;)<sub>k</sub>-N<sub>b</sub>&#x2032;-Y&#x2032;Y&#x2032;Y&#x2032;-N<sub>b</sub>&#x2032;X&#x2032;X&#x2032;X&#x2032;)<sub>l</sub>-N&#x2032;<sub>a</sub>-<i>n</i><sub>p</sub>&#x2032;3&#x2032;&#x2003;&#x2003;(II)<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0377" num="0360">wherein:</p><p id="p-0378" num="0361">k and 1 are each independently 0 or 1;</p><p id="p-0379" num="0362">p&#x2032; and q&#x2032; are each independently 0-6;</p><p id="p-0380" num="0363">each N<sub>a</sub>&#x2032; independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;</p><p id="p-0381" num="0364">each N<sub>b</sub>&#x2032; independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;</p><p id="p-0382" num="0365">each n<sub>p</sub>&#x2032; and n<sub>q</sub>&#x2032; independently represent an overhang nucleotide;</p><p id="p-0383" num="0366">wherein N<sub>b</sub>&#x2032; and Y&#x2032; do not have the same modification; and</p><p id="p-0384" num="0367">X&#x2032;X&#x2032;X&#x2032;, Y&#x2032;Y&#x2032;Y&#x2032;, and Z&#x2032;Z&#x2032;Z&#x2032; each independently represent one motif of three identical modifications on three consecutive nucleotides.</p><p id="p-0385" num="0368">In some embodiments, the N<sub>a</sub>&#x2032; or N<sub>b</sub>&#x2032; comprises modifications of alternating pattern.</p><p id="p-0386" num="0369">The Y&#x2032;Y&#x2032;Y&#x2032; motif occurs at or near the cleavage site of the antisense strand. For example, when the dsRNAi agent has a duplex region of 17-23 nucleotides in length, the Y&#x2032;Y&#x2032;Y&#x2032; motif can occur at positions 9, 10, 11; 10, 11, 12; 11, 12, 13; 12, 13, 14; or 13, 14, 15 of the antisense strand, with the count starting from the first nucleotide, from the 5&#x2032;-end; or optionally, the count starting at the first paired nucleotide within the duplex region, from the 5&#x2032;-end. Preferably, the Y&#x2032;Y&#x2032;Y&#x2032; motif occurs at positions 11, 12, 13.</p><p id="p-0387" num="0370">In certain embodiments, Y&#x2032;Y&#x2032;Y&#x2032; motif is all 2&#x2032;-OMe modified nucleotides.</p><p id="p-0388" num="0371">In certain embodiments, k is 1 and 1 is 0, or k is 0 and 1 is 1, or both k and 1 are 1.</p><p id="p-0389" num="0372">The antisense strand can therefore be represented by the following formulas:</p><p id="p-0390" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>q</sub>&#x2032;-N<sub>a</sub>&#x2032;-Z&#x2032;Z&#x2032;Z&#x2032;-N<sub>b</sub>&#x2032;-Y&#x2032;Y&#x2032;Y&#x2032;-N<sub>a</sub>&#x2032;-<i>n</i><sub>p</sub>,3&#x2032;&#x2003;&#x2003;(IIb);<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0391" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>q</sub>&#x2032;-N<sub>a</sub>&#x2032;-Y&#x2032;Y&#x2032;Y&#x2032;-N<sub>b</sub>&#x2032;-X&#x2032;X&#x2032;X&#x2032;-<i>n</i><sub>p</sub>,3&#x2032;&#x2003;&#x2003;(IIc); or<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0392" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>q</sub>&#x2032;-N<sub>a</sub>&#x2032;-Z&#x2032;Z&#x2032;Z&#x2032;-N<sub>b</sub>&#x2032;-Y&#x2032;Y&#x2032;Y&#x2032;-N<sub>b</sub>&#x2032;-X&#x2032;X&#x2032;X&#x2032;-N<sub>a</sub>&#x2032;-<i>n</i><sub>p</sub>&#x2032;3&#x2032;&#x2003;&#x2003;(IId).<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0393" num="0373">When the antisense strand is represented by formula (IIb), N<sub>b</sub>&#x2032; represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N<sub>a</sub>&#x2032; independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.</p><p id="p-0394" num="0374">When the antisense strand is represented as formula (IIc), N<sub>b</sub>&#x2032; represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N<sub>a</sub>&#x2032; independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.</p><p id="p-0395" num="0375">When the antisense strand is represented as formula (IId), each N<sub>b</sub>&#x2032; independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N<sub>a</sub>&#x2032; independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Preferably, N<sub>b </sub>is 0, 1, 2, 3, 4, 5, or 6.</p><p id="p-0396" num="0376">In other embodiments, k is 0 and 1 is 0 and the antisense strand may be represented by the formula:</p><p id="p-0397" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>p</sub>,-N<sub>a</sub>&#x2032;-Y&#x2032;Y&#x2032;Y&#x2032;-N<sub>a</sub>&#x2032;-<i>n</i><sub>q&#x2032;</sub>,3&#x2032;&#x2003;&#x2003;(Ia).<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0398" num="0377">When the antisense strand is represented as formula (IIa), each N<sub>a</sub>&#x2032; independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Each of X&#x2032;, Y&#x2032; and Z&#x2032; may be the same or different from each other.</p><p id="p-0399" num="0378">Each nucleotide of the sense strand and antisense strand may be independently modified with LNA, CRN, UNA, cEt, HNA, CeNA, 2&#x2032;-methoxyethyl, 2&#x2032;-O-methyl, 2&#x2032;-O-allyl, 2&#x2032;-C-allyl, 2&#x2032;-hydroxyl, or 2&#x2032;-fluoro. For example, each nucleotide of the sense strand and antisense strand is independently modified with 2&#x2032;-O-methyl or 2&#x2032;-fluoro. Each X, Y, Z, X&#x2032;, Y&#x2032;, and Z&#x2032;, in particular, may represent a 2&#x2032;-O-methyl modification or a 2&#x2032;-fluoro modification.</p><p id="p-0400" num="0379">In some embodiments, the sense strand of the dsRNAi agent may contain YYY motif occurring at 9, 10, and 11 positions of the strand when the duplex region is 21 nt, the count starting from the first nucleotide from the 5&#x2032;-end, or optionally, the count starting at the first paired nucleotide within the duplex region, from the 5&#x2032;-end; and Y represents 2&#x2032;-F modification. The sense strand may additionally contain XXX motif or ZZZ motifs as wing modifications at the opposite end of the duplex region; and XXX and ZZZ each independently represents a 2&#x2032;-OMe modification or 2&#x2032;-F modification.</p><p id="p-0401" num="0380">In some embodiments the antisense strand may contain Y&#x2032;Y&#x2032;Y&#x2032; motif occurring at positions 11, 12, 13 of the strand, the count starting from the first nucleotide from the 5&#x2032;-end, or optionally, the count starting at the first paired nucleotide within the duplex region, from the 5&#x2032;-end; and Y&#x2032; represents 2&#x2032;-O-methyl modification. The antisense strand may additionally contain X&#x2032;X&#x2032;X&#x2032; motif or Z&#x2032;Z&#x2032;Z&#x2032; motifs as wing modifications at the opposite end of the duplex region; and X&#x2032;X&#x2032;X&#x2032; and Z&#x2032;Z&#x2032;Z&#x2032; each independently represents a 2&#x2032;-OMe modification or 2&#x2032;-F modification.</p><p id="p-0402" num="0381">The sense strand represented by any one of the above formulas (Ia), (Ib), (Ic), and (Id) forms a duplex with a antisense strand being represented by any one of formulas (IIa), (IIb), (IIc), and (IId), respectively.</p><p id="p-0403" num="0382">Accordingly, the dsRNAi agents for use in the methods of the invention may comprise a sense strand and an antisense strand, each strand having 14 to 30 nucleotides, the iRNA duplex represented by formula (III):</p><p id="p-0404" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>sense: 5<i>&#x2032;n</i><sub>p</sub>-N<sub>a</sub>-(XXX)<sub>i</sub>-N<sub>b</sub>-YYY-N<sub>b</sub>-(ZZZ)<sub>j</sub>-N<sub>a</sub>-<i>n</i><sub>q</sub>3&#x2032;<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0405" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>antisense: 3<i>&#x2032;n</i><sub>p</sub>&#x2032;-N<sub>a</sub>&#x2032;-(X&#x2032;X&#x2032;X&#x2032;)<sub>k</sub>-N<sub>b</sub>&#x2032;-Y&#x2032;Y&#x2032;Y&#x2032;-N<sub>b</sub>&#x2032;-(Z&#x2032;Z&#x2032;Z&#x2032;)<sub>l</sub>N<sub>a</sub>&#x2032;-<i>n</i><sub>q</sub>&#x2032;5&#x2032;&#x2003;&#x2003;(III)<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0406" num="0383">wherein:</p><p id="p-0407" num="0384">i, j, k, and 1 are each independently 0 or 1;</p><p id="p-0408" num="0385">p, p&#x2032;, q, and q&#x2032; are each independently 0-6;</p><p id="p-0409" num="0386">each N<sub>a </sub>and N<sub>a</sub>&#x2032; independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides; each N<sub>b </sub>and N<sub>b</sub>&#x2032; independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;</p><p id="p-0410" num="0387">wherein each n<sub>p</sub>&#x2032;, n<sub>p</sub>, n<sub>q</sub>&#x2032;, and n<sub>q</sub>, each of which may or may not be present, independently represents an overhang nucleotide; and</p><p id="p-0411" num="0388">XXX, YYY, ZZZ, X&#x2032;X&#x2032;X&#x2032;, Y&#x2032;Y&#x2032;Y&#x2032;, and Z&#x2032;Z&#x2032;Z&#x2032; each independently represent one motif of three identical modifications on three consecutive nucleotides.</p><p id="p-0412" num="0389">In one embodiment, i is 0 and j is 0; or i is 1 and j is 0; or i is 0 and j is 1; or both i and j are 0; or both i and j are 1. In another embodiment, k is 0 and 1 is 0; or k is 1 and 1 is 0; k is 0 and 1 is 1; or both k and 1 are 0; or both k and 1 are 1.</p><p id="p-0413" num="0390">Exemplary combinations of the sense strand and antisense strand forming an iRNA duplex include the formulas below:</p><p id="p-0414" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>p</sub>-N<sub>a</sub>-YYY-N<sub>a</sub>-<i>n</i><sub>q</sub>3&#x2032;<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0415" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>3<i>&#x2032;n</i><sub>p</sub>&#x2032;-N<sub>a</sub>&#x2032;-Y&#x2032;Y&#x2032;Y&#x2032;-N<sub>a</sub><i>&#x2032;n</i><sub>q</sub>&#x2032;5&#x2032;&#x2003;&#x2003;(IIIa)<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0416" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>p</sub>-N<sub>a</sub>-YYY-N<sub>b</sub>-ZZZ-N<sub>a</sub>-<i>n</i><sub>q</sub>3&#x2032;<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0417" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>3<i>&#x2032;n</i><sub>p</sub>&#x2032;-N<sub>a</sub>&#x2032;-Y&#x2032;Y&#x2032;Y&#x2032;-N<sub>b</sub>&#x2032;-Z&#x2032;Z&#x2032;Z&#x2032;-N<sub>a</sub><i>&#x2032;n</i><sub>q</sub>&#x2032;5&#x2032;&#x2003;&#x2003;(IIIb)<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0418" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>p</sub>-N<sub>a</sub>-XXX-N<sub>b</sub>-YYY-N<sub>a</sub>-<i>n</i><sub>q</sub>3&#x2032;<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0419" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>3<i>&#x2032;n</i><sub>p</sub>&#x2032;-N<sub>a</sub>&#x2032;-X&#x2032;X&#x2032;X&#x2032;-N<sub>b</sub>&#x2032;-Y&#x2032;Y&#x2032;Y&#x2032;-N<sub>a</sub>&#x2032;-<i>n</i><sub>q</sub>&#x2032;5&#x2032;)<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0420" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>5<i>&#x2032;n</i><sub>p</sub>-N<sub>a</sub>-XXX-N<sub>b</sub>-YYY-N<sub>b</sub>-ZZZ-N<sub>a</sub>-<i>n</i><sub>q</sub>3&#x2032;<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0421" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>3<i>&#x2032;n</i><sub>p</sub>&#x2032;-N<sub>a</sub>&#x2032;-X&#x2032;X&#x2032;X&#x2032;-N<sub>b</sub>&#x2032;-Y&#x2032;Y&#x2032;Y&#x2032;-N<sub>b</sub>&#x2032;-Z&#x2032;Z&#x2032;Z&#x2032;-N<sub>a</sub>-<i>n</i><sub>q</sub>&#x2032;5&#x2032;&#x2003;&#x2003;(IIId)<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0422" num="0391">When the dsRNAi agent is represented by formula (IIIa), each N<sub>a </sub>independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.</p><p id="p-0423" num="0392">When the dsRNAi agent is represented by formula (IIIb), each N<sub>b </sub>independently represents an oligonucleotide sequence comprising 1-10, 1-7, 1-5, or 1-4 modified nucleotides. Each N<sub>a </sub>independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.</p><p id="p-0424" num="0393">When the dsRNAi agent is represented as formula (IIc), each N<sub>b</sub>, N<sub>b</sub>&#x2032; independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N<sub>a </sub>independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.</p><p id="p-0425" num="0394">When the dsRNAi agent is represented as formula (IIId), each N<sub>b</sub>, N<sub>b</sub>&#x2032; independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N<sub>a</sub>, N<sub>a</sub>&#x2032; independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Each of N<sub>a</sub>, N<sub>a</sub>&#x2032;, N<sub>b</sub>, and N<sub>b</sub>&#x2032; independently comprises modifications of alternating pattern.</p><p id="p-0426" num="0395">Each of X, Y, and Z in formulas (III), (IIIa), (IIIb), (IIIc), and (IIId) may be the same or different from each other.</p><p id="p-0427" num="0396">When the dsRNAi agent is represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), at least one of the Y nucleotides may form a base pair with one of the Y&#x2032; nucleotides. Alternatively, at least two of the Y nucleotides form base pairs with the corresponding Y&#x2032; nucleotides; or all three of the Y nucleotides all form base pairs with the corresponding Y&#x2032; nucleotides.</p><p id="p-0428" num="0397">When the dsRNAi agent is represented by formula (IIIb) or (IIId), at least one of the Z nucleotides may form a base pair with one of the Z&#x2032; nucleotides. Alternatively, at least two of the Z nucleotides form base pairs with the corresponding Z&#x2032; nucleotides; or all three of the Z nucleotides all form base pairs with the corresponding Z&#x2032; nucleotides.</p><p id="p-0429" num="0398">When the dsRNAi agent is represented as formula (IIc) or (IIId), at least one of the X nucleotides may form a base pair with one of the X&#x2032; nucleotides. Alternatively, at least two of the X nucleotides form base pairs with the corresponding X&#x2032; nucleotides; or all three of the X nucleotides all form base pairs with the corresponding X&#x2032; nucleotides.</p><p id="p-0430" num="0399">In certain embodiments, the modification on the Y nucleotide is different than the modification on the Y&#x2032; nucleotide, the modification on the Z nucleotide is different than the modification on the Z&#x2032; nucleotide, or the modification on the X nucleotide is different than the modification on the X&#x2032; nucleotide.</p><p id="p-0431" num="0400">In certain embodiments, when the dsRNAi agent is represented by formula (IIId), the N<sub>a </sub>modifications are 2&#x2032;-O-methyl or 2&#x2032;-fluoro modifications. In other embodiments, when the RNAi agent is represented by formula (IIId), the N<sub>a </sub>modifications are 2&#x2032;-O-methyl or 2&#x2032;-fluoro modifications and n<sub>p</sub>&#x2032;&#x3e;0 and at least one n<sub>p</sub>&#x2032; is linked to a neighboring nucleotide a via phosphorothioate linkage. In yet other embodiments, when the RNAi agent is represented by formula (IIId), the N<sub>a </sub>modifications are 2&#x2032;-O-methyl or 2&#x2032;-fluoro modifications, n<sub>p</sub>&#x2032;&#x3e;0 and at least one n<sub>p</sub>&#x2032; is linked to a neighboring nucleotide via phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker (described below). In other embodiments, when the RNAi agent is represented by formula (IIId), the N<sub>a </sub>modifications are 2&#x2032;-O-methyl or 2&#x2032;-fluoro modifications, n<sub>p</sub>&#x2032;&#x3e;0 and at least one n<sub>p</sub>&#x2032; is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.</p><p id="p-0432" num="0401">In some embodiments, when the dsRNAi agent is represented by formula (IIIa), the N<sub>a </sub>modifications are 2&#x2032;-O-methyl or 2&#x2032;-fluoro modifications, n<sub>p</sub>&#x2032;&#x3e;0 and at least one n<sub>p</sub>&#x2032; is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.</p><p id="p-0433" num="0402">In some embodiments, the dsRNAi agent is a multimer containing at least two duplexes represented by formula (III), (IIIa), (IIIb), (IIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.</p><p id="p-0434" num="0403">In some embodiments, the dsRNAi agent is a multimer containing three, four, five, six, or more duplexes represented by formula (III), (IIIa), (IIIb), (IIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.</p><p id="p-0435" num="0404">In one embodiment, two dsRNAi agents represented by at least one of formulas (III), (IIIa), (IIIb), (IIIc), and (IIId) are linked to each other at the 5&#x2032; end, and one or both of the 3&#x2032; ends, and are optionally conjugated to a ligand. Each of the agents can target the same gene or two different genes; or each of the agents can target same gene at two different target sites.</p><p id="p-0436" num="0405">In certain embodiments, an RNAi agent of the invention may contain a low number of nucleotides containing a 2&#x2032;-fluoro modification, e.g., 10 or fewer nucleotides with 2&#x2032;-fluoro modification. For example, the RNAi agent may contain 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 nucleotides with a 2&#x2032;-fluoro modification. In a specific embodiment, the RNAi agent of the invention contains 10 nucleotides with a 2&#x2032;-fluoro modification, e.g., 4 nucleotides with a 2&#x2032;-fluoro modification in the sense strand and 6 nucleotides with a 2&#x2032;-fluoro modification in the antisense strand. In another specific embodiment, the RNAi agent of the invention contains 6 nucleotides with a 2&#x2032;-fluoro modification, e.g., 4 nucleotides with a 2&#x2032;-fluoro modification in the sense strand and 2 nucleotides with a 2&#x2032;-fluoro modification in the antisense strand.</p><p id="p-0437" num="0406">In other embodiments, an RNAi agent of the invention may contain an ultra low number of nucleotides containing a 2&#x2032;-fluoro modification, e.g., 2 or fewer nucleotides containing a 2&#x2032;-fluoro modification. For example, the RNAi agent may contain 2, 1 of 0 nucleotides with a 2&#x2032;-fluoro modification. In a specific embodiment, the RNAi agent may contain 2 nucleotides with a 2&#x2032;-fluoro modification, e.g., 0 nucleotides with a 2-fluoro modification in the sense strand and 2 nucleotides with a 2&#x2032;-fluoro modification in the antisense strand.</p><p id="p-0438" num="0407">Various publications describe multimeric iRNAs that can be used in the methods of the invention. Such publications include WO2007/091269, U.S. Pat. No. 7,858,769, WO2010/141511, WO2007/117686, WO2009/014887, and WO2011/031520 the entire contents of each of which are hereby incorporated herein by reference.</p><p id="p-0439" num="0408">As described in more detail below, the iRNA that contains conjugations of one or more carbohydrate moieties to an iRNA can optimize one or more properties of the iRNA. In many cases, the carbohydrate moiety will be attached to a modified subunit of the iRNA. For example, the ribose sugar of one or more ribonucleotide subunits of a iRNA can be replaced with another moiety, e.g., a non-carbohydrate (preferably cyclic) carrier to which is attached a carbohydrate ligand. A ribonucleotide subunit in which the ribose sugar of the subunit has been so replaced is referred to herein as a ribose replacement modification subunit (RRMS). A cyclic carrier may be a carbocyclic ring system, i.e., all ring atoms are carbon atoms, or a heterocyclic ring system, i.e., one or more ring atoms may be a heteroatom, e.g., nitrogen, oxygen, sulfur. The cyclic carrier may be a monocyclic ring system, or may contain two or more rings, e.g. fused rings. The cyclic carrier may be a fully saturated ring system, or it may contain one or more double bonds.</p><p id="p-0440" num="0409">The ligand may be attached to the polynucleotide via a carrier. The carriers include (i) at least one &#x201c;backbone attachment point,&#x201d; preferably two &#x201c;backbone attachment points&#x201d; and (ii) at least one &#x201c;tethering attachment point.&#x201d; A &#x201c;backbone attachment point&#x201d; as used herein refers to a functional group, e.g. a hydroxyl group, or generally, a bond available for, and that is suitable for incorporation of the carrier into the backbone, e.g., the phosphate, or modified phosphate, e.g., sulfur containing, backbone, of a ribonucleic acid. A &#x201c;tethering attachment point&#x201d; (TAP) in some embodiments refers to a constituent ring atom of the cyclic carrier, e.g., a carbon atom or a heteroatom (distinct from an atom which provides a backbone attachment point), that connects a selected moiety. The moiety can be, e.g., a carbohydrate, e.g. monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide. Optionally, the selected moiety is connected by an intervening tether to the cyclic carrier. Thus, the cyclic carrier will often include a functional group, e.g., an amino group, or generally, provide a bond, that is suitable for incorporation or tethering of another chemical entity, e.g., a ligand to the constituent ring.</p><p id="p-0441" num="0410">The iRNA may be conjugated to a ligand via a carrier, wherein the carrier can be cyclic group or acyclic group; preferably, the cyclic group is selected from pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolane, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl, and decalin; preferably, the acyclic group is a serinol backbone or diethanolamine backbone.</p><p id="p-0442" num="0411">In another embodiment of the invention, an iRNA agent comprises a sense strand and an antisense strand, each strand having 14 to 40 nucleotides. The RNAi agent may be represented by formula (L):</p><p id="p-0443" num="0000"><chemistry id="CHEM-US-00005" num="00005"><img id="EMI-C00005" he="35.98mm" wi="123.19mm" file="US20230002765A1-20230105-C00005.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0444" num="0000">In formula (L), B1, B2, B3, B1&#x2032;, B2&#x2032;, B3&#x2032;, and B4&#x2032; each are independently a nucleotide containing a modification selected from the group consisting of 2&#x2032;-O-alkyl, 2&#x2032;-substituted alkoxy, 2&#x2032;-substituted alkyl, 2&#x2032;-halo, ENA, and BNA/LNA. In one embodiment, B1, B2, B3, B1&#x2032;, B2&#x2032;, B3&#x2032;, and B4&#x2032; each contain 2&#x2032;-OMe modifications. In one embodiment, B1, B2, B3, B1&#x2032;, B2&#x2032;, B3&#x2032;, and B4&#x2032; each contain 2&#x2032;-OMe or 2&#x2032;-F modifications. In one embodiment, at least one of B1, B2, B3, B1&#x2032;, B2&#x2032;, B3&#x2032;, and B4&#x2032; contain 2&#x2032;-O-N-methylacetamido (2&#x2032;-O-NMA) modification.</p><p id="p-0445" num="0412">C1 is a thermally destabilizing nucleotide placed at a site opposite to the seed region of the antisense strand (i.e., at positions 2-8 of the 5&#x2032;-end of the antisense strand). For example, C1 is at a position of the sense strand that pairs with a nucleotide at positions 2-8 of the 5&#x2032;-end of the antisense strand. In one example, C1 is at position 15 from the 5&#x2032;-end of the sense strand. C1 nucleotide bears the thermally destabilizing modification which can include abasic modification; mismatch with the opposing nucleotide in the duplex; and sugar modification such as 2&#x2032;-deoxy modification or acyclic nucleotide e.g., unlocked nucleic acids (UNA) or glycerol nucleic acid (GNA). In one embodiment, C1 has thermally destabilizing modification selected from the group consisting of: i) mismatch with the opposing nucleotide in the antisense strand; ii) abasic modification selected from the group consisting of:</p><p id="p-0446" num="0000"><chemistry id="CHEM-US-00006" num="00006"><img id="EMI-C00006" he="63.67mm" wi="60.45mm" file="US20230002765A1-20230105-C00006.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0447" num="0000">and iii) sugar modification selected from the group consisting of:</p><p id="p-0448" num="0000"><chemistry id="CHEM-US-00007" num="00007"><img id="EMI-C00007" he="154.43mm" wi="74.93mm" file="US20230002765A1-20230105-C00007.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0449" num="0000">wherein B is a modified or unmodified nucleobase, R<sup>1 </sup>and R<sup>2 </sup>independently are H, halogen, OR<sub>3</sub>, or alkyl; and R<sub>3 </sub>is H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar. In one embodiment, the thermally destabilizing modification in C1 is a mismatch selected from the group consisting of G:G, G:A, G:U, G:T, A:A, A:C, C:C, C:U, C:T, U:U, T:T, and U:T; and optionally, at least one nucleobase in the mismatch pair is a 2&#x2032;-deoxy nucleobase. In one example, the thermally destabilizing modification in C1 is GNA or</p><p id="p-0450" num="0000"><chemistry id="CHEM-US-00008" num="00008"><img id="EMI-C00008" he="26.84mm" wi="22.78mm" file="US20230002765A1-20230105-C00008.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0451" num="0000">T1, T1&#x2032;, T2&#x2032;, and T3&#x2032; each independently represent a nucleotide comprising a modification providing the nucleotide a steric bulk that is less or equal to the steric bulk of a 2&#x2032;-OMe modification. A steric bulk refers to the sum of steric effects of a modification. Methods for determining steric effects of a modification of a nucleotide are known to one skilled in the art. The modification can be at the 2&#x2032; position of a ribose sugar of the nucleotide, or a modification to a non-ribose nucleotide, acyclic nucleotide, or the backbone of the nucleotide that is similar or equivalent to the 2&#x2032; position of the ribose sugar, and provides the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2&#x2032;-OMe modification. For example, T1, T1&#x2032;, T2&#x2032;, and T3&#x2032; are each independently selected from DNA, RNA, LNA, 2&#x2032;-F, and 2&#x2032;-F-5&#x2032;-methyl. In one embodiment, T1 is DNA. In one embodiment, T1&#x2032; is DNA, RNA or LNA. In one embodiment, T2&#x2032; is DNA or RNA. In one embodiment, T3&#x2032; is DNA or RNA.<br/>n<sup>1</sup>, n<sup>3</sup>, and q<sup>1 </sup>are independently 4 to 15 nucleotides in length.<br/>n<sup>5</sup>, q<sup>3</sup>, and q<sup>7 </sup>are independently 1-6 nucleotide(s) in length.<br/>n<sup>4</sup>, q<sup>2</sup>, and q<sup>6 </sup>are independently 1-3 nucleotide(s) in length; alternatively, n<sup>4 </sup>is 0.<br/>q<sup>5 </sup>is independently 0-10 nucleotide(s) in length.<br/>n<sup>2 </sup>and q<sup>4 </sup>are independently 0-3 nucleotide(s) in length.</p><p id="p-0452" num="0413">Alternatively, n<sup>4 </sup>is 0-3 nucleotide(s) in length.</p><p id="p-0453" num="0414">In one embodiment, n<sup>4 </sup>can be 0. In one example, n<sup>4 </sup>is 0, and q<sup>2 </sup>and q<sup>6 </sup>are 1. In another example, n<sup>4 </sup>is 0, and q<sup>2 </sup>and q<sup>6 </sup>are 1, with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand).</p><p id="p-0454" num="0415">In one embodiment, n<sup>4</sup>, q<sup>2</sup>, and q<sup>6 </sup>are each 1.</p><p id="p-0455" num="0416">In one embodiment, n<sup>2</sup>, n<sup>4</sup>, q<sup>2</sup>, q<sup>4</sup>, and q<sup>6 </sup>are each 1.</p><p id="p-0456" num="0417">In one embodiment, C1 is at position 14-17 of the 5&#x2032;-end of the sense strand, when the sense strand is 19-22 nucleotides in length, and n<sup>4 </sup>is 1. In one embodiment, C1 is at position 15 of the 5&#x2032;-end of the sense strand</p><p id="p-0457" num="0418">In one embodiment, T3&#x2032; starts at position 2 from the 5&#x2032; end of the antisense strand. In one example, T3&#x2032; is at position 2 from the 5&#x2032; end of the antisense strand and q<sup>6 </sup>is equal to 1.</p><p id="p-0458" num="0419">In one embodiment, T1&#x2032; starts at position 14 from the 5&#x2032; end of the antisense strand. In one example, T1&#x2032; is at position 14 from the 5&#x2032; end of the antisense strand and q<sup>2 </sup>is equal to 1.</p><p id="p-0459" num="0420">In an exemplary embodiment, T3&#x2032; starts from position 2 from the 5&#x2032; end of the antisense strand and T1&#x2032; starts from position 14 from the 5&#x2032; end of the antisense strand. In one example, T3&#x2032; starts from position 2 from the 5&#x2032; end of the antisense strand and q<sup>6 </sup>is equal to 1 and T1&#x2032; starts from position 14 from the 5&#x2032; end of the antisense strand and q<sup>2 </sup>is equal to 1.</p><p id="p-0460" num="0421">In one embodiment, T1&#x2032; and T3&#x2032; are separated by 11 nucleotides in length (i.e. not counting the T1&#x2032; and T3&#x2032; nucleotides).</p><p id="p-0461" num="0422">In one embodiment, T1&#x2032; is at position 14 from the 5&#x2032; end of the antisense strand. In one example, T1&#x2032; is at position 14 from the 5&#x2032; end of the antisense strand and q<sup>2 </sup>is equal to 1, and the modification at the 2&#x2032; position or positions in a non-ribose, acyclic or backbone that provide less steric bulk than a 2&#x2032;-OMe ribose.</p><p id="p-0462" num="0423">In one embodiment, T3&#x2032; is at position 2 from the 5&#x2032; end of the antisense strand. In one example, T3&#x2032; is at position 2 from the 5&#x2032; end of the antisense strand and q<sup>6 </sup>is equal to 1, and the modification at the 2&#x2032; position or positions in a non-ribose, acyclic or backbone that provide less than or equal to steric bulk than a 2&#x2032;-OMe ribose.</p><p id="p-0463" num="0424">In one embodiment, T1 is at the cleavage site of the sense strand. In one example, T1 is at position 11 from the 5&#x2032; end of the sense strand, when the sense strand is 19-22 nucleotides in length, and n<sup>2 </sup>is 1. In an exemplary embodiment, T1 is at the cleavage site of the sense strand at position 11 from the 5&#x2032; end of the sense strand, when the sense strand is 19-22 nucleotides in length, and n<sup>2 </sup>is 1, In one embodiment, T2&#x2032; starts at position 6 from the 5&#x2032; end of the antisense strand. In one example, T2&#x2032; is at positions 6-10 from the 5&#x2032; end of the antisense strand, and q<sup>4 </sup>is 1.</p><p id="p-0464" num="0425">In an exemplary embodiment, T1 is at the cleavage site of the sense strand, for instance, at position 11 from the 5&#x2032; end of the sense strand, when the sense strand is 19-22 nucleotides in length, and n<sup>2 </sup>is 1; T1&#x2032; is at position 14 from the 5&#x2032; end of the antisense strand, and q<sup>2 </sup>is equal to 1, and the modification to T1&#x2032; is at the 2&#x2032; position of a ribose sugar or at positions in a non-ribose, acyclic or backbone that provide less steric bulk than a 2&#x2032;-OMe ribose; T2&#x2032; is at positions 6-10 from the 5&#x2032; end of the antisense strand, and q<sup>4 </sup>is 1; and T3&#x2032; is at position 2 from the 5&#x2032; end of the antisense strand, and q<sup>6 </sup>is equal to 1, and the modification to T3&#x2032; is at the 2&#x2032; position or at positions in a non-ribose, acyclic or backbone that provide less than or equal to steric bulk than a 2&#x2032;-OMe ribose.</p><p id="p-0465" num="0426">In one embodiment, T2&#x2032; starts at position 8 from the 5&#x2032; end of the antisense strand. In one example, T2&#x2032; starts at position 8 from the 5&#x2032; end of the antisense strand, and q<sup>4 </sup>is 2.</p><p id="p-0466" num="0427">In one embodiment, T2&#x2032; starts at position 9 from the 5&#x2032; end of the antisense strand. In one example, T2&#x2032; is at position 9 from the 5&#x2032; end of the antisense strand, and q<sup>4 </sup>is 1.</p><p id="p-0467" num="0428">In one embodiment, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 1, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 6, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand).</p><p id="p-0468" num="0429">In one embodiment, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 1, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 6, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand).</p><p id="p-0469" num="0430">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1.</p><p id="p-0470" num="0431">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand).</p><p id="p-0471" num="0432">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 6, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 7, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1.</p><p id="p-0472" num="0433">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 6, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 7, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand).</p><p id="p-0473" num="0434">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 1, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 6, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1.</p><p id="p-0474" num="0435">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 1, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 6, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand).</p><p id="p-0475" num="0436">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 5, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 1, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; optionally with at least 2 additional TT at the 3&#x2032;-end of the antisense strand.</p><p id="p-0476" num="0000">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 5, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 1, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; optionally with at least 2 additional TT at the 3&#x2032;-end of the antisense strand; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand).</p><p id="p-0477" num="0437">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1.</p><p id="p-0478" num="0438">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5&#x2032;-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end).</p><p id="p-0479" num="0439">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1.</p><p id="p-0480" num="0440">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand).</p><p id="p-0481" num="0441">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1.</p><p id="p-0482" num="0442">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand).</p><p id="p-0483" num="0443">The RNAi agent can comprise a phosphorus-containing group at the 5&#x2032;-end of the sense strand or antisense strand. The 5&#x2032;-end phosphorus-containing group can be 5&#x2032;-end phosphate (5&#x2032;-P), 5&#x2032;-end phosphorothioate (5&#x2032;-PS), 5&#x2032;-end phosphorodithioate (5&#x2032;-PS<sub>2</sub>), 5&#x2032;-end vinylphosphonate (5&#x2032;-VP), 5&#x2032;-end methylphosphonate (MePhos), or 5&#x2032;-deoxy-5&#x2032;-C-malonyl</p><p id="p-0484" num="0000"><chemistry id="CHEM-US-00009" num="00009"><img id="EMI-C00009" he="24.55mm" wi="36.58mm" file="US20230002765A1-20230105-C00009.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0485" num="0000">When the 5&#x2032;-end phosphorus-containing group is 5&#x2032;-end vinylphosphonate (5&#x2032;-VP), the 5&#x2032;-VP can be either 5&#x2032;-E-VP isomer (i.e., trans-vinylphosphate,</p><p id="p-0486" num="0000"><chemistry id="CHEM-US-00010" num="00010"><img id="EMI-C00010" he="33.27mm" wi="28.36mm" file="US20230002765A1-20230105-C00010.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0487" num="0000">5&#x2032;-Z-VP isomer (i.e., cis-vinylphosphate,</p><p id="p-0488" num="0000"><chemistry id="CHEM-US-00011" num="00011"><img id="EMI-C00011" he="25.48mm" wi="32.43mm" file="US20230002765A1-20230105-C00011.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0489" num="0000">or mixtures thereof.<br/>In one embodiment, the RNAi agent comprises a phosphorus-containing group at the 5&#x2032;-end of the sense strand. In one embodiment, the RNAi agent comprises a phosphorus-containing group at the 5&#x2032;-end of the antisense strand.</p><p id="p-0490" num="0444">In one embodiment, the RNAi agent comprises a 5&#x2032;-P. In one embodiment, the RNAi agent comprises a 5&#x2032;-P in the antisense strand.</p><p id="p-0491" num="0445">In one embodiment, the RNAi agent comprises a 5&#x2032;-PS. In one embodiment, the RNAi agent comprises a 5&#x2032;-PS in the antisense strand.</p><p id="p-0492" num="0446">In one embodiment, the RNAi agent comprises a 5&#x2032;-VP. In one embodiment, the RNAi agent comprises a 5&#x2032;-VP in the antisense strand. In one embodiment, the RNAi agent comprises a 5&#x2032;-E-VP in the antisense strand. In one embodiment, the RNAi agent comprises a 5&#x2032;-Z-VP in the antisense strand.</p><p id="p-0493" num="0447">In one embodiment, the RNAi agent comprises a 5&#x2032;-PS<sub>2</sub>. In one embodiment, the RNAi agent comprises a 5&#x2032;-PS<sub>2 </sub>in the antisense strand.</p><p id="p-0494" num="0448">In one embodiment, the RNAi agent comprises a 5&#x2032;-PS<sub>2</sub>. In one embodiment, the RNAi agent comprises a 5&#x2032;-deoxy-5&#x2032;-C-malonyl in the antisense strand.</p><p id="p-0495" num="0000">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>1 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>5 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-PS.</p><p id="p-0496" num="0449">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>1 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>5 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-P.</p><p id="p-0497" num="0450">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-VP. The 5&#x2032;-VP may be 5&#x2032;-E-VP, 5&#x2032;-Z-VP, or combination thereof.</p><p id="p-0498" num="0451">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-PS<sub>2</sub>.</p><p id="p-0499" num="0452">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-deoxy-5&#x2032;-C-malonyl.</p><p id="p-0500" num="0453">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-P.</p><p id="p-0501" num="0454">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-PS.</p><p id="p-0502" num="0455">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-VP. The 5&#x2032;-VP may be 5&#x2032;-E-VP, 5&#x2032;-Z-VP, or combination thereof.</p><p id="p-0503" num="0000">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-PS<sub>2</sub>.</p><p id="p-0504" num="0456">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-deoxy-5&#x2032;-C-malonyl.</p><p id="p-0505" num="0457">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-P.</p><p id="p-0506" num="0458">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1. The dsRNA agent also comprises a 5&#x2032;-PS.</p><p id="p-0507" num="0459">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-VP. The 5&#x2032;-VP may be 5&#x2032;-E-VP, 5&#x2032;-Z-VP, or combination thereof.</p><p id="p-0508" num="0460">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-PS<sub>2</sub>.</p><p id="p-0509" num="0461">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-deoxy-5&#x2032;-C-malonyl.</p><p id="p-0510" num="0462">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end). The RNAi agent also comprises a 5&#x2032;-P.</p><p id="p-0511" num="0463">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end). The RNAi agent also comprises a 5&#x2032;-PS.</p><p id="p-0512" num="0464">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end). The RNAi agent also comprises a 5&#x2032;-VP. The 5&#x2032;-VP may be 5&#x2032;-E-VP, 5&#x2032;-Z-VP, or combination thereof.</p><p id="p-0513" num="0465">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end). The RNAi agent also comprises a 5&#x2032;-PS<sub>2</sub>.</p><p id="p-0514" num="0466">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end). The RNAi agent also comprises a 5&#x2032;-deoxy-5&#x2032;-C-malonyl.</p><p id="p-0515" num="0000">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-P.</p><p id="p-0516" num="0467">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-PS.</p><p id="p-0517" num="0468">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-VP. The 5&#x2032;-VP may be 5&#x2032;-E-VP, 5&#x2032;-Z-VP, or combination thereof.</p><p id="p-0518" num="0000">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1. The dsRNAi RNA agent also comprises a 5&#x2032;-PS<sub>2</sub>.</p><p id="p-0519" num="0469">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-deoxy-5&#x2032;-C-malonyl.</p><p id="p-0520" num="0470">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-P.</p><p id="p-0521" num="0471">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-PS.</p><p id="p-0522" num="0472">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-VP. The 5&#x2032;-VP may be 5&#x2032;-E-VP, 5&#x2032;-Z-VP, or combination thereof.</p><p id="p-0523" num="0473">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-PS<sub>2</sub>.</p><p id="p-0524" num="0474">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-deoxy-5&#x2032;-C-malonyl.</p><p id="p-0525" num="0475">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-P.</p><p id="p-0526" num="0476">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-PS.</p><p id="p-0527" num="0477">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-VP. The 5&#x2032;-VP may be 5&#x2032;-E-VP, 5&#x2032;-Z-VP, or combination thereof.</p><p id="p-0528" num="0478">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-PS<sub>2</sub>.</p><p id="p-0529" num="0479">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1. The RNAi agent also comprises a 5&#x2032;-deoxy-5&#x2032;-C-malonyl.</p><p id="p-0530" num="0480">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-P.</p><p id="p-0531" num="0481">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-PS.</p><p id="p-0532" num="0482">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-VP. The 5&#x2032;-VP may be 5&#x2032;-E-VP, 5&#x2032;-Z-VP, or combination thereof.</p><p id="p-0533" num="0483">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-PS<sub>2</sub>.</p><p id="p-0534" num="0484">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-deoxy-5&#x2032;-C-malonyl.</p><p id="p-0535" num="0485">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-P and a targeting ligand. In one embodiment, the 5&#x2032;-P is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0536" num="0486">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-PS and a targeting ligand. In one embodiment, the 5&#x2032;-PS is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0537" num="0487">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-VP (e.g., a 5&#x2032;-E-VP, 5&#x2032;-Z-VP, or combination thereof), and a targeting ligand.</p><p id="p-0538" num="0488">In one embodiment, the 5&#x2032;-VP is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0539" num="0489">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-PS<sub>2 </sub>and a targeting ligand. In one embodiment, the 5&#x2032;-PS<sub>2 </sub>is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0540" num="0490">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-deoxy-5&#x2032;-C-malonyl and a targeting ligand. In one embodiment, the 5&#x2032;-deoxy-5&#x2032;-C-malonyl is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0541" num="0491">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end). The RNAi agent also comprises a 5&#x2032;-P and a targeting ligand. In one embodiment, the 5&#x2032;-P is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0542" num="0492">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end). The RNAi agent also comprises a 5&#x2032;-PS and a targeting ligand. In one embodiment, the 5&#x2032;-PS is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0543" num="0493">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end). The RNAi agent also comprises a 5&#x2032;-VP (e.g., a 5&#x2032;-E-VP, 5&#x2032;-Z-VP, or combination thereof) and a targeting ligand. In one embodiment, the 5&#x2032;-VP is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0544" num="0494">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end). The RNAi agent also comprises a 5&#x2032;-PS<sub>2 </sub>and a targeting ligand. In one embodiment, the 5&#x2032;-PS<sub>2 </sub>is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0545" num="0495">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-OMe, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end). The RNAi agent also comprises a 5&#x2032;-deoxy-5&#x2032;-C-malonyl and a targeting ligand. In one embodiment, the 5&#x2032;-deoxy-5&#x2032;-C-malonyl is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0546" num="0496">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-P and a targeting ligand. In one embodiment, the 5&#x2032;-P is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0547" num="0497">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-PS and a targeting ligand. In one embodiment, the 5&#x2032;-PS is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0548" num="0498">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-VP (e.g., a 5&#x2032;-E-VP, 5&#x2032;-Z-VP, or combination thereof) and a targeting ligand. In one embodiment, the 5&#x2032;-VP is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0549" num="0499">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-PS<sub>2 </sub>and a targeting ligand. In one embodiment, the 5&#x2032;-PS<sub>2 </sub>is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0550" num="0500">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, T2&#x2032; is 2&#x2032;-F, q<sup>4 </sup>is 2, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 5, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-deoxy-5&#x2032;-C-malonyl and a targeting ligand. In one embodiment, the 5&#x2032;-deoxy-5&#x2032;-C-malonyl is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0551" num="0501">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-P and a targeting ligand. In one embodiment, the 5&#x2032;-P is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0552" num="0502">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-PS and a targeting ligand. In one embodiment, the 5&#x2032;-PS is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0553" num="0503">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-VP (e.g., a 5&#x2032;-E-VP, 5&#x2032;-Z-VP, or combination thereof) and a targeting ligand. In one embodiment, the 5&#x2032;-VP is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0554" num="0504">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-PS<sub>2 </sub>and a targeting ligand. In one embodiment, the 5&#x2032;-PS<sub>2 </sub>is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0555" num="0505">In one embodiment, B1 is 2&#x2032;-OMe or 2&#x2032;-F, n<sup>1 </sup>is 8, T1 is 2&#x2032;F, n<sup>2 </sup>is 3, B2 is 2&#x2032;-OMe, n<sup>3 </sup>is 7, n<sup>4 </sup>is 0, B3 is 2&#x2032;-OMe, n<sup>5 </sup>is 3, B1&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>1 </sup>is 9, T1&#x2032; is 2&#x2032;-F, q<sup>2 </sup>is 1, B2&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>3 </sup>is 4, q<sup>4 </sup>is 0, B3&#x2032; is 2&#x2032;-OMe or 2&#x2032;-F, q<sup>5 </sup>is 7, T3&#x2032; is 2&#x2032;-F, q<sup>6 </sup>is 1, B4&#x2032; is 2&#x2032;-F, and q<sup>7 </sup>is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5&#x2032;-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5&#x2032;-end of the antisense strand). The RNAi agent also comprises a 5&#x2032;-deoxy-5&#x2032;-C-malonyl and a targeting ligand. In one embodiment, the 5&#x2032;-deoxy-5&#x2032;-C-malonyl is at the 5&#x2032;-end of the antisense strand, and the targeting ligand is at the 3&#x2032;-end of the sense strand.</p><p id="p-0556" num="0506">In a particular embodiment, an RNAi agent of the present invention comprises:<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0507">(a) a sense strand having:        <ul id="ul0003" list-style="none">            <li id="ul0003-0001" num="0508">(i) a length of 21 nucleotides;</li>            <li id="ul0003-0002" num="0509">(ii) an ASGPR ligand attached to the 3&#x2032;-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker; and</li>            <li id="ul0003-0003" num="0510">(iii) 2&#x2032;-F modifications at positions 1, 3, 5, 7, 9 to 11, 13, 17, 19, and 21, and 2&#x2032;-OMe modifications at positions 2, 4, 6, 8, 12, 14 to 16, 18, and 20 (counting from the 5&#x2032; end); and</li>        </ul>        </li>        <li id="ul0002-0002" num="0511">(b) an antisense strand having:        <ul id="ul0004" list-style="none">            <li id="ul0004-0001" num="0512">(i) a length of 23 nucleotides;</li>            <li id="ul0004-0002" num="0513">(ii) 2&#x2032;-OMe modifications at positions 1, 3, 5, 9, 11 to 13, 15, 17, 19, 21, and 23, and 2&#x2032;F modifications at positions 2, 4, 6 to 8, 10, 14, 16, 18, 20, and 22 (counting from the 5&#x2032; end); and</li>            <li id="ul0004-0003" num="0514">(iii) phosphorothioate internucleotide linkages between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5&#x2032; end);</li>        </ul>        </li>        <li id="ul0002-0003" num="0515">wherein the dsRNA agents have a two nucleotide overhang at the 3&#x2032;-end of the antisense strand, and a blunt end at the 5&#x2032;-end of the antisense strand.</li>    </ul>    </li></ul></p><p id="p-0557" num="0516">In another particular embodiment, an RNAi agent of the present invention comprises:<ul id="ul0005" list-style="none">    <li id="ul0005-0001" num="0000">    <ul id="ul0006" list-style="none">        <li id="ul0006-0001" num="0517">(a) a sense strand having:        <ul id="ul0007" list-style="none">            <li id="ul0007-0001" num="0518">(i) a length of 21 nucleotides;</li>            <li id="ul0007-0002" num="0519">(ii) an ASGPR ligand attached to the 3&#x2032;-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;</li>            <li id="ul0007-0003" num="0520">(iii) 2&#x2032;-F modifications at positions 1, 3, 5, 7, 9 to 11, 13, 15, 17, 19, and 21, and 2&#x2032;-OMe modifications at positions 2, 4, 6, 8, 12, 14, 16, 18, and 20 (counting from the 5&#x2032; end); and</li>            <li id="ul0007-0004" num="0521">(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5&#x2032; end);</li>        </ul>        </li>        <li id="ul0006-0002" num="0522">and</li>        <li id="ul0006-0003" num="0523">(b) an antisense strand having:        <ul id="ul0008" list-style="none">            <li id="ul0008-0001" num="0524">(i) a length of 23 nucleotides;</li>            <li id="ul0008-0002" num="0525">(ii) 2&#x2032;-OMe modifications at positions 1, 3, 5, 7, 9, 11 to 13, 15, 17, 19, and 21 to 23, and 2&#x2032;F modifications at positions 2, 4, 6, 8, 10, 14, 16, 18, and 20 (counting from the 5&#x2032; end); and</li>            <li id="ul0008-0003" num="0526">(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5&#x2032; end);<br/>wherein the RNAi agents have a two nucleotide overhang at the 3&#x2032;-end of the antisense strand, and a blunt end at the 5&#x2032;-end of the antisense strand.</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0558" num="0527">In another particular embodiment, a RNAi agent of the present invention comprises:<ul id="ul0009" list-style="none">    <li id="ul0009-0001" num="0000">    <ul id="ul0010" list-style="none">        <li id="ul0010-0001" num="0528">(a) a sense strand having:        <ul id="ul0011" list-style="none">            <li id="ul0011-0001" num="0529">(i) a length of 21 nucleotides;</li>            <li id="ul0011-0002" num="0530">(ii) an ASGPR ligand attached to the 3&#x2032;-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;</li>            <li id="ul0011-0003" num="0531">(iii) 2&#x2032;-OMe modifications at positions 1 to 6, 8, 10, and 12 to 21, 2&#x2032;-F modifications at positions 7, and 9, and a deoxy-nucleotide (e.g. dT) at position 11 (counting from the 5&#x2032; end); and</li>            <li id="ul0011-0004" num="0532">(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5&#x2032; end);</li>        </ul>        </li>        <li id="ul0010-0002" num="0533">and</li>        <li id="ul0010-0003" num="0534">(b) an antisense strand having:        <ul id="ul0012" list-style="none">            <li id="ul0012-0001" num="0535">(i) a length of 23 nucleotides;</li>            <li id="ul0012-0002" num="0536">(ii) 2&#x2032;-OMe modifications at positions 1, 3, 7, 9, 11, 13, 15, 17, and 19 to 23, and 2&#x2032;-F modifications at positions 2, 4 to 6, 8, 10, 12, 14, 16, and 18 (counting from the 5&#x2032; end); and</li>            <li id="ul0012-0003" num="0537">(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5&#x2032; end);<br/>wherein the RNAi agents have a two nucleotide overhang at the 3&#x2032;-end of the antisense strand, and a blunt end at the 5&#x2032;-end of the antisense strand.</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0559" num="0538">In another particular embodiment, a RNAi agent of the present invention comprises:<ul id="ul0013" list-style="none">    <li id="ul0013-0001" num="0000">    <ul id="ul0014" list-style="none">        <li id="ul0014-0001" num="0539">(a) a sense strand having:        <ul id="ul0015" list-style="none">            <li id="ul0015-0001" num="0540">(i) a length of 21 nucleotides;</li>            <li id="ul0015-0002" num="0541">(ii) an ASGPR ligand attached to the 3&#x2032;-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;</li>            <li id="ul0015-0003" num="0542">(iii) 2&#x2032;-OMe modifications at positions 1 to 6, 8, 10, 12, 14, and 16 to 21, and 2&#x2032;-F modifications at positions 7, 9, 11, 13, and 15; and</li>            <li id="ul0015-0004" num="0543">(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5&#x2032; end);</li>        </ul>        </li>        <li id="ul0014-0002" num="0544">and</li>        <li id="ul0014-0003" num="0545">(b) an antisense strand having:        <ul id="ul0016" list-style="none">            <li id="ul0016-0001" num="0546">(i) a length of 23 nucleotides;</li>            <li id="ul0016-0002" num="0547">(ii) 2&#x2032;-OMe modifications at positions 1, 5, 7, 9, 11, 13, 15, 17, 19, and 21 to 23, and 2&#x2032;-F modifications at positions 2 to 4, 6, 8, 10, 12, 14, 16, 18, and 20 (counting from the 5&#x2032; end); and</li>            <li id="ul0016-0003" num="0548">(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5&#x2032; end);<br/>wherein the RNAi agents have a two nucleotide overhang at the 3&#x2032;-end of the antisense strand, and a blunt end at the 5&#x2032;-end of the antisense strand.</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0560" num="0549">In another particular embodiment, a RNAi agent of the present invention comprises:<ul id="ul0017" list-style="none">    <li id="ul0017-0001" num="0000">    <ul id="ul0018" list-style="none">        <li id="ul0018-0001" num="0550">(a) a sense strand having:        <ul id="ul0019" list-style="none">            <li id="ul0019-0001" num="0551">(i) a length of 21 nucleotides;</li>            <li id="ul0019-0002" num="0552">(ii) an ASGPR ligand attached to the 3&#x2032;-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;</li>            <li id="ul0019-0003" num="0553">(iii) 2&#x2032;-OMe modifications at positions 1 to 9, and 12 to 21, and 2&#x2032;-F modifications at positions 10, and 11; and</li>            <li id="ul0019-0004" num="0554">(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5&#x2032; end);</li>        </ul>        </li>        <li id="ul0018-0002" num="0555">and</li>        <li id="ul0018-0003" num="0556">(b) an antisense strand having:        <ul id="ul0020" list-style="none">            <li id="ul0020-0001" num="0557">(i) a length of 23 nucleotides;</li>            <li id="ul0020-0002" num="0558">(ii) 2&#x2032;-OMe modifications at positions 1, 3, 5, 7, 9, 11 to 13, 15, 17, 19, and 21 to 23, and 2&#x2032;-F modifications at positions 2, 4, 6, 8, 10, 14, 16, 18, and 20 (counting from the 5&#x2032; end); and</li>            <li id="ul0020-0003" num="0559">(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5&#x2032; end);<br/>wherein the RNAi agents have a two nucleotide overhang at the 3&#x2032;-end of the antisense strand, and a blunt end at the 5&#x2032;-end of the antisense strand.</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0561" num="0560">In another particular embodiment, a RNAi agent of the present invention comprises:<ul id="ul0021" list-style="none">    <li id="ul0021-0001" num="0000">    <ul id="ul0022" list-style="none">        <li id="ul0022-0001" num="0561">(a) a sense strand having:        <ul id="ul0023" list-style="none">            <li id="ul0023-0001" num="0562">(i) a length of 21 nucleotides;</li>            <li id="ul0023-0002" num="0563">(ii) an ASGPR ligand attached to the 3&#x2032;-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;</li>            <li id="ul0023-0003" num="0564">(iii) 2&#x2032;-F modifications at positions 1, 3, 5, 7, 9 to 11, and 13, and 2&#x2032;-OMe modifications at positions 2, 4, 6, 8, 12, and 14 to 21; and</li>            <li id="ul0023-0004" num="0565">(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5&#x2032; end);</li>        </ul>        </li>        <li id="ul0022-0002" num="0566">and</li>        <li id="ul0022-0003" num="0567">(b) an antisense strand having:        <ul id="ul0024" list-style="none">            <li id="ul0024-0001" num="0568">(i) a length of 23 nucleotides;</li>            <li id="ul0024-0002" num="0569">(ii) 2&#x2032;-OMe modifications at positions 1, 3, 5 to 7, 9, 11 to 13, 15, 17 to 19, and 21 to 23, and 2&#x2032;-F modifications at positions 2, 4, 8, 10, 14, 16, and 20 (counting from the 5&#x2032; end); and</li>            <li id="ul0024-0003" num="0570">(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5&#x2032; end);<br/>wherein the RNAi agents have a two nucleotide overhang at the 3&#x2032;-end of the antisense strand, and a blunt end at the 5&#x2032;-end of the antisense strand.</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0562" num="0571">In another particular embodiment, a RNAi agent of the present invention comprises:<ul id="ul0025" list-style="none">    <li id="ul0025-0001" num="0000">    <ul id="ul0026" list-style="none">        <li id="ul0026-0001" num="0572">(a) a sense strand having:        <ul id="ul0027" list-style="none">            <li id="ul0027-0001" num="0573">(i) a length of 21 nucleotides;</li>            <li id="ul0027-0002" num="0574">(ii) an ASGPR ligand attached to the 3&#x2032;-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;</li>            <li id="ul0027-0003" num="0575">(iii) 2&#x2032;-OMe modifications at positions 1, 2, 4, 6, 8, 12, 14, 15, 17, and 19 to 21, and 2&#x2032;-F modifications at positions 3, 5, 7, 9 to 11, 13, 16, and 18; and</li>            <li id="ul0027-0004" num="0576">(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5&#x2032; end);</li>        </ul>        </li>        <li id="ul0026-0002" num="0577">and</li>        <li id="ul0026-0003" num="0578">(b) an antisense strand having:        <ul id="ul0028" list-style="none">            <li id="ul0028-0001" num="0579">(i) a length of 25 nucleotides;</li>            <li id="ul0028-0002" num="0580">(ii) 2&#x2032;-OMe modifications at positions 1, 4, 6, 7, 9, 11 to 13, 15, 17, and 19 to 23, 2&#x2032;-F modifications at positions 2, 3, 5, 8, 10, 14, 16, and 18, and desoxy-nucleotides (e.g. dT) at positions 24 and 25 (counting from the 5&#x2032; end); and</li>            <li id="ul0028-0003" num="0581">(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5&#x2032; end);<br/>wherein the RNAi agents have a four nucleotide overhang at the 3&#x2032;-end of the antisense strand, and a blunt end at the 5&#x2032;-end of the antisense strand.</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0563" num="0582">In another particular embodiment, a RNAi agent of the present invention comprises:<ul id="ul0029" list-style="none">    <li id="ul0029-0001" num="0000">    <ul id="ul0030" list-style="none">        <li id="ul0030-0001" num="0583">(a) a sense strand having:        <ul id="ul0031" list-style="none">            <li id="ul0031-0001" num="0584">(i) a length of 21 nucleotides;</li>            <li id="ul0031-0002" num="0585">(ii) an ASGPR ligand attached to the 3&#x2032;-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;</li>            <li id="ul0031-0003" num="0586">(iii) 2&#x2032;-OMe modifications at positions 1 to 6, 8, and 12 to 21, and 2&#x2032;-F modifications at positions 7, and 9 to 11; and</li>            <li id="ul0031-0004" num="0587">(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5&#x2032; end);</li>        </ul>        </li>        <li id="ul0030-0002" num="0588">and</li>        <li id="ul0030-0003" num="0589">(b) an antisense strand having:        <ul id="ul0032" list-style="none">            <li id="ul0032-0001" num="0590">(i) a length of 23 nucleotides;</li>            <li id="ul0032-0002" num="0591">(ii) 2&#x2032;-OMe modifications at positions 1, 3 to 5, 7, 8, 10 to 13, 15, and 17 to 23, and 2&#x2032;-F modifications at positions 2, 6, 9, 14, and 16 (counting from the 5&#x2032; end); and</li>            <li id="ul0032-0003" num="0592">(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5&#x2032; end);<br/>wherein the RNAi agents have a two nucleotide overhang at the 3&#x2032;-end of the antisense strand, and a blunt end at the 5&#x2032;-end of the antisense strand.</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0564" num="0593">In another particular embodiment, a RNAi agent of the present invention comprises:<ul id="ul0033" list-style="none">    <li id="ul0033-0001" num="0000">    <ul id="ul0034" list-style="none">        <li id="ul0034-0001" num="0594">(a) a sense strand having:        <ul id="ul0035" list-style="none">            <li id="ul0035-0001" num="0595">(i) a length of 21 nucleotides;</li>            <li id="ul0035-0002" num="0596">(ii) an ASGPR ligand attached to the 3&#x2032;-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;</li>            <li id="ul0035-0003" num="0597">(iii) 2&#x2032;-OMe modifications at positions 1 to 6, 8, and 12 to 21, and 2&#x2032;-F modifications at positions 7, and 9 to 11; and</li>            <li id="ul0035-0004" num="0598">(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5&#x2032; end);</li>        </ul>        </li>        <li id="ul0034-0002" num="0599">and</li>        <li id="ul0034-0003" num="0600">(b) an antisense strand having:        <ul id="ul0036" list-style="none">            <li id="ul0036-0001" num="0601">(i) a length of 23 nucleotides;</li>            <li id="ul0036-0002" num="0602">(ii) 2&#x2032;-OMe modifications at positions 1, 3 to 5, 7, 10 to 13, 15, and 17 to 23, and 2&#x2032;-F modifications at positions 2, 6, 8, 9, 14, and 16 (counting from the 5&#x2032; end); and</li>            <li id="ul0036-0003" num="0603">(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5&#x2032; end);<br/>wherein the RNAi agents have a two nucleotide overhang at the 3&#x2032;-end of the antisense strand, and a blunt end at the 5&#x2032;-end of the antisense strand.</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0565" num="0604">In another particular embodiment, a RNAi agent of the present invention comprises:<ul id="ul0037" list-style="none">    <li id="ul0037-0001" num="0000">    <ul id="ul0038" list-style="none">        <li id="ul0038-0001" num="0605">(a) a sense strand having:        <ul id="ul0039" list-style="none">            <li id="ul0039-0001" num="0606">(i) a length of 19 nucleotides;</li>            <li id="ul0039-0002" num="0607">(ii) an ASGPR ligand attached to the 3&#x2032;-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;</li>            <li id="ul0039-0003" num="0608">(iii) 2&#x2032;-OMe modifications at positions 1 to 4, 6, and 10 to 19, and 2&#x2032;-F modifications at positions 5, and 7 to 9; and</li>            <li id="ul0039-0004" num="0609">(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5&#x2032; end);</li>        </ul>        </li>        <li id="ul0038-0002" num="0610">and</li>        <li id="ul0038-0003" num="0611">(b) an antisense strand having:        <ul id="ul0040" list-style="none">            <li id="ul0040-0001" num="0612">(i) a length of 21 nucleotides;</li>            <li id="ul0040-0002" num="0613">(ii) 2&#x2032;-OMe modifications at positions 1, 3 to 5, 7, 10 to 13, 15, and 17 to 21, and 2&#x2032;-F modifications at positions 2, 6, 8, 9, 14, and 16 (counting from the 5&#x2032; end); and</li>            <li id="ul0040-0003" num="0614">(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5&#x2032; end);<br/>wherein the RNAi agents have a two nucleotide overhang at the 3&#x2032;-end of the antisense strand, and a blunt end at the 5&#x2032;-end of the antisense strand.</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0566" num="0615">In certain embodiments, the iRNA for use in the methods of the invention is an agent selected from agents listed in Table 3, Table 5, or Table 6. These agents may further comprise a ligand.</p><heading id="h-0013" level="1">VII. Ligands</heading><p id="p-0567" num="0616">The double-stranded RNAi gents for use in the methods of the invention may optionally be conjugated to one or more ligands, moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the iRNA e.g., into a cell. The ligand can be attached to the sense strand, antisense strand or both strands, at the 3&#x2032;-end, 5&#x2032;-end or both ends. For instance, the ligand may be conjugated to the sense strand. In some embodiments, the ligand is conjugated to the 3&#x2032;-end of the sense strand.</p><p id="p-0568" num="0617">Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., <i>Proc. Natl. Acid. Sci. USA, </i>1989, 86: 6553-6556). In other embodiments, the ligand is cholic acid (Manoharan et al., <i>Biorg. Med. Chem. Let., </i>1994, 4:1053-1060), a thioether, e.g., beryl-S-tritylthiol (Manoharan et al., <i>Ann. N. Y. Acad. Sci., </i>1992, 660:306-309; Manoharan et al., <i>Biorg. Med. Chem</i>. Let., 1993, 3:2765-2770), a thiocholesterol (Oberhauser et al., <i>Nucl. Acids Res., </i>1992, 20:533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., <i>EMBO J, </i>1991, 10:1111-1118; Kabanov et al., <i>FEBS Lett., </i>1990, 259:327-330; Svinarchuk et al., <i>Biochimie, </i>1993, 75:49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate (Manoharan et al., <i>Tetrahedron Lett., </i>1995, 36:3651-3654; Shea et al., <i>Nucl. Acids Res., </i>1990, 18:3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., <i>Nucleosides </i>&#x26; <i>Nucleotides, </i>1995, 14:969-973), or adamantane acetic acid (Manoharan et al., <i>Tetrahedron Lett., </i>1995, 36:3651-3654), a palmityl moiety (Mishra et al., <i>Biochim. Biophys. Acta, </i>1995, 1264:229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., <i>J. Pharmacol. Exp. Ther., </i>1996, 277:923-937). In one embodiment, the ligand is a GalNAc ligand. In particularly some embodiments, the ligand is GalNAc3. The ligands are coupled, preferably covalently, either directly or indirectly via an intervening tether.</p><p id="p-0569" num="0618">In certain embodiments, a ligand alters the distribution, targeting, or lifetime of an iRNA agent into which it is incorporated. In preferred embodiments a ligand provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand. Preferred ligands do not take part in duplex pairing in a duplexed nucleic acid.</p><p id="p-0570" num="0619">Ligands can include a naturally occurring substance, such as a protein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, N-acetylglucosamine, N-acetylgalactosamine, or hyaluronic acid); or a lipid. The ligand can also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid. Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolied) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacryllic acid), N-isopropylacrylamide polymers, or polyphosphazine. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.</p><p id="p-0571" num="0620">Ligands can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid or protein, e.g., an antibody, that binds to a specified cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, vitamin A, biotin, or an RGD peptide or RGD peptide mimetic. In certain embodiments, the ligand is a multivalent galactose, e.g., an N-acetyl-galactosamine.</p><p id="p-0572" num="0621">Other examples of ligands include dyes, intercalating agents (e.g. acridines), cross-linkers (e.g. psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g. EDTA), lipophilic molecules, e.g., cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine) and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG]<sub>2</sub>, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g. biotin), transport/absorption facilitators (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or AP.</p><p id="p-0573" num="0622">Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a hepatic cell. Ligands can also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF-&#x3ba;B.</p><p id="p-0574" num="0623">The ligand can be a substance, e.g., a drug, which can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cell's cytoskeleton, e.g., by disrupting the cell's microtubules, microfilaments, or intermediate filaments. The drug can be, for example, taxol, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.</p><p id="p-0575" num="0624">In some embodiments, a ligand attached to an iRNA as described herein acts as a pharmacokinetic modulator (PK modulator). PK modulators include lipophiles, bile acids, steroids, phospholipid analogues, peptides, protein binding agents, PEG, vitamins, etc. Exemplary PK modulators include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglyceride, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin. Oligonucleotides that comprise a number of phosphorothioate linkages are also known to bind to serum protein, thus short oligonucleotides, e.g., oligonucleotides of about 5 bases, 10 bases, 15 bases, or 20 bases, comprising multiple of phosphorothioate linkages in the backbone are also amenable to the present invention as ligands (e.g. as PK modulating ligands). In addition, aptamers that bind serum components (e.g. serum proteins) are also suitable for use as PK modulating ligands in the embodiments described herein.</p><p id="p-0576" num="0625">Ligand-conjugated iRNAs of the invention may be synthesized by the use of an oligonucleotide that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the oligonucleotide (described below). This reactive oligonucleotide may be reacted directly with commercially-available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto.</p><p id="p-0577" num="0626">The oligonucleotides used in the conjugates of the present invention may be conveniently and routinely made through the well-known technique of solid-phase synthesis.</p><p id="p-0578" num="0627">In the ligand-conjugated iRNAs and ligand-molecule bearing sequence-specific linked nucleosides of the present invention, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligand-bearing building blocks.</p><p id="p-0579" num="0628">When using nucleotide-conjugate precursors that already bear a linking moiety, the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then reacted with the linking moiety to form the ligand-conjugated oligonucleotide. In some embodiments, the oligonucleotides or linked nucleosides of the present invention are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to the standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used in oligonucleotide synthesis.</p><p id="p-0580" num="0629">A. Lipid Conjugates</p><p id="p-0581" num="0630">In certain embodiments, the ligand or conjugate is a lipid or lipid-based molecule. Such a lipid or lipid-based molecule preferably binds a serum protein, e.g., human serum albumin (HSA). An HSA binding ligand allows for distribution of the conjugate to a target tissue, e.g., a non-kidney target tissue of the body. For example, the target tissue can be the liver, including parenchymal cells of the liver. Other molecules that can bind HSA can also be used as ligands. For example, naproxen or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, or (c) can be used to adjust binding to a serum protein, e.g., HSA.</p><p id="p-0582" num="0631">A lipid based ligand can be used to inhibit, e.g., control the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly can be used to target the conjugate to the kidney.</p><p id="p-0583" num="0632">In certain embodiments, the lipid based ligand binds HSA. Preferably, it binds HSA with a sufficient affinity such that the conjugate will be preferably distributed to a non-kidney tissue. However, it is preferred that the affinity not be so strong that the HSA-ligand binding cannot be reversed.</p><p id="p-0584" num="0633">In other embodiments, the lipid based ligand binds HSA weakly or not at all, such that the conjugate will be preferably distributed to the kidney. Other moieties that target to kidney cells can also be used in place of, or in addition to, the lipid based ligand.</p><p id="p-0585" num="0634">In another aspect, the ligand is a moiety, e.g., a vitamin, which is taken up by a target cell, e.g., a proliferating cell. These are particularly useful for treating disorders characterized by unwanted cell proliferation, e.g., of the malignant or non-malignant type, e.g., cancer cells.</p><p id="p-0586" num="0635">Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include are B vitamin, e.g., folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by target cells such as liver cells. Also included are HSA and low density lipoprotein (LDL).</p><p id="p-0587" num="0636">B. Cell Permeation Agents</p><p id="p-0588" num="0637">In another aspect, the ligand is a cell-permeation agent, preferably a helical cell-permeation agent. Preferably, the agent is amphipathic. An exemplary agent is a peptide such as tat or antennopedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. The helical agent is preferably an alpha-helical agent, which preferably has a lipophilic and a lipophobic phase.</p><p id="p-0589" num="0638">The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The attachment of peptide and peptidomimetics to iRNA agents can affect pharmacokinetic distribution of the iRNA, such as by enhancing cellular recognition and absorption. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.</p><p id="p-0590" num="0639">A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (e.g., consisting primarily of Tyr, Trp, or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS). An exemplary hydrophobic MTS-containing peptide is RFGF having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 13). An RFGF analogue (e.g., amino acid sequence AALLPVLLAAP (SEQ ID NO: 14) containing a hydrophobic MTS can also be a targeting moiety. The peptide moiety can be a &#x201c;delivery&#x201d; peptide, which can carry large polar molecules including peptides, oligonucleotides, and protein across cell membranes. For example, sequences from the HIV Tat protein (GRKKRRQRRRPPQ (SEQ ID NO: 15) and the <i>Drosophila </i>Antennapedia protein (RQIKIWFQNRRMKWKK (SEQ ID NO: 16) have been found to be capable of functioning as delivery peptides. A peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature, 354:82-84, 1991). Examples of a peptide or peptidomimetic tethered to a dsRNA agent via an incorporated monomer unit for cell targeting purposes is an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized.</p><p id="p-0591" num="0640">An RGD peptide for use in the compositions and methods of the invention may be linear or cyclic, and may be modified, e.g., glycosylated or methylated, to facilitate targeting to a specific tissue(s). RGD-containing peptides and peptidiomimemtics may include D-amino acids, as well as synthetic RGD mimics. In addition to RGD, one can use other moieties that target the integrin ligand. Preferred conjugates of this ligand target PECAM-1 or VEGF.</p><p id="p-0592" num="0641">A &#x201c;cell permeation peptide&#x201d; is capable of permeating a cell, e.g., a microbial cell, such as a bacterial or fungal cell, or a mammalian cell, such as a human cell. A microbial cell-permeating peptide can be, for example, an &#x3b1;-helical linear peptide (e.g., LL-37 or Ceropin P1), a disulfide bond-containing peptide (e.g., &#x3b1;-defensin, &#x3b2;-defensin or bactenecin), or a peptide containing only one or two dominating amino acids (e.g., PR-39 or indolicidin). A cell permeation peptide can also include a nuclear localization signal (NLS). For example, a cell permeation peptide can be a bipartite amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-1 gp41 and the NLS of SV40 large T antigen (Simeoni et al., Nucl. Acids Res. 31:2717-2724, 2003).</p><p id="p-0593" num="0642">C. Carbohydrate Conjugates</p><p id="p-0594" num="0643">In some embodiments of the compositions and methods of the invention, an iRNA further comprises a carbohydrate. The carbohydrate conjugated iRNA is advantageous for the in vivo delivery of nucleic acids, as well as compositions suitable for in vivo therapeutic use, as described herein. As used herein, &#x201c;carbohydrate&#x201d; refers to a compound which is either a carbohydrate per se made up of one or more monosaccharide units having at least 6 carbon atoms (which can be linear, branched or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom; or a compound having as a part thereof a carbohydrate moiety made up of one or more monosaccharide units each having at least six carbon atoms (which can be linear, branched or cyclic), with an oxygen, nitrogen or sulfur atom bonded to each carbon atom. Representative carbohydrates include the sugars (mono-, di-, tri-, and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides such as starches, glycogen, cellulose and polysaccharide gums. Specific monosaccharides include C5 and above (e.g., C5, C6, C7, or C8) sugars; di- and trisaccharides include sugars having two or three monosaccharide units (e.g., C5, C6, C7, or C8).</p><p id="p-0595" num="0644">In certain embodiments, a carbohydrate conjugate for use in the compositions and methods of the invention is a monosaccharide.</p><p id="p-0596" num="0645">In one embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is selected from the group consisting of:</p><p id="p-0597" num="0000"><chemistry id="CHEM-US-00012" num="00012"><img id="EMI-C00012" he="203.12mm" wi="152.40mm" file="US20230002765A1-20230105-C00012.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00013" num="00013"><img id="EMI-C00013" he="228.60mm" wi="152.40mm" file="US20230002765A1-20230105-C00013.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00014" num="00014"><img id="EMI-C00014" he="220.47mm" wi="152.40mm" file="US20230002765A1-20230105-C00014.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00015" num="00015"><img id="EMI-C00015" he="242.74mm" wi="158.67mm" file="US20230002765A1-20230105-C00015.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00016" num="00016"><img id="EMI-C00016" he="229.95mm" wi="157.99mm" file="US20230002765A1-20230105-C00016.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00017" num="00017"><img id="EMI-C00017" he="225.13mm" wi="152.40mm" file="US20230002765A1-20230105-C00017.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00018" num="00018"><img id="EMI-C00018" he="169.42mm" wi="152.40mm" file="US20230002765A1-20230105-C00018.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0598" num="0646">In another embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is a monosaccharide. In one embodiment, the monosaccharide is an N-acetylgalactosamine, such as</p><p id="p-0599" num="0000"><chemistry id="CHEM-US-00019" num="00019"><img id="EMI-C00019" he="70.95mm" wi="122.09mm" file="US20230002765A1-20230105-C00019.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0600" num="0647">Another representative carbohydrate conjugate for use in the embodiments described herein includes, but is not limited to,</p><p id="p-0601" num="0000"><chemistry id="CHEM-US-00020" num="00020"><img id="EMI-C00020" he="155.96mm" wi="158.75mm" file="US20230002765A1-20230105-C00020.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0602" num="0000">when one of X or Y is an oligonucleotide, the other is a hydrogen.</p><p id="p-0603" num="0648">In some embodiments, a suitable ligand is a ligand disclosed in WO 2019/055633, the entire contents of which are incorporated herein by reference. In one embodiment the ligand comprises the structure below:</p><p id="p-0604" num="0000"><chemistry id="CHEM-US-00021" num="00021"><img id="EMI-C00021" he="47.07mm" wi="75.95mm" file="US20230002765A1-20230105-C00021.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0605" num="0649">In certain embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a monovalent linker. In some embodiments, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a bivalent linker. In yet other embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a trivalent linker.</p><p id="p-0606" num="0650">In one embodiment, the double stranded RNAi agents of the invention comprise one GalNAc or GalNAc derivative attached to the iRNA agent, e.g., the 5&#x2032;end of the sense strand of a dsRNA agent, or the 5&#x2032; end of one or both sense strands of a dual targeting RNAi agent as described herein.</p><p id="p-0607" num="0651">In another embodiment, the double stranded RNAi agents of the invention comprise a plurality (e.g., 2, 3, 4, 5, or 6) GalNAc or GalNAc derivatives, each independently attached to a plurality of nucleotides of the double stranded RNAi agent through a plurality of monovalent linkers.</p><p id="p-0608" num="0652">In some embodiments, for example, when the two strands of an iRNA agent of the invention are part of one larger molecule connected by an uninterrupted chain of nucleotides between the 3&#x2032;-end of one strand and the 5&#x2032;-end of the respective other strand forming a hairpin loop comprising, a plurality of unpaired nucleotides, each unpaired nucleotide within the hairpin loop may independently comprise a GalNAc or GalNAc derivative attached via a monovalent linker.</p><p id="p-0609" num="0653">In some embodiments, the carbohydrate conjugate further comprises one or more additional ligands as described above, such as, but not limited to, a PK modulator or a cell permeation peptide.</p><p id="p-0610" num="0654">Additional carbohydrate conjugates and linkers suitable for use in the present invention include those described in PCT Publication Nos. WO 2014/179620 and WO 2014/179627, the entire contents of each of which are incorporated herein by reference.</p><p id="p-0611" num="0655">D. Linkers</p><p id="p-0612" num="0656">In some embodiments, the conjugate or ligand described herein can be attached to an iRNA oligonucleotide with various linkers that can be cleavable or non-cleavable.</p><p id="p-0613" num="0657">The term &#x201c;linker&#x201d; or &#x201c;linking group&#x201d; means an organic moiety that connects two parts of a compound, e.g., covalently attaches two parts of a compound. Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NR8, C(O), C(O)NH, SO, SO<sub>2</sub>, SO<sub>2</sub>NH or a chain of atoms, such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylhererocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylhereroaryl, which one or more methylenes can be interrupted or terminated by O, S, S(O), SO<sub>2</sub>, N(R8), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclic; where R8 is hydrogen, acyl, aliphatic, or substituted aliphatic. In one embodiment, the linker is about 1-24 atoms, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18, 7-17, 8-17, 6-16, 7-17, or 8-16 atoms.</p><p id="p-0614" num="0658">A cleavable linking group is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In a preferred embodiment, the cleavable linking group is cleaved at least about 10 times, 20, times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, or more, or at least 100 times faster in a target cell or under a first reference condition (which can, e.g., be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, e.g., be selected to mimic or represent conditions found in the blood or serum).</p><p id="p-0615" num="0659">Cleavable linking groups are susceptible to cleavage agents, e.g., pH, redox potential, or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include: redox agents which are selected for particular substrates or which have no substrate specificity, including, e.g., oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction; esterases; endosomes or agents that can create an acidic environment, e.g., those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.</p><p id="p-0616" num="0660">A cleavable linkage group, such as a disulfide bond can be susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5.0. Some linkers will have a cleavable linking group that is cleaved at a preferred pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.</p><p id="p-0617" num="0661">A linker can include a cleavable linking group that is cleavable by a particular enzyme. The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted. For example, a liver-targeting ligand can be linked to a cationic lipid through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other cell-types rich in esterases include cells of the lung, renal cortex, and testis.</p><p id="p-0618" num="0662">Linkers that contain peptide bonds can be used when targeting cell types rich in peptidases, such as liver cells and synoviocytes.</p><p id="p-0619" num="0663">In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, e.g., blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It can be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In preferred embodiments, useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).</p><p id="p-0620" num="0664">i. Redox Cleavable Linking Groups</p><p id="p-0621" num="0665">In certain embodiments, a cleavable linking group is a redox cleavable linking group that is cleaved upon reduction or oxidation. An example of reductively cleavable linking group is a disulphide linking group (&#x2014;S&#x2014;S&#x2014;). To determine if a candidate cleavable linking group is a suitable &#x201c;reductively cleavable linking group,&#x201d; or for example is suitable for use with a particular iRNA moiety and particular targeting agent one can look to methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents know in the art, which mimic the rate of cleavage which would be observed in a cell, e.g., a target cell. The candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions. In one, candidate compounds are cleaved by at most about 10% in the blood. In other embodiments, useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood (or under in vitro conditions selected to mimic extracellular conditions). The rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.</p><p id="p-0622" num="0666">ii. Phosphate-Based Cleavable Linking Groups</p><p id="p-0623" num="0667">In other embodiments, a cleavable linker comprises a phosphate-based cleavable linking group. A phosphate-based cleavable linking group is cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells. Examples of phosphate-based linking groups are &#x2014;O&#x2014;P(O)(ORk)-O&#x2014;, &#x2014;O&#x2014;P(S)(ORk)-O&#x2014;, &#x2014;O&#x2014;P(S)(SRk)-O&#x2014;, &#x2014;S&#x2014;P(O)(ORk)-O&#x2014;, &#x2014;O&#x2014;P(O)(ORk)-S&#x2014;, &#x2014;S&#x2014;P(O)(ORk)-S&#x2014;, &#x2014;O&#x2014;P(S)(ORk)-S&#x2014;, &#x2014;S&#x2014;P(S)(ORk)-O&#x2014;, &#x2014;O&#x2014;P(O)(Rk)-O&#x2014;, &#x2014;O&#x2014;P(S)(Rk)-O&#x2014;, &#x2014;S&#x2014;P(O)(Rk)-O&#x2014;, &#x2014;S&#x2014;P(S)(Rk)-O&#x2014;, &#x2014;S&#x2014;P(O)(Rk)-S&#x2014;, &#x2014;O&#x2014;P(S)(Rk)-S&#x2014;. Preferred embodiments are &#x2014;O&#x2014;P(O)(OH)&#x2014;O&#x2014;, &#x2014;O&#x2014;P(S)(OH)&#x2014;O&#x2014;, &#x2014;O&#x2014;P(S)(SH)&#x2014;O&#x2014;, &#x2014;S&#x2014;P(O)(OH)&#x2014;O&#x2014;, &#x2014;O&#x2014;P(O)(OH)&#x2014;S&#x2014;, &#x2014;S&#x2014;P(O)(OH)&#x2014;S&#x2014;, &#x2014;O&#x2014;P(S)(OH)&#x2014;S&#x2014;, &#x2014;S&#x2014;P(S)(OH)&#x2014;O&#x2014;, &#x2014;O&#x2014;P(O)(H)&#x2014;O&#x2014;, &#x2014;O&#x2014;P(S)(H)&#x2014;O&#x2014;, &#x2014;S&#x2014;P(O)(H)&#x2014;O, &#x2014;S&#x2014;P(S)(H)&#x2014;O&#x2014;, &#x2014;S&#x2014;P(O)(H)&#x2014;S&#x2014;, and &#x2014;O&#x2014;P(S)(H)&#x2014;S&#x2014;. A preferred embodiment is &#x2014;O&#x2014;P(O)(OH)&#x2014;O&#x2014;. These candidates can be evaluated using methods analogous to those described above.</p><p id="p-0624" num="0668">iii. Acid Cleavable Linking Groups</p><p id="p-0625" num="0669">In other embodiments, a cleavable linker comprises an acid cleavable linking group. An acid cleavable linking group is a linking group that is cleaved under acidic conditions. In preferred embodiments acid cleavable linking groups are cleaved in an acidic environment with a pH of about 6.5 or lower (e.g., about 6.0, 5.5, 5.0, or lower), or by agents such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups. Examples of acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids. Acid cleavable groups can have the general formula &#x2014;C&#x2550;NN&#x2014;, C(O)O, or &#x2014;OC(O). A preferred embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.</p><p id="p-0626" num="0670">iv. Ester-Based Linking Groups</p><p id="p-0627" num="0671">In other embodiments, a cleavable linker comprises an ester-based cleavable linking group. An ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in cells. Examples of ester-based cleavable linking groups include, but are not limited to, esters of alkylene, alkenylene and alkynylene groups. Ester cleavable linking groups have the general formula &#x2014;C(O)O&#x2014;, or &#x2014;OC(O)&#x2014;. These candidates can be evaluated using methods analogous to those described above.</p><p id="p-0628" num="0672">v. Peptide-Based Cleaving Groups</p><p id="p-0629" num="0673">In yet other embodiments, a cleavable linker comprises a peptide-based cleavable linking group. A peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (e.g., dipeptides, tripeptides etc.) and polypeptides. Peptide-based cleavable groups do not include the amide group (&#x2014;C(O)NH&#x2014;). The amide group can be formed between any alkylene, alkenylene or alkynelene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide based cleavage group is generally limited to the peptide bond (i.e., the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula &#x2014;NHCHRAC(O)NHCHRBC(O)&#x2014;, where RA and RB are the R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.</p><p id="p-0630" num="0674">In some embodiments, an iRNA of the invention is conjugated to a carbohydrate through a linker. Non-limiting examples of iRNA carbohydrate conjugates with linkers of the compositions and methods of the invention include but are not limited to</p><p id="p-0631" num="0000"><chemistry id="CHEM-US-00022" num="00022"><img id="EMI-C00022" he="243.42mm" wi="158.33mm" file="US20230002765A1-20230105-C00022.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00023" num="00023"><img id="EMI-C00023" he="214.12mm" wi="158.41mm" file="US20230002765A1-20230105-C00023.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0632" num="0000">when one of X or Y is an oligonucleotide, the other is a hydrogen.</p><p id="p-0633" num="0675">In certain embodiments of the compositions and methods of the invention, a ligand is one or more &#x201c;GalNAc&#x201d; (N-acetylgalactosamine) derivatives attached through a bivalent or trivalent branched linker.</p><p id="p-0634" num="0000">In one embodiment, a dsRNA of the invention is conjugated to a bivalent or trivalent branched linker selected from the group of structures shown in any of formula (XLV)-(XLVI):</p><p id="p-0635" num="0000"><chemistry id="CHEM-US-00024" num="00024"><img id="EMI-C00024" he="111.08mm" wi="69.93mm" file="US20230002765A1-20230105-C00024.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0636" num="0000">wherein:<br/>q2A, q2B, q3A, q3B, q4A, q4B, q5A, q5B and q5C represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;<br/>P<sup>2A </sup>P<sup>2B</sup>, P<sup>3A</sup>, P<sup>3B</sup>, P<sup>4A</sup>, P<sup>4B</sup>, P<sup>5A</sup>, P<sup>5B</sup>, P<sup>5C</sup>, T<sup>2A</sup>, T<sup>2B</sup>, T<sup>3A</sup>, T<sup>3B</sup>, T<sup>4A</sup>, T<sup>4B</sup>, T<sup>4B</sup>, T<sup>4A</sup>, T<sup>5B</sup>, T<sup>5C </sup>are each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), CH<sub>2</sub>, CH<sub>2</sub>NH or CH<sub>2</sub>O; Q<sup>2A</sup>, Q<sup>2B</sup>, Q<sup>3A</sup>, Q<sup>3B</sup>, Q<sup>4A</sup>, Q<sup>4B</sup>, Q<sup>5A</sup>, Q<sup>5B</sup>, Q<sup>5C </sup>are independently for each occurrence absent, alkylene, substituted alkylene wherein one or more methylenes can be interrupted or terminated by one or more of O, S, S(O), SO<sub>2</sub>, N(R<sup>N</sup>), C(R&#x2032;)&#x2550;C(R&#x2033;), C&#x2261;C or C(O);<br/>R<sup>2A</sup>, R<sup>2B</sup>, R<sup>3A</sup>, R<sup>3B</sup>, R<sup>4A</sup>, R<sup>4B</sup>, R<sup>5A</sup>, R<sup>5B</sup>, R<sup>5C </sup>are each independently for each occurrence absent NH, O, S, CH<sub>2</sub>, C(O)O, C(O)NH, NHCH(R<sup>a</sup>)C(O), &#x2014;C(O)&#x2014;CH(R<sup>a</sup>)&#x2014;NH&#x2014;, CO, CH&#x2550;N&#x2014;O, N</p><p id="p-0637" num="0000"><chemistry id="CHEM-US-00025" num="00025"><img id="EMI-C00025" he="59.52mm" wi="63.67mm" file="US20230002765A1-20230105-C00025.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0638" num="0000">or heterocyclyl; L<sup>2A</sup>, L<sup>2B</sup>, L<sup>3A</sup>, L<sup>3B</sup>, L<sup>4A</sup>, L<sup>4B</sup>, L<sup>5A</sup>, L<sup>5B </sup>and L<sup>5C </sup>represent the ligand; i.e. each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; and R<sup>a </sup>is H or amino acid side chain. Trivalent conjugating GalNAc derivatives are particularly useful for use with RNAi agents for inhibiting the expression of a target gene, such as those of formula (XLIX):</p><p id="p-0639" num="0000"><chemistry id="CHEM-US-00026" num="00026"><img id="EMI-C00026" he="61.47mm" wi="69.93mm" file="US20230002765A1-20230105-C00026.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0640" num="0000">wherein L<sup>5A </sup>L<sup>5B </sup>and L<sup>5C </sup>represent a monosaccharide, such as GalNAc derivative.</p><p id="p-0641" num="0676">Examples of suitable bivalent and trivalent branched linker groups conjugating GalNAc derivatives include, but are not limited to, the structures recited above as formulas II, VII, XI, X, and XIII.</p><p id="p-0642" num="0677">Representative U.S. Patents that teach the preparation of RNA conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928; 5,688,941; 6,294,664; 6,320,017; 6,576,752; 6,783,931; 6,900,297; 7,037,646; and 8,106,022, the entire contents of each of which are hereby incorporated herein by reference.</p><p id="p-0643" num="0678">It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications can be incorporated in a single compound or even at a single nucleoside within an iRNA. The present invention also includes iRNA compounds that are chimeric compounds.</p><p id="p-0644" num="0679">&#x201c;Chimeric&#x201d; iRNA compounds or &#x201c;chimeras,&#x201d; in the context of this invention, are iRNA compounds, preferably dsRNAi agents, that contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of a dsRNA compound. These iRNAs typically contain at least one region wherein the RNA is modified so as to confer upon the iRNA increased resistance to nuclease degradation, increased cellular uptake, or increased binding affinity for the target nucleic acid. An additional region of the iRNA can serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of iRNA inhibition of gene expression. Consequently, comparable results can often be obtained with shorter iRNAs when chimeric dsRNAs are used, compared to phosphorothioate deoxy dsRNAs hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.</p><p id="p-0645" num="0680">In certain instances, the RNA of an iRNA can be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to iRNAs in order to enhance the activity, cellular distribution or cellular uptake of the iRNA, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Kubo, T. et al., <i>Biochem. Biophys. Res. Comm., </i>2007, 365(1):54-61; Letsinger et al., <i>Proc. Natl. Acad. Sci. USA, </i>1989, 86:6553), cholic acid (Manoharan et al., <i>Bioorg. Med. Chem. Lett., </i>1994, 4:1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., <i>Ann. N.Y. Acad. Sci., </i>1992, 660:306; Manoharan et al., <i>Bioorg. Med. Chem. Let., </i>1993, 3:2765), a thiocholesterol (Oberhauser et al., <i>Nucl. Acids Res., </i>1992, 20:533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., <i>EMBO J., </i>1991, 10:111; Kabanov et al., <i>FEBS Lett., </i>1990, 259:327; Svinarchuk et al., <i>Biochimie, </i>1993, 75:49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., <i>Tetrahedron Lett., </i>1995, 36:3651; Shea et al., <i>Nucl. Acids Res., </i>1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan et al., <i>Nucleosides </i>&#x26; <i>Nucleotides, </i>1995, 14:969), or adamantane acetic acid (Manoharan et al., <i>Tetrahedron Lett., </i>1995, 36:3651), a palmityl moiety (Mishra et al., <i>Biochim. Biophys. Acta, </i>1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. <i>Pharmacol. Exp. Ther., </i>1996, 277:923). Representative United States patents that teach the preparation of such RNA conjugates have been listed above. Typical conjugation protocols involve the synthesis of RNAs bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction can be performed either with the RNA still bound to the solid support or following cleavage of the RNA, in solution phase. Purification of the RNA conjugate by HPLC typically affords the pure conjugate.</p><heading id="h-0014" level="1">VIII. Pharmaceutical Compositions of the Invention</heading><p id="p-0646" num="0681">The present invention also includes pharmaceutical compositions and formulations which include the iRNAs for use in the methods of the invention. In one embodiment, provided herein are pharmaceutical compositions containing an iRNA, as described herein, and a pharmaceutically acceptable carrier. The pharmaceutical compositions containing the iRNA are useful for preventing or treating an AGT associated disorder, e.g., hypertension. Such pharmaceutical compositions are formulated based on the mode of delivery.</p><p id="p-0647" num="0682">The pharmaceutical compositions comprising RNAi agents of the invention may be, for example, solutions with or without a buffer, or compositions containing pharmaceutically acceptable carriers. Such compositions include, for example, aqueous or crystalline compositions, liposomal formulations, micellar formulations, emulsions, and gene therapy vectors.</p><p id="p-0648" num="0683">In the methods of the invention, the RNAi agent may be administered in a solution. A free RNAi agent may be administered in an unbuffered solution, e.g., in saline or in water. Alternatively, the free siRNA may also be administered in a suitable buffer solution. The buffer solution may comprise acetate, citrate, prolamine, carbonate, or phosphate, or any combination thereof. In one embodiment, the buffer solution is phosphate buffered saline (PBS). The pH and osmolarity of the buffer solution containing the RNAi agent can be adjusted such that it is suitable for administering to a subject.</p><p id="p-0649" num="0684">In some embodiments, the buffer solution further comprises an agent for controlling the osmolarity of the solution, such that the osmolarity is kept at a desired value, e.g., at the physiologic values of the human plasma. Solutes which can be added to the buffer solution to control the osmolarity include, but are not limited to, proteins, peptides, amino acids, non-metabolized polymers, vitamins, ions, sugars, metabolites, organic acids, lipids, or salts. In some embodiments, the agent for controlling the osmolarity of the solution is a salt. In certain embodiments, the agent for controlling the osmolarity of the solution is sodium chloride or potassium chloride.</p><p id="p-0650" num="0685">In some embodiments, the pharmaceutical compositions of the invention are pyrogen free or non-pyrogenic.</p><p id="p-0651" num="0686">The pharmaceutical compositions of the present invention can be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration can be topical (e.g., by a transdermal patch), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal, oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; subdermal, e.g., via an implanted device; or intracranial, e.g., by intraparenchymal, intrathecal or intraventricular, administration.</p><p id="p-0652" num="0687">One example is compositions that are formulated for systemic administration via parenteral delivery, e.g., by subcutaneous (SC), intramuscular (IM), or intravenous (IV) delivery. The pharmaceutical compositions of the invention may be administered in dosages sufficient to inhibit expression of an AGT gene.</p><p id="p-0653" num="0688">The pharmaceutical compositions of the invention may be administered in dosages sufficient to inhibit expression of an AGT gene. In some embodiments, a fixed dose of about 50 mg to about 800 mg (e.g., about 50 to about 200 mg, about 50 mg to about 500 mg, about 100 mg to about 800 mg, about 100 mg to about 500 mg, about 100 mg to about 300 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 500 mg, about 200 mg to about 800 mg, about 300 mg to about 800 mg, about 300 mg to about 500 mg, about 300 mg to about 4000 mg, about 400 mg to about 800 mg, about 400 mg to about 500 mg, e.g., about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or about 800 mg) of the iRNA agents are administered to the subject.</p><p id="p-0654" num="0689">A repeat-dose regimen may include administration of a therapeutic amount of iRNA on a regular basis, such as every month, every two months, every three months, every four months, every five months, every six months, once every 3-6 months, or once a year. In certain embodiments, the iRNA is administered about once per month to about once per quarter to about once per six months.</p><p id="p-0655" num="0690">After an initial treatment regimen, the treatments can be administered on a less frequent basis. Duration of treatment can be determined based on the severity of disease.</p><p id="p-0656" num="0691">In other embodiments, a single dose of the pharmaceutical compositions can be long lasting, such that doses are administered at not more than 1, 2, 3, 4, 5 or 6 month intervals. In some embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered about once per month. In other embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered quarterly (i.e., about every three months). In other embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered twice per year (i.e., about once every six months).</p><p id="p-0657" num="0692">The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to mutations present in the subject, previous treatments, the general health or age of the subject, and other diseases present. Moreover, treatment of a subject with a prophylactically or therapeutically effective amount, as appropriate, of a composition can include a single treatment or a series of treatments.</p><p id="p-0658" num="0693">The iRNA can be delivered in a manner to target a particular tissue (e.g., hepatocytes).</p><p id="p-0659" num="0694">Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions can be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids, and self-emulsifying semisolids. Formulations include those that target the liver.</p><p id="p-0660" num="0695">The pharmaceutical formulations of the present invention, which can conveniently be presented in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers.</p><heading id="h-0015" level="1">IX. Kits</heading><p id="p-0661" num="0696">The present invention also provides kits for performing any of the methods of the invention. Such kits include one or more double stranded RNAi agent(s) and instructions for use, e.g., instructions for administering a fixed dose of a double stranded RNAi agent(s). The double stranded RNAi agent may be in a vial or a pre-filled syringe. The kits may optionally further comprise means for administering the double stranded RNAi agent (e.g., an injection device, such as a pre-filled syringe), or means for measuring the inhibition of AGT (e.g., means for measuring the inhibition of AGT mRNA, AGT protein, and/or AGT activity). Such means for measuring the inhibition of AGT may comprise a means for obtaining a sample from a subject, such as, e.g., a plasma sample. The kits of the invention may optionally further comprise means for determining the therapeutically effective or prophylactically effective amount.</p><p id="p-0662" num="0697">Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the iRNAs and methods featured in the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.</p><p id="p-0663" num="0698">This invention is further illustrated by the following examples which should not be construed as limiting. The entire contents of all references, patents and published patent applications cited throughout this application, as well as the Sequence Listing, are hereby incorporated herein by reference.</p><heading id="h-0016" level="1">EXAMPLES</heading><p id="p-0664" num="0699">Abbreviations of nucleotide monomers used in nucleic acid sequence representation. It will be understood that these monomers, when present in an oligonucleotide, are mutually linked by 5&#x2032;-3&#x2032;-phosphodiester bonds unless otherwise indicated.</p><p id="p-0665" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="168pt" align="left"/><thead><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row><row><entry>Abbreviation</entry><entry>Nucleotide(s)</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>A</entry><entry>Adenosine-3&#x2032;-phosphate</entry></row><row><entry>Af</entry><entry>2&#x2032;-fluoroadenosine-3&#x2032;-phosphate</entry></row><row><entry>Afs</entry><entry>2&#x2032;-fluoroadenosine-3&#x2032;-phosphorothioate</entry></row><row><entry>As</entry><entry>adenosine-3&#x2032;-phosphorothioate</entry></row><row><entry>C</entry><entry>cytidine-3&#x2032;-phosphate</entry></row><row><entry>Cf</entry><entry>2&#x2032;-fluorocytidine-3&#x2032;-phosphate</entry></row><row><entry>Cfs</entry><entry>2&#x2032;-fluorocytidine-3&#x2032;-phosphorothioate</entry></row><row><entry>Cs</entry><entry>cytidine-3&#x2032;-phosphorothioate</entry></row><row><entry>G</entry><entry>guanosine-3&#x2032;-phosphate</entry></row><row><entry>Gf</entry><entry>2&#x2032;-fluoroguanosine-3&#x2032;-phosphate</entry></row><row><entry>Gfs</entry><entry>2&#x2032;-fluoroguanosine-3&#x2032;-phosphorothioate</entry></row><row><entry>Gs</entry><entry>guanosine-3&#x2032;-phosphorothioate</entry></row><row><entry>T</entry><entry>5&#x2032;-methyluridine-3&#x2032;-phosphate</entry></row><row><entry>Tf</entry><entry>2&#x2032;-fluoro-5-methyluridine-3&#x2032;-phosphate</entry></row><row><entry>Tfs</entry><entry>2&#x2019;-fluoro-5-methyluridine-3&#x2032;-phosphorothioate</entry></row><row><entry>Ts</entry><entry>5-methyluridine-3&#x2032;-phosphorothioate</entry></row><row><entry>U</entry><entry>Uridine-3&#x2032;-phosphate</entry></row><row><entry>Uf</entry><entry>2&#x2032;-fluorouridine-3&#x2032;-phosphate</entry></row><row><entry>Ufs</entry><entry>2&#x2032;-fluorouridine-3&#x2032;-phosphorothioate</entry></row><row><entry>Us</entry><entry>uridine-3&#x2032;-phosphorothioate</entry></row><row><entry>N</entry><entry>any nucleotide, modified or unmodified</entry></row><row><entry>a</entry><entry>2&#x2032;-O-methyladenosine-3&#x2032;-phosphate</entry></row><row><entry>as</entry><entry>2&#x2032;-O-methyladenosine-3&#x2032;-phosphorothioate</entry></row><row><entry>c</entry><entry>2&#x2032;-O-methylcytidine-3&#x2032;-phosphate</entry></row><row><entry>cs</entry><entry>2&#x2032;-O-methylcytidine-3&#x2032;-phosphorothioate</entry></row><row><entry>g</entry><entry>2&#x2032;-O-methylguanosine-3&#x2032;-phosphate</entry></row><row><entry>gs</entry><entry>2&#x2032;-O-methylguanosine-3&#x2032;-phosphorothioate</entry></row><row><entry>t</entry><entry>2&#x2032;-O-methyl-5-methyluridine-3&#x2032;-phosphate</entry></row><row><entry>ts</entry><entry>2&#x2032;-O-methyl-5-methyluridine-3&#x2032;-phosphorothioate</entry></row><row><entry>u</entry><entry>2&#x2032;-O-methyluridine-3&#x2032;-phosphate</entry></row><row><entry>us</entry><entry>2&#x2032;-O-methyluridine-3&#x2032;-phosphorothioate</entry></row><row><entry>s</entry><entry>phosphorothioate linkage</entry></row><row><entry>L96</entry><entry>N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol</entry></row><row><entry/><entry>(Hyp-(GalNAc-alkyl)3)</entry></row><row><entry>(Agn)</entry><entry>Adenosine-glycol nucleic acid (GNA)</entry></row><row><entry>(Cgn)</entry><entry>Cytidine-glycol nucleic acid (GNA)</entry></row><row><entry>(Ggn)</entry><entry>Guanosine-glycol nucleic acid (GNA)</entry></row><row><entry>(Tgn)</entry><entry>Thymidine-glycol nucleic acid (GNA) S-Isomer</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0017" level="1">Example 1. Phase 1 Clinical Trial of AGT dsRNA</heading><p id="p-0666" num="0700">A multicenter, randomized, double-blind, active comparator single dose and multiple dose clinical trial was designed to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of subcutaneous administration of (SC) AD-85481 to patients with hypertension.</p><p id="p-0667" num="0701">This study includes 4 parts:</p><p id="p-0668" num="0702">Part A: single ascending dose (SAD) phase in hypertensive patients;</p><p id="p-0669" num="0703">Part B: Single dose (SD) in hypertensive patients with controlled salt intake;</p><p id="p-0670" num="0704">Part C: Multiple dose (MD) phase in hypertensive patients; and</p><p id="p-0671" num="0705">Part D: Multiple dose (MD) phase in hypertensive patients who are obese.</p><p id="p-0672" num="0706">Ongoing reviews of safety, tolerability, and available PD and PK data were collected in all parts of the study.</p><p id="p-0673" num="0707">Diagnosis and Main Eligibility Criteria</p><p id="p-0674" num="0708">This study included adults 18 to 65 years of age with hypertension (mean sitting systolic blood pressure [SBP] of &#x3e;130 and &#x2264;159 mmHg). Patients with secondary hypertension or mean sitting diastolic blood pressure [DBP]&#x2265;100 mmHg were excluded. Patients with clinically significant medical conditions or comorbidities that would interfere with study compliance or data interpretation (including diabetes mellitus or history of any cardiovascular event) or who were currently taking or anticipated using medications known to affect blood pressure were also excluded.</p><p id="p-0675" num="0709">Study Drug, Dose, and Mode of Administration</p><p id="p-0676" num="0710">Study drug, AD-85481, a chemically modified, N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (siRNA) designed to suppress production of angiotensinogen (AGT) as a strategy to lower blood pressure in individuals with hypertension, was administered either as a single subcutaneous injection (Parts A and B) or 2 subcutaneous injections administered once at Week 1 and once at Week 12 (Parts C and D).</p><heading id="h-0018" level="2">Unmodified and Modified Nucleotide Sequence of AD-85481</heading><p id="p-0677" num="0711"></p><p id="p-0678" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="105pt" align="left"/><colspec colname="3" colwidth="28pt" align="left"/><colspec colname="4" colwidth="154pt" align="left"/><colspec colname="5" colwidth="28pt" align="left"/><thead><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry/><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry></row><row><entry>Strand</entry><entry>Unmodified&#x2003;(5&#x2032;&#x2003;to&#x2003;3&#x2032;)</entry><entry>ID</entry><entry>Modified&#x2003;(5&#x2032;&#x2003;to&#x2003;3&#x2032;)</entry><entry>ID</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>Antis</entry><entry>UGUACUCUCAUUGUGGAUGACGA</entry><entry>&#x2003;9</entry><entry>usGfsuac(Tgn)cucauugUfgGfaugacsgsa</entry><entry>11</entry></row><row><entry> </entry></row><row><entry>Sense</entry><entry>GUCAUCCACAAUGAGAGUACA</entry><entry>10</entry><entry>gsuscaucCfaCfAfAfugagaguaca</entry><entry>12</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0679" num="0712">The chemical modifications are defined as follows: a is 2&#x2032;-O-methyladenosine-3&#x2032;-phosphate, c is 2&#x2032;-O-methylcytidine-3&#x2032;-phosphate, g is 2&#x2032;-O-methylguanosine-3&#x2032;-phosphate, u is 2&#x2032;-O-methyluridine-3&#x2032;-phosphate, Af is 2&#x2032;-fluoroadenosine-3&#x2032;-phosphate, Cf is 2&#x2032;-fluorocytidine-3&#x2032;-phosphate, Gf is 2&#x2032;-fluoroguanosine-3&#x2032;-phosphate, Uf is 2&#x2032;-fluorouridine-3&#x2032;-phosphate, (Ggn) is guanosine-glycol nucleic acid (GNA), and s is phosphorothioate linkage. The 3&#x2032;end of the sense strand is covalently linked to an N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol (also referred to as Hyp-(GalNAc-alkyl)3 or L96) ligand.</p><p id="p-0680" num="0713">Placebo Control, Dose, and Mode of Administration</p><p id="p-0681" num="0714">In Parts A and B, the control drug for AD-85481 was a placebo (normal saline 0.9% for subcutaneous administration).</p><p id="p-0682" num="0715">In Parts C and D, the dummy treatment for AD-85481 is normal saline 0.9% for subcutaneous administration. The dummy treatment for irbesartan is an inert dummy tablet that matches the appearance of irbesartan.</p><p id="p-0683" num="0716">Active Comparator Control, Dose, and Mode of Administration</p><p id="p-0684" num="0717">In Parts C and D of this study, once daily oral (PO) doses of 150 mg irbesartan is used as the active comparator.</p><p id="p-0685" num="0718">Duration of Treatment and Study Participation</p><p id="p-0686" num="0719">A single subcutaneous dose of AD-85481 was administered in Parts A and B. In Parts C and D, 2 subcutaneous doses of study drug are administered over 12 weeks.</p><p id="p-0687" num="0720">Statistical Methods</p><p id="p-0688" num="0721">The sample size was based on practical considerations and is consistent with this type of early phase study.</p><p id="p-0689" num="0722">The Full Analysis Set (FAS) included all patients who received any amount of study drug grouped according to the treatment to which they were randomized. The PK Analysis Set included all patients who received at least 1 dose of study drug and have at least 1 post-dose blood sample for determination of AD-85481 concentrations and have evaluable PK data. The PD Analysis Set included all patients who received at least 1 dose of study drug and who had at least 1 post-dose blood sample for the determination of serum AGT.</p><p id="p-0690" num="0723">AD-85481 activity was analyzed using the FAS. The PK and PD Analysis Sets were used to conduct PK and PD analyses, respectively.</p><p id="p-0691" num="0724">Statistical analyses are primarily descriptive in nature. Descriptive statistics (e.g., mean, standard deviation, median, minimum, and maximum) are presented for continuous variables. Frequencies and percentages are presented for categorical and ordinal variables. Descriptive statistics are provided for clinical laboratory data, electrocardiogram (ECG), and vital signs data.</p><p id="p-0692" num="0725">Study Design Rationale</p><p id="p-0693" num="0726">A Phase 1, multi-center, randomized, double-blind study of AD-85481 was administered subcutaneously (SC) to patients with hypertension. The primary objective for the study was to evaluate the safety and tolerability of single or multiple doses of AD-85481 in patients with hypertension. The study was conducted in 4 parts: a single ascending dose (SAD) phase (Part A), a single dose (SD) phase in patients with controlled salt intake (Part B), a multiple dose (MD) phase (Part C), and a MD phase in obese patients (Part D).</p><p id="p-0694" num="0727">The study was designed to provide initial insight into the safety and tolerability of AD-85481. Based upon the known safety profile of approved antihypertensives, this study was designed to carefully monitor blood pressure, serum electrolytes, and creatinine, with frequent data collection during the anticipated nadir of AGT (estimated to be 4-6 weeks after AD-85481 dose). Clinical laboratory assessments and blood pressure data were collected periodically after study drug administration to correspond with the AGT nadir.</p><p id="p-0695" num="0728">In addition to safety of AD-85481, this study was designed to enable insights into the following secondary or exploratory research questions.</p><p id="p-0696" num="0729">Pharmacodynamic (PD) of AD-85481: PD effect was directly demonstrated by serial measurements of serum AGT to determine the change from basline in the level of plasma AGT. Downstream effectors of AGT (plasma renin concentration, plasma renin activity, angiotensin I, angiotensin II, aldosterone) may also be measured in blood and urine specimens as exploratory biomarkers.</p><p id="p-0697" num="0730">Pharmacokinentic (PK) of AD-85481: PK parameters of AD-85481 were assessed by determination of plasma and urine levels of AD-85481 and potential metabolites, e.g., by qPCR.</p><p id="p-0698" num="0731">Blood pressure reduction: This study enrolled patients with hypertension (initially corresponding to Grade 1 per ESC/ESH criteria) to enable the assessment of therapeutic blood pressure reduction. Single dose phases (Parts A and B) are of short duration and use an inert placebo group. To adhere to best ethical standards, longer MD phases (Parts C and D) use an established angiotensin II-receptor blocker (ARB) (irbesartan) as an active comparator to AD-85481 treatment. Exploratory assessments of AD-85481 include change from baseline in SBP and DBP assessed by 24 hour ambulatory blood pressure monitoring (ABPM) and the change from baseline in SBP and DBP assessed by oscillometric automated office blood pressure (AOBP) and by oscillometric home blood pressure monitoring (HBPM).</p><p id="p-0699" num="0732">As recommended by current guidance, patients discontinue prior antihypertensive medications for approximately 3-4 weeks prior to study drug administration and blood pressure was monitored with both automated office blood pressure (AOBP) measurements and by outpatient 24-hour ambulatory blood pressure monitoring (ABPM). In addition to having greater precision, the latter method assesses peak-to-trough blood pressure ratios and circadian rhythms (including potential restoration of the normal nocturnal blood pressure dipping pattern that is lost in 24-35% of hypertensive patients). More frequent (daily) measurements are collected through a third method, oscillometric home blood pressure monitoring (HBPM), to characterize gradual PD effects and to provide close safety monitoring for potential hypotension while not in the clinic.</p><p id="p-0700" num="0733">Impact of Low Salt Intake on Blood Pressure Response to AD-85481: Because hypertension is salt-sensitive in some patients, all study patients receive educational materials on diet with instructions to limit sodium consumption to approximately 2.0 g per day from screening through end of treatment (EOT). Of note, this is the sodium intake recommended in the 2018 ESC/ESH Guidelines for both hypertensive patients and for the general population.</p><p id="p-0701" num="0734">Additionally, the Part B study 1 cohort of patients with controlled salt intake are studied to evaluate potential for augmented pharmacology and safety in a low-salt state (1.15 g sodium per day), which has been demonstrated previously with other RAAS-inhibiting drugs. Part B patients complete a 2-week dietary subprotocol that varies sodium consumption to directly test for salt-sensitive blood pressure responses. During Part B, food is prepared in research/metabolic kitchens according to a common protocol and provided to patients. Patients are inpatient for the first week of the 2-week subprotocol to promote compliance with a low-salt diet and to enhance monitoring for potential augmented AD-85481 pharmacology upon the introduction of salt deprivation. After AGT lowering and salt deprivation, the blood pressure response to high salt intake alone is characterized. Exploratory endpoints on the effects of AD-85481 include determination of change from baseline in SBP and DBP assessed by ABPM and AOBP under low vs high salt conditions</p><p id="p-0702" num="0735">Obesity: The majority of patients with hypertension are expected to be overweight or obese. Additionally, increased adiposity is likely to be causally associated with hypertension. Part D studies 1 cohort of patients with body mass index (BMI) in the Class I to III obesity range to evaluate the impact of weight on PK and PD parameters.</p><p id="p-0703" num="0736">As preclinical studies have implicated AGT as a contributor to both diet-induced obesity and hepatic steatosis via mechanisms that may be distinct from classic RAAS pathways, weight loss is evaluated as an exploratory endpoint. Anthropometrics (waist circumference, waist-to-hip ratio) and a radiographic assessment of body composition (dual-energy x-ray absorptiometry; DEXA) are collected to determine if weight changes are due to loss of body fat. Biochemical parameters of lipid and glucose metabolism (lipid profile, HbA1c, fasting glucose) that improve with weight reduction are measured approximately every 3 months. Of note, Parts A, B, and C enroll patients in the normal to overweight, and mild (Class I) obesity range (BMI &#x2265;18 kg/m<sup>2 </sup>and &#x2264;35 kg/m<sup>2</sup>). The single cohort in Part D is restricted to obese patients (BMI &#x3e;30 kg/m<sup>2 </sup>and &#x2264;50 kg/m<sup>2</sup>). Exploratory endpoints on the effects of AD-85481 include determination of change from baseline in body weight, waist circumference, waist-to-hip ratio, and body composition (as assessed by dual-energy x-ray absorptiometry (DEXA)) in obese patients.</p><p id="p-0704" num="0737">Further exploratory objectives of the study overall include assessment of the effect of ALN-AD-85481 on metabolic syndrome parameters by determining the change from baseline in HbA1c, fasting plasma glucose, and serum lipid profile; and assessment of the effect of AD-85481 on exploratory biomarkers of the RAAS by determining the change from baseline in plasma renin concentration, plasma renin activity, angiotensin I, angiotensin II, and aldosterone.</p><p id="p-0705" num="0738">Study Drug Dosing and Progression.</p><p id="p-0706" num="0739">Doses for Part A are 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, and &#x2264;400 mg. There were 12 patients in each of the 6 cohorts (with 3 optional cohorts for evaluation of interim dose levels, lower dose levels, or expansions of previous cohorts may be enrolled in Part A to better characterize the dose response or safety and tolerability) with a 2:1 randomization of AD-85481:placebo. The lowest dose is not expected to have an effect on blood pressure lowering. Blood pressure lowering activity was expected to be first observed at the 50 mg dose with a lowering of serum AGT of at least 80%.</p><heading id="h-0019" level="2">Phase I-Part A</heading><p id="p-0707" num="0740">Lowering of serum AGT from baseline in Part A. Subjects meeting inclusion and exclusion criteria were administered a single dose of AD-85481 or placebo on Day 1. Blood samples were collected prior to administration of AD-85481 or placebo, weekly for 6 weeks after administration, at week 8 and week 12 post treatment, and then every 3 months during the follow-up period. Serum AGT level was determined by solid phase sandwich ELISA and lowering of AGT from baseline was determined at each of the time points.</p><p id="p-0708" num="0741">A total of 60 patients with hypertension completed treatment in Part A of the study. Patients received either placebo (n=4 per cohort) or AD-85481 (n=8 per cohort). The demographics and baseline characteristics of subjects participating in Part A are presented in the table below.</p><p id="p-0709" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="35pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="35pt" align="center"/><thead><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry/><entry>Placebo</entry><entry>10 mg</entry><entry>25 mg</entry><entry>50 mg</entry><entry>100 mg</entry><entry>200 mg</entry></row><row><entry/><entry>(N = 20)</entry><entry>(N = 8)</entry><entry>(N = 8)</entry><entry>(N = 8)</entry><entry>(N = 8)</entry><entry>(N = 8)</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>Age, years; median</entry><entry>&#x2002;52</entry><entry>&#x2002;53</entry><entry>&#x2002;56</entry><entry>&#x2002;41</entry><entry>&#x2002;56</entry><entry>&#x2002;56</entry></row><row><entry>(range)</entry><entry>(36-64)</entry><entry>(37-60)</entry><entry>(47-63)</entry><entry>(35-64)</entry><entry>(35-65)</entry><entry>(43-64)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="35pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="35pt" align="center"/><colspec colname="8" colwidth="35pt" align="center"/><tbody valign="top"><row><entry>Gender</entry><entry>Male</entry><entry>&#x2003;9</entry><entry>&#x2003;7</entry><entry>&#x2003;2</entry><entry>&#x2003;7</entry><entry>&#x2003;3</entry><entry>&#x2003;5</entry></row><row><entry/><entry>Female</entry><entry>&#x2002;11</entry><entry>&#x2003;1</entry><entry>&#x2003;6</entry><entry>&#x2003;1</entry><entry>&#x2003;5</entry><entry>&#x2003;3</entry></row><row><entry>Race</entry><entry>White</entry><entry>&#x2002;14</entry><entry>&#x2003;6</entry><entry>&#x2003;4</entry><entry>&#x2003;3</entry><entry>&#x2003;4</entry><entry>&#x2003;6</entry></row><row><entry/><entry>Black</entry><entry>&#x2003;5</entry><entry>&#x2003;1</entry><entry>&#x2003;4</entry><entry>&#x2003;4</entry><entry>&#x2003;2</entry><entry>&#x2003;2</entry></row><row><entry/><entry>Asian</entry><entry>&#x2003;0</entry><entry>&#x2003;1</entry><entry>&#x2003;0</entry><entry>&#x2003;0</entry><entry>&#x2003;2</entry><entry>&#x2003;0</entry></row><row><entry/><entry>Other</entry><entry>&#x2003;1</entry><entry>&#x2003;0</entry><entry>&#x2003;0</entry><entry>&#x2003;1</entry><entry>&#x2003;0</entry><entry>&#x2003;0</entry></row><row><entry>Blood</entry><entry>24 h ABPM</entry><entry>141</entry><entry>139</entry><entry>141</entry><entry>135</entry><entry>136</entry><entry>139</entry></row><row><entry>Pressure</entry><entry>SBP</entry><entry>(126, 153)</entry><entry>(130, 147)</entry><entry>(132, 157)</entry><entry>(113, 144)</entry><entry>(131, 152)</entry><entry>(129, 154)</entry></row><row><entry/><entry>median</entry><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>(range)</entry><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>24 h ABPM</entry><entry>&#x2002;87</entry><entry>&#x2002;84</entry><entry>&#x2002;91</entry><entry>&#x2002;84</entry><entry>&#x2002;86</entry><entry>&#x2002;83</entry></row><row><entry/><entry>DBP</entry><entry>(72-102)</entry><entry>(76, 93)</entry><entry>(75, 103)</entry><entry>(74, 91)</entry><entry>(80, 90)</entry><entry>(75, 95)</entry></row><row><entry/><entry>median</entry><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>(range)</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0710" num="0742">Safety profile in Part A. The primary objective for the study was to evaluate the safety and tolerability of single doses of AD-85481 in patients with hypertension. As demonstrated in the table below, the safety profile of AD-85481 was acceptable with no safety concerns. Most adverse events were mild or moderate in severity and were resolved without intervention. There was neither death or adverse events leading to study withdrawal, nor treatment-related serious adverse events (SAEs). Severe SAE of prostate cancer was reported in 1 patient who received 200 mg, based upon a biopsy that was performed in the screening period and was reported as positive after dosing. No patient required intervention for low blood pressure, and no clinically significant elevations in serum alanine aminotransferase (ALT), serum creatinine, or serum potassium were observed during the course of the study. Five patients reported mild injection site reactions</p><p id="p-0711" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="105pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="35pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="35pt" align="center"/><thead><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry>Patients Reporting an</entry><entry>Placebo</entry><entry>10 mg</entry><entry>25 mg</entry><entry>50 mg</entry><entry>100 mg</entry><entry>200 mg</entry></row><row><entry>Adverse Event (AE), N</entry><entry>(N = 20)</entry><entry>(N = 8)</entry><entry>(N = 8)</entry><entry>(N = 8)</entry><entry>(N = 8)</entry><entry>(N = 8)</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="105pt" align="left"/><colspec colname="2" colwidth="35pt" align="char" char="."/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="35pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="35pt" align="center"/><tbody valign="top"><row><entry>At least 1 adverse event</entry><entry>17</entry><entry>5</entry><entry>7</entry><entry>6</entry><entry>7</entry><entry>7</entry></row><row><entry>At least 1 serious adverse event</entry><entry>1</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>1</entry></row><row><entry>At least 1 severe adverse event</entry><entry>1</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>1</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0712" num="0743">The effects of administration of a single dose of AD-85481 on the level of serum AGT are presented in <figref idref="DRAWINGS">FIG. <b>1</b></figref>.</p><p id="p-0713" num="0744">A mean maximum AGT lowering of 54% was observed at 10 mg dose with a mean lowering at 4 weeks of 52% at the 10 mg single dose.</p><p id="p-0714" num="0745">A mean maximum AGT lowering of 69% was observed at the 25 mg dose with a mean lowering at 4 weeks of 69% at the 25 mg single dose.</p><p id="p-0715" num="0746">A mean maximum AGT lowering of 74% was observed at the 50 mg dose with a mean lowering at 4 weeks of 68% at the 50 mg single dose.</p><p id="p-0716" num="0747">A mean maximum AGT lowering of 94% was observed at the 100 mg dose with a mean lowering at 4 weeks of 92% at the 100 mg single dose.</p><p id="p-0717" num="0748">A mean maximum AGT lowering of 96% was observed at the 200 mg dose with a mean lowering at 4 weeks of 95% at the 200 mg single dose.</p><p id="p-0718" num="0749">These data demonstrate a durable dose-dependent reduction of serum AGT after treatment with a single dose of AD-85481. In addition, a greater than 90% reduction in serum AGT levels was observed in subjects receiving higher single doses of AD-85481, and the reduction in AGT persisted for greater than 3 months, e.g., demonstrating that a chronic dosing administration interval of at least once quarterly would be effective.</p><p id="p-0719" num="0750">Modulation of blood pressure from baseline in Part A. Assessments of AD-85481 included change from baseline in SBP and DBP assessed by 24 hour ambulatory blood pressure monitoring (ABPM) and the change from baseline in SBP and DBP assessed by oscillometric automated office blood pressure (AOBP) and by oscillometric home blood pressure monitoring (HBPM).</p><p id="p-0720" num="0751">As depicted in <figref idref="DRAWINGS">FIG. <b>2</b></figref>, a single 100 mg dose of AD-85481, reduced systolic and diastolic blood pressures by about 10.1 mmHg and about 5.5 mmHg, respectively, at Week 8 when compared to placebo as determined by 24 hour ambulatory blood pressure measurements (ABPM). After a single 200 mg dose of AD-85481, reductions in systolic and diastolic blood pressures of about 11 mmHg and about 7.7 mmHg, respectively, at Week 8 compared to placebo were observed, as determined by 24 hour ambulatory blood pressure measurements (ABPM).</p><p id="p-0721" num="0752">These data demonstrate a dose-dependent reduction in SBP and DBP in subjects receiving single doses of AD-85481. Specifically, greater than 10 mmHg reduction in 24 hour SBP was observed at Week 8 after a single dose of AD-85481 (e.g., 100 mg or 200 mg).</p><heading id="h-0020" level="1">SUMMARY</heading><p id="p-0722" num="0753">In summary, this single ascending dose study characterized the maximum effect of AD-85481 and demonstrated the durability of AD-85481 treatment for a period of over 3 months. These data demonstrate that single subcutaneous doses of AD-85481 (also referred to ALN-AGT01) were well tolerated in patients with mild to moderate hypertension, with no treatment-related serious adverse events. Administration of AD-85481 led to a dose-dependent and durable reduction of serum AGT. AGT reductions of greater than 90% were observed after higher single doses of AD-85481 that persisted for &#x2265;3 months, demonstrating that an infrequent dosing interval is required.</p><p id="p-0723" num="0754">Blood pressure reductions mirrored AGT knockdown following administration of a single fixed dose of AD-85481, with &#x3e;10 mm Hg reduction in 24 hour SBP observed at 8 weeks after single doses of 100 mg or higher.</p><p id="p-0724" num="0755">As compared to current methods and therapeutics to treat hypertension, many of which are associated with negative effects on kidney function, these data further demonstrate that liver-specific silencing of AGT is effective and, thus, provide improved renal safety. The prolonged duration of action of AD-85481 is further superior to current therapeutics in that it may provide a consistent and durable blood pressure response, blunting of diurnal BP variation, and enhanced adherence since infrequent dosing is required and there is a reduction in overall pill burden.</p><heading id="h-0021" level="1">EQUIVALENTS</heading><p id="p-0725" num="0756">Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed by the scope of the following claims.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002765A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-chemistry idref="CHEM-US-00001" cdx-file="US20230002765A1-20230105-C00001.CDX" mol-file="US20230002765A1-20230105-C00001.MOL"/><us-chemistry idref="CHEM-US-00002" cdx-file="US20230002765A1-20230105-C00002.CDX" mol-file="US20230002765A1-20230105-C00002.MOL"/><us-chemistry idref="CHEM-US-00003" cdx-file="US20230002765A1-20230105-C00003.CDX" mol-file="US20230002765A1-20230105-C00003.MOL"/><us-chemistry idref="CHEM-US-00004" cdx-file="US20230002765A1-20230105-C00004.CDX" mol-file="US20230002765A1-20230105-C00004.MOL"/><us-chemistry idref="CHEM-US-00005" cdx-file="US20230002765A1-20230105-C00005.CDX" mol-file="US20230002765A1-20230105-C00005.MOL"/><us-chemistry idref="CHEM-US-00006" cdx-file="US20230002765A1-20230105-C00006.CDX" mol-file="US20230002765A1-20230105-C00006.MOL"/><us-chemistry idref="CHEM-US-00007" cdx-file="US20230002765A1-20230105-C00007.CDX" mol-file="US20230002765A1-20230105-C00007.MOL"/><us-chemistry idref="CHEM-US-00008" cdx-file="US20230002765A1-20230105-C00008.CDX" mol-file="US20230002765A1-20230105-C00008.MOL"/><us-chemistry idref="CHEM-US-00009" cdx-file="US20230002765A1-20230105-C00009.CDX" mol-file="US20230002765A1-20230105-C00009.MOL"/><us-chemistry idref="CHEM-US-00010" cdx-file="US20230002765A1-20230105-C00010.CDX" mol-file="US20230002765A1-20230105-C00010.MOL"/><us-chemistry idref="CHEM-US-00011" cdx-file="US20230002765A1-20230105-C00011.CDX" mol-file="US20230002765A1-20230105-C00011.MOL"/><us-chemistry idref="CHEM-US-00012" cdx-file="US20230002765A1-20230105-C00012.CDX" mol-file="US20230002765A1-20230105-C00012.MOL"/><us-chemistry idref="CHEM-US-00013" cdx-file="US20230002765A1-20230105-C00013.CDX" mol-file="US20230002765A1-20230105-C00013.MOL"/><us-chemistry idref="CHEM-US-00014" cdx-file="US20230002765A1-20230105-C00014.CDX" mol-file="US20230002765A1-20230105-C00014.MOL"/><us-chemistry idref="CHEM-US-00015" cdx-file="US20230002765A1-20230105-C00015.CDX" mol-file="US20230002765A1-20230105-C00015.MOL"/><us-chemistry idref="CHEM-US-00016" cdx-file="US20230002765A1-20230105-C00016.CDX" mol-file="US20230002765A1-20230105-C00016.MOL"/><us-chemistry idref="CHEM-US-00017" cdx-file="US20230002765A1-20230105-C00017.CDX" mol-file="US20230002765A1-20230105-C00017.MOL"/><us-chemistry idref="CHEM-US-00018" cdx-file="US20230002765A1-20230105-C00018.CDX" mol-file="US20230002765A1-20230105-C00018.MOL"/><us-chemistry idref="CHEM-US-00019" cdx-file="US20230002765A1-20230105-C00019.CDX" mol-file="US20230002765A1-20230105-C00019.MOL"/><us-chemistry idref="CHEM-US-00020" cdx-file="US20230002765A1-20230105-C00020.CDX" mol-file="US20230002765A1-20230105-C00020.MOL"/><us-chemistry idref="CHEM-US-00021" cdx-file="US20230002765A1-20230105-C00021.CDX" mol-file="US20230002765A1-20230105-C00021.MOL"/><us-chemistry idref="CHEM-US-00022" cdx-file="US20230002765A1-20230105-C00022.CDX" mol-file="US20230002765A1-20230105-C00022.MOL"/><us-chemistry idref="CHEM-US-00023" cdx-file="US20230002765A1-20230105-C00023.CDX" mol-file="US20230002765A1-20230105-C00023.MOL"/><us-chemistry idref="CHEM-US-00024" cdx-file="US20230002765A1-20230105-C00024.CDX" mol-file="US20230002765A1-20230105-C00024.MOL"/><us-chemistry idref="CHEM-US-00025" cdx-file="US20230002765A1-20230105-C00025.CDX" mol-file="US20230002765A1-20230105-C00025.MOL"/><us-chemistry idref="CHEM-US-00026" cdx-file="US20230002765A1-20230105-C00026.CDX" mol-file="US20230002765A1-20230105-C00026.MOL"/><us-chemistry idref="CHEM-US-00027" cdx-file="US20230002765A1-20230105-C00027.CDX" mol-file="US20230002765A1-20230105-C00027.MOL"/><us-chemistry idref="CHEM-US-00028" cdx-file="US20230002765A1-20230105-C00028.CDX" mol-file="US20230002765A1-20230105-C00028.MOL"/><us-math idrefs="MATH-US-00001" nb-file="US20230002765A1-20230105-M00001.NB"><img id="EMI-M00001" he="6.01mm" wi="76.20mm" file="US20230002765A1-20230105-M00001.TIF" alt="embedded image " img-content="math" img-format="tif"/></us-math><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A method for inhibiting the expression of an angiotensinogen (AGT) gene in a subject, the method comprising administering to the subject a fixed dose of about 50 mg to about 800 mg of a double-stranded ribonucleic acid (RNAi) agent, or salt thereof,<claim-text>wherein the double-stranded RNAi agent or salt thereof, comprises a sense strand and an antisense strand forming a double stranded region,</claim-text><claim-text>wherein the antisense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10);</claim-text><claim-text>wherein the double-stranded RNAi agent, or salt thereof, comprises at least one modified nucleotide; and</claim-text><claim-text>wherein at least one of the modifications on the nucleotides is a thermally destabilizing nucleotide modification, thereby inhibiting the expression of the AGT gene in the subject.</claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. A method for treating a subject that would benefit from reduction in angiotensinogen (AGT) expression, the method comprising administering to the subject a fixed dose of about 50 mg to about 800 mg of a double-stranded ribonucleic acid (RNAi) agent, or salt thereof,<claim-text>wherein the double-stranded RNAi agent, or salt thereof, comprises a sense strand and an antisense strand forming a double stranded region,</claim-text><claim-text>wherein the antisense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10);</claim-text><claim-text>wherein the double-stranded RNAi agent, or salt thereof, comprises at least one modified nucleotide; and</claim-text><claim-text>wherein at least one of the modifications on the nucleotides is a thermally destabilizing nucleotide modification, thereby treating the subject that would benefit from reduction in AGT expression.</claim-text></claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. A method for treating a subject having an angiotensinogen- (AGT-) associated disorder, the method comprising administering to the subject a fixed dose of about 50 mg to about 800 mg of a double-stranded ribonucleic acid (RNAi) agent, or salt thereof,<claim-text>wherein the double-stranded RNAi agent, or salt thereof, comprises a sense strand and an antisense strand forming a double stranded region,</claim-text><claim-text>wherein the antisense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO:10);</claim-text><claim-text>wherein the double-stranded RNAi agent, or salt thereof, comprises at least one modified nucleotide;</claim-text><claim-text>wherein at least one of the modifications on the nucleotides is a thermally destabilizing nucleotide modification, thereby treating the subject having the AGT-associated disorder.</claim-text></claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. A method for decreasing blood pressure level in a subject, the method comprising administering to the subject a fixed dose of about 50 mg to about 800 mg of a double-stranded ribonucleic acid (RNAi) agent, or salt thereof,<claim-text>wherein the double-stranded RNAi agent, or salt thereof, comprises a sense strand and an antisense strand forming a double stranded region,</claim-text><claim-text>wherein the antisense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence UGUACUCUCAUUGUGGAUGACGA (SEQ ID NO: 9) and the sense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides of the nucleotide sequence GUCAUCCACAAUGAGAGUACA (SEQ ID NO: 10);</claim-text><claim-text>wherein the double-stranded RNAi agent, or salt thereof, comprises at least one modified nucleotide;</claim-text><claim-text>wherein at least one of the modifications on the nucleotides is a thermally destabilizing nucleotide modification, thereby decreasing the blood pressure level in the subject.</claim-text></claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the fixed dose is administered to the subject at an interval of once a month; once every three months; or once every six months.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. (canceled)</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. (canceled)</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the subject is administered a fixed dose of about 50 mg to about 200 mg; a fixed dose of about 200 mg to about 400 mg; or a fixed dose of about 400 mg to about 800 mg.</claim-text></claim><claim id="CLM-09-17" num="09-17"><claim-text><b>9</b>.-<b>17</b>. (canceled)</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the double stranded RNAi agent, or salt thereof, is administered to the subject subcutaneously or intravenously.</claim-text></claim><claim id="CLM-19-25" num="19-25"><claim-text><b>19</b>.-<b>25</b>. (canceled)</claim-text></claim><claim id="CLM-00026" num="00026"><claim-text><b>26</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein substantially all of the nucleotides of the sense strand are modified nucleotides; substantially all of the nucleotides of the antisense strand are modified nucleotides; all of the nucleotides of the sense strand are modified nucleotides; or all of the nucleotides of the antisense strand are modified nucleotides.</claim-text></claim><claim id="CLM-27-29" num="27-29"><claim-text><b>27</b>.-<b>29</b>. (canceled)</claim-text></claim><claim id="CLM-00030" num="00030"><claim-text><b>30</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein at least one of the nucleotide modifications is selected from the group consisting of a deoxy-nucleotide, a 3&#x2032;-terminal deoxy-thymine (dT) nucleotide, a 2&#x2032;-O-methyl modified nucleotide, a 2&#x2032;-fluoro modified nucleotide, a 2&#x2032;-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2&#x2032;-amino-modified nucleotide, a 2&#x2032;-O-allyl-modified nucleotide, 2&#x2032;-C-alkyl-modified nucleotide, 2&#x2032;-hydroxly-modified nucleotide, a 2&#x2032;-methoxyethyl modified nucleotide, a 2&#x2032;-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5&#x2032;-phosphate, a nucleotide comprising a 5&#x2032;-phosphate mimic, a thermally destabilizing nucleotide, a glycol modified nucleotide (GNA), and a 2-O&#x2014;(N-methylacetamide) modified nucleotide; and combinations thereof.</claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. (canceled)</claim-text></claim><claim id="CLM-00032" num="00032"><claim-text><b>32</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the double stranded region is 19-23 nucleotide pairs in length, 19-21 nucleotide pairs in length, 21-23 nucleotide pairs in length, or 21 nucleotide pairs in length.</claim-text></claim><claim id="CLM-00033" num="00033"><claim-text><b>33</b>. (canceled)</claim-text></claim><claim id="CLM-00034" num="00034"><claim-text><b>34</b>. (canceled)</claim-text></claim><claim id="CLM-00035" num="00035"><claim-text><b>35</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein at least one strand comprises a 3&#x2032; overhang of at least 1 nucleotide or a 3&#x2032; overhang of at least 2 nucleotides.</claim-text></claim><claim id="CLM-00036" num="00036"><claim-text><b>36</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the double-stranded RNAi agent, or salt thereof, further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.</claim-text></claim><claim id="CLM-37-44" num="37-44"><claim-text><b>37</b>.-<b>44</b>. (canceled)</claim-text></claim><claim id="CLM-00045" num="00045"><claim-text><b>45</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>,<claim-text>wherein the antisense strand comprises a modified nucleotide sequence comprising at least 19 contiguous nucleotides of the modified nucleotide sequence usGfsuac(Tgn)cucauugUfgGfaugacsgsa (SEQ ID NO: 11) and the sense strand comprises a modified nucleotide sequence comprising at least 19 contiguous nucleotides of the modified nucleotide sequence gsuscaucCfaCfAfAfugagaguaca (SEQ ID NO: 12);</claim-text><claim-text>wherein a is 2&#x2032;-O-methyladenosine-3&#x2032;-phosphate, c is 2&#x2032;-O-methylcytidine-3&#x2032;-phosphate, g is 2&#x2032;-O-methylguanosine-3&#x2032;-phosphate, u is 2&#x2032;-O-methyluridine-3&#x2032;-phosphate, Af is 2&#x2032;-fluoroadenosine-3&#x2032;-phosphate, Cf is 2&#x2032;-fluorocytidine-3&#x2032;-phosphate, Gf is 2&#x2032;-fluoroguanosine-3&#x2032;-phosphate, Uf is 2&#x2032;-fluorouridine-3&#x2032;-phosphate, (Tgn) is thymidine-glycol nucleic acid (GNA)S-Isomer, and s is a phosphorothioate linkage, thereby inhibiting the expression of the AGT gene in the subject.</claim-text></claim-text></claim><claim id="CLM-46-69" num="46-69"><claim-text><b>46</b>-<b>69</b>. (canceled)</claim-text></claim><claim id="CLM-00070" num="00070"><claim-text><b>70</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the double stranded RNAi agent, or salt thereof, further comprises a ligand.</claim-text></claim><claim id="CLM-00071" num="00071"><claim-text><b>71</b>. The method of <claim-ref idref="CLM-00070">claim 70</claim-ref>, wherein the ligand is conjugated to the 3&#x2032; end of the sense strand.</claim-text></claim><claim id="CLM-00072" num="00072"><claim-text><b>72</b>. The method of <claim-ref idref="CLM-00071">claim 71</claim-ref>, wherein the ligand is an N-acetylgalactosamine (GalNAc) derivative.</claim-text></claim><claim id="CLM-00073" num="00073"><claim-text><b>73</b>. The method of <claim-ref idref="CLM-00072">claim 72</claim-ref>, wherein the GalNAc derivative comprises one or more GalNAc derivatives attached through a monovalent, bivalent, or trivalent branched linker.</claim-text></claim><claim id="CLM-00074" num="00074"><claim-text><b>74</b>. The method of <claim-ref idref="CLM-00072">claim 72</claim-ref>, wherein the ligand is</claim-text><claim-text><chemistry id="CHEM-US-00027" num="00027"><img id="EMI-C00027" he="67.99mm" wi="108.80mm" file="US20230002765A1-20230105-C00027.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="CLM-00075" num="00075"><claim-text><b>75</b>. The method of <claim-ref idref="CLM-00074">claim 74</claim-ref>, wherein the 3&#x2032; end of the sense strand is conjugated to the ligand as shown in the following schematic</claim-text><claim-text><chemistry id="CHEM-US-00028" num="00028"><img id="EMI-C00028" he="81.70mm" wi="156.38mm" file="US20230002765A1-20230105-C00028.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>and, wherein X is O or S or wherein X is O.</claim-text></claim><claim id="CLM-00076" num="00076"><claim-text><b>76</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, where the subject is a human.</claim-text></claim><claim id="CLM-00077" num="00077"><claim-text><b>77</b>. The method of <claim-ref idref="CLM-00076">claim 76</claim-ref>, wherein the subject has a systolic blood pressure of at least 130 mm Hg; a diastolic blood pressure of at least 80 mm Hg; a systolic blood pressure of at least 140 mm Hg: or a diastolic blood pressure of at least 80 mm Hg.</claim-text></claim><claim id="CLM-00078" num="00078"><claim-text><b>78</b>. (canceled)</claim-text></claim><claim id="CLM-00079" num="00079"><claim-text><b>79</b>. (canceled)</claim-text></claim><claim id="CLM-00080" num="00080"><claim-text><b>80</b>. The method of <claim-ref idref="CLM-00002">claim 2</claim-ref>, wherein the disorder that would benefit from reduction in AGT expression is an AGT-associated disorder.</claim-text></claim><claim id="CLM-00081" num="00081"><claim-text><b>81</b>. The method of <claim-ref idref="CLM-00003">claim 3</claim-ref>, wherein the AGT associated disorder is selected from the group consisting of high blood pressure, hypertension, borderline hypertension, primary hypertension, secondary hypertension isolated systolic or diastolic hypertension, pregnancy-associated hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt hypertension, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, labile hypertension; hypertensive heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis, vasculopathy, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiac myopathy, nocturnal hypotension, glomerulosclerosis, coarctation of the aorta, aortic aneurism, ventricular fibrosis, heart failure, myocardial infarction, angina, stroke, renal disease, renal failure, systemic sclerosis, intrauterine growth restriction (IUGR), fetal growth restriction, obesity, liver steatosis/fatty liver, non-alcoholic Steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD); glucose intolerance, type 2 diabetes, and metabolic syndrome.</claim-text></claim><claim id="CLM-82-86" num="82-86"><claim-text><b>82</b>.-<b>86</b>. (canceled)</claim-text></claim><claim id="CLM-00087" num="00087"><claim-text><b>87</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising administering to the subject a therapeutic agent for treatment of hypertension.</claim-text></claim><claim id="CLM-88-90" num="88-90"><claim-text><b>88</b>.-<b>90</b>. (canceled)</claim-text></claim><claim id="CLM-00091" num="00091"><claim-text><b>91</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the RNAi agent, or salt thereof, is present in a pharmaceutical composition.</claim-text></claim><claim id="CLM-92-97" num="92-97"><claim-text><b>92</b>.-<b>97</b>. (canceled)</claim-text></claim></claims></us-patent-application>